<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Arch Toxicol</journal-id><journal-id journal-id-type="iso-abbrev">Arch Toxicol</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Archives of Toxicology</journal-title></journal-title-group><issn pub-type="ppub">0340-5761</issn><issn pub-type="epub">1432-0738</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7603454</article-id><article-id pub-id-type="pmcid-ver">PMC7603454.1</article-id><article-id pub-id-type="pmcaid">7603454</article-id><article-id pub-id-type="pmcaiid">7603454</article-id><article-id pub-id-type="pmid">33111191</article-id><article-id pub-id-type="doi">10.1007/s00204-020-02936-7</article-id><article-id pub-id-type="publisher-id">2936</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Inhibition and induction of CYP enzymes in humans: an update</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5048-4363</contrib-id><name name-style="western"><surname>Hakkola</surname><given-names initials="J">Jukka</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hukkanen</surname><given-names initials="J">Janne</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Turpeinen</surname><given-names initials="M">Miia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Pelkonen</surname><given-names initials="O">Olavi</given-names></name><address><email>olavi.pelkonen@oulu.fi</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.10858.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 0941 4873</institution-id><institution>Research Unit of Biomedicine, Pharmacology and Toxicology, </institution><institution>University of Oulu, </institution></institution-wrap>POB 5000, 90014 Oulu, Finland </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.10858.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 0941 4873</institution-id><institution>Biocenter Oulu, </institution><institution>University of Oulu, </institution></institution-wrap>Oulu, Finland </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.10858.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 0941 4873</institution-id><institution>Medical Research Center Oulu, </institution><institution>University of Oulu and Oulu University Hospital, </institution></institution-wrap>Oulu, Finland </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.10858.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 0941 4873</institution-id><institution>Research Unit of Internal Medicine, Medical Research Center Oulu, </institution><institution>University of Oulu and Oulu University Hospital, </institution></institution-wrap>Oulu, Finland </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.10858.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 0941 4873</institution-id><institution>Administration Center, Medical Research Center Oulu, </institution><institution>University of Oulu and Oulu University Hospital, </institution></institution-wrap>Oulu, Finland </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="ppub"><year>2020</year></pub-date><volume>94</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">367941</issue-id><fpage>3671</fpage><lpage>3722</lpage><history><date date-type="received"><day>3</day><month>9</month><year>2020</year></date><date date-type="accepted"><day>12</day><month>10</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>27</day><month>10</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>10</day><month>11</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-03-30 20:25:11.943"><day>30</day><month>03</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="204_2020_Article_2936.pdf"/><abstract id="Abs1"><p id="Par1">The cytochrome P450 (CYP) enzyme family is the most important enzyme system catalyzing the phase 1 metabolism of pharmaceuticals and other xenobiotics such as herbal remedies and toxic compounds in the environment. The inhibition and induction of CYPs are major mechanisms causing pharmacokinetic drug&#8211;drug interactions. This review presents a comprehensive update on the inhibitors and inducers of the specific CYP enzymes in humans. The focus is on the more recent human in vitro and in vivo findings since the publication of our previous review on this topic in 2008. In addition to the general presentation of inhibitory drugs and inducers of human CYP enzymes by drugs, herbal remedies, and toxic compounds, an in-depth view on tyrosine-kinase inhibitors and antiretroviral HIV medications as victims and perpetrators of drug&#8211;drug interactions is provided as examples of the current trends in the field. Also, a concise overview of the mechanisms of CYP induction is presented to aid the understanding of the induction phenomena.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cytochrome P450</kwd><kwd>Inhibition</kwd><kwd>Induction</kwd><kwd>Drug&#8211;drug interaction</kwd><kwd>Herbal remedies</kwd><kwd>Environmental toxicants</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002341</institution-id><institution>Academy of Finland</institution></institution-wrap></funding-source><award-id>286743</award-id><award-id>323706</award-id><principal-award-recipient><name name-style="western"><surname>Hakkola</surname><given-names>Jukka</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008723</institution-id><institution>Suomen L&#228;&#228;ketieteen S&#228;&#228;ti&#246;</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005633</institution-id><institution>Syd&#228;ntutkimuss&#228;&#228;ti&#246;</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100011935</institution-id><institution>Pohjois-Suomen Terveydenhuollon Tukis&#228;&#228;ti&#246;</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100013500</institution-id><institution>Diabetestutkimuss&#228;&#228;ti&#246;</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>University of Oulu including Oulu University Hospital</institution></funding-source></award-group><open-access><p>Open access funding provided by University of Oulu including Oulu University Hospital.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag GmbH Germany, part of Springer Nature 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Inhibition and induction of cytochrome P450 (CYP) enzymes are central mechanisms, resulting in clinically significant drug&#8211;drug interactions (DDI). Today, characteristics and regulatory factors of various CYP enzymes have been elucidated to a considerable extent (Manikandan and Nagini <xref ref-type="bibr" rid="CR281">2018</xref>; Zanger and Schwab <xref ref-type="bibr" rid="CR540">2013</xref>). Detailed mechanisms of inhibition have been uncovered by studies on isolated or expressed enzymes and tissue fractions. Nuclear receptors as important xenobiotic-sensing transcription factors and as regulators of CYP induction have been elucidated (Wang et al. <xref ref-type="bibr" rid="CR498">2012</xref>).</p><p id="Par3">Prediction on the basis of in vitro studies is now an integral part of early drug development (Lu and Di <xref ref-type="bibr" rid="CR273">2020</xref>) as well as of the medicines agency guidelines (EMA, FDA, and MHLW/PMDA). Computational models such as physiologically based pharmacokinetic models are now being used for quantitative prediction of in vivo interactions from in vitro experiments (Kato <xref ref-type="bibr" rid="CR226">2020</xref>; Min and Bae <xref ref-type="bibr" rid="CR308">2017</xref>), and these models are used extensively by drug developers before and during clinical trials. After preclinical studies, there is an ultimate need of human in vivo studies and observations on inhibition and induction. Obviously, such information is absolutely needed for clinical drug treatment to prevent possible adverse outcomes and ensure safety.</p><p id="Par4">In addition to drugs, humans are exposed to a large number of other chemical substances through diet, use of cosmetics, in workplaces, by environmental pollutants, etc., and many of these chemicals are in vitro inhibitors or inducers of CYP enzymes but compared to pharmaceutics often poorly characterized. The risk posed by these chemicals is difficult or impossible to assess without reliable in vitro&#8211;in vivo extrapolation, which is only possible by having proven in vivo inhibitors or inducers (and non-effective substances) as reference items.</p><p id="Par5">With these premises in mind, and pointing to the profound developments in drug research and regulation (see the guest editorial, Pelkonen et al., in this issue), we have collected and updated the information about human in vivo inhibitors and inducers, which would constitute a curated compilation for the use as a reference for other in-depth studies. The main focus is on data published after 2008, and in many instances, we point to our earlier review for references before 2008 (Pelkonen et al. <xref ref-type="bibr" rid="CR352">2008</xref>).</p></sec><sec id="Sec2"><title>Progress since 2008</title><p id="Par6">We previously reviewed CYP inhibition and induction 12&#160;years ago (Pelkonen et al. <xref ref-type="bibr" rid="CR352">2008</xref>). In 2008, we stated that, because multiplicity and variability of CYP enzymes are an important complicating factor in pharmacological and toxicological research and regulation, and predictive and pre-empting measures are a top priority, and thus, the development of predictive in vitro approaches is necessary and should be based on the firm background of basic research on the phenomena of inhibition and induction and their underlying mechanisms. Consequently, we focused on covering both inhibition and induction of CYP enzymes, always keeping in mind the basic mechanisms on which to build predictive and preventive in vitro approaches to be validated by in vivo studies. These principles still apply today. Nevertheless, since 2008, further progress has been made in the research of CYP inhibition and induction and the application of the knowledge. Furthermore, very important development has happened in the characteristics of new drugs.</p></sec><sec id="Sec3"><title>New pharmaceuticals since 2008</title><p id="Par7">It is obvious that the spectrum of new drugs has changed since 2008 (see the guest editorial Pelkonen et al. in this issue and (de la Torre and Albericio <xref ref-type="bibr" rid="CR104">2020</xref>; Yu et al. <xref ref-type="bibr" rid="CR536">2019</xref>). Biological drugs, proteins, and peptides or oligonucleotides occupy nowadays a sizable share of new drugs (see Internet sites of major drug agencies: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/scripts/cder/daf/">https://www.accessdata.fda.gov/scripts/cder/daf/</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/medicines">https://www.ema.europa.eu/en/medicines</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html">https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html</ext-link>) and their role in DDIs in general is supposed to be in the pharmacodynamics sphere; specifically, CYP-associated DDIs are not expected. Consequently, small-molecular new chemical entities represent a smaller contribution into the new drugs, and these are more thoroughly studied during the developmental phases with in vitro tools and during clinical trials with focus on specific enzymes and transporters depicted by the in vitro information. The efficiency of the in vitro and in vivo tools as formulated in guidance documents from major authorities (EMA <xref ref-type="bibr" rid="CR1000">2012</xref>, FDA <xref ref-type="bibr" rid="CR1001">2020</xref>, MHLW/PMDA <xref ref-type="bibr" rid="CR1003">2018</xref>)<xref ref-type="fn" rid="Fn1">1</xref> is demonstrated by the fact that there have been no major surprises leading to drug withdrawals among novel drugs during the last 10&#8211;15&#160;years. Advancements in the pharmacokinetic research include the recognition that many less-studied non-CYP enzymes and especially several transporters have emerged as interaction targets.</p><p id="Par9">Shifts in approved drug classes have led to the situation that anticancer and antiviral (HIV) drugs are major molecules in CYP-associated DDIs. These shifts are probably behind the observation that CYP3A4 substrates form a majority of the drugs suspected or shown as causing CYP-associated interactions. The observation that there seem to be only a few inducers among newly approved drugs may be explained by the thrust in the development of small molecule drugs towards more potent and specific molecules. This has led to a relative decrease of clinical doses, which often are too small to cause a significant CYP induction.</p></sec><sec id="Sec4"><title>Tyrosine (protein) kinase inhibitors as an example of CYP-mediated DDIs</title><p id="Par10">Tyrosine kinase inhibitors (TKIs) form a relatively novel class of (mainly) anticancer agents, which has been expanding tremendously over the last 2 decades. Because of their &#8220;precision&#8221; targets, TKIs offer a more effective and safer option in many cancers compared to the cytostatic agents. Because their pharmacodynamic targets are a diverse, even if functionally related, set of enzymes, it is not surprising that their chemical structures as well as their metabolism and general pharmacokinetic characteristics are rather variable. However, TKIs actually are well represented in DDI sections of reference books and reviews, especially regarding their metabolic features and transporter involvements [see, e.g., (Gay et al. <xref ref-type="bibr" rid="CR148">2017</xref>; Hussaarts et al. <xref ref-type="bibr" rid="CR196">2019</xref>; Jackson et al. <xref ref-type="bibr" rid="CR204">2018</xref>)]. In this section, the TKI-associated CYP-DDIs are presented as an example of current concerns of clinically important CYP interactions.</p><sec id="Sec5"><title>Drugs selected</title><p id="Par11">The drugs covered here include protein or tyrosine-kinase inhibitors (TKIs) approved by EMA and/or FDA until 2018. There are a number of TKIs that have been discarded in the last rounds of development, but this source of useful compounds remains largely untapped for the analysis of DDIs. However, a scan of literature and physician&#8217;s desk references demonstrate that many of the approved TKIs are predominantly CYP3A4 substrates and many of them display a potential to inhibit or induce CYP enzymes. Consequently, it is a good opportunity to look at various interaction characteristics of these TKIs for the purposes of this review. Some salient features are collected in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Tyrosine (protein) kinase inhibitor anticancer drugs as CYP substrates, inhibitors, and inducers</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="MO1" orientation="portrait" xlink:href="204_2020_2936_Tab1a_HTML.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="MO111" orientation="portrait" xlink:href="204_2020_2936_Tab1b_HTML.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="MO1111" orientation="portrait" xlink:href="204_2020_2936_Tab1c_HTML.jpg"/><table-wrap-foot><p><italic toggle="yes">Act.met.</italic> active metabolite(s) (if reported or published), <italic toggle="yes">PGP</italic> P-glycoprotein, <italic toggle="yes">NR</italic> no results or not reported, <italic toggle="yes">TDI</italic> time-dependent inhibition</p><p><sup>1</sup>E: excretion of a drug as an unchanged parent. M: metabolism&#8212;the extent and contributions of CYP isoforms&#8217; other xenobiotic-metabolizing enzymes if known</p><p><sup>2</sup>Usually, strong inducers (rifampicin) and inhibitors (ketoconazole, itraconazole) of CYP3A4 were studied. Other perpetrators are assigned with appropriate CYP enzyme. Color code: red, strong effect; orange, moderate effect; light brown, weak/minor effect; green, no (significant) effect; yellow, information in need</p><p><sup>3</sup>Major sources drug monographs from FDA, EMA, and FIMEA; the latest uploaded documents were retrieved. Publications in general literature were sought and used for additional evidence for conclusions</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec6"><title>Key publications</title><p id="Par12">An important element in research of TKIs is that the crucial development leading to authorization has occurred at the time when in vitro and in vivo studies for predicting and estimating CYP interactions have been refined to the extent that there has been a possibility for fact-based go/no-go decisions and that there are tools to estimate the contribution of particular CYP enzymes and their predictable interaction consequences. On the other hand, much of the available published material is of regulatory nature, i.e., drug monographs in national formularies, and thus detailed experimental and clinical results may not be available for open scrutiny. Thus, we have been mostly dependent on material that is not publicly peer-reviewed (naturally regulators have had access to original studies), but on the other hand, studies providing the basis for official drug monographs are expected to be of high quality. Furthermore, many of them have appeared in the public literature later on. Otherwise, publicly available studies are often rather sporadic regarding individual drugs, but, nevertheless, we have referred to them when they provide additional or confirmatory information.</p></sec><sec id="Sec7"><title>TKI as a victim drug</title><p id="Par13">As can be seen in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>, a large majority of TKIs, 41 out of 43 drugs, is metabolized by CYP3A4/5 at least to a certain extent. Other CYP enzymes, such as CYP1A2, CYP2B6, CYP2C, and CYP2D6, contribute to the metabolism of some TKIs, but only binimetinib is metabolized to a small extent by CYP1A2 and CYP2C9 and not at all by CYP3A4/5. It is perhaps appropriate to note that the exact contribution of any single CYP is often rather difficult to quantitate precisely, but usually it is possible to state, whether CYP3A4 is responsible for a major or minor share of the metabolism. In vitro studies with human liver preparations or human hepatocytes are often crucial in this respect. In any case, it is not often possible to find in regulatory filings important parameters to describe enzyme kinetics, although some information may be found in the public literature.</p><p id="Par14">The extent and relative isoform contribution of CYP-associated metabolism of individual TKIs is one of the crucial factors leading to clinically significant DDI potential. As the anticancer effect is of paramount interest for the developer of the compound, the clinician, and ultimately the patient, some risks of off-target effects including DDIs are accepted that would not be deemed acceptable when developing drugs for other less serious indications.</p><p id="Par15">In DDI clinical studies, it is customary to use inhibitors and inducers which are known to have a strong effect. In most cases, rifampicin is used as an inducer and ketoconazole or itraconazole as an inhibitor. However, the strength of effect of a perpetrator is dependent on the metabolic characteristics of a victim, i.e., affinity to the principal enzyme, relative contribution of a specific enzyme to overall metabolism or PK behavior of a drug, and alternative enzymatic and excretory clearance routes. Consequently, the interaction outcome of a &#8220;strong&#8221; perpetrator may be strong, moderate, or weak, dependent on a specific victim. The intensity of inhibition or induction is defined by the FDA on the basis of the AUC change (FDA 2020).<xref ref-type="fn" rid="Fn2">2</xref> Strong, moderate, and weak inhibitors give rise to an increase in AUC of a victim at least fivefold, between two and fivefold, and 1.25- to 2-fold, respectively. For induction, corresponding AUC classes are an AUC decrease by&#8201;&gt;&#8201;80%, between 50 and 80% and between 20 and 50%. As stated above, even a &#8220;strong&#8221; inhibitor or inducer could result in strong, moderate, or weak effect, dependent on characteristics of a victim. Obviously, this classification provides only a rough yardstick for assessing the likelihood or clinical significance of an interaction and many other factors such as concentration&#8211;effect relationships of a victim may be more significant.</p><p id="Par17">Regarding 43 TKI drugs in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>, the metabolism of 30 of them is strongly or moderately and seven weakly inhibited and/or induced by &#8220;strong&#8221; CYP3A4 perpetrators and only five are classified as having no CYP3A4-associated DDIs as victims. Among these &#8220;negatives&#8221;, CYP3A4 plays either a minor or no role in elimination: afatinib is excreted mainly unchanged, binimetinib is metabolized by hydrolysis, lenvatinib is predominantly excreted unchanged and metabolized by aldehyde oxidase, nintedanib is eliminated by P-glycoprotein, and vismodegib is eliminated only to a minor extent by CYPs. It is fair to conclude that a majority of clinically used TKIs are CYP3A4 substrates, although the contribution of CYP3A4 to the overall elimination may be decreased by other metabolic or transporter routes [see, e.g., (Fenner et al. <xref ref-type="bibr" rid="CR135">2009</xref>; Yu et al. <xref ref-type="bibr" rid="CR533">2017a</xref>, <xref ref-type="bibr" rid="CR534">b</xref>, <xref ref-type="bibr" rid="CR536">2019</xref>)].</p></sec><sec id="Sec8"><title>TKIs as CYP inhibitors</title><p id="Par18">Most TKIs in Table&#160;<xref rid="Tab1" ref-type="table">1</xref> have been screened for inhibitory potential using in vitro human liver microsomal assays consisting of major CYP activities from CYP1A2 to CYP3A4/5. In seven cases, no inhibition in vitro was detected, whereas for the rest of the drugs, the in vitro classifications ranged from &#8220;studied&#8221; to &#8220;some&#8221; or &#8220;weak inhibition&#8221;, and in a few cases even &#8220;moderate or strong inhibitory action&#8221;. However, on the basis of the published regulatory text, it is difficult to quantify &#8220;weak&#8221; or &#8220;strong&#8221; effect. Often, the regulatory text noted that inhibition was present or non-existent &#8220;at clinically relevant concentrations&#8221;. In certain cases, in vitro studies were followed by in vivo studies in which CYP-selective probe drugs were employed. For example, with respect to CYP3A4 substrates, inhibition was classified as strong for idelalisib&#8211;midazolam, imatinib&#8211;simvastatin and nilotinib&#8211;midazolam, moderate for crizotinib&#8211;midazolam, dasatinib&#8211;simvastatin, and ribociclib&#8211;midazolam, and weak for larotrectinib&#8211;midazolam, palbociclib&#8211;midazolam, and pazopanib&#8211;midazolam. Regarding CYP2D6 substrates, inhibition was classified as weak in two cases: gefitinib&#8211;metoprolol and pazopanib&#8211;dextromethorphan. Regarding CYP2C8, lapatinib inhibited weakly paclitaxel elimination, and with CYP1A2, vemurafenib inhibited moderately tizanidine and caffeine elimination. Altogether, it can be concluded that the cases CYP inhibition by TKIs, regarded worthy a warning in the regulatory desk reference, were rather few. However, occasionally, there were warnings that seemed to be based only on in vitro results and/or subsequent physiologically based pharmacokinetic (PBPK) simulations (Yu et al. <xref ref-type="bibr" rid="CR536">2019</xref>).</p></sec><sec id="Sec9"><title>TKIs as CYP inducers</title><p id="Par19">According to the guidelines of major regulatory agencies, potential CYP induction should be studied in human-cultured hepatocytes in vitro or in an analogous cellular system. In most cases, appropriate studies have been performed and the outcome registered in the drug monograph. In 14 cases, no information on in vitro induction studies could be found (in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>, these are marked by NR, no results or not reported). No induction of the major inducible CYPs has been found in 14 cases and a clear response emerged in 10 cases (brigatinib, dabrafenib, ibrutinib, idelalisib, midostaurin, nilotinib, olaparib, osimertanib, pazopanib, and vemurafenib). In vivo studies were performed with 4 TKIs which resulted in a moderate induction with erlotinib&#8211;quinine or midazolam, and dabrafenib&#8211;midazolam or warfarin, and a weak induction with midostaurin&#8211;midazolam and vemurafenib&#8211;midazolam. Encorafenib was suspected of exhibiting autoinduction. However, regulatory texts are not always reliable regarding negative findings and it may well be that additional in vitro and in vivo studies have been performed but not reported. Based on this analysis, it can be concluded that TKIs do not often display clinically significant induction potency in humans in vivo.</p></sec><sec id="Sec10"><title>Active metabolites</title><p id="Par20">At least 13 TKIs have at least one active metabolite. However, there may be several types of active metabolites regarding potential effects and outcomes. Several TKIs have pharmacodynamically active metabolites with a similar, although not necessarily equipotent, pharmacodynamic action as the parent. In some cases, a pharmacodynamically active metabolite may also have CYP-interaction potential. A special case is regorafenib, which has two CYP3A4-associated active metabolites with equal effect compared to the parent. This makes the assessment of interactions quite complex and uncertain. For example, although rifampicin exposure slightly decreased the AUC of the parent compound, it increased the AUC of one active metabolite by 2.6-fold. Thus, it is quite difficult to estimate the net pharmacodynamic effect.</p><p id="Par21">Another mechanism is the so-called time-dependent inhibition (TDI), often due to the tight or irreversible binding of an active metabolite with the catalyzing enzyme leading to its inactivation (mechanism-based inhibition) or potentially due to formation of a more potent inhibitory metabolite. Both terms, TDI and mechanism-based inhibition, are used in this review. The evaluation of TDI would require appropriate in vitro studies, which were not usually available concerning TKIs. A recent review (Jackson et al. <xref ref-type="bibr" rid="CR204">2018</xref>) listed the following TKIs as potential candidates in this category: axitinib, bosutinib, dasatinib, imatinib, erlotinib, gefitinib, lapatinib, nilotinib, pazopanib, and sunitinib. However, company or authority data are not usually detailed enough in this respect, and more appropriate and detailed information is provided only rarely in published articles (Filppula et al. <xref ref-type="bibr" rid="CR137">2018</xref>; Kenny et al. <xref ref-type="bibr" rid="CR229">2012</xref>; Mao et al. <xref ref-type="bibr" rid="CR283">2016</xref>).</p><p id="Par22">The generation of reactive metabolites has quite often been studied by drug companies developing the TKIs, since the reactive metabolites could potentially induce hepatotoxicity and form a threat for withdrawal during development or, worse, after the regulatory approval. Thus, at least in the following cases, reactive metabolites have been identified for clinically available tyrosine-kinase inhibitors: axitinib (Wang et al. <xref ref-type="bibr" rid="CR502">2020</xref>), dasatinib (Li et al. <xref ref-type="bibr" rid="CR265">2009</xref>), erlotinib (Li et al. <xref ref-type="bibr" rid="CR265">2009</xref>; Zhao et al. <xref ref-type="bibr" rid="CR544">2018</xref>), gefitinib (Li et al. <xref ref-type="bibr" rid="CR265">2009</xref>), imatinib (Li et al. <xref ref-type="bibr" rid="CR266">2014</xref>), lapatinib (Takakusa et al. <xref ref-type="bibr" rid="CR451">2011</xref>; Teng et al. <xref ref-type="bibr" rid="CR458">2010</xref>), ponatinib (Lin et al. <xref ref-type="bibr" rid="CR269">2017</xref>), and sunitinib (Amaya et al. <xref ref-type="bibr" rid="CR13">2018</xref>). It is, however, difficult to ascertain a specific reactive metabolite to cause a certain TDI, especially when the presence of a reactive metabolite has been deduced on the basis of trapping agents (Mao et al. <xref ref-type="bibr" rid="CR283">2016</xref>).</p></sec></sec><sec id="Sec11"><title>Antiretroviral HIV drugs</title><p id="Par23">The antiretroviral human immunodeficiency virus (HIV) drugs (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>) are of considerable interest for DDIs in research and therapy for two main reasons. First, the group contains two drugs (ritonavir and cobicistat) that are mainly used as pharmacokinetic enhancers, &#8220;boosters&#8221;, due to their strong and mechanism-based inhibitory action towards CYP3A4, the predominant enzyme metabolizing anti-HIV-protease inhibitors (Tseng et al. <xref ref-type="bibr" rid="CR471">2017</xref>). These boosters are rather rare examples of intentional, beneficial utilization of CYP-DDIs. The second reason is due to the frequent use of combinations of various antiviral drugs; up to four drugs in fixed combinations, although pharmacodynamic benefits are the major reasons to use such combinations.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Antiretroviral HIV drugs as CYP substrates, inhibitors and inducers</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Antiretroviral drug</th><th align="left" colspan="2" rowspan="1">As a CYP substrate</th><th align="left" colspan="2" rowspan="1">As a CYP inhibitor</th><th align="left" rowspan="2" colspan="1">As a CYP inducer</th><th align="left" rowspan="2" colspan="1">References<sup>b</sup></th></tr><tr><th align="left" colspan="1" rowspan="1">As a victim<sup>a</sup></th><th align="left" colspan="1" rowspan="1">Perpetrators (effect assignments in parentheses)</th><th align="left" colspan="1" rowspan="1">Target enzymes</th><th align="left" colspan="1" rowspan="1">Victim drugs (effect assignments in parentheses)</th></tr></thead><tbody><tr><td align="left" colspan="7" rowspan="1">Pharmacokinetic enhancers (boosters)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Cobicistat</td><td align="left" colspan="1" rowspan="1"><p>E:&#8201;&gt;&#8201;80%</p><p>M: 3A4, 2D6 (minor)</p></td><td align="left" colspan="1" rowspan="1">Strong 3A4 inducers (moderate)</td><td align="left" colspan="1" rowspan="1">3A4 (mechanism-based), 2D6 (weak)</td><td align="left" colspan="1" rowspan="1">Atorvastatin, rosuvastatin, etc.</td><td align="left" colspan="1" rowspan="1">No significant in vitro</td><td align="left" colspan="1" rowspan="1">Cattaneo et al. (<xref ref-type="bibr" rid="CR62">2019</xref>), Sherman et al. (<xref ref-type="bibr" rid="CR421">2015</xref>), Tseng et al. (<xref ref-type="bibr" rid="CR471">2017</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Ritonavir</td><td align="left" colspan="1" rowspan="1"><p>E:&#8201;&gt;&#8201;50%</p><p>M: 3A4, 2D6 (minor)</p></td><td align="left" colspan="1" rowspan="1"><p>Strong 3A4 inhibitors ketoconazole (minor)</p><p>Strong 3A4 inducers rifampicin (moderate)</p></td><td align="left" colspan="1" rowspan="1">3A4 (mechanism-based), 2D6, 2C9</td><td align="left" colspan="1" rowspan="1">3A4-, 2D6- and 2C9-substrates variable effects</td><td align="left" colspan="1" rowspan="1">1A2, 2B6, 2C8, 2C9, 2C19 in vitro; in vivo minor or moderate effects</td><td align="left" colspan="1" rowspan="1">Cattaneo et al. (<xref ref-type="bibr" rid="CR62">2019</xref>), Cooper et al. (<xref ref-type="bibr" rid="CR91">2003</xref>), Tseng et al. (<xref ref-type="bibr" rid="CR471">2017</xref>)</td></tr><tr><td align="left" colspan="7" rowspan="1">Protease inhibitors</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Atazanavir (+cobicistat)</td><td align="left" colspan="1" rowspan="1">M: 3A4</td><td align="left" colspan="1" rowspan="1"><p>Strong 3A4 inducers rifampicin (strong)</p><p>Efavirenz (moderate)</p></td><td align="left" colspan="1" rowspan="1">3A4 (mechanism-based), 2C8 (weak)</td><td align="left" colspan="1" rowspan="1">3A4 substrates (from weak to strong)</td><td align="left" colspan="1" rowspan="1">No effect in vitro or in vivo</td><td align="left" colspan="1" rowspan="1">Tseng et al. (<xref ref-type="bibr" rid="CR471">2017</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Darunavir (+ritonavir)</td><td align="left" colspan="1" rowspan="1">M: 3A4, 2D6</td><td align="left" colspan="1" rowspan="1">3A4-inducers and inhibitors (variable observed or predicted effects)</td><td align="left" colspan="1" rowspan="1">3A4, 2D6</td><td align="left" colspan="1" rowspan="1">3A4 substrates (from weak to moderate)</td><td align="left" colspan="1" rowspan="1">2C9? warfarin</td><td align="left" colspan="1" rowspan="1">Tseng et al. (<xref ref-type="bibr" rid="CR471">2017</xref>), Wagner et al. (<xref ref-type="bibr" rid="CR490">2017</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Fosamprenavir (amprenavir) (+ritonavir)</td><td align="left" colspan="1" rowspan="1">M: 3A4</td><td align="left" colspan="1" rowspan="1">3A4-inducers and inhibitors (variable observed or predicted effects)</td><td align="left" colspan="1" rowspan="1">3A4</td><td align="left" colspan="1" rowspan="1">3A4 substrates (from weak to moderate)</td><td align="left" colspan="1" rowspan="1">3A4; in vivo effect minor or moderate</td><td align="left" colspan="1" rowspan="1">Justesen et al. (<xref ref-type="bibr" rid="CR217">2003</xref>), Sale et al. (<xref ref-type="bibr" rid="CR404">2002</xref>), Tran et al. (<xref ref-type="bibr" rid="CR469">2002</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Lopinavir (+ritonavir)</td><td align="left" colspan="1" rowspan="1">M: 3A4</td><td align="left" colspan="1" rowspan="1">3A4-inducers and inhibitors (variable observed or predicted effects)</td><td align="left" colspan="1" rowspan="1">3A4</td><td align="left" colspan="1" rowspan="1">3A4 substrates (from weak to moderate)</td><td align="left" colspan="1" rowspan="1">3A4, in vivo effect minor at most</td><td align="left" colspan="1" rowspan="1">Wagner et al. (<xref ref-type="bibr" rid="CR490">2017</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Nelfinavir</td><td align="left" colspan="1" rowspan="1">M: 3A4, 2C19</td><td align="left" colspan="1" rowspan="1"><p>3A4-inducers and inhibitors (weak to moderate)</p><p>2C19-inhibitors (weak to moderate)</p></td><td align="left" colspan="1" rowspan="1">3A4</td><td align="left" colspan="1" rowspan="1">Midazolam (moderate)</td><td align="left" colspan="1" rowspan="1"><p>In vitro 1A2, 2B6, 2C19</p><p>In vivo 1A2 (moderate), 2B6 (weak) and 2C9 (weak)</p></td><td align="left" colspan="1" rowspan="1">Kirby et al. (<xref ref-type="bibr" rid="CR236">2011a</xref>, <xref ref-type="bibr" rid="CR237">b</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Saquinavir (+ritonavir)</td><td align="left" colspan="1" rowspan="1">3A4</td><td align="left" colspan="1" rowspan="1">3A4-inducers and inhibitors (variable observed or predicted effects)</td><td align="left" colspan="1" rowspan="1">3A4</td><td align="left" colspan="1" rowspan="1">Midazolam (strong)</td><td align="left" colspan="1" rowspan="1">3A4, in vivo minor effect at most</td><td align="left" colspan="1" rowspan="1">Dickinson et al. (<xref ref-type="bibr" rid="CR110">2008</xref>), Eagling et al. (<xref ref-type="bibr" rid="CR123">2002</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Tipranavir (+ritonavir)</td><td align="left" colspan="1" rowspan="1">3A4</td><td align="left" colspan="1" rowspan="1">2B6 and 3A4-inducers and inhibitors (variable observed or predicted effects)</td><td char="." align="left" colspan="1" rowspan="1">2D6</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">3A4, 1A2, 2C19 combination in vivo moderate or strong effect</td><td align="left" colspan="1" rowspan="1">Tseng et al. (<xref ref-type="bibr" rid="CR471">2017</xref>)</td></tr><tr><td align="left" colspan="7" rowspan="1">Integrase strand transfer inhibitors</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Bictegravir</td><td align="left" colspan="1" rowspan="1">M: 3A4, UGT1A1 (about equal)</td><td align="left" colspan="1" rowspan="1"><p>3A4 inhibitors: voriconazole (weak), atanazavir (moderate)</p><p>3A4 inducers: rifabutin (moderate), rifampicin (strong)</p></td><td align="left" colspan="1" rowspan="1">No significant effects in vitro/in vivo</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">No significant effects in vitro/in vivo</td><td align="left" colspan="1" rowspan="1">Gallant et al. (<xref ref-type="bibr" rid="CR144">2017</xref>), Sax et al. (<xref ref-type="bibr" rid="CR410">2017</xref>), <xref ref-type="bibr" rid="CR542">Zhang et al. (2017)</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Dolutegravir</td><td align="left" colspan="1" rowspan="1"><p>E:&#8201;~&#8201;50%</p><p>M: UGT1A1; 3A4 (minor)</p></td><td align="left" colspan="1" rowspan="1">Strong 3A4 inducers: ritonavir, efavirenz, rifampicin (no significant effect)</td><td align="left" colspan="1" rowspan="1">No effect in vivo</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">No effect in vivo</td><td align="left" colspan="1" rowspan="1">Kandel and Walmsley (<xref ref-type="bibr" rid="CR221">2015</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Elvitegravir</td><td align="left" colspan="1" rowspan="1"><p>E: 95%</p><p>M: 3A4 (minor)</p></td><td align="left" colspan="1" rowspan="1">Inducers; rifabutin, efavirenz, etc. (minor effect at most)</td><td align="left" colspan="1" rowspan="1">Minor effect in vitro at most</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2C9?</td><td align="left" colspan="1" rowspan="1">Lee et al. (<xref ref-type="bibr" rid="CR261">2012</xref>), Tseng et al. (<xref ref-type="bibr" rid="CR471">2017</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Raltegravir</td><td align="left" colspan="1" rowspan="1"><p>E: major</p><p>M: UGT1A, no CYPs</p></td><td align="left" colspan="1" rowspan="1">No significant effects</td><td align="left" colspan="1" rowspan="1">No in vitro/in vivo</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">No in vitro/in vivo</td><td align="left" colspan="1" rowspan="1">Okeke and Hicks (<xref ref-type="bibr" rid="CR324">2011</xref>)</td></tr><tr><td align="left" colspan="7" rowspan="1">Non-nucleoside reverse transcriptase inhibitors</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Doravirine</td><td align="left" colspan="1" rowspan="1">M: 3A4</td><td align="left" colspan="1" rowspan="1"><p>Strong 3A4 inhibitors ritonavir, ketoconazole (moderate)</p><p>Strong 3A4 inducers rifampicin (strong)</p></td><td align="left" colspan="1" rowspan="1">No in vitro/in vivo</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">In vivo 3A4 (weak)</td><td align="left" colspan="1" rowspan="1">Khalilieh et al. (<xref ref-type="bibr" rid="CR231">2019</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Efavirenz</td><td align="left" colspan="1" rowspan="1">M: 2B6 (primary), 2A6, 3A4</td><td align="left" colspan="1" rowspan="1">2B6 and 3A4-inducers and inhibitors (variable observed or predicted effects)</td><td align="left" colspan="1" rowspan="1">2C9, 2C19, 3A4</td><td align="left" colspan="1" rowspan="1">In vivo variable effects</td><td align="left" colspan="1" rowspan="1"><p>3A4, 2B6 in vitro</p><p>2B6 autoinduction</p><p>2A6, 2B6, 2C19, 3A4 in vivo variable effects</p></td><td align="left" colspan="1" rowspan="1">Best and Goicoechea (<xref ref-type="bibr" rid="CR37">2008</xref>), Marzolini et al. (<xref ref-type="bibr" rid="CR287">2017</xref>), McDonagh et al. (<xref ref-type="bibr" rid="CR294">2015</xref>), Metzger et al. (<xref ref-type="bibr" rid="CR301">2019</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Etravirine</td><td align="left" colspan="1" rowspan="1">M: 3A4, 2C9, 2C19</td><td align="left" colspan="1" rowspan="1">Inhibitors and inducers variable effects</td><td align="left" colspan="1" rowspan="1">2C9, 2C19</td><td align="left" colspan="1" rowspan="1">In vitro variable effects</td><td align="left" colspan="1" rowspan="1">3A4</td><td align="left" colspan="1" rowspan="1">Havens et al. (<xref ref-type="bibr" rid="CR173">2020</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Nevirapine</td><td align="left" colspan="1" rowspan="1">M: 3A4, 2B6</td><td align="left" colspan="1" rowspan="1"><p>Rifampicin (moderate)</p><p>Fluconazole (strong)</p></td><td align="left" colspan="1" rowspan="1">3A4, 2B6 (both weak)</td><td align="left" colspan="1" rowspan="1">Weak or no effects in vitro or in vivo</td><td align="left" colspan="1" rowspan="1"><p>3A4, 2B6</p><p>In vivo autoinduction</p><p>In vivo weak or moderate effect at most</p></td><td align="left" colspan="1" rowspan="1">Ena et al. (<xref ref-type="bibr" rid="CR126">2012</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Rilpivirine</td><td align="left" colspan="1" rowspan="1">M: 3A4</td><td align="left" colspan="1" rowspan="1"><p>Rifampicin (moderate)</p><p>Ketoconazole (moderate)</p></td><td align="left" colspan="1" rowspan="1">3A4</td><td align="left" colspan="1" rowspan="1">No/minor effects in vivo at most</td><td align="left" colspan="1" rowspan="1">No in vitro/in vivo</td><td align="left" colspan="1" rowspan="1">Crauwels et al. (<xref ref-type="bibr" rid="CR94">2013</xref>)</td></tr><tr><td align="left" colspan="7" rowspan="1">C&#8211;C chemokine receptor type 5</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Maraviroc</td><td align="left" colspan="1" rowspan="1">M: 3A4</td><td align="left" colspan="1" rowspan="1">Strong 3A4 inducers and inhibitors (strong)</td><td align="left" colspan="1" rowspan="1">3A4 (weak)</td><td align="left" colspan="1" rowspan="1">No significant inhibition in vitro or in vivo</td><td align="left" colspan="1" rowspan="1">No induction in vitro or in vivo</td><td align="left" colspan="1" rowspan="1">Abel et al. (<xref ref-type="bibr" rid="CR4">2009</xref>)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>M, elimination by metabolism, E excretion as an unchanged drug</p><p><sup>b</sup>Principal source for the information of this table is based on the AIDS Info: Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services. 2020 [cited 2020 March 20]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf">https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf</ext-link></p></table-wrap-foot></table-wrap></p><p id="Par24">The use of combinations makes it challenging to evaluate, especially in therapeutic situations, potential DDIs with other drug treatments of individual patients. The FDA or EMA-approved drug monographs contain extensive tabulated information about experimentally and/or clinically observed, or predicted DDIs, which often are difficult) to translate into clinically useful advice in actual patients. It is expected that in the future, DDI-predicting PBPK-models and artificial intelligence-based algorithms would aid clinical decisions [see, e.g., (Ryu et al. <xref ref-type="bibr" rid="CR400">2018</xref>; Varma et al. <xref ref-type="bibr" rid="CR484">2015</xref>)].</p><p id="Par25">Cobicistat and ritonavir are especially employed in combination with HIV-protease inhibitors which are CYP3A4 substrates. CYP3A4-associated metabolism is very potently inhibited, because both boosters are mechanism-based inhibitors and block protease inhibitor metabolism and clearance almost completely thus extending drug exposure and the ensuing effect. They are also used in combination with other classes of HIV drugs, especially in fixed multidrug combinations containing protease inhibitors.</p><p id="Par26">Pharmacokinetic interactions could also be based on processes involving transporters, e.g., P-glycoprotein. Many HIV drugs are ligands of various transporters and consequently interactions with other ligands may occur (Alam et al. <xref ref-type="bibr" rid="CR12">2016</xref>). This review will not cover transporter-mediated interactions as the focus is on CYP-DDIs.</p><p id="Par27">Nucleoside reverse transcriptase inhibitors (abacavir, emtricitabine, lamivudine, tenofovir alafenamide, tenofovir disoproxil, and zidovudine) and the only fusion inhibitor (enfuvirtide) are devoid of CYP inhibition potential, because they are not metabolized by, or interacting with, CYP enzymes and most of them are renally eliminated. They are also not known to cause CYP induction.</p></sec><sec id="Sec12"><title>Herbal/botanical natural products interacting with drugs</title><p id="Par28">Herbal and/or botanical (medicinal) products are used in the treatment of various diseases, often as a &#8216;self-treatment&#8217; by the patient and many times unbeknownst to the treating physician (Paine and Roe <xref ref-type="bibr" rid="CR337">2018</xref>). From the drug-interaction point of view, a challenge is that herbal products are usually complex mixtures of constituents that can vary substantially in both content and concentration depending on the preparation and, furthermore, when isolated they can behave very differently (Kellogg et al. <xref ref-type="bibr" rid="CR228">2019</xref>; Paine et al. <xref ref-type="bibr" rid="CR338">2018</xref>; Sevior and Ahokas <xref ref-type="bibr" rid="CR418">2017</xref>). These problems are exaggerated by inadequacies of product regulation and standardization, thus leaving a physician without essential information and thus being at the mercy of very variable and often blatantly poor-quality literature (Pelkonen et al. <xref ref-type="bibr" rid="CR353">2014</xref>). Especially, there is a dearth of quality scientific data on potential herb&#8211;drug interactions for even widely used herbal medicines. In this review, interactions resulting in induction of CYP enzymes are detailed in Table&#160;<xref rid="Tab14" ref-type="table">14</xref>. Regarding inhibitory interactions, only a few well-characterized examples (resveratrol, quercetin) have been included as &#8216;clinically significant&#8217; perpetrators (see Table&#160;<xref rid="Tab4" ref-type="table">4</xref>). According to literature reviews on herbal-associated CYP interactions [see, e.g., (Hermann and von Richter <xref ref-type="bibr" rid="CR178">2012</xref>; Izzo and Ernst <xref ref-type="bibr" rid="CR202">2009</xref>)], a large number of herbal preparations are interacting with CYP enzymes at the level of in vitro incubations, but there are variable and uncertain evidence on interactions in vivo. Also, major agency guidances pay little attention to these natural products; only EMA has a rather general entry in the interaction guidance, while FDA is treating herbal products as food supplements. The WHO document on herbal&#8211;drug interactions is under preparation and is expected shortly; it is hoped to set the stage for further scientific research and regulatory guidance to assess the clinical significance of herb&#8211;drug interactions.</p></sec><sec id="Sec13"><title>CYP substrates and inhibitors</title><sec id="Sec14"><title>General</title><p id="Par29">Data on substrates and inhibitors of major xenobiotic-metabolizing CYP enzymes are collected in Tables&#160;<xref rid="Tab3" ref-type="table">3</xref>, <xref rid="Tab4" ref-type="table">4</xref>, <xref rid="Tab5" ref-type="table">5</xref>, <xref rid="Tab6" ref-type="table">6</xref>, <xref rid="Tab7" ref-type="table">7</xref>, <xref rid="Tab8" ref-type="table">8</xref>, <xref rid="Tab9" ref-type="table">9</xref>, <xref rid="Tab10" ref-type="table">10</xref> and <xref rid="Tab11" ref-type="table">11</xref>. It is obvious that due to the vast literature, this survey cannot include all the possible substrates and inhibitors for CYP enzymes, instead certain restrictions had to be applied. Obviously, &#8216;the clinical significance&#8217; is one of the overriding criterium, although it is very difficult to define. In this review, &#8216;the clinical significance&#8217; means that the first-hand assessment of the drug, mostly on the basis of information in the regulatory dossier, has resulted in the inclusion of the drug in the list (see above the section on tyrosine-kinase inhibitors). However, &#8216;the clinical significance&#8217; is dependent on many determinants including in vitro studies, clinical trials with reference substrates and inhibitors (these studies may be available at the time of approval), published non-regulatory studies and clinical experiences, etc. In the end, we have to admit that a certain measure of personal experience has been applied in the current review. Predominantly, only currently used drugs are listed, but some well-established, although withdrawn drugs are provided as reference. Also a few well-studied examples of in vitro substances are included because of their use as reference substrates or inhibitors.<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>Substrates and inhibitors of CYP3A4/5 enzyme</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5" rowspan="1">Reference substrates recommended by major regulatory agencies<sup>a</sup></th></tr><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Reaction</th><th align="left" colspan="1" rowspan="1">Km (&#956;M) in vitro (HLMs) (plasma conc)<sup>b</sup></th><th align="left" colspan="1" rowspan="1">Specificity near Km</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Midazolam in vitro, in vivo</td><td align="left" colspan="1" rowspan="1">1&#8242;-Hydroxylation/elimination</td><td align="left" colspan="1" rowspan="1">1&#8211;14 (0.8)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Triazolam in vitro, in vivo</td><td align="left" colspan="1" rowspan="1">4-Hydroxylation/elimination</td><td align="left" colspan="1" rowspan="1">238&#8211;304 (0.06)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Testosterone in vitro</td><td align="left" colspan="1" rowspan="1">6&#946;-Hydroxylation</td><td align="left" colspan="1" rowspan="1">33&#8211;94 (na)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="5" rowspan="1">Substrates potentially affected by strong CYP3A4 inhibitors<sup>c</sup></td></tr><tr><td align="left" colspan="5" rowspan="1">Highly selective/sensitive: alfentanil, alprazolam, aprepitant, atorvastatin, avanafil, budesonide, buspirone, colchicine, conivaptan, cyclosporin A, darifenacin, darunavir, dasatinib, dihydroergotamine (and ergotamine), docetaxel, dronedarone, ebastine, eletriptan, eliglustat, eplerenone, everolimus, felodipine, fentanyl, flibanserin, guanfacine, ibrutinib, indinavir, lomitapide, lovastatin, lurasidone, maraviroc, midazolam, naloxegol, nifedipine, nisoldipine, pimozide, quetiapine, quinidine, rilpivirine, rivaroxaban, saquinavir, sildenafil, simeprevir, simvastatin, sirolimus, sonidegib, tacrolimus, tadalafil, ticagrelor, tipranavir, tolvaptan, triazolam, vardenafil, and vincristine</td></tr><tr><td align="left" colspan="5" rowspan="1">Additional protein tyrosine-kinase inhibitors, see Table&#160;<xref rid="Tab1" ref-type="table">1</xref> for details</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5" rowspan="1">Reference inhibitors recommended by major regulatory agencies<sup>a</sup></th></tr><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Mode of inhibition</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">K</italic><sub><italic toggle="yes">i</italic></sub>/IC<sub>50</sub> (&#956;M) in in vitro (plasma conc)<sup>b</sup></th><th align="left" colspan="1" rowspan="1">CYP selectivity and other CYPs inhibited</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Ketoconazole in vitro, in vivo</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">0.0037&#8211;0.028 (2&#8211;6)</td><td align="left" colspan="1" rowspan="1">Moderate (2C, 1A2, 2D6)</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Itraconazole in vitro, in vivo</td><td align="left" colspan="1" rowspan="1">Competitive (metabolites)</td><td align="left" colspan="1" rowspan="1">0.013&#8211;0.27 (0.6&#8211;2.8)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786; Yoshida et al. (<xref ref-type="bibr" rid="CR529">2018</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Azamulin in vitro</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">0.03&#8211;0.24 (na)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">Parmentier et al. (<xref ref-type="bibr" rid="CR347">2017</xref>), Stresser et al. (<xref ref-type="bibr" rid="CR440">2004</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Fluconazole</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">5.4&#8211;13.1 (6&#8211;30)</td><td align="left" colspan="1" rowspan="1">Moderate (2C9, 2C19)</td><td align="left" colspan="1" rowspan="1">Niwa et al. (<xref ref-type="bibr" rid="CR320">2005</xref>), Yoshida et al. (<xref ref-type="bibr" rid="CR529">2018</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Troleandomycin in vitro</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td char="." align="char" colspan="1" rowspan="1">0.26</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786; Yadav et al. (<xref ref-type="bibr" rid="CR521">2018</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Verapamil</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">2.3&#8211;2.9 (0.1&#8211;0.6)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Ritonavir in vivo</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">0.019&#8211;0.17 (7&#8211;15)</td><td align="left" colspan="1" rowspan="1">Moderate (2C9)</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Clarithromycin in vivo</td><td align="left" colspan="1" rowspan="1">Mechanism-based (comp)</td><td align="left" colspan="1" rowspan="1">0.8 (5.5&#8211;10) (0.3&#8211;2.7)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Erythromycin in vivo</td><td align="left" colspan="1" rowspan="1">Mechanism-based (comp)</td><td align="left" colspan="1" rowspan="1">1.0 (16&#8211;19) (1&#8211;8)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">Akiyoshi et al. (<xref ref-type="bibr" rid="CR11">2013</xref>), Kanamitsu et al. (<xref ref-type="bibr" rid="CR220">2000</xref>)</td></tr><tr><td align="left" colspan="5" rowspan="1">Inhibitors of potential clinical significance</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Voriconazole</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">3.0 (4&#8211;17)</td><td align="left" colspan="1" rowspan="1">Poor (2B6, 2C9, 2C19)</td><td align="left" colspan="1" rowspan="1">Jeong et al. (<xref ref-type="bibr" rid="CR208">2009a</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Posaconazole</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">? (&lt;&#8201;0.1?) (1)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">Groll et al. (<xref ref-type="bibr" rid="CR160">2017</xref>), Krishna et al. (<xref ref-type="bibr" rid="CR247">2009</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Indinavir</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">0.17&#8211;0.5 (&gt;&#8201;0.16)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Nelfinavir</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">1&#8211;4.8 (&gt;&#8201;1.4)</td><td align="left" colspan="1" rowspan="1">Moderate (CYP2D6)</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Saquinavir</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">0.65&#8211;2.99 (&gt;&#8201;0.37)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Diltiazem</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">2.2&#8211;5.0 (0.1&#8211;0.6)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Telithromycin</td><td align="left" colspan="1" rowspan="1">Mechanism-based (competitive)</td><td align="left" colspan="1" rowspan="1">1.05 (3.65) (2.5)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">Elsby et al. (<xref ref-type="bibr" rid="CR124">2019</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Gestodene</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">46 (0.02)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786; Palovaara et al. (<xref ref-type="bibr" rid="CR5000">2000</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Ceritinib</bold></td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">0.16&#8211;0.2 (0.9&#8211;2.7)</td><td align="left" colspan="1" rowspan="1">Moderate (2C9)</td><td align="left" colspan="1" rowspan="1">Zhao et al. (<xref ref-type="bibr" rid="CR545">2020</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Idelalisib</bold></td><td align="left" colspan="1" rowspan="1">Mechanism-based (metabolite)</td><td align="left" colspan="1" rowspan="1">5.1 (0.5&#8211;5)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">Ramanathan et al. (<xref ref-type="bibr" rid="CR378">2016</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Imatinib</td><td align="left" colspan="1" rowspan="1">Competitive?</td><td align="left" colspan="1" rowspan="1">8 (1&#8211;4)</td><td align="left" colspan="1" rowspan="1">Moderate</td><td align="left" colspan="1" rowspan="1">O&#8217;Brien et al. (<xref ref-type="bibr" rid="CR321">2003</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Lapatinib</bold></td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td char="." align="char" colspan="1" rowspan="1">1.7</td><td align="left" colspan="1" rowspan="1">High (3A5: 37.6 uM)</td><td align="left" colspan="1" rowspan="1">Chan et al. (<xref ref-type="bibr" rid="CR65">2012</xref>), Teng et al. (<xref ref-type="bibr" rid="CR458">2010</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Nilotinib</bold></td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">0.4&#8211;7 (2&#8211;3)</td><td align="left" colspan="1" rowspan="1">Moderate (2C8, 2C9, 2D6)</td><td align="left" colspan="1" rowspan="1">Tian et al. (<xref ref-type="bibr" rid="CR463">2018</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Osimertinib</bold></td><td align="left" colspan="1" rowspan="1">Mechanism-based competitive</td><td align="left" colspan="1" rowspan="1">2.5&#8211;5.1 (1.5&#8211;3)</td><td align="left" colspan="1" rowspan="1">Moderate (2C8)</td><td align="left" colspan="1" rowspan="1">Pilla Reddy et al. (<xref ref-type="bibr" rid="CR360">2018</xref>), Vishwanathan et al. (<xref ref-type="bibr" rid="CR487">2019</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Stiripentol</bold></td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">80 (8&#8211;40)</td><td align="left" colspan="1" rowspan="1">Moderate (CYP1A2, 2D6)</td><td align="left" colspan="1" rowspan="1">Tran et al. (<xref ref-type="bibr" rid="CR467">1997</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Dronedarone</bold></td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">0.87 (0.15&#8211;0.3)</td><td align="left" colspan="1" rowspan="1">Moderate (2J2)</td><td align="left" colspan="1" rowspan="1">Hong et al. (<xref ref-type="bibr" rid="CR183">2016</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Boceprevir</bold></td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">6.1 (0.2&#8211;1.5)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">Chu et al. (<xref ref-type="bibr" rid="CR85">2013</xref>), Wilby et al. (<xref ref-type="bibr" rid="CR510">2012</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Telaprevir</bold></td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">0.19&#8211;0.36 (3&#8211;4.5)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">Chapron et al. (<xref ref-type="bibr" rid="CR69">2015</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Cobicistat</bold></td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">0.032 (0.9)</td><td align="left" colspan="1" rowspan="1">Moderate</td><td align="left" colspan="1" rowspan="1">Hossain et al. (<xref ref-type="bibr" rid="CR186">2017</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Netupitant</bold></td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">1.9&#8211;5.7 (0.3&#8211;1)</td><td align="left" colspan="1" rowspan="1">Moderate (2C9)</td><td align="left" colspan="1" rowspan="1">Giuliano et al. (<xref ref-type="bibr" rid="CR153">2012</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Isavuconazole</bold></td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">0.62&#8211;1.93 (5.71)</td><td align="left" colspan="1" rowspan="1">Moderate (2C, 2D6)</td><td align="left" colspan="1" rowspan="1">Townsend et al. (<xref ref-type="bibr" rid="CR466">2017</xref>), Yamazaki et al. (<xref ref-type="bibr" rid="CR523">2017</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Grapefruit juice</bold></td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">Not applicable</td><td align="left" colspan="1" rowspan="1">Low? (multiple CYPs)</td><td align="left" colspan="1" rowspan="1">Bailey et al. (<xref ref-type="bibr" rid="CR26">2013</xref>); Hanley et al. (<xref ref-type="bibr" rid="CR172">2011</xref>)</td></tr><tr><td align="left" colspan="5" rowspan="1">Moderate inhibitors<sup>c</sup> (regulatory documents): amprenavir, aprepitant, atazanavir, ciprofloxacin, crizotinib, darunavir/ritonavir, diltiazem, fosamprenavir, and gestodene</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">na</italic> not available, <italic toggle="yes">nk</italic> not known</p><p><sup>&#9786;</sup>For older references, see (Pelkonen et al. <xref ref-type="bibr" rid="CR352">2008</xref>). Newer inhibitors, since 2008, have been indicated in bold</p><p><sup>a</sup>Appropriate guidance documents of EMA (<xref ref-type="bibr" rid="CR1000">2012</xref>), FDA (<xref ref-type="bibr" rid="CR1001">2020</xref>), and MHLW/PMDA (<xref ref-type="bibr" rid="CR1003">2018</xref>) recommending the listed reference compounds for in vitro and in vivo studies. The use of two structurally unrelated CYP3A4/5 substrates for evaluation of in vitro CYP3A4/5 inhibition is recommended</p><p><sup>b</sup>Km or <italic toggle="yes">K</italic><sub><italic toggle="yes">i</italic></sub>/IC<sub>50</sub> values were taken mostly from in vitro human microsomal incubations. Therapeutic (&#8220;control&#8221;) plasma concentrations were mainly taken from two compilations (Schulz et al. <xref ref-type="bibr" rid="CR415">2012</xref>, <xref ref-type="bibr" rid="CR416">2020</xref>) or the referenced publications listed</p><p><sup>c</sup>The list is compiled from various published reviews, databases, and guidelines and drug labels of major drug agencies (EMA, FDA, MHLW/PMDA) as well as publicly available databases (Hoffmann et al. <xref ref-type="bibr" rid="CR181">2014</xref>; Preissner et al. <xref ref-type="bibr" rid="CR368">2010</xref>). Database address: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://bioinformatics.charite.de/transformer/">http://bioinformatics.charite.de/transformer/</ext-link></p></table-wrap-foot></table-wrap><table-wrap id="Tab4" position="float" orientation="portrait"><label>Table&#160;4</label><caption><p>Substrates and inhibitors of CYP1A2 enzyme</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5" rowspan="1">Reference substrates recommended by major regulatory agencies<sup>a</sup></th></tr><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Reaction/assay measurement</th><th align="left" colspan="1" rowspan="1">Km (&#956;M) in vitro (plasma conc)<sup>b</sup></th><th align="left" colspan="1" rowspan="1">Specificity near Km</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Phenacetin in vitro probe (withdrawn)</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">O</italic>-De-ethylation</td><td align="left" colspan="1" rowspan="1">10&#8211;50 (na)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786; Zhou et al. (<xref ref-type="bibr" rid="CR1004">2009</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Ethoxyresorufin in vitro probe (non-drug)</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">O</italic>-De-ethylation</td><td align="left" colspan="1" rowspan="1">0.11&#8211;0.23 (na)</td><td align="left" colspan="1" rowspan="1">Moderate (CYP1A1)</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Caffeine in vivo probe</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>-Demethylation elimination rate (in vivo)<sup>c</sup></td><td align="left" colspan="1" rowspan="1">200&#8211;500 (20&#8211;50)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786; Thorn et al. (<xref ref-type="bibr" rid="CR460">2012</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Theophylline in vivo probe</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>-Demethylation elimination rate (in vivo)</td><td align="left" colspan="1" rowspan="1">280&#8211;1230 (10&#8211;30)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786; Britz et al. (<xref ref-type="bibr" rid="CR50">2019</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Tizanidine in vivo probe</td><td align="left" colspan="1" rowspan="1">Elimination rate (in vivo)</td><td align="left" colspan="1" rowspan="1">nk (0.6)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786; (Granfors et al. (<xref ref-type="bibr" rid="CR158">2005</xref>), Karjalainen et al. (<xref ref-type="bibr" rid="CR223">2008</xref>)</td></tr><tr><td align="left" colspan="5" rowspan="1">Substrates potentially affected by strong CYP1A2 inhibitors<sup>c</sup> (Faber et al. <xref ref-type="bibr" rid="CR129">2005</xref>; Wang and Zhou <xref ref-type="bibr" rid="CR494">2009</xref>)</td></tr><tr><td align="left" colspan="5" rowspan="1">Sensitive/moderate: <bold>agomelatine</bold>, <bold>alosteron</bold>, clozapine, duloxetine, flutamide, frovatriptan, guanabenz, leflunomide, lidocaine, melatonin, mexiletine, mirtazapine, olanzapine, pirfenidone, propranolol, <bold>ramelteon</bold>, <bold>ramosetron</bold>, riluzole, <bold>ropinirole</bold>, ropivacaine, tacrine, <bold>tasimelteon</bold>, thalidomide, triamterene, zolmitriptan, zolpidem, and zileuton</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5" rowspan="1">Reference inhibitors recommended by major regulatory agencies<sup>a</sup></th></tr><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Mode of inhibition</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">K</italic><sub><italic toggle="yes">i</italic></sub>/IC50 (&#956;M) in vitro (plasma conc)<sup>b</sup></th><th align="left" colspan="1" rowspan="1">CYP selectivity (other CYPs inhibited)</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">&#945;-Naphthoflavone in vitro (non-drug)</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">0.01 (na)</td><td align="left" colspan="1" rowspan="1">Moderate (CYP1A1)</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Furafylline in vitro (withdrawn)</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">0.6&#8211;0.7 (nk)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Enoxacin in vivo</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">65&#8211;170 (3&#8211;12)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Fluvoxamine in vivo</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">0.12&#8211;0.24 (0.2&#8211;0.7)</td><td align="left" colspan="1" rowspan="1">Moderate (minor 2B6, 2C9, 2C19, 2D6)</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="5" rowspan="1">Inhibitors of potential clinical significance</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Amiodarone (metabolites)</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">0.46 (1.5&#8211;3)</td><td align="left" colspan="1" rowspan="1">Moderate (2D6, 3A4)</td><td align="left" colspan="1" rowspan="1">McDonald et al. (<xref ref-type="bibr" rid="CR295">2015</xref>), Ohyama et al. (<xref ref-type="bibr" rid="CR323">2000</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Ciprofloxacin</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">90&#8211;290 (7.5&#8211;12)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786; Granfors et al. (<xref ref-type="bibr" rid="CR157">2004</xref>), Raaska and Neuvonen (<xref ref-type="bibr" rid="CR376">2000</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Isoniazid</td><td align="left" colspan="1" rowspan="1">Competitive mechanism-based</td><td align="left" colspan="1" rowspan="1">56 (36&#8211;73)</td><td align="left" colspan="1" rowspan="1">Low (2C19, 3A4, 2A6)</td><td align="left" colspan="1" rowspan="1">Wen et al. (<xref ref-type="bibr" rid="CR506">2002</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Mexiletine</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">4.3&#8211;8.3 (3&#8211;11)</td><td align="left" colspan="1" rowspan="1">Moderate (1A1)</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Propafenone</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">21 (1&#8211;6)</td><td align="left" colspan="1" rowspan="1">Moderate (2D6, 3A4)</td><td align="left" colspan="1" rowspan="1">&#9786; Dean (<xref ref-type="bibr" rid="CR105">2012</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Thiabendazole</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">1.4 (na)</td><td align="left" colspan="1" rowspan="1">nk</td><td align="left" colspan="1" rowspan="1">Bapiro et al. (<xref ref-type="bibr" rid="CR28">2005</xref>), Coulet et al. (<xref ref-type="bibr" rid="CR93">1998</xref>), Thelingwani et al. (<xref ref-type="bibr" rid="CR459">2009</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<bold>Vemurafenib</bold></td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">~ 30 (100)</td><td align="left" colspan="1" rowspan="1">Moderate (2B6, 2C9, 3A4)</td><td align="left" colspan="1" rowspan="1">Zhang et al. (<xref ref-type="bibr" rid="CR541">2017a</xref>, <xref ref-type="bibr" rid="CR542">b</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Resveratrol (non-drug)</td><td align="left" colspan="1" rowspan="1">Competitive?</td><td align="left" colspan="1" rowspan="1">500 (na)</td><td align="left" colspan="1" rowspan="1">poor (1A1, 3A4)</td><td align="left" colspan="1" rowspan="1">Chang et al. (<xref ref-type="bibr" rid="CR67">2001</xref>), Chun et al. (<xref ref-type="bibr" rid="CR86">1999</xref>)</td></tr><tr><td align="left" colspan="5" rowspan="1">Moderate/weak inhibitors<sup>c</sup>: acyclovir, allopurinol, caffeine, cimetidine, daidzein, disulfiram, Echinacea, ethinylestradiol, famotidine, gestodene, norfloxacin, piperine, propafenone, propranolol, terbinafine, ticlopidine, verapamil, and zileuton</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">na</italic> not available, <italic toggle="yes">nk</italic> not known</p><p><sup>&#9786;</sup>For older references, see (Pelkonen et al. <xref ref-type="bibr" rid="CR352">2008</xref>). Newer inhibitors, since 2008, have been indicated in bold</p><p><sup>a</sup>Appropriate guidance documents of EMA (<xref ref-type="bibr" rid="CR1000">2012</xref>), FDA (<xref ref-type="bibr" rid="CR1001">2020</xref>), and MHLW/PMDA (<xref ref-type="bibr" rid="CR1003">2018</xref>) recommending the listed reference compounds for in vitro and in vivo studies. The use of two structurally unrelated CYP3A4/5 substrates for evaluation of in vitro CYP3A4/5 inhibition is recommended</p><p><sup>b</sup>Km or <italic toggle="yes">K</italic><sub><italic toggle="yes">i</italic></sub>/IC<sub>50</sub> values were taken mostly from in vitro human microsomal incubations. Therapeutic (&#8220;control&#8221;) plasma concentrations were mainly taken from two compilations (Schulz et al. <xref ref-type="bibr" rid="CR415">2012</xref>, <xref ref-type="bibr" rid="CR416">2020</xref>) or the referenced publications listed</p><p><sup>c</sup>The list is compiled from various published reviews, databases, and guidelines and drug labels of major drug agencies (EMA, FDA, and MHLW/PMDA) as well as publicly available databases (Hoffmann et al. <xref ref-type="bibr" rid="CR181">2014</xref>; Preissner et al. <xref ref-type="bibr" rid="CR368">2010</xref>). Database address: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://bioinformatics.charite.de/transformer/">http://bioinformatics.charite.de/transformer/</ext-link></p></table-wrap-foot></table-wrap><table-wrap id="Tab5" position="float" orientation="portrait"><label>Table&#160;5</label><caption><p>Substrates and inhibitors of CYP2B6 enzyme</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5" rowspan="1">Reference substrates recommended by major regulatory agencies<sup>a</sup></th></tr><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Reaction/assay measurement</th><th align="left" colspan="1" rowspan="1">Km (&#956;M) in vitro (plasma conc)<sup>b</sup></th><th align="left" colspan="1" rowspan="1">Specificity near Km</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Bupropion (in vitro, in vivo)</td><td align="left" colspan="1" rowspan="1">Hydroxylation</td><td align="left" colspan="1" rowspan="1">89&#8211;130 (15&#8211;40)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Efavirenz (in vitro, in vivo)</td><td align="left" colspan="1" rowspan="1">8-Hydroxylation</td><td align="left" colspan="1" rowspan="1">17&#8211;23 (3&#8211;10)</td><td align="left" colspan="1" rowspan="1">Moderate (CYP1A2, 3A4)</td><td align="left" colspan="1" rowspan="1">&#9786; Manosuthi et al. (<xref ref-type="bibr" rid="CR282">2013</xref>)</td></tr><tr><td align="left" colspan="5" rowspan="1">Substrates potentially affected by strong CYP2B6 inhibitors<sup>c</sup> (Hedrich et al. <xref ref-type="bibr" rid="CR174">2016</xref>)</td></tr><tr><td align="left" colspan="5" rowspan="1">Highly/moderately sensitive: artemether, artemisinin, cyclophosphamide, diazepam, Ifosfamide, ketamine, mephenytoin, mephobarbital, methadone, nicotine, pethidine (meperidine), propofol, piclamilast, selegiline, and temazepam</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5" rowspan="1">Reference inhibitors recommended by major regulatory agencies<sup>a</sup></th></tr><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Mode of inhibition</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">K</italic><sub><italic toggle="yes">i</italic></sub>/IC50 (&#956;M) in vitro (plasma conc)<sup>b</sup></th><th align="left" colspan="1" rowspan="1">CYP selectivity and other CYPs inhibited</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Ticlopidine (in vitro, in vivo)</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">0.2&#8211;0.8 (3&#8211;8)</td><td align="left" colspan="1" rowspan="1">Moderate (CYP1A2, 2C19, 2D6)</td><td align="left" colspan="1" rowspan="1">&#9786; Palacharla et al. (<xref ref-type="bibr" rid="CR340">2018</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">ThioTEPA (in vitro)</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">2.8&#8211;3.8 (3&#8211;20)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786; Bae et al. (<xref ref-type="bibr" rid="CR24">2013</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Sertraline (in vivo)</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">3.2 (0.1&#8211;0.5)</td><td align="left" colspan="1" rowspan="1">Moderate</td><td align="left" colspan="1" rowspan="1">Hesse et al. (<xref ref-type="bibr" rid="CR179">2000</xref>), Palacharla et al. (<xref ref-type="bibr" rid="CR340">2018</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Phencyclidine (in vivo)</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">2 (0.1&#8211;1)</td><td align="left" colspan="1" rowspan="1">Moderate</td><td align="left" colspan="1" rowspan="1">Jushchyshyn et al. (<xref ref-type="bibr" rid="CR216">2006</xref>), Walsky and Obach (<xref ref-type="bibr" rid="CR492">2007</xref>)</td></tr><tr><td align="left" colspan="5" rowspan="1">Inhibitors of potential clinical significance</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<bold>Canagliflozin</bold></td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">16 (0.6&#8211;3)</td><td align="left" colspan="1" rowspan="1">Poor (2E1, 3A4, 2C19, 2C9)</td><td align="left" colspan="1" rowspan="1">Yu et al. (<xref ref-type="bibr" rid="CR530">2014</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Clopidogrel (pro-drug)</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">1.1 (0.02)</td><td align="left" colspan="1" rowspan="1">Moderate (2C19, 2C9)</td><td align="left" colspan="1" rowspan="1">&#9786; Backman et al. (<xref ref-type="bibr" rid="CR23">2016</xref>), Wang et al. (<xref ref-type="bibr" rid="CR499">2015</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;17-&#945;-Ethynylestradiol</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">0.8 (0.3&#160;nM)</td><td align="left" colspan="1" rowspan="1">Moderate (1A2)</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<bold>Sonidegib</bold></td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">0.045 (0.3&#8211;1)</td><td align="left" colspan="1" rowspan="1">Moderate (CYP2C9)</td><td align="left" colspan="1" rowspan="1">Yu et al. (<xref ref-type="bibr" rid="CR533">2017a</xref>, <xref ref-type="bibr" rid="CR534">b</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<bold>Voriconazole</bold></td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">0.40 (5.7&#8211;11.5)</td><td align="left" colspan="1" rowspan="1">Poor (2C9, 2C19, 3A)</td><td align="left" colspan="1" rowspan="1">Jeong et al. (<xref ref-type="bibr" rid="CR208">2009a</xref>, <xref ref-type="bibr" rid="CR209">b</xref>)</td></tr><tr><td align="left" colspan="5" rowspan="1">Potential (moderate/weak) inhibitors<sup>c</sup></td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">na</italic> not available, <italic toggle="yes">nk</italic> not known</p><p><sup>&#9786;</sup>For older references, see (Pelkonen et al. <xref ref-type="bibr" rid="CR352">2008</xref>). Newer inhibitors, since 2008, have been indicated in bold</p><p><sup>a</sup>Appropriate guidance documents of EMA (<xref ref-type="bibr" rid="CR1000">2012</xref>), FDA (<xref ref-type="bibr" rid="CR1001">2020</xref>), and MHLW/PMDA (<xref ref-type="bibr" rid="CR1003">2018</xref>) recommending the listed reference compounds for in vitro and in vivo studies. The use of two structurally unrelated CYP3A4/5 substrates for evaluation of in vitro CYP3A4/5 inhibition is recommended</p><p><sup>b</sup>Km or <italic toggle="yes">K</italic><sub><italic toggle="yes">i</italic></sub>/IC<sub>50</sub> values were taken mostly from in vitro human microsomal incubations. Therapeutic (&#8220;control&#8221;) plasma concentrations were mainly taken from two compilations (Schulz et al. <xref ref-type="bibr" rid="CR415">2012</xref>, <xref ref-type="bibr" rid="CR416">2020</xref>) or the referenced publications listed</p><p><sup>c</sup>The list is compiled from various published reviews, databases, and guidelines and drug labels of major drug agencies (EMA, FDA, and MHLW/PMDA) as well as publicly available databases (Hoffmann et al. <xref ref-type="bibr" rid="CR181">2014</xref>; Preissner et al. <xref ref-type="bibr" rid="CR368">2010</xref>). Database address: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://bioinformatics.charite.de/transformer/">http://bioinformatics.charite.de/transformer/</ext-link></p></table-wrap-foot></table-wrap><table-wrap id="Tab6" position="float" orientation="portrait"><label>Table&#160;6</label><caption><p>Substrates and inhibitors of CYP2C8 enzyme</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5" rowspan="1">Reference substrates recommended by major regulatory agencies<sup>a</sup></th></tr><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Reaction/assay measurement</th><th align="left" colspan="1" rowspan="1">Km (&#956;M) in HLMs (plasma conc)<sup>b</sup></th><th align="left" colspan="1" rowspan="1">Specificity near Km</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Repaglinide (in vivo)</td><td align="left" colspan="1" rowspan="1">Oxidation</td><td align="left" colspan="1" rowspan="1">24 (0.1&#8211;0.45)</td><td align="left" colspan="1" rowspan="1">Moderate (CYP3A4)</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Paclitaxel (in vitro)</td><td align="left" colspan="1" rowspan="1">6&#945;-Hydroxylation</td><td align="left" colspan="1" rowspan="1">2.5&#8211;19 (0.3&#8211;0.8)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Amodiaquine (in vitro)</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>-De-ethylation</td><td align="left" colspan="1" rowspan="1">1.9&#8211;3.4 (0.15)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786; Bohnert et al. (<xref ref-type="bibr" rid="CR46">2016</xref>)</td></tr><tr><td align="left" colspan="5" rowspan="1">Substrates potentially affected by strong CYP2C8 inhibitors</td></tr><tr><td align="left" colspan="5" rowspan="1">Highly selective: pioglitazone, rosiglitazone, and tazarotenic acid</td></tr><tr><td align="left" colspan="5" rowspan="1">Moderately selective (other CYPs in parentheses): chloroquine (CYP3A4) and dasabuvir (3A4)</td></tr><tr><td align="left" colspan="5" rowspan="1">Poorly selective (other CYPs in parentheses): amiodarone (CYP1A2, 2C19, 3A4)</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5" rowspan="1">Reference inhibitors recommended by major regulatory agencies</th></tr><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Mode of inhibition</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">K</italic><sub><italic toggle="yes">i</italic></sub>/IC50 (&#956;M) in vitro (plasma conc)<sup>b</sup></th><th align="left" colspan="1" rowspan="1">CYP selectivity and other CYPs inhibited</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Montelukast in vivo</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">0.009&#8211;0.15 (0.05&#8211;0.5)</td><td align="left" colspan="1" rowspan="1">Moderate (CYP2C9, 3A4)</td><td align="left" colspan="1" rowspan="1">&#9786; Bohnert et al. (<xref ref-type="bibr" rid="CR46">2016</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Quercetin in vivo (non-drug)</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">1.1&#8211;1.6 (0.4)</td><td align="left" colspan="1" rowspan="1">Poor (CYP1A2, 2E1, 3A4)</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Phenelzine in vitro, in vivo</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">1.2 (0.1&#8211;1.5)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Kahma et al. (<xref ref-type="bibr" rid="CR218">2019</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Clopidogrel in vitro, in vivo</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">na (0.02)</td><td align="left" colspan="1" rowspan="1">Moderate (CYP2C19, 2C9)</td><td align="left" colspan="1" rowspan="1">&#9786; Backman et al. (<xref ref-type="bibr" rid="CR23">2016</xref>), Kahma et al. (<xref ref-type="bibr" rid="CR218">2019</xref>), Tornio et al. (<xref ref-type="bibr" rid="CR464">2014</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Gemfibrozil (glucuronide) in vitro, in vivo</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">52&#8211;75 (100)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786; Kahma et al. (<xref ref-type="bibr" rid="CR218">2019</xref>)</td></tr><tr><td align="left" colspan="5" rowspan="1">Inhibitors of potential clinical significance</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<bold>Dabrafenib</bold></td><td align="left" colspan="1" rowspan="1">Competitive</td><td char="." align="char" colspan="1" rowspan="1">8.2</td><td align="left" colspan="1" rowspan="1">Poor (2C9, 2C19, 3A4)</td><td align="left" colspan="1" rowspan="1">Lawrence et al. (<xref ref-type="bibr" rid="CR259">2014</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<bold>Deferasirox</bold></td><td align="left" colspan="1" rowspan="1">na</td><td align="left" colspan="1" rowspan="1">na (50)</td><td align="left" colspan="1" rowspan="1">Moderate (1A2. 3A4)</td><td align="left" colspan="1" rowspan="1">Pakkir Maideen et al. (<xref ref-type="bibr" rid="CR339">2018</xref>), Skerjanec et al. (<xref ref-type="bibr" rid="CR427">2010</xref>), Tanaka (<xref ref-type="bibr" rid="CR454">2014</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Trimethoprim</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">29&#8211;32 (4&#8211;9)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<bold>Teriflunomide</bold></td><td align="left" colspan="1" rowspan="1">na</td><td align="left" colspan="1" rowspan="1">na (100)</td><td align="left" colspan="1" rowspan="1">Moderate (1A2)</td><td align="left" colspan="1" rowspan="1">Cada et al. (<xref ref-type="bibr" rid="CR56">2013</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<bold>Vorapaxar</bold></td><td align="left" colspan="1" rowspan="1">Competitive?</td><td align="left" colspan="1" rowspan="1">0.86 (0.15)</td><td align="left" colspan="1" rowspan="1">Moderate (2C9)</td><td align="left" colspan="1" rowspan="1">Yu et al. (<xref ref-type="bibr" rid="CR531">2016a</xref>, <xref ref-type="bibr" rid="CR532">b</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<bold>Belinostat</bold></td><td align="left" colspan="1" rowspan="1">na</td><td align="left" colspan="1" rowspan="1">100 (80)</td><td align="left" colspan="1" rowspan="1">Moderate (2C9)</td><td align="left" colspan="1" rowspan="1">Monograph</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<bold>Idelalisib</bold></td><td align="left" colspan="1" rowspan="1">Competitive?</td><td align="left" colspan="1" rowspan="1">13 (4)</td><td align="left" colspan="1" rowspan="1">Moderate (3A4, 2C9)</td><td align="left" colspan="1" rowspan="1">Yu et al. (<xref ref-type="bibr" rid="CR531">2016a</xref>, <xref ref-type="bibr" rid="CR532">b</xref>)</td></tr><tr><td align="left" colspan="5" rowspan="1">Potential and/or putative inhibitors:<sup>c</sup> (Polasek et al. <xref ref-type="bibr" rid="CR1002">2004</xref>) amiodarone, verapamil, nortriptyline, fluoxetine, and isoniazid. <bold>tasimelteon</bold></td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">na</italic> not available, <italic toggle="yes">nk</italic> not known</p><p><sup>&#9786;</sup>For older references, see (Pelkonen et al. <xref ref-type="bibr" rid="CR352">2008</xref>). Newer inhibitors, since 2008, have been indicated in bold</p><p><sup>a</sup>Appropriate guidance documents of EMA (<xref ref-type="bibr" rid="CR1000">2012</xref>), FDA (<xref ref-type="bibr" rid="CR1001">2020</xref>), and MHLW/PMDA (<xref ref-type="bibr" rid="CR1003">2018</xref>) recommending the listed reference compounds for in vitro and in vivo studies. The use of two structurally unrelated CYP3A4/5 substrates for evaluation of in vitro CYP3A4/5 inhibition is recommended</p><p><sup>b</sup>Km or <italic toggle="yes">K</italic><sub><italic toggle="yes">i</italic></sub>/IC<sub>50</sub> values were taken mostly from in vitro human microsomal incubations. Therapeutic (&#8220;control&#8221;) plasma concentrations were mainly taken from two compilations (Schulz et al. <xref ref-type="bibr" rid="CR415">2012</xref>, Schulz et al. <xref ref-type="bibr" rid="CR416">2020</xref>) or the referenced publications listed</p><p><sup>c</sup>The list is compiled from various published reviews, databases, and guidelines and drug labels of major drug agencies (EMA, FDA, and MHLW/PMDA) as well as publicly available databases (Hoffmann et al. <xref ref-type="bibr" rid="CR181">2014</xref>; Preissner et al. <xref ref-type="bibr" rid="CR368">2010</xref>). Database address: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://bioinformatics.charite.de/transformer/">http://bioinformatics.charite.de/transformer/</ext-link></p></table-wrap-foot></table-wrap><table-wrap id="Tab7" position="float" orientation="portrait"><label>Table&#160;7</label><caption><p>Substrates and inhibitors of CYP2C9 enzyme</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5" rowspan="1">Reference substrates recommended by major regulatory agencies<sup>a</sup></th></tr><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Reaction</th><th align="left" colspan="1" rowspan="1">Km (&#956;M) in HLMs (plasma conc)<sup>b</sup></th><th align="left" colspan="1" rowspan="1">Specificity near Km</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">S-warfarin in vitro, in vivo</td><td align="left" colspan="1" rowspan="1">7-Hydroxylation</td><td align="left" colspan="1" rowspan="1">3&#8211;4 (3&#8211;23)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Diclofenac in vitro</td><td align="left" colspan="1" rowspan="1">4-Hydroxylation</td><td align="left" colspan="1" rowspan="1">2&#8211;22 (2&#8211;10)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Tolbutamide in vivo</td><td align="left" colspan="1" rowspan="1">Hydroxylation</td><td align="left" colspan="1" rowspan="1">60&#8211;580 (150&#8211;340)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="5" rowspan="1">Substrates potentially affected by strong CYP2C9 inhibitors:<sup>c</sup> (Daly et al. <xref ref-type="bibr" rid="CR100">2017</xref>; Van Booven et al. <xref ref-type="bibr" rid="CR477">2010</xref>) bosentan, celecoxib, cyclophosphamide, flurbiprofen, fluvastatin, glibenclamide, glimepiride, glipizide, ibuprofen, indomethacin, irbesartan, lornoxicam, losartan, mefenamic acid, meloxicam, naproxen, nateglinide, phenytoin, tamoxiphen, and tenoxicam</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5" rowspan="1">Reference inhibitors recommended by major regulatory agencies<sup>a</sup></th></tr><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Mode of inhibition</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">K</italic><sub><italic toggle="yes">i</italic></sub> (&#956;M) in HLMs (plasma conc)<sup>2</sup></th><th align="left" colspan="1" rowspan="1">CYP selectivity and other CYPs inhibited</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Sulphaphenazole in vitro</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">0.3 (300&#8211;500)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Tienilic acid in vitro (withdrawn)</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">5 (150)</td><td align="left" colspan="1" rowspan="1">na</td><td align="left" colspan="1" rowspan="1">Hutzler et al. (<xref ref-type="bibr" rid="CR197">2009</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Fluconazole in vivo</td><td align="left" colspan="1" rowspan="1">Mixed type</td><td align="left" colspan="1" rowspan="1">7&#8211;8 (6&#8211;30)</td><td align="left" colspan="1" rowspan="1">Poor (2C19, 3A4)</td><td align="left" colspan="1" rowspan="1">Back et al. (<xref ref-type="bibr" rid="CR21">1988</xref>), Kunze et al. (<xref ref-type="bibr" rid="CR248">1996</xref>)</td></tr><tr><td align="left" colspan="5" rowspan="1">Inhibitors of potential clinical significance</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Amiodarone</td><td align="left" colspan="1" rowspan="1">Non-competitive</td><td align="left" colspan="1" rowspan="1">95 (0.8&#8211;4)</td><td align="left" colspan="1" rowspan="1">Poor (2D6, 3A4)</td><td align="left" colspan="1" rowspan="1">Heimark et al. (<xref ref-type="bibr" rid="CR175">1992</xref>), Ohyama et al. (<xref ref-type="bibr" rid="CR323">2000</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<bold>Ceritinib</bold></td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">0.24 (0.9&#8211;2.7)</td><td align="left" colspan="1" rowspan="1">Moderate (3A4)</td><td align="left" colspan="1" rowspan="1">Zhao et al. (<xref ref-type="bibr" rid="CR545">2020</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<bold>Etravirine</bold></td><td align="left" colspan="1" rowspan="1">Competitive?</td><td align="left" colspan="1" rowspan="1">na (0.7&#8211;5)</td><td align="left" colspan="1" rowspan="1">Moderate (2C19)</td><td align="left" colspan="1" rowspan="1">Havens et al. (<xref ref-type="bibr" rid="CR173">2020</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<bold>Sonidegib</bold></td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">1.7 (0.3&#8211;1)</td><td align="left" colspan="1" rowspan="1">Moderate (3A4)</td><td align="left" colspan="1" rowspan="1">Yu et al. (<xref ref-type="bibr" rid="CR531">2016a</xref>, <xref ref-type="bibr" rid="CR532">b</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<bold>Stiripentol</bold></td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">na (4&#8211;40)</td><td align="left" colspan="1" rowspan="1">Poor (1A2, 2D6, 3A4)</td><td align="left" colspan="1" rowspan="1">Tran et al. (<xref ref-type="bibr" rid="CR467">1997</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<bold>Vemurafenib</bold></td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">5.9 (100)</td><td align="left" colspan="1" rowspan="1">Poor (1A2, 2B6, 3A4)</td><td align="left" colspan="1" rowspan="1">(RW.ERROR&#8212;unable to find reference:doc:5ef341eae4b0f33707a95cec)</td></tr><tr><td align="left" colspan="5" rowspan="1">Moderate/weak inhibitors<sup>c</sup>: capecitabine, cotrimoxazole, fluvastatin, fluvoxamine, metronidazole, miconazole, oxandrolone, sulfinpyrazone, voriconazole, and zafirlukast (Wu et al. <xref ref-type="bibr" rid="CR518">2013</xref>)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">na</italic> not available, <italic toggle="yes">nk</italic> not known</p><p><sup>&#9786;</sup>For older references, see (Pelkonen et al. <xref ref-type="bibr" rid="CR352">2008</xref>). Newer inhibitors, since 2008, have been indicated in bold</p><p><sup>a</sup>Appropriate guidance documents of EMA (<xref ref-type="bibr" rid="CR1000">2012</xref>), FDA (<xref ref-type="bibr" rid="CR1001">2020</xref>), and MHLW/PMDA (<xref ref-type="bibr" rid="CR1003">2018</xref>) recommending the listed reference compounds for in vitro and in vivo studies. The use of two structurally unrelated CYP3A4/5 substrates for evaluation of in vitro CYP3A4/5 inhibition is recommended</p><p><sup>b</sup>Km or <italic toggle="yes">K</italic><sub><italic toggle="yes">i</italic></sub>/IC<sub>50</sub> values were taken mostly from in vitro human microsomal incubations. Therapeutic (&#8220;control&#8221;) plasma concentrations, either range or maximal, were mainly taken from two compilations (Schulz et al. <xref ref-type="bibr" rid="CR415">2012</xref>, <xref ref-type="bibr" rid="CR416">2020</xref>) or the referenced publications listed</p><p><sup>c</sup>The list is compiled from various published reviews, databases, and guidelines and drug labels of major drug agencies (EMA, FDA, and MHLW/PDMA) as well as publicly available databases (Hoffmann et al. <xref ref-type="bibr" rid="CR181">2014</xref>; Preissner et al. <xref ref-type="bibr" rid="CR368">2010</xref>). Database address: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://bioinformatics.charite.de/transformer/">http://bioinformatics.charite.de/transformer/</ext-link></p></table-wrap-foot></table-wrap><table-wrap id="Tab8" position="float" orientation="portrait"><label>Table&#160;8</label><caption><p>Substrates and inhibitors of CYP2C19 enzyme</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5" rowspan="1">Reference substrates recommended by major regulatory agencies<sup>a</sup></th></tr><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Reaction</th><th align="left" colspan="1" rowspan="1">Km (&#956;M) in HLMs (plasma conc)<sup>c</sup></th><th align="left" colspan="1" rowspan="1">Specificity near Km</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">S</italic>-Mephenytoin (in vitro)</td><td align="left" colspan="1" rowspan="1">4&#8242;-Hydroxylation</td><td align="left" colspan="1" rowspan="1">23&#8211;169 (0.4&#8211;2)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Omeprazole (in vivo)</td><td align="left" colspan="1" rowspan="1">5-Hydroxylation elimination</td><td align="left" colspan="1" rowspan="1">6&#8211;10 (0.2&#8211;10)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Lanzoprazole (in vivo)</td><td align="left" colspan="1" rowspan="1">5-Hydroxylation elimination</td><td align="left" colspan="1" rowspan="1">15&#8211;17 (0.1&#8211;1)</td><td align="left" colspan="1" rowspan="1">Moderate (3A4)</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="5" rowspan="1">Substrates potentially affected by strong CYP2C19 inhibitors<sup>c</sup></td></tr><tr><td align="left" colspan="5" rowspan="1">Citalopram (2D6, 3A4), clobazam, clomipramine, diazepam (3A4), lansoprazole (3A4), pantoprazole (3A4), phenytoin, proguanil (3A4), propranolol, and rabeprazole (CYP3A4)</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5" rowspan="1">Reference inhibitors recommended by major regulatory agencies<sup>a</sup></th></tr><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Mode of inhibition</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">K</italic><sub><italic toggle="yes">i</italic></sub>/IC50 (&#956;M) in vitro (plasma conc)<sup>b</sup></th><th align="left" colspan="1" rowspan="1">CYP selectivity and other CYPs inhibited</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">-(&#8722;)-<italic toggle="yes">N</italic>-3-Benzyl-phenobarbital in vitro (non-drug)</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">0.079&#8211;0.12 (na)</td><td align="left" colspan="1" rowspan="1">&#8220;Not specific&#8221;</td><td align="left" colspan="1" rowspan="1">Cai et al. (<xref ref-type="bibr" rid="CR57">2004</xref>), Suzuki et al. (<xref ref-type="bibr" rid="CR446">2002</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">S</italic>-(+)-<italic toggle="yes">N</italic>-3-Benzyl-nirvanol in vitro (non-drug)</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">0.2 (na)</td><td align="left" colspan="1" rowspan="1">&#8220;Not specific&#8221;</td><td align="left" colspan="1" rowspan="1">Suzuki et al. (<xref ref-type="bibr" rid="CR446">2002</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Nootkatone in vitro (non-drug)</td><td align="left" colspan="1" rowspan="1">nk</td><td align="left" colspan="1" rowspan="1">0.5 (nk)</td><td align="left" colspan="1" rowspan="1">Poor (CYP2A6)</td><td align="left" colspan="1" rowspan="1">Tassaneeyakul et al. (<xref ref-type="bibr" rid="CR457">2000</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Loratadine</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">0.76 (0.05)</td><td align="left" colspan="1" rowspan="1">Poor (2D6, 3&#176;4, 2E1)</td><td align="left" colspan="1" rowspan="1">Barecki et al. (<xref ref-type="bibr" rid="CR30">2001</xref>), Ramanathan et al. (2018)</td></tr><tr><td align="left" colspan="1" rowspan="1">Ticlopidine</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">1.2 (3&#8211;8)</td><td align="left" colspan="1" rowspan="1">Poor (CYP2B6, 1&#176;2, 2D6)</td><td align="left" colspan="1" rowspan="1">Ha-Duong et al. (<xref ref-type="bibr" rid="CR167">2001</xref>), Ko et al. (<xref ref-type="bibr" rid="CR240">2000</xref>), Turpeinen et al. (<xref ref-type="bibr" rid="CR474">2006</xref>)</td></tr><tr><td align="left" colspan="5" rowspan="1">Inhibitors of potential clinical significance</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Omeprazole</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">2&#8211;3 (0.2&#8211;10)</td><td align="left" colspan="1" rowspan="1">Moderate (2C9, 3A4)</td><td align="left" colspan="1" rowspan="1">Chiba et al. (<xref ref-type="bibr" rid="CR80">1993</xref>), Funck-Brentano et al. (<xref ref-type="bibr" rid="CR143">1997</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Fluvoxamine</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">0.29 (0.13&#8211;0.53)</td><td align="left" colspan="1" rowspan="1">Moderate (1A2)</td><td align="left" colspan="1" rowspan="1">Iga (<xref ref-type="bibr" rid="CR199">2016</xref>), Kong et al. (<xref ref-type="bibr" rid="CR244">2014</xref>), Yasui-Furukori et al. (<xref ref-type="bibr" rid="CR524">2004</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<bold>Modafinil</bold></td><td align="left" colspan="1" rowspan="1">competitive</td><td align="left" colspan="1" rowspan="1">39 (6&#8211;15)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">Robertson et al. (<xref ref-type="bibr" rid="CR389">2000</xref>), Rowland et al. (<xref ref-type="bibr" rid="CR399">2018</xref>)</td></tr><tr><td align="left" colspan="5" rowspan="1"><p>Moderate/weak inhibitors<sup>c</sup>: Wu et al. (<xref ref-type="bibr" rid="CR518">2013</xref>)</p><p>Carbamazepine, cimetidine, esomeprazole, etravirine, felbamate, fluconazole, fluoxetine, ketoconazole, moclobemide, and voriconazole</p></td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">na</italic> not available, <italic toggle="yes">nk</italic> not known</p><p><sup>&#9786;</sup>For older references, see (Pelkonen et al. <xref ref-type="bibr" rid="CR352">2008</xref>). Newer inhibitors, since 2008, have been indicated in bold</p><p><sup>a</sup>Appropriate guidance documents of EMA (<xref ref-type="bibr" rid="CR1000">2012</xref>), FDA (<xref ref-type="bibr" rid="CR1001">2020</xref>), and MHLW/PMDA (<xref ref-type="bibr" rid="CR1003">2018</xref>) recommending the listed reference compounds for in vitro and in vivo studies. The use of two structurally unrelated CYP3A4/5 substrates for evaluation of in vitro CYP3A4/5 inhibition is recommended</p><p><sup>b</sup>Km or <italic toggle="yes">K</italic><sub><italic toggle="yes">i</italic></sub>/IC<sub>50</sub> values were taken mostly from in vitro human microsomal incubations. Therapeutic (&#8220;control&#8221;) plasma concentrations, either range or maximal, were mainly taken from two compilations (Schulz et al. <xref ref-type="bibr" rid="CR415">2012</xref>, <xref ref-type="bibr" rid="CR416">2020</xref>) or the referenced publications listed</p><p><sup>c</sup>The list is compiled from various published reviews, databases, and guidelines and drug labels of major drug agencies (EMA, FDA, MHLW/PDMA) as well as publicly available databases(Hoffmann et al. <xref ref-type="bibr" rid="CR181">2014</xref>; Preissner et al. <xref ref-type="bibr" rid="CR368">2010</xref>). Database address: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://bioinformatics.charite.de/transformer/">http://bioinformatics.charite.de/transformer/</ext-link></p></table-wrap-foot></table-wrap><table-wrap id="Tab9" position="float" orientation="portrait"><label>Table&#160;9</label><caption><p>Substrates and inhibitors of CYP2D6 enzyme</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5" rowspan="1">Reference substrates recommended by major regulatory agencies<sup>a</sup></th></tr><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Reaction</th><th align="left" colspan="1" rowspan="1">Km (&#956;M) in vitro (plasma conc)<sup>b</sup></th><th align="left" colspan="1" rowspan="1">Specificity near Km</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Bufuralol (withdrawn) in vitro</td><td align="left" colspan="1" rowspan="1">1&#8242;-Hydroxylation</td><td align="left" colspan="1" rowspan="1">3&#8211;30 (2)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Dextromethorphan in vitro, in vivo</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">O</italic>-Demethylation</td><td align="left" colspan="1" rowspan="1">2.8&#8211;22 (0.5)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Metoprolol in vivo</td><td align="left" colspan="1" rowspan="1">Elimination</td><td align="left" colspan="1" rowspan="1">7.4 (1.85)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">Dean (2011), Berger et al. (2018)</td></tr><tr><td align="left" colspan="1" rowspan="1">Desipramine in vivo</td><td align="left" colspan="1" rowspan="1">2-Hydroxylation</td><td align="left" colspan="1" rowspan="1">10&#8211;15 (2.0)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Nebivolol in vivo</td><td align="left" colspan="1" rowspan="1">Elimination</td><td align="left" colspan="1" rowspan="1">1.8 (0.05)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">Hu et al. (<xref ref-type="bibr" rid="CR190">2016</xref>), Lefebvre et al. (<xref ref-type="bibr" rid="CR262">2007</xref>)</td></tr><tr><td align="left" colspan="5" rowspan="1">Substrates potentially affected by strong CYP2D6 inhibitors<sup>c</sup></td></tr><tr><td align="left" colspan="5" rowspan="1">Highly sensitive: atomoxetine, codeine, nortriptyline, perphenazine, tolterodine, and R-venlafaxine</td></tr><tr><td align="left" colspan="5" rowspan="1">Moderately sensitive (other CYPs in parentheses): <bold>eliglustat</bold> (CYP3A4), encainide, imipramine, propafenone (CYP3A4), propranolol, thioridazine (CYP2C19, CYP3A4), tramadol (CYP3A4), trimipramine, and S-venlafaxine</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5" rowspan="1">Reference inhibitors recommended by major regulatory agencies<sup>a</sup></th></tr><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Mode of inhibition</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">K</italic><sub><italic toggle="yes">i</italic></sub> (&#956;M) in vitro (HLMs) (plasma conc)<sup>b</sup></th><th align="left" colspan="1" rowspan="1">CYP selectivity and other CYPs inhibited</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Quinidine in vitro, in vivo</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">0.018&#8211;0.06 (6&#8211;15)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Paroxetine in vitro, in vivo</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">0.15 (0.01&#8211;0.2)</td><td align="left" colspan="1" rowspan="1">Moderate (2C9, 2C19)</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Fluoxetine in vivo</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">0.6 (0.5&#8211;1.6)</td><td align="left" colspan="1" rowspan="1">Moderate (2C9, 2C19)</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Mirabegron</bold> in vivo</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">4.3 (0.01&#8211;0.2)</td><td align="left" colspan="1" rowspan="1">Moderate (CYP3A4)</td><td align="left" colspan="1" rowspan="1">Krauwinkel et al. (<xref ref-type="bibr" rid="CR246">2014</xref>), Takusagawa et al. (<xref ref-type="bibr" rid="CR452">2012</xref>)</td></tr><tr><td align="left" colspan="5" rowspan="1">Inhibitors of potential clinical significance</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Bupropion</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">21 (15&#8211;40)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">Reese et al. (<xref ref-type="bibr" rid="CR386">2008</xref>), Sager et al. (<xref ref-type="bibr" rid="CR403">2017</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Sertraline</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">0.7 (0.02&#8211;0.5)</td><td align="left" colspan="1" rowspan="1">Moderate (2C9, 2C19)</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Terbinafine</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">0.028&#8211;0.044 (0.03&#8211;0.1)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<bold>Stiripentol</bold></td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">(4&#8211;40)</td><td align="left" colspan="1" rowspan="1">Poor</td><td align="left" colspan="1" rowspan="1">Tran et al. (<xref ref-type="bibr" rid="CR467">1997</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<bold>Rolapitant</bold></td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">&gt;7 (1)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">Wang et al. (<xref ref-type="bibr" rid="CR500">2017</xref>), Wang et al. (<xref ref-type="bibr" rid="CR501">2018</xref>)</td></tr><tr><td align="left" colspan="5" rowspan="1">Potential inhibitors (mostly weak and/or putative)<sup>c</sup>: aprepitant, alogliptin, cobicistat, crizotinib, eliglustat, and panobinostat</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">na</italic> not available, <italic toggle="yes">nk</italic> not known</p><p><sup>&#9786;</sup>For older references, see (Pelkonen et al. <xref ref-type="bibr" rid="CR352">2008</xref>). Newer inhibitors, since 2008, have been indicated in bold</p><p><sup>a</sup>Appropriate guidance documents of EMA/EU (<xref ref-type="bibr" rid="CR1000">2012</xref>), FDA/USA (<xref ref-type="bibr" rid="CR1001">2020</xref>), and MHLW/PMDA (<xref ref-type="bibr" rid="CR1003">2018</xref>) recommending the listed reference compounds for in vitro and in vivo studies. The use of two structurally unrelated CYP3A4/5 substrates for evaluation of in vitro CYP3A4/5 inhibition is recommended</p><p><sup>b</sup>Km or <italic toggle="yes">K</italic><sub><italic toggle="yes">i</italic></sub>/IC<sub>50</sub> values were taken mostly from in vitro human microsomal incubations. Therapeutic (&#8220;control&#8221;) plasma concentrations, either range or maximal, were mainly taken from two compilations (Schulz et al. <xref ref-type="bibr" rid="CR415">2012</xref>, <xref ref-type="bibr" rid="CR416">2020</xref>) or the referenced publications listed</p><p><sup>c</sup>The list is compiled from various published reviews, databases, and guidelines and drug labels of major drug agencies (EMA, FDA, MHLW/PDMA) as well as publicly available databases (Hoffmann et al. <xref ref-type="bibr" rid="CR181">2014</xref>; Preissner et al. <xref ref-type="bibr" rid="CR368">2010</xref>). Database address: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://bioinformatics.charite.de/transformer/">http://bioinformatics.charite.de/transformer/</ext-link></p></table-wrap-foot></table-wrap><table-wrap id="Tab10" position="float" orientation="portrait"><label>Table&#160;10</label><caption><p>Substrates and inhibitors of CYP2A6 enzyme</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5" rowspan="1">Reference substrates (no recommendations by major regulatory agencies)</th></tr><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Reaction/assay measurement</th><th align="left" colspan="1" rowspan="1">Km (&#956;M) in in vitro HLMs (plasma conc)<sup>a</sup></th><th align="left" colspan="1" rowspan="1">Specificity near Km</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Nicotine in vitro (in vivo)<sup>c</sup></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>-1&#8242;-Oxidation (elimination)</td><td align="left" colspan="1" rowspan="1">65&#8211;95 (0.03&#8211;0.2)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Coumarin in vitro (in vivo)<sup>c</sup></td><td align="left" colspan="1" rowspan="1">7-Hydroxylation</td><td align="left" colspan="1" rowspan="1">0.2&#8211;2.4 (max. 5)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="5" rowspan="1"><p>Substrates potentially affected by strong CYP2A6 inhibitors<sup>b</sup> (see (Tanner and Tyndale <xref ref-type="bibr" rid="CR456">2017</xref>)</p><p>artemisinin, artesunate, caffeine, cotinine, letrozole, efavirenz, pilocarpine, tegafur, tyrosol, and valproic acid</p></td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5" rowspan="1">Reference inhibitors (no recommendations by major regulatory agencies)</th></tr><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Mode of inhibition</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">K</italic><sub><italic toggle="yes">i</italic></sub> (&#956;M) in HLMs (plasma conc)<sup>a</sup></th><th align="left" colspan="1" rowspan="1">CYP selectivity and other CYPs inhibited</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Tranylcypromine</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">0.08&#8211;0.2 (0.4)</td><td align="left" colspan="1" rowspan="1">Moderate (2E1)</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Methoxsalen</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">0.2&#8211;0.8 (0.12&#8211;1)</td><td align="left" colspan="1" rowspan="1">Moderate (1A2)</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="5" rowspan="1">Inhibitors</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<bold>Letrozole</bold></td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">4.6 (0.5)</td><td align="left" colspan="1" rowspan="1">Moderate (2C19)</td><td align="left" colspan="1" rowspan="1">Jeong et al. (<xref ref-type="bibr" rid="CR208">2009a</xref>, <xref ref-type="bibr" rid="CR209">b</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Pilocarpine</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">1 (0.05)</td><td align="left" colspan="1" rowspan="1">High?</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<italic toggle="yes">Trans</italic>-cinnamic aldehyde (non-drug)</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">6.1 (nk)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">Chan et al. (<xref ref-type="bibr" rid="CR66">2016</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Tryptamine (non-drug)</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">0.2 (nk)</td><td align="left" colspan="1" rowspan="1">Poor (CYP1A2)</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">na</italic> not available, <italic toggle="yes">nk</italic> not known</p><p><sup>&#9786;</sup>For older references, see (Pelkonen et al. <xref ref-type="bibr" rid="CR352">2008</xref>). Newer inhibitors, since 2008, have been indicated in bold</p><p><sup>a</sup>Km or <italic toggle="yes">K</italic><sub><italic toggle="yes">i</italic></sub>/IC<sub>50</sub> values were taken mostly from in vitro human microsomal incubations. Therapeutic (&#8220;control&#8221;) plasma concentrations, either range or maximal, were mainly taken from two compilations (Schulz et al. <xref ref-type="bibr" rid="CR415">2012</xref>, <xref ref-type="bibr" rid="CR416">2020</xref>) or the referenced publications listed</p><p><sup>b</sup>The list is compiled from various published reviews, databases, and guidelines and drug labels of major drug agencies (EMA, FDA, and MHLW/PMDA) as well as publicly available databases (Hoffmann et al. <xref ref-type="bibr" rid="CR181">2014</xref>; Preissner et al. <xref ref-type="bibr" rid="CR368">2010</xref>). Database address: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://bioinformatics.charite.de/transformer/">http://bioinformatics.charite.de/transformer/</ext-link></p><p><sup>c</sup>Nicotine and coumarin are used in various commodities, and could be used as probes also in vivo in small doses</p></table-wrap-foot></table-wrap><table-wrap id="Tab11" position="float" orientation="portrait"><label>Table&#160;11</label><caption><p>Substrates and inhibitors of CYP2E1 enzyme</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5" rowspan="1">Reference substrates (no recommendations by major regulatory agencies)</th></tr><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Reaction</th><th align="left" colspan="1" rowspan="1">Km (&#956;M) in vitro (HLMs) (plasma conc)<sup>a</sup></th><th align="left" colspan="1" rowspan="1">Specificity near Km</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Chlorzoxazone<sup>a,b</sup></td><td align="left" colspan="1" rowspan="1">6-Hydroxylation</td><td align="left" colspan="1" rowspan="1">39&#8211;157 (170)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786; Ernstg&#229;rd et al. (<xref ref-type="bibr" rid="CR127">2004</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-Nitrophenol (non-drug)</td><td align="left" colspan="1" rowspan="1">3-Hydroxylation (nk)</td><td align="left" colspan="1" rowspan="1">24&#8211;30</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786; Collom et al. (<xref ref-type="bibr" rid="CR90">2008</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Aniline (non-drug)</td><td align="left" colspan="1" rowspan="1">4-Hydroxylation</td><td align="left" colspan="1" rowspan="1">6&#8211;24</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Lauric acid (non-drug)</td><td align="left" colspan="1" rowspan="1">11-Hydroxylation</td><td char="." align="char" colspan="1" rowspan="1">130</td><td align="left" colspan="1" rowspan="1">Moderate (CYP4A)</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="5" rowspan="1">Substrates potentially affected by strong CYP2E1 inhibitors<sup>b</sup> acetaminophen (paracetamol), theophylline, enflurane, and halothane</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5" rowspan="1">Reference inhibitors (no recommendations by major regulatory agencies)</th></tr><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Mode of inhibition</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">K</italic><sub><italic toggle="yes">i</italic></sub>/IC50 (&#956;M) in vitro (plasma conc)<sup>b</sup></th><th align="left" colspan="1" rowspan="1">CYP selectivity and other CYPs inhibited</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">4-Methylpyrazole</td><td align="left" colspan="1" rowspan="1">Competitive</td><td align="left" colspan="1" rowspan="1">2.0 (17&#8211;250)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">Collom et al. (<xref ref-type="bibr" rid="CR90">2008</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Diethyldithiocarbamate (DDC, non-drug)</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">5.3&#8211;34 (na)</td><td align="left" colspan="1" rowspan="1">Poor (1A2, 2A6, 2B6, 2C8, 3A4)</td><td align="left" colspan="1" rowspan="1">&#9786; Pratt-Hyatt et al. (<xref ref-type="bibr" rid="CR367">2010</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Pyridine (non-drug)</td><td align="left" colspan="1" rowspan="1">Not known</td><td align="left" colspan="1" rowspan="1">0.4, 11.8 (na)</td><td align="left" colspan="1" rowspan="1">High</td><td align="left" colspan="1" rowspan="1">&#9786; Jones et al. (<xref ref-type="bibr" rid="CR215">2011</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Disulfiram (in vivo)</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">Via DDC</td><td align="left" colspan="1" rowspan="1">Moderate (CYP2A6)</td><td align="left" colspan="1" rowspan="1">&#9786;</td></tr><tr><td align="left" colspan="1" rowspan="1">Clomethiazole</td><td align="left" colspan="1" rowspan="1">Mechanism-based</td><td align="left" colspan="1" rowspan="1">1.0 (10)</td><td align="left" colspan="1" rowspan="1">Moderate (2A6)</td><td align="left" colspan="1" rowspan="1">&#9786; Stresser et al. (<xref ref-type="bibr" rid="CR441">2016</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Diallyl sulfide (non-drug)</td><td align="left" colspan="1" rowspan="1">COMPETITIVE?</td><td align="left" colspan="1" rowspan="1">6.3&#8211;17.3 (na)</td><td align="left" colspan="1" rowspan="1">High?</td><td align="left" colspan="1" rowspan="1">&#9786; Rao et al. (<xref ref-type="bibr" rid="CR379">2015</xref>)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">na</italic> not available, <italic toggle="yes">nk</italic> not known</p><p><sup>&#9786;</sup>For older references, see (Pelkonen et al. <xref ref-type="bibr" rid="CR352">2008</xref>)</p><p><sup>a</sup> Km or <italic toggle="yes">K</italic><sub><italic toggle="yes">i</italic></sub>/IC<sub>50</sub> values were taken mostly from in vitro human microsomal incubations. Therapeutic (&#8220;control&#8221;) plasma concentrations, either range or maximal, were mainly taken from two compilations (Schulz et al. <xref ref-type="bibr" rid="CR415">2012</xref>, <xref ref-type="bibr" rid="CR416">2020</xref>) or the referenced publications listed</p><p><sup>b</sup>The list is compiled from various published reviews, databases, and guidelines and drug labels of major drug agencies (EMA, FDA, MHLW/PMDA) as well as publicly available databases (Hoffmann et al. <xref ref-type="bibr" rid="CR181">2014</xref>; Preissner et al. <xref ref-type="bibr" rid="CR368">2010</xref>). Database address: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://bioinformatics.charite.de/transformer/">http://bioinformatics.charite.de/transformer/</ext-link></p></table-wrap-foot></table-wrap></p></sec><sec id="Sec15"><title>Reference substrates and inhibitors</title><p id="Par30">Reference substrates and inhibitors recommended by major regulatory agencies, FDA, EMA, and MHLW/PMDA, have been collected in the upper part of Tables&#160;<xref rid="Tab3" ref-type="table">3</xref>, <xref rid="Tab4" ref-type="table">4</xref>, <xref rid="Tab5" ref-type="table">5</xref>, <xref rid="Tab6" ref-type="table">6</xref>, <xref rid="Tab7" ref-type="table">7</xref>, <xref rid="Tab8" ref-type="table">8</xref>, <xref rid="Tab9" ref-type="table">9</xref>, <xref rid="Tab10" ref-type="table">10</xref> and <xref rid="Tab11" ref-type="table">11</xref>. The basic requirement is that the compound is metabolized totally or preferably by a single CYP enzyme, and this has been demonstrated in vitro and in vivo. In in vitro assay, the formation of the CYP-associated metabolite is followed, but in in vivo studies, often, the elimination of the parent is measured due to, e.g., further metabolism of a CYP-associated metabolite. Naturally, in the human in vivo studies, approved drugs have to be used, but the lists contain also a few substances which are either withdrawn drugs or experimental substances (e.g., azamulin). These are used only in in vitro tests to investigate basic in vitro interactions in connection with early drug development or in mechanistic studies later on.</p></sec><sec id="Sec16"><title>Sensitive substrates</title><p id="Par31">In addition to reference substrates and inhibitors, appropriate lists of substrates and inhibitors of definitive clinical potential are compiled. Of potential substrates, only the so-called &#8220;strongly and/or moderately sensitive&#8221; substrates have been listed as extractions from reviews of individual CYP enzymes. Usually, sensitive substrates are metabolized almost completely or to a significant extent (&gt;&#8201;25%) by the CYP enzyme concerned, so that the inhibition by a specific inhibitor will lead to a significant increase in the exposure to a substrate. However, there are a number of substrates which are actually metabolically activated by an enzyme and, consequently, the inhibition of metabolism leads to a pharmacodynamically reverse outcome and this is an important point to remember when assessing potential consequences of an interaction. However, perhaps, a more common situation is where pharmacologically active metabolites contribute to the action of the parent drug and the final outcome of the interaction may be more difficult to define.</p></sec><sec id="Sec17"><title>Clinically significant inhibitors</title><p id="Par32">Among inhibitors, the listed substances contain mostly &#8220;strong&#8221; or at least &#8220;moderate&#8221; inhibitors for a given CYP enzyme. This implies a relatively strong affinity to an enzyme at concentrations achieved in clinical situations. For this reason, an inhibition constant or a corresponding measure (IC50, <italic toggle="yes">K</italic><sub><italic toggle="yes">i</italic></sub>) and actual therapeutic concentration (if known) have been given in tables. Furthermore, mechanism of inhibition, most commonly competitive or mechanism-based inhibition, is of importance for the extent and length of inhibition.</p><p id="Par33">The extent of inhibition is also heavily dependent on characteristics of a victim drug, its affinity to an enzyme, and a fraction of a victim metabolized by an enzyme. However, clinical situations could be much more complex. Consequently, quantitative measures of inhibitory potency are only guiding by nature, but may still suggest at least a significant possibility of inhibitory interaction in clinical drug use.</p><p id="Par34">It should be kept in mind that the inhibition mechanisms may be very complex and may need extensive in-depth experiments to uncover the details of inhibition and the consequent in vitro and in vivo outcomes (Asaumi et al. <xref ref-type="bibr" rid="CR17">2018</xref>; Korzekwa et al. <xref ref-type="bibr" rid="CR245">2014</xref>; Lutz and Isoherranen <xref ref-type="bibr" rid="CR277">2012</xref>; Roberts et al. <xref ref-type="bibr" rid="CR388">2008</xref>; Varma et al. <xref ref-type="bibr" rid="CR484">2015</xref>). We have used a dichotomous expression of competitive vs mechanism-based inhibition, although the outcome of inhibition may be modified by more complex mechanisms.</p><p id="Par35">It should also be stressed that the concentration of a drug interacting with the enzyme may be different from the plasma concentration, which is usually readily available from clinical trials and later monitoring activities. It has been suggested that the use of unbound cytosolic concentrations&#8212;as a proxy for total/unbound plasma concentrations&#8212;would improve the prediction of in vivo DDIs (Filppula et al. <xref ref-type="bibr" rid="CR138">2019</xref>). For practical reasons, we have listed the total plasma concentrations, not unbound concentrations, because there exists some uncertainty about which one is in better correlation with the drug concentration at the enzyme site. Also, it is not known whether there is a direct relation between unbound concentrations in plasma and cell cytosol. It has to be recognized that drugs bind to intracellular structures, mainly proteins and lipids, and the ensuing unbound concentration could be different from the unbound plasma concentration. A reliable method to measure the drug concentration at the effector site of an enzyme is needed.</p><p id="Par36">Because the available literature on CYP inhibition is enormous, we have made use of our previous review (Pelkonen et al. <xref ref-type="bibr" rid="CR352">2008</xref>) as a collective reference to the older literature (Tables&#160;<xref rid="Tab3" ref-type="table">3</xref>, <xref rid="Tab4" ref-type="table">4</xref>, <xref rid="Tab5" ref-type="table">5</xref>, <xref rid="Tab6" ref-type="table">6</xref>, <xref rid="Tab7" ref-type="table">7</xref>, <xref rid="Tab8" ref-type="table">8</xref>, <xref rid="Tab9" ref-type="table">9</xref>, <xref rid="Tab10" ref-type="table">10</xref>, <xref rid="Tab11" ref-type="table">11</xref>). In addition, we have referred to more recent papers if they have added significant new information. For many newer substances, publicly available regulatory dossiers have been a primary source of information, although they do not necessarily provide strictly quantitative information about DDIs.</p></sec><sec id="Sec18"><title>Substrates and inhibitors of individual CYPs</title><sec id="Sec19"><title>CYP3A4/CYP3A5</title><p id="Par37">Table&#160;<xref rid="Tab3" ref-type="table">3</xref> presents a collection of compounds participating as substrates and/or inhibitors in clinically relevant CYP3A4-associated DDIs, which is by far the most important area of CYP-based interactions. The table lists also&#8201;&gt;&#8201;10 inhibitors (in bold), which have come to the market since our previous review in 2008 (Pelkonen et al. <xref ref-type="bibr" rid="CR352">2008</xref>).</p><p id="Par38">On the basis of analyses of Yu et al. (<xref ref-type="bibr" rid="CR530">2014</xref>, <xref ref-type="bibr" rid="CR531">2016a</xref>, <xref ref-type="bibr" rid="CR532">b</xref>, <xref ref-type="bibr" rid="CR533">2017a</xref>, <xref ref-type="bibr" rid="CR534">b</xref>, <xref ref-type="bibr" rid="CR535">2018</xref>, <xref ref-type="bibr" rid="CR536">2019</xref>) on FDA-approved drugs (close to 150 between 2013 and 2017), roughly 65% were substrates, 30% inhibitors and about 5% inducers of CYP3A. This is not to say that a similar portion should cause DDI consequences of clinical significance, because the establishment of clinical significance would require at least some in vivo trials and/or observations. Currently, the use of reference perpetrators (e.g., ketoconazole and rifampicin) or substrates (e.g., midazolam) is practically mandatory to aid the assessment of clinical significance.</p><p id="Par39">Usually, it is not possible to indicate what would be a contribution of CYP3A5 for the DDI effect. However, if need be there are in vitro tools to study the CYP3A5 contribution into the metabolism or the effect of a studied drug (Guo et al. <xref ref-type="bibr" rid="CR162">2020</xref>; Lolodi et al. <xref ref-type="bibr" rid="CR271">2017</xref>). The most comprehensive literature on the role of CYP3A5 is available for tacrolimus, see (Birdwell et al. <xref ref-type="bibr" rid="CR39">2015</xref>; Chen and Prasad <xref ref-type="bibr" rid="CR70">2018</xref>).</p></sec><sec id="Sec20"><title>CYP1A2</title><p id="Par40">The list of substrates potentially affected by CYP1A2 inhibitors (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>) contains at least 13 &#8220;new&#8221; drugs [compared with the previous review in 2008 (Pelkonen et al. <xref ref-type="bibr" rid="CR352">2008</xref>)], whereas only one inhibitor of potential clinical significance, vemurafenib (see also Table&#160;<xref rid="Tab1" ref-type="table">1</xref>), has appeared since 2008. Resveratrol has been added to the table as an example of an ingredient in a large number of consumable products, including red wine. However, it seems to be a moderate CYP1A2 inhibitor at the best.</p></sec><sec id="Sec21"><title>CYP2B6</title><p id="Par41">There are only three &#8220;new&#8221; drugs added into the list of inhibitors, canagliflozin, sonidegib, and voriconazole, and the first two are probably only moderate-to-weak inhibitors. The list of substrates potentially affected by strong CYP2B6 inhibitors contains almost exclusively &#8220;old&#8221; drugs.</p></sec><sec id="Sec22"><title>CYP2C8</title><p id="Par42">In addition of recommended substrates and inhibitors, Table&#160;<xref rid="Tab6" ref-type="table">6</xref> lists 6 &#8216;new&#8217; inhibitors of CYP2C8. However, in the immediate analysis, some recently registered drugs, which were shown to be CYP2C8 inhibitors in in vitro studies, were difficult to classify. For example, according to the regulatory dossier studies, tasimelteon was shown to be a weak in vitro inhibitor of CYP2C8 (IC<sub>50</sub>&#8201;&gt;&#8201;100&#160;&#181;M), whereas vorapaxar was a relatively potent in vitro inhibitor (IC<sub>50</sub> 0.86&#160;&#181;M), but still both did not affect CYP2C8-associated rosiglitazone elimination in vivo [drug monographs, (Yu et al. <xref ref-type="bibr" rid="CR531">2016a</xref>, <xref ref-type="bibr" rid="CR532">b</xref>)]. Consequently, tasimelteon is mentioned only in the group of putative inhibitors, waiting for additional in vivo investigations to classify more convincingly, whereas vorapaxar is listed in the category of inhibitors of potential clinical significance due to its low IC<sub>50</sub> value as compared with the in vivo plasma concentration.</p></sec><sec id="Sec23"><title>CYP2C9</title><p id="Par43">The list of victim drugs of CYP2C9 (Table&#160;<xref rid="Tab7" ref-type="table">7</xref>) is relatively long, altogether 20 substances. It reflects the importance of CYP2C9 in metabolizing clinically widely used drugs, practically all of which are &#8220;old&#8221; drugs and many of them used for 20&#8211;30&#160;years. There are five &#8220;new&#8221; drugs as CYP2C9 inhibitors of potential clinical significance, three of them kinase inhibitors (ceritinib, sonidegib, and vemurafenib). The only &#8220;old&#8221; inhibitor is the widely used antiarrhythmic amiodarone, which is used in research projects as an example of a drug with a very long half-life, complex kinetics and multiple potential interactions (McDonald et al. <xref ref-type="bibr" rid="CR295">2015</xref>).</p></sec><sec id="Sec24"><title>CYP2C19</title><p id="Par44">Since the previous review (Pelkonen et al. <xref ref-type="bibr" rid="CR352">2008</xref>), only one &#8220;new&#8221; drug (modafinil) has been added in the list of inhibitors of potential clinical significance. Reference inhibitors recommended by major regulatory agencies are not specific for CYP2C19-mediated metabolism; however, they can be used together with other information such as data obtained from experiments done with recombinant enzyme systems.</p></sec><sec id="Sec25"><title>CYP2D6</title><p id="Par45">The classic polymorphic CYP enzyme was discovered decades ago, mainly based on debrisoquine hydroxylation studies. Debrisoquine, a classic probe drug [see (Pelkonen et al. <xref ref-type="bibr" rid="CR352">2008</xref>)], was withdrawn from clinical use a long time ago, and consequently from the lists of reference probe drugs. The current list of recommended reference inhibitors includes the only &#8220;new&#8221; drug, mirabegron (Table&#160;<xref rid="Tab9" ref-type="table">9</xref>). In fact, there are not many &#8220;new&#8221; drugs listed in Table&#160;<xref rid="Tab9" ref-type="table">9</xref>. One of the reasons may be the well-known problems related to CYP2D6 pharmacogenetics and drug&#8211;drug interactions, and likelihood of &#8220;killing&#8221; of molecules displaying CYP2D6 metabolism and/or inhibitory potency early in the drug development process.</p></sec><sec id="Sec26"><title>CYP2A6</title><p id="Par46">Since our review in 2008 (Pelkonen et al. <xref ref-type="bibr" rid="CR352">2008</xref>), only one drug (letrozole) has been added to the list of substrates or inhibitors (Table&#160;<xref rid="Tab10" ref-type="table">10</xref>). Letrozole was added to the list of CYP2A6 inhibitors on the basis of an in vitro study (Jeong et al. <xref ref-type="bibr" rid="CR209">2009b</xref>); no clinical studies have been undertaken. Only 5 out of 102 FDA-approved drugs between 2013 and 2016 were at least partial substrates and/or inhibitors of CYP2A6 principally on the basis of in vitro experiments and none of them were considered as &#8216;clinically significant&#8217; even potentially (Yu et al. <xref ref-type="bibr" rid="CR535">2018</xref>). Our own view over the years since 2007 (see the accompanying article, Pelkonen et al., this volume) is similar: although CYP2A6 was occasionally mentioned in drug labels as a target of in vitro inhibition (no quantitative information provided), no in vitro observations were translated into potentially clinical significance.</p><p id="Par47"><italic toggle="yes">CYP2E1</italic> is another enzyme that has been only rarely observed to associate with clinically significant interactions (Table&#160;<xref rid="Tab11" ref-type="table">11</xref>). According to our own experiences (Pelkonen et al., this volume) and those of Yu et al. (<xref ref-type="bibr" rid="CR530">2014</xref>, <xref ref-type="bibr" rid="CR531">2016a</xref>, <xref ref-type="bibr" rid="CR532">b</xref>, <xref ref-type="bibr" rid="CR533">2017a</xref>, <xref ref-type="bibr" rid="CR534">b</xref>, <xref ref-type="bibr" rid="CR535">2018</xref>, <xref ref-type="bibr" rid="CR536">2019</xref>), CYP2E1 has been mentioned only rarely in drug monographs and there have been no &#8216;clinically significant&#8217; interactions since 2008. This is also reflected in a lack of officially recommended reference compounds to study metabolism or inhibition associated with CYP2E1. However, it is known that CYP2E1 is of importance in the metabolism of several small-molecular xenobiotics and its role in biochemical consequences of heavy alcohol consumption should be duly noted.</p></sec></sec></sec><sec id="Sec27"><title>Mechanisms of CYP induction</title><sec id="Sec28"><title>Xenobiotic-sensing receptors as mediators of CYP induction</title><p id="Par48">The induction of drug metabolism has been known since 1950s and it was early on understood to have important consequences for the action of drugs. However, the mechanistic basis behind induction remained enigmatic for decades. Discovery of the xenobiotic-sensing receptors, aryl hydrocarbon receptor (AHR) at 1970s and pregnane X receptor (PXR) and constitutive androstane receptor (CAR) at 1990s, as the molecular mediators of the CYP induction was a major step forward in understanding the mechanisms of induction (Baes et al. <xref ref-type="bibr" rid="CR25">1994</xref>; Honkakoski et al. <xref ref-type="bibr" rid="CR184">1998</xref>; Kliewer et al. <xref ref-type="bibr" rid="CR238">1998</xref>; Poland et al. <xref ref-type="bibr" rid="CR365">1976</xref>).</p><p id="Par49">The xenobiotic-sensing receptors are ligand-activated transcription factors belonging structurally either to the nuclear receptors or the basic-helix&#8211;loop&#8211;helix Per-Arnt-Sim (bHLH-PAS) proteins. Today, activation of these receptors and subsequent CYP induction can be studied with a number of in silico, in vitro, and cell-based methods enabling relatively good prediction of in vivo induction (Bernasconi et al. <xref ref-type="bibr" rid="CR36">2019</xref>; Kato <xref ref-type="bibr" rid="CR226">2020</xref>; Pelkonen et al. <xref ref-type="bibr" rid="CR352">2008</xref>). However, not all the compounds found to be activators in cell or other in vitro assays are actual in vivo activators because of pharmacokinetic or other factors. It has also become clear that AHR, PXR, and CAR not only control the elimination of xenobiotics, but regulate also many other endogenous functions and signaling pathways and their activation may be involved in many chronic diseases such as metabolic diseases and cancer (Hakkola et al. <xref ref-type="bibr" rid="CR168">2018</xref>).</p></sec><sec id="Sec29"><title>PXR and CAR, the xenobiotic-sensing nuclear receptors</title><p id="Par50">PXR, systematic name NR1I2, and CAR, systematic name NR1I3, belong to the same subfamily of nuclear receptors. Their tissue expression profile is quite limited, and both are predominantly expressed in the liver, PXR also in the intestine (Wang et al. <xref ref-type="bibr" rid="CR498">2012</xref>). Low levels can be found in some other tissues. PXR and CAR ligand-binding sites have evolved to accommodate various foreign chemicals, and therefore, they play a major role in sensing of the chemical environment. The basis for their ligand promiscuity is large and flexible ligand-binding pockets that can accommodate a wide range of ligands with diverse structural and physicochemical properties (Buchman et al. <xref ref-type="bibr" rid="CR51">2018</xref>).</p><p id="Par51">Especially, the PXR ligand-binding pocket is very large (1200&#8211;1600&#160;&#197;<sup>3</sup>) and adaptable allowing a great number of compounds with different structures to bind and activate PXR, thus making PXR an ideal sensor for chemical environment (Buchman et al. <xref ref-type="bibr" rid="CR51">2018</xref>). The CAR ligand-binding pocket is smaller (~&#8201;600&#160;&#197;<sup>3</sup>) and less flexible than that of PXR and, therefore, apparently can accommodate a smaller number of chemicals (Buchman et al. <xref ref-type="bibr" rid="CR51">2018</xref>). However, also CAR can be activated with many different compounds. From the point of view of clinically important drug&#8211;drug interactions, PXR activation probably represents the most important induction mechanism. However, PXR and CAR also share many important pharmaceuticals as ligands.</p><p id="Par52">While the DNA-binding domains of PXR and CAR are quite conserved across species, the ligand-binding domains differ significantly. Consequently, there are important species differences in the ligand preferences of these xenobiotic-sensing receptors hindering translation of in vivo results from the experimental animals to the humans (Blumberg et al. <xref ref-type="bibr" rid="CR42">1998</xref>; Lehmann et al. <xref ref-type="bibr" rid="CR263">1998</xref>). A classic example is rifampicin that induces efficiently the human PXR but poorly the mouse counterpart. Vice versa, PCN (pregnenolone-16&#945;-carbonitrile) prefers the mouse PXR over the human PXR. Similarly, TCPOBOP (1,4-bis-[2-(3,5-dichloropyridyloxy)]benzene, 3,3&#8242;,5,5&#8242;-tetrachloro-1,4-bis(pyridyloxy)benzene) activates the mouse CAR, but not the human CAR, while CITCO (6-(4-Chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-<italic toggle="yes">O</italic>-(3,4-dichlorobenzyl)oxime) is an agonist for the human CAR with little affinity to the mouse CAR (Chai et al. <xref ref-type="bibr" rid="CR64">2016</xref>). To overcome the problem of species differences in ligand preference, PXR and CAR-humanized mouse models have been developed (Scheer et al. <xref ref-type="bibr" rid="CR411">2008</xref>).</p><p id="Par53">Aptly named as constitutive androstane receptor (or less frequently constitutively active receptor), CAR displays ligand-independent, constitutive transcriptional activity (Chai et al. <xref ref-type="bibr" rid="CR64">2016</xref>; Kobayashi et al. <xref ref-type="bibr" rid="CR241">2015</xref>). This has been especially evident in experiments utilizing exogenous expression of CAR in hepatic cell lines. In primary hepatocytes or in the liver in vivo, the constitutive activity may be limited by mainly cytoplasmic localization of the unliganded receptor as part of a multiprotein complex. Upon ligand binding, CAR dissociates from the chaperone proteins allowing translocation to nucleus. In addition to classical ligand binding, CAR may be activated indirectly. Phenobarbital is the prime example of an indirect CAR activator (Kobayashi et al. <xref ref-type="bibr" rid="CR241">2015</xref>). The mechanism of CAR activation by phenobarbital is complex and involves repression of epidermal growth factor (EGF) receptor (EGFR) signaling through the competitive inhibition of EGF&#8211;EGFR interaction. Subsequently, phosphorylation of receptor for activated C kinase 1 (RACK1) is reduced allowing RACK1 to interact with CAR and protein phosphatase 2A. This ternary interaction then enables CAR dephosphorylation and, consequently, translocation to nucleus (Kobayashi et al. <xref ref-type="bibr" rid="CR241">2015</xref>).</p><p id="Par54">In response to ligand binding, both PXR and CAR transfer from the cytosol to the nucleus and form heterodimers with another nuclear receptor, retinoid X receptor (RXR). The heterodimer is then able to bind to the DNA elements including both direct and everted repeats of the sequence AGGTCA and its variants. The agonist-bound nuclear receptor activates transcription through coactivator recruitment modifying chromatin structure and engaging transcription initiation complex. In addition to this classical nuclear receptor function, PXR and CAR form also protein&#8211;protein interactions broadening the cellular functions under the control of these nuclear receptors (Oladimeji et al. <xref ref-type="bibr" rid="CR325">2016</xref>; Pavek <xref ref-type="bibr" rid="CR351">2016</xref>). This mode of action may be especially important for the gene repression by the receptors. Furthermore, the PXR and CAR function may be fine-tuned by phosphorylation status and other posttranslational modifications (Cui et al. <xref ref-type="bibr" rid="CR97">2016</xref>; Smutny et al. <xref ref-type="bibr" rid="CR434">2013</xref>; Staudinger et al. <xref ref-type="bibr" rid="CR439">2011</xref>).</p><p id="Par55">PXR targets several CYP enzymes with major importance in drug metabolism including the most predominant drug-metabolizing CYP enzyme CYP3A4. Along with the CYP3A subfamily, PXR regulates many other important drug-metabolism CYPs. Chromatin immunoprecipitation sequencing (ChIP-Seq) analysis of PXR binding in HepG2 cells in response to rifampicin treatment detected rifampicin-induced regions close to <italic toggle="yes">CYP2A6</italic>, <italic toggle="yes">CYP2B6</italic>, <italic toggle="yes">CYP2C8</italic>, <italic toggle="yes">CYP2C9</italic>, <italic toggle="yes">CYP2C19</italic>, <italic toggle="yes">CYP3A4,</italic> and <italic toggle="yes">CYP3A7</italic> genes (Smith et al. <xref ref-type="bibr" rid="CR433">2014</xref>). In addition, several CYP genes with less-defined roles in drug metabolism and many phase 2 enzymes were found to interact with PXR (Smith et al. <xref ref-type="bibr" rid="CR433">2014</xref>).</p><p id="Par56">CYP2B6 has been much studied as a classical CAR target gene, but the CAR target gene profile appears to be fairly overlapping with PXR (Kobayashi et al. <xref ref-type="bibr" rid="CR241">2015</xref>). No ChIP-Seq analysis revealing the CAR binding to human CYP genes has been published so far, although the human CAR interactome has been studied in a mouse model (Niu et al. <xref ref-type="bibr" rid="CR319">2018</xref>). Interestingly, this investigation showed that CAR targets several genes coding for other transcription factors including PXR and AHR introducing additional level of complexity to the induction mechanisms (Niu et al. <xref ref-type="bibr" rid="CR319">2018</xref>).</p><p id="Par57">RXR functions as a binding partner for PXR and CAR as well as several other type 2 nuclear receptors. Although RXR is often regarded as a passive partner, RXR may also bind ligands such as 9-<italic toggle="yes">cis</italic> retinoic acid (de Almeida and Conda-Sheridan <xref ref-type="bibr" rid="CR102">2019</xref>) and it has been reported that RXR ligands may modulate function of the dimers formed by RXR and the xenobiotic-sensing receptors (Chen et al. <xref ref-type="bibr" rid="CR73">2010</xref>). It has also been reported that retinoids could induce CYP3A4 through RXR/VDR heterodimers and RXR homodimers (Wang et al. <xref ref-type="bibr" rid="CR497">2008</xref>).</p></sec><sec id="Sec30"><title>AHR</title><p id="Par58">Aryl hydrocarbon receptor (AHR) belongs to the bHLH-PAS family of transcription factors (Nebert <xref ref-type="bibr" rid="CR313">2017</xref>). AHR is activated especially by toxins and environmental contaminants including the classical activator 2,3,7,8-tetrachlorodibenzo-<italic toggle="yes">p</italic>-dioxin (TCDD) and it has great toxicological significance (Kawajiri and Fujii-Kuriyama <xref ref-type="bibr" rid="CR227">2017</xref>). However, also some pharmaceutical ligands such as omeprazole activate AHR (Quattrochi and Tukey <xref ref-type="bibr" rid="CR375">1993</xref>). Many endogenous ligands have been identified for AHR including some originating from the microbiota (Bock <xref ref-type="bibr" rid="CR43">2019</xref>; Kawajiri and Fujii-Kuriyama <xref ref-type="bibr" rid="CR227">2017</xref>).</p><p id="Par59">AHR is ubiquitously expressed in most tissues with high expression in placenta, lung, heart, pancreas, and liver (Dolwick et al. <xref ref-type="bibr" rid="CR114">1993</xref>). In absence of a ligand, AHR is sequestered to the cytosol in a complex with several proteins. Ligand binding-induced conformational change releases AHR from the chaperone proteins and allows translocation to the nucleus, where it heterodimerizes with another bHLH-PAS protein, aryl hydrocarbon receptor nuclear translocator (ARNT) (Kawajiri and Fujii-Kuriyama <xref ref-type="bibr" rid="CR227">2017</xref>; Nebert <xref ref-type="bibr" rid="CR313">2017</xref>). AHR/ARNT-dimer is then able to bind the so-called xenobiotic-response-elements (XRE) in the vicinity of the target genes to promote transcription. One of the target genes is aryl hydrocarbon receptor repressor (AHRR), which acts as a negative feedback mechanism (Bock <xref ref-type="bibr" rid="CR43">2019</xref>).</p><p id="Par60">Among the CYPs, AHR mainly regulates the members of the CYP1 family, of which only CYP1A2 plays an important role in hepatic drug metabolism. In several extrahepatic tissues, AHR efficiently induces CYP1A1 and CYP1B1 (Bock <xref ref-type="bibr" rid="CR43">2019</xref>). In the other CYP families, AHR has been found to regulate some members in the CYP2 family including CYP2S1 (Saarikoski et al. <xref ref-type="bibr" rid="CR401">2005</xref>). In mouse, also Cyp2a5 is regulated by AHR, but no similar evidence exist for the human ortholog CYP2A6 (Arpiainen et al. <xref ref-type="bibr" rid="CR16">2005</xref>). AHR also regulates several phase 2 drug-metabolizing enzymes. In addition to drug metabolism, AHR plays important role in multiple physiological functions such as immunity, cell growth and differentiation, and prolonged activation may cause toxicity (Hakkola et al. <xref ref-type="bibr" rid="CR168">2018</xref>; Kawajiri and Fujii-Kuriyama <xref ref-type="bibr" rid="CR227">2017</xref>; Nebert <xref ref-type="bibr" rid="CR313">2017</xref>; Rothhammer and Quintana <xref ref-type="bibr" rid="CR398">2019</xref>).</p></sec><sec id="Sec31"><title>Other transcriptional mechanisms mediating CYP induction</title><p id="Par61">In addition to the xenobiotic-sensing receptors, some other transcription factors have been shown to mediate induction of CYP enzymes in response to chemical exposure. Some classical steroid receptors have been shown to regulate CYP genes. In contrast to the xenobiotic-sensing nuclear receptors, these nuclear receptors are more restricted in ligand preference and act as homodimer. Accordingly, estradiol induces CYP2A6 directly through estrogen receptor &#945; (ER&#945;) binding to the 5&#8242;-flanking region of the gene (Higashi et al. <xref ref-type="bibr" rid="CR180">2007</xref>).</p><p id="Par62">Glucocorticoids regulate CYP expression; however, the mechanisms are diverse. Some glucocorticoids such as dexamethasone are PXR ligands explaining the observed CYP induction. However, others like methylprednisolone activate poorly the human PXR (Shukla et al. <xref ref-type="bibr" rid="CR423">2011</xref>). In fact, glucocorticoid receptor (GR) activation induces expression of PXR and CAR that may explain in many cases the CYP induction by glucocorticoids (Pascussi et al. <xref ref-type="bibr" rid="CR349">2001</xref>, <xref ref-type="bibr" rid="CR350">2003</xref>). However, also direct GR-mediated regulation of the CYP2C and CYP3A genes has been reported (Chen et al. <xref ref-type="bibr" rid="CR71">2003</xref>; Ferguson et al. <xref ref-type="bibr" rid="CR136">2005</xref>; Gerbal-Chaloin et al. <xref ref-type="bibr" rid="CR149">2002</xref>; Hukkanen et al. <xref ref-type="bibr" rid="CR193">2003</xref>; Matsunaga et al. <xref ref-type="bibr" rid="CR288">2004</xref>). For the CYP3A genes, this has been shown in the lung and fetal liver, i.e., in the absence of PXR and CAR expression (Hukkanen et al. <xref ref-type="bibr" rid="CR193">2003</xref>; Matsunaga et al. <xref ref-type="bibr" rid="CR288">2004</xref>).</p><p id="Par63">Nuclear factor-erythroid 2-related factor 2 (NRF2) (the official name: Nuclear factor-erythroid-derived 2-like 2, NFE2L2) is a transcription factor belonging to the cap-n-collar subfamily of basic region&#8211;leucine zipper-type transcription factors (Suzuki and Yamamoto <xref ref-type="bibr" rid="CR445">2015</xref>). NRF2 expression is controlled at the level of protein stability and under unstressed conditions NRF2 is targeted to proteasomal degradation by its interaction partner Kelch-like ECH-associated protein 1 (KEAP1). KEAP1 functions as a redox sensor and contains several highly reactive cysteines that, upon modification by electrophilic molecules, prevent it from targeting NRF2 for proteasomal degradation. Therefore, in response to oxidative stress, NFR2 is stabilized, accumulates to the nucleus, and forms heterodimers with small musculoaponeurotic fibrosarcoma oncogene homologue (sMAF) proteins. The NRF2/sMAF-dimer binds to the antioxidant response element (ARE) in the regulatory regions of the target genes (Cuadrado et al. <xref ref-type="bibr" rid="CR96">2019</xref>).</p><p id="Par64">NRF2 pathway is activated in response to oxidative stress produced by many toxic compounds such as heavy metals like cadmium and lead (Abu-Bakar et al. <xref ref-type="bibr" rid="CR8">2013</xref>). NRF2 regulates multiple cell functions, among them antioxidative response and xenobiotic biotransformation (Cuadrado et al. <xref ref-type="bibr" rid="CR96">2019</xref>). However, within the xenobiotic metabolism machinery, NRF2 mainly targets phase 2 enzymes, and among the CYP enzymes, only a limited number of CYP2 genes are regulated by NRF2 (K. C. Wu et al. <xref ref-type="bibr" rid="CR517">2012</xref>). The best-characterized CYP target is the mouse gene Cyp2a5 (Abu-Bakar et al. <xref ref-type="bibr" rid="CR7">2007</xref>; L&#228;ms&#228; et al. <xref ref-type="bibr" rid="CR256">2010</xref>). Also the closely related human gene CYP2A6 is regulated by NRF2 (Abu-Bakar et al. <xref ref-type="bibr" rid="CR8">2013</xref>; Yokota et al. <xref ref-type="bibr" rid="CR527">2011</xref>). Interestingly, the AHR and NRF2 pathways crosstalk at multiple levels (K&#246;hle and Bock <xref ref-type="bibr" rid="CR242">2007</xref>).</p></sec><sec id="Sec32"><title>Post-transcriptional regulation</title><p id="Par65">Some CYPs are regulated at the post-transcriptional level. The most important example is CYP2E1. CYP2E1 protein has a short half-life and protein stabilization represents a major level of CYP2E1 regulation. The labile CYP2E1 protein is stabilized by xenobiotics such as ethanol, acetone, pyrazole, and isoniazid (Carroccio et al. <xref ref-type="bibr" rid="CR60">1994</xref>; Song et al. <xref ref-type="bibr" rid="CR436">1989</xref>). A few CYPs have been shown to be regulated by xenobiotics at the level of mRNA stability. mRNA stabilization has been shown convincingly for the mouse form Cyp2a5, which, in response to pyrazole treatment, is regulated by heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) binding to the 3&#8242;-untranslated region of the Cyp2a5 mRNA (Abu-Bakar et al. <xref ref-type="bibr" rid="CR8">2013</xref>). The human CYP2A6 appears to be regulated by a similar mechanism (Christian et al. <xref ref-type="bibr" rid="CR84">2004</xref>). During the recent years, many CYPs have been shown to be targeted by microRNAs that may also potentially mediate the post-transcriptional effects of chemical exposure (Yu et al. <xref ref-type="bibr" rid="CR531">2016a</xref>, <xref ref-type="bibr" rid="CR532">b</xref>).</p></sec></sec><sec id="Sec33"><title>The in vivo induction of human CYP enzymes with drugs, herbal medicines, and environmental chemicals</title><p id="Par66">In the following section, we will present the current status on the knowledge of the human in vivo induction. The following tables present the medications (Table&#160;<xref rid="Tab12" ref-type="table">12</xref>), environmental contaminants (Table&#160;<xref rid="Tab13" ref-type="table">13</xref>), and the herbal remedies and nutritional exposures (Table&#160;<xref rid="Tab14" ref-type="table">14</xref>) known to induce human CYP enzymes. Only human in vivo inducers are listed based on the following criteria: the compound induces a specific CYP enzyme as assessed by (1) the pharmacokinetics of an established CYP-specific probe, (2) the established CYP-specific metabolic pathway of an endogenous metabolite (such as 6&#946;-hydroxycortisol and 4&#946;-hydroxycholesterol for CYP3A4), or (3) tissue-level expression of a CYP enzyme mRNA or protein. Also, supporting in vitro mechanistic evidence was required for compounds with only one published report of in vivo induction. However, the mechanistic evidence was not required if the inducer was a structural analog of a well-established inducer (this pertains especially to various barbiturates). Supporting evidence was not required if at least two studies report the induction. For medications, only those in current clinical use are listed. For withdrawn pharmaceuticals, reader is advised to consult previously published reviews (Hukkanen <xref ref-type="bibr" rid="CR191">2012</xref>; Zanger and Schwab <xref ref-type="bibr" rid="CR540">2013</xref>). Only CYP enzymes in families 1&#8211;3 are covered here.<table-wrap id="Tab12" position="float" orientation="portrait"><label>Table&#160;12</label><caption><p>Medications as in vivo inducers of human cytochrome P450 enzymes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Enzyme</th><th align="left" colspan="1" rowspan="1">Class of inducers</th><th align="left" colspan="1" rowspan="1">Inducing medication</th><th align="left" colspan="1" rowspan="1">Receptor(s) implicated</th><th align="left" colspan="1" rowspan="1">Tissues</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">CYP1A1</td><td align="left" colspan="1" rowspan="1">Proton pump inhibitors</td><td align="left" colspan="1" rowspan="1">Omeprazole</td><td align="left" colspan="1" rowspan="1">AHR</td><td align="left" colspan="1" rowspan="1">Duodenum</td><td align="left" colspan="1" rowspan="1">Buchthal et al. (<xref ref-type="bibr" rid="CR52">1995</xref>), McDonnell et al. (<xref ref-type="bibr" rid="CR296">1992</xref>)</td></tr><tr><td align="left" rowspan="10" colspan="1">CYP1A2</td><td align="left" colspan="1" rowspan="1">Antibiotics</td><td align="left" colspan="1" rowspan="1">Rifampicin</td><td align="left" colspan="1" rowspan="1">PXR indirectly?</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Backman et al. (<xref ref-type="bibr" rid="CR22">2006</xref>), Robson et al. (<xref ref-type="bibr" rid="CR393">1984</xref>), Wietholtz et al. (<xref ref-type="bibr" rid="CR509">1995</xref>)</td></tr><tr><td align="left" rowspan="2" colspan="1">Antiepileptics</td><td align="left" colspan="1" rowspan="1">Carbamazepine</td><td align="left" colspan="1" rowspan="1">CAR/PXR indirectly?</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping and expression)</td><td align="left" colspan="1" rowspan="1">Lucas et al. (<xref ref-type="bibr" rid="CR274">1998</xref>), Oscarson et al. (<xref ref-type="bibr" rid="CR330">2006</xref>), Parker et al. (<xref ref-type="bibr" rid="CR346">1998</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Phenytoin</td><td align="left" colspan="1" rowspan="1">CAR/PXR indirectly?</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Miller et al. (<xref ref-type="bibr" rid="CR306">1984</xref>), Wietholtz et al. (<xref ref-type="bibr" rid="CR508">1989</xref>)</td></tr><tr><td align="left" rowspan="2" colspan="1">Antiretrovirals</td><td align="left" colspan="1" rowspan="1">Nelfinavir</td><td align="left" colspan="1" rowspan="1">PXR indirectly?</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Kirby et al. (2011)</td></tr><tr><td align="left" colspan="1" rowspan="1">Ritonavir</td><td align="left" colspan="1" rowspan="1">PXR indirectly?</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Hsu et al. (<xref ref-type="bibr" rid="CR188">1998</xref>), Kirby et al. (2011), Penzak et al. (<xref ref-type="bibr" rid="CR354">2002</xref>)</td></tr><tr><td align="left" rowspan="3" colspan="1">Barbiturates</td><td align="left" colspan="1" rowspan="1">Pentobarbital</td><td align="left" colspan="1" rowspan="1">CAR and PXR indirectly?</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Dahlqvist et al. (<xref ref-type="bibr" rid="CR98">1989</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Phenobarbital</td><td align="left" colspan="1" rowspan="1">CAR and PXR indirectly?</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Landay et al. (<xref ref-type="bibr" rid="CR257">1978</xref>), Saccar et al. (<xref ref-type="bibr" rid="CR402">1985</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Secobarbital</td><td align="left" colspan="1" rowspan="1">CAR and PXR indirectly?</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Paladino et al. (<xref ref-type="bibr" rid="CR341">1983</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Immunosuppressants</td><td align="left" colspan="1" rowspan="1">Teriflunomide</td><td align="left" colspan="1" rowspan="1">CAR?</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Aubagio summary of product characteristics<sup>a</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Proton pump inhibitors</td><td align="left" colspan="1" rowspan="1">Omeprazole</td><td align="left" colspan="1" rowspan="1">AHR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping and expression)</td><td align="left" colspan="1" rowspan="1">Diaz et al. (<xref ref-type="bibr" rid="CR108">1990</xref>), Rost et al. (<xref ref-type="bibr" rid="CR397">1994</xref>), Rost and Roots (<xref ref-type="bibr" rid="CR396">1994</xref>)</td></tr><tr><td align="left" rowspan="5" colspan="1">CYP2A6</td><td align="left" colspan="1" rowspan="1">Antiepileptics</td><td align="left" colspan="1" rowspan="1">Carbamazepine</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping and expression)</td><td align="left" colspan="1" rowspan="1">Oscarson et al. (<xref ref-type="bibr" rid="CR330">2006</xref>), Williams et al. (<xref ref-type="bibr" rid="CR513">2010</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Antimalarials</td><td align="left" colspan="1" rowspan="1">Artemisinin</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Asimus et al. (<xref ref-type="bibr" rid="CR19">2008</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Antiretrovirals</td><td align="left" colspan="1" rowspan="1">Efavirenz</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Metzger et al. (<xref ref-type="bibr" rid="CR301">2019</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Barbiturates</td><td align="left" colspan="1" rowspan="1">Phenobarbital</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (expression)</td><td align="left" colspan="1" rowspan="1">Cashman et al. (<xref ref-type="bibr" rid="CR61">1992</xref>), Kyerematen et al. (<xref ref-type="bibr" rid="CR251">1990</xref>), Yamano et al. (<xref ref-type="bibr" rid="CR522">1990</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Estrogens</td><td align="left" colspan="1" rowspan="1">Ethinyl estradiol (of oral contraceptives)</td><td align="left" colspan="1" rowspan="1">ER</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Benowitz et al. (<xref ref-type="bibr" rid="CR33">2006</xref>), Berlin et al. (<xref ref-type="bibr" rid="CR34">2007</xref>), Sinues et al. (<xref ref-type="bibr" rid="CR426">2008</xref>)</td></tr><tr><td align="left" rowspan="13" colspan="1">CYP2B6</td><td align="left" colspan="1" rowspan="1">Antibiotics</td><td align="left" colspan="1" rowspan="1">Rifampicin</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Chung et al. (<xref ref-type="bibr" rid="CR88">2011</xref>), Loboz et al. (<xref ref-type="bibr" rid="CR270">2006</xref>), Lopez-Cortes et al. (<xref ref-type="bibr" rid="CR272">2002</xref>)</td></tr><tr><td align="left" rowspan="2" colspan="1">Antiepileptics</td><td align="left" colspan="1" rowspan="1">Carbamazepine</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping and expression)</td><td align="left" colspan="1" rowspan="1">Ji et al. (<xref ref-type="bibr" rid="CR210">2008</xref>), Ketter et al. (<xref ref-type="bibr" rid="CR230">1995</xref>, Oscarson et al. (<xref ref-type="bibr" rid="CR330">2006</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Phenytoin</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Slattery et al. (<xref ref-type="bibr" rid="CR428">1996</xref>), Williams et al. (<xref ref-type="bibr" rid="CR512">1999</xref>)</td></tr><tr><td align="left" rowspan="5" colspan="1">Antimalarials</td><td align="left" colspan="1" rowspan="1">Arteether</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Elsherbiny et al. (<xref ref-type="bibr" rid="CR125">2008</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Artemether</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Elsherbiny et al. (<xref ref-type="bibr" rid="CR125">2008</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Artemisinin</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Elsherbiny et al. (<xref ref-type="bibr" rid="CR125">2008</xref>), Simonsson et al. (<xref ref-type="bibr" rid="CR424">2003</xref>), Zang et al. (<xref ref-type="bibr" rid="CR539">2014</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Artesunate</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Elsherbiny et al. (<xref ref-type="bibr" rid="CR125">2008</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Dihydroartemisinin</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Elsherbiny et al. (<xref ref-type="bibr" rid="CR125">2008</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Antipyretic analgesic</td><td align="left" colspan="1" rowspan="1">Metamizole</td><td align="left" colspan="1" rowspan="1">Unknown</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping and expression)</td><td align="left" colspan="1" rowspan="1">Qin et al. (<xref ref-type="bibr" rid="CR372">2012</xref>), Saussele et al. (<xref ref-type="bibr" rid="CR409">2007</xref>)</td></tr><tr><td align="left" rowspan="3" colspan="1">Antiretrovirals</td><td align="left" colspan="1" rowspan="1">Efavirenz</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping), white blood cells</td><td align="left" colspan="1" rowspan="1">Kharasch et al. (<xref ref-type="bibr" rid="CR233">2012</xref>), Meyer zu Schwabedissen et al. (<xref ref-type="bibr" rid="CR302">2012</xref>), Ngaimisi et al. (<xref ref-type="bibr" rid="CR314">2010</xref>), Robertson et al. (<xref ref-type="bibr" rid="CR391">2008a</xref>, <xref ref-type="bibr" rid="CR392">b</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Nelfinavir</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Kirby et al. (<xref ref-type="bibr" rid="CR236">2011a</xref>, <xref ref-type="bibr" rid="CR237">b</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Ritonavir</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Kharasch et al. (<xref ref-type="bibr" rid="CR232">2008</xref>), Kirby et al. (<xref ref-type="bibr" rid="CR236">2011a</xref>, <xref ref-type="bibr" rid="CR237">b</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Barbiturates</td><td align="left" colspan="1" rowspan="1">Phenobarbital</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Jao et al. (<xref ref-type="bibr" rid="CR207">1972</xref>)</td></tr><tr><td align="left" rowspan="3" colspan="1">CYP2C8</td><td align="left" rowspan="2" colspan="1">Antibiotics</td><td align="left" colspan="1" rowspan="1">Rifampicin</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping), small intestine enterocytes</td><td align="left" colspan="1" rowspan="1">Glaeser et al. (<xref ref-type="bibr" rid="CR154">2005</xref>), Jaakkola et al. (<xref ref-type="bibr" rid="CR203">2006</xref>), Niemi et al. (<xref ref-type="bibr" rid="CR317">2000</xref>, <xref ref-type="bibr" rid="CR318">2004)</xref>, Park et al. (<xref ref-type="bibr" rid="CR345">2004</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Flucloxacillin</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Du et al. (<xref ref-type="bibr" rid="CR116">2013</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Antiepileptics</td><td align="left" colspan="1" rowspan="1">Carbamazepine</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (expression)</td><td align="left" colspan="1" rowspan="1">Oscarson et al. (<xref ref-type="bibr" rid="CR330">2006</xref>)</td></tr><tr><td align="left" rowspan="16" colspan="1">CYP2C9</td><td align="left" colspan="1" rowspan="1">Antiandrogens</td><td align="left" colspan="1" rowspan="1">Apalutamide</td><td align="left" colspan="1" rowspan="1">PXR?</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Duran et al. (<xref ref-type="bibr" rid="CR119">2020</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Enzalutamide</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Gibbons et al. (<xref ref-type="bibr" rid="CR150">2015</xref>)</td></tr><tr><td align="left" rowspan="4" colspan="1">Antibiotics</td><td align="left" colspan="1" rowspan="1">Dicloxacillin</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Stage et al. (<xref ref-type="bibr" rid="CR438">2018</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Nafcillin</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Kim et al. (<xref ref-type="bibr" rid="CR234">2007</xref>), King et al. (<xref ref-type="bibr" rid="CR235">2018</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Rifabutin</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Lutz et al. (<xref ref-type="bibr" rid="CR278">2018</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Rifampicin</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping), duodenum</td><td align="left" colspan="1" rowspan="1">Glaeser et al. (<xref ref-type="bibr" rid="CR154">2005</xref>), O&#8217;Reilly (<xref ref-type="bibr" rid="CR327">1974</xref>), Oscarson et al. (<xref ref-type="bibr" rid="CR331">2007</xref>), Williamson et al. (<xref ref-type="bibr" rid="CR514">1998</xref>), Zilly et al. (<xref ref-type="bibr" rid="CR549">1975</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Antiemetics</td><td align="left" colspan="1" rowspan="1">Aprepitant</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Depre et al. (<xref ref-type="bibr" rid="CR107">2005</xref>), Shadle et al. (<xref ref-type="bibr" rid="CR419">2004</xref>)</td></tr><tr><td align="left" rowspan="2" colspan="1">Antiepileptics</td><td align="left" colspan="1" rowspan="1">Carbamazepine</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping and expression)</td><td align="left" colspan="1" rowspan="1">Herman et al. (<xref ref-type="bibr" rid="CR177">2006</xref>), Lai et al. (<xref ref-type="bibr" rid="CR252">1992</xref>), Oscarson et al. (<xref ref-type="bibr" rid="CR330">2006</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Phenytoin</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Chetty et al. (<xref ref-type="bibr" rid="CR77">1998</xref>), Dickinson et al. (<xref ref-type="bibr" rid="CR109">1985</xref>)</td></tr><tr><td align="left" rowspan="2" colspan="1">Antiretrovirals</td><td align="left" colspan="1" rowspan="1">Nelfinavir</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Kirby et al. (<xref ref-type="bibr" rid="CR236">2011a</xref>, <xref ref-type="bibr" rid="CR237">b</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Ritonavir</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Kirby et al. (<xref ref-type="bibr" rid="CR236">2011a</xref>, <xref ref-type="bibr" rid="CR237">b</xref>), Lim et al. (<xref ref-type="bibr" rid="CR268">2004</xref>), Yeh et al. (<xref ref-type="bibr" rid="CR525">2006</xref>)</td></tr><tr><td align="left" rowspan="3" colspan="1">Barbiturates</td><td align="left" colspan="1" rowspan="1">Pentobarbital</td><td align="left" colspan="1" rowspan="1">CAR/PXR?</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Yoshida et al. (<xref ref-type="bibr" rid="CR528">1993</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Phenobarbital</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Goldberg et al. (<xref ref-type="bibr" rid="CR155">1996</xref>), Orme and Breckenridge (<xref ref-type="bibr" rid="CR329">1976</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Secobarbital</td><td align="left" colspan="1" rowspan="1">CAR/PXR?</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Breckenridge and Orme (<xref ref-type="bibr" rid="CR49">1971</xref>), O&#8217;Reilly et al. (<xref ref-type="bibr" rid="CR328">1980</xref>), Udall (<xref ref-type="bibr" rid="CR475">1975</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Endothelin receptor antagonists</td><td align="left" colspan="1" rowspan="1">Bosentan</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">van Giersbergen et al. (<xref ref-type="bibr" rid="CR481">2002</xref>), Weber et al. (<xref ref-type="bibr" rid="CR504">1999a</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Kinase inhibitor</td><td align="left" colspan="1" rowspan="1">Dabrafenib</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Suttle et al. (<xref ref-type="bibr" rid="CR444">2015</xref>)</td></tr><tr><td align="left" rowspan="13" colspan="1">CYP2C19</td><td align="left" colspan="1" rowspan="1">Antiandrogens</td><td align="left" colspan="1" rowspan="1">Apalutamide</td><td align="left" colspan="1" rowspan="1">PXR?</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Duran et al. (<xref ref-type="bibr" rid="CR119">2020</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Enzalutamide</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Gibbons et al. (<xref ref-type="bibr" rid="CR150">2015</xref>)</td></tr><tr><td align="left" rowspan="2" colspan="1">Antibiotics</td><td align="left" colspan="1" rowspan="1">Dicloxacillin</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Stage et al. (<xref ref-type="bibr" rid="CR438">2018</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Rifampicin</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping), duodenum</td><td align="left" colspan="1" rowspan="1">Feng et al. (<xref ref-type="bibr" rid="CR134">1998</xref>), Oscarson et al. (<xref ref-type="bibr" rid="CR331">2007</xref>), Zhou et al. (<xref ref-type="bibr" rid="CR547">1990</xref>), Zilly et al. (<xref ref-type="bibr" rid="CR549">1975</xref>)</td></tr><tr><td align="left" rowspan="2" colspan="1">Antiepileptics</td><td align="left" colspan="1" rowspan="1">Carbamazepine</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (expression)</td><td align="left" colspan="1" rowspan="1">Oscarson et al. (<xref ref-type="bibr" rid="CR330">2006</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Phenytoin</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Richter et al. (<xref ref-type="bibr" rid="CR387">1980</xref>)</td></tr><tr><td align="left" rowspan="3" colspan="1">Antimalarials</td><td align="left" colspan="1" rowspan="1">Arteether</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Asimus et al. (<xref ref-type="bibr" rid="CR18">2007</xref>), Elsherbiny et al. (<xref ref-type="bibr" rid="CR125">2008</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Artemether</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Elsherbiny et al. (<xref ref-type="bibr" rid="CR125">2008</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Artemisinin</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Asimus et al. (<xref ref-type="bibr" rid="CR18">2007</xref>), Elsherbiny et al. (<xref ref-type="bibr" rid="CR125">2008</xref>), Mihara et al. (<xref ref-type="bibr" rid="CR304">1999</xref>), Svensson et al. (<xref ref-type="bibr" rid="CR448">1998</xref>)</td></tr><tr><td align="left" rowspan="2" colspan="1">Antiretrovirals</td><td align="left" colspan="1" rowspan="1">Efavirenz</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Michaud et al. (<xref ref-type="bibr" rid="CR303">2012</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Ritonavir (with lopinavir or tipranivir)</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Dumond et al. (<xref ref-type="bibr" rid="CR118">2010</xref>), Yeh et al. (<xref ref-type="bibr" rid="CR525">2006</xref>)</td></tr><tr><td align="left" rowspan="2" colspan="1">Barbiturates</td><td align="left" colspan="1" rowspan="1">Pentobarbital</td><td align="left" colspan="1" rowspan="1">CAR/PXR?</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Heinemeyer et al. (<xref ref-type="bibr" rid="CR176">1987</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Phenobarbital</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping and expression)</td><td align="left" colspan="1" rowspan="1">Lecamwasam et al. (<xref ref-type="bibr" rid="CR260">1975</xref>), Richter et al. (<xref ref-type="bibr" rid="CR387">1980</xref>)</td></tr><tr><td align="left" rowspan="2" colspan="1">CYP2E1</td><td align="left" colspan="1" rowspan="1">Antibiotics</td><td align="left" colspan="1" rowspan="1">Isoniazid</td><td align="left" colspan="1" rowspan="1">Stabilization</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping), blood lymphocytes</td><td align="left" colspan="1" rowspan="1">Chien et al. (<xref ref-type="bibr" rid="CR81">1997</xref>), Mazze et al. (<xref ref-type="bibr" rid="CR290">1982</xref>), O&#8217;Shea et al. (<xref ref-type="bibr" rid="CR333">1997</xref>), Walubo et al. (<xref ref-type="bibr" rid="CR493">2005</xref>), Zand et al. <xref ref-type="bibr" rid="CR538">1993</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Retinoid receptor modulators</td><td align="left" colspan="1" rowspan="1">All-<italic toggle="yes">trans</italic>-retinoic acid</td><td align="left" colspan="1" rowspan="1">RXR?</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Adedoyin et al. (<xref ref-type="bibr" rid="CR9">1998</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">CYP2S1</td><td align="left" colspan="1" rowspan="1">Retinoid receptor modulators</td><td align="left" colspan="1" rowspan="1">Topical all-<italic toggle="yes">trans</italic> retinoic acid</td><td align="left" colspan="1" rowspan="1">RXR?</td><td align="left" colspan="1" rowspan="1">Skin</td><td align="left" colspan="1" rowspan="1">Smith et al. (<xref ref-type="bibr" rid="CR429">2003</xref>)</td></tr><tr><td align="left" rowspan="45" colspan="1">CYP3A4</td><td align="left" colspan="1" rowspan="1">Antiandrogens</td><td align="left" colspan="1" rowspan="1">Apalutamide</td><td align="left" colspan="1" rowspan="1">PXR?</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Duran et al. (<xref ref-type="bibr" rid="CR119">2020</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Enzalutamide</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Belderbos et al. (<xref ref-type="bibr" rid="CR31">2018</xref>), Gibbons et al. (<xref ref-type="bibr" rid="CR150">2015</xref>), Schwartzberg et al. (<xref ref-type="bibr" rid="CR417">2017</xref>)</td></tr><tr><td align="left" rowspan="6" colspan="1">Antibiotics</td><td align="left" colspan="1" rowspan="1">Dicloxacillin</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Stage et al. (<xref ref-type="bibr" rid="CR438">2018</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Flucloxacillin</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Fan et al. (<xref ref-type="bibr" rid="CR132">2019</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Nafcillin</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Lang et al. (<xref ref-type="bibr" rid="CR258">2003</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Rifabutin</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Barditch-Crovo et al. (<xref ref-type="bibr" rid="CR29">1999</xref>), Perucca et al. (<xref ref-type="bibr" rid="CR357">1988</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Rifampicin</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping and expression), duodenum</td><td align="left" colspan="1" rowspan="1">Greiner et al. (<xref ref-type="bibr" rid="CR159">1999</xref>), Kolars et al. (<xref ref-type="bibr" rid="CR243">1992</xref>), Marschall et al. (<xref ref-type="bibr" rid="CR285">2005</xref>), McAllister et al. (<xref ref-type="bibr" rid="CR291">1983</xref>), Ohnhaus and Park (<xref ref-type="bibr" rid="CR322">1979</xref>), Perucca et al. (<xref ref-type="bibr" rid="CR357">1988</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Rifapentine</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Birmingham et al. (<xref ref-type="bibr" rid="CR40">1978</xref>), Vital Durand et al. (<xref ref-type="bibr" rid="CR488">1986</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Antidiarrheals</td><td align="left" colspan="1" rowspan="1">Telotristat ethyl</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Yu et al. (<xref ref-type="bibr" rid="CR536">2019</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Antiemetics</td><td align="left" colspan="1" rowspan="1">Aprepitant</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Shadle et al. (<xref ref-type="bibr" rid="CR419">2004</xref>)</td></tr><tr><td align="left" rowspan="5" colspan="1">Antiepileptics</td><td align="left" colspan="1" rowspan="1">Carbamazepine</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping, expression)</td><td align="left" colspan="1" rowspan="1">Crawford et al. (<xref ref-type="bibr" rid="CR95">1990</xref>), Moreland et al. (<xref ref-type="bibr" rid="CR310">1982</xref>), Oscarson et al. (<xref ref-type="bibr" rid="CR330">2006</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Phenytoin</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping, expression)</td><td align="left" colspan="1" rowspan="1">Crawford et al. (<xref ref-type="bibr" rid="CR95">1990</xref>), Thummel et al. (<xref ref-type="bibr" rid="CR462">1994</xref>), Werk et al. (<xref ref-type="bibr" rid="CR507">1964</xref>), Xu et al. (<xref ref-type="bibr" rid="CR520">2006</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Oxcarbazepine</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Andreasen et al. (<xref ref-type="bibr" rid="CR14">2007</xref>), Klosterskov Jensen et al. (<xref ref-type="bibr" rid="CR239">1992</xref>, Zaccara et al. (<xref ref-type="bibr" rid="CR537">1993</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Rufinamide</td><td align="left" colspan="1" rowspan="1">Unknown</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Perucca et al. (<xref ref-type="bibr" rid="CR358">2008</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Topiramate</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Rosenfeld et al. (<xref ref-type="bibr" rid="CR395">1997</xref>)</td></tr><tr><td align="left" rowspan="3" colspan="1">Antimalarials</td><td align="left" colspan="1" rowspan="1">Artemether</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Asimus et al. (<xref ref-type="bibr" rid="CR18">2007</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Artemisinin</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Asimus et al. (<xref ref-type="bibr" rid="CR18">2007</xref>), Zang et al. (<xref ref-type="bibr" rid="CR539">2014</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Dihydroartemisinin</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Asimus et al. (<xref ref-type="bibr" rid="CR18">2007</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Antineoplastic agents</td><td align="left" colspan="1" rowspan="1">Vinblastine</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Smith et al. (<xref ref-type="bibr" rid="CR432">2010</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Antipyretic analgesic</td><td align="left" colspan="1" rowspan="1">Metamizole</td><td align="left" colspan="1" rowspan="1">Unknown</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping and expression)</td><td align="left" colspan="1" rowspan="1">Caraco et al. (<xref ref-type="bibr" rid="CR58">1999</xref>), Saussele et al. (<xref ref-type="bibr" rid="CR409">2007</xref>)</td></tr><tr><td align="left" rowspan="6" colspan="1">Antiretrovirals</td><td align="left" colspan="1" rowspan="1">Efavirenz</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Fellay et al. (<xref ref-type="bibr" rid="CR133">2005</xref>), Mouly et al. (<xref ref-type="bibr" rid="CR311">2002</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Etravirine</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Kakuda et al. (<xref ref-type="bibr" rid="CR219">2014</xref>), Scholler-Gyure et al. (<xref ref-type="bibr" rid="CR414">2009</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Fosamprenavir (and metabolite amprenavir)</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Justesen et al. (<xref ref-type="bibr" rid="CR217">2003</xref>), Kashuba et al. (<xref ref-type="bibr" rid="CR224">2005</xref>), Tran et al. (<xref ref-type="bibr" rid="CR469">2002</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Nevirapine</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Dailly et al. (<xref ref-type="bibr" rid="CR99">2006</xref>), Mildvan et al. (<xref ref-type="bibr" rid="CR305">2002</xref>), Solas et al. (<xref ref-type="bibr" rid="CR435">2004</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Ritonavir</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Hsu et al. (<xref ref-type="bibr" rid="CR187">1997</xref>), Ouellet et al. (<xref ref-type="bibr" rid="CR334">1998</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Tipranavir</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Boehringer-Ingelheim (<xref ref-type="bibr" rid="CR45">2005</xref>)</td></tr><tr><td align="left" rowspan="2" colspan="1">Barbiturates</td><td align="left" colspan="1" rowspan="1">Pentobarbital</td><td align="left" colspan="1" rowspan="1">CAR/PXR?</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Berman and Green (<xref ref-type="bibr" rid="CR35">1971</xref>), Schellens et al. (<xref ref-type="bibr" rid="CR412">1989</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Phenobarbital</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Back et al. (<xref ref-type="bibr" rid="CR20">1980</xref>), Burstein and Klaiber (<xref ref-type="bibr" rid="CR55">1965</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Bile acid derivatives</td><td align="left" colspan="1" rowspan="1">Ursodeoxycholic acid</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Bodin et al. (<xref ref-type="bibr" rid="CR44">2001</xref>), Marschall et al. (<xref ref-type="bibr" rid="CR285">2005</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Cystic fibrosis medications</td><td align="left" colspan="1" rowspan="1">Lumacaftor</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">ORKAMBI summary of product characteristics<sup>b</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Endothelin receptor antagonists</td><td align="left" colspan="1" rowspan="1">Bosentan</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Dingemanse et al. (<xref ref-type="bibr" rid="CR111">2003</xref>), Weber et al. (<xref ref-type="bibr" rid="CR505">1999b</xref>)</td></tr><tr><td align="left" rowspan="4" colspan="1">Glucocorticoids</td><td align="left" colspan="1" rowspan="1">Dexamethasone</td><td align="left" colspan="1" rowspan="1">GR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">McCune et al. (<xref ref-type="bibr" rid="CR293">2000</xref>), Roberts et al. (<xref ref-type="bibr" rid="CR388">2008</xref>), Watkins et al. (<xref ref-type="bibr" rid="CR503">1989</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Methylprednisolone</td><td align="left" colspan="1" rowspan="1">GR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Kuypers et al. (<xref ref-type="bibr" rid="CR250">2004</xref>), Villikka et al. (<xref ref-type="bibr" rid="CR486">2001</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Prednisolone</td><td align="left" colspan="1" rowspan="1">GR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Press et al. (<xref ref-type="bibr" rid="CR369">2010</xref>), van Duijnhoven et al. (<xref ref-type="bibr" rid="CR479">2003</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Prednisone</td><td align="left" colspan="1" rowspan="1">GR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Anglicheau et al. (<xref ref-type="bibr" rid="CR15">2003</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Herpes virus medications</td><td align="left" colspan="1" rowspan="1">Amenamevir</td><td align="left" colspan="1" rowspan="1">Unknown</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Adeloye et al. (<xref ref-type="bibr" rid="CR10">2018</xref>), Kusawake et al. (<xref ref-type="bibr" rid="CR249">2017</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Gout medications</td><td align="left" colspan="1" rowspan="1">Lesinurad</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Gillen et al. (<xref ref-type="bibr" rid="CR151">2017</xref>)</td></tr><tr><td align="left" rowspan="2" colspan="1">Retinoid receptor modulators</td><td align="left" colspan="1" rowspan="1">Alitretinoin (9-cis retinoic acid)</td><td align="left" colspan="1" rowspan="1">RXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Schmitt-Hoffmann et al. (<xref ref-type="bibr" rid="CR413">2011</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Bexarotene</td><td align="left" colspan="1" rowspan="1">RXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Padda et al. (<xref ref-type="bibr" rid="CR336">2013</xref>), Wakelee et al. (<xref ref-type="bibr" rid="CR491">2012</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Steroidogenesis inhibitors</td><td align="left" colspan="1" rowspan="1">Mitotane</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Bledsoe et al. (<xref ref-type="bibr" rid="CR41">1964</xref>), van Erp et al. (<xref ref-type="bibr" rid="CR480">2011</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Stimulants</td><td align="left" colspan="1" rowspan="1">Modafinil (and its <italic toggle="yes">R</italic>-enantiomer armodafinil)</td><td align="left" colspan="1" rowspan="1">Unknown</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Darwish et al. (<xref ref-type="bibr" rid="CR101">2008</xref>), Robertson et al. (<xref ref-type="bibr" rid="CR390">2002</xref>)</td></tr><tr><td align="left" rowspan="4" colspan="1">Kinase inhibitors</td><td align="left" colspan="1" rowspan="1">Dabrafenib</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Lawrence et al. (<xref ref-type="bibr" rid="CR259">2014</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Erlotinib</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping</td><td align="left" colspan="1" rowspan="1">Svedberg et al. (<xref ref-type="bibr" rid="CR447">2019</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Midostaurin</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Gu et al. (<xref ref-type="bibr" rid="CR161">2018</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Vemurafenib</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Zhang et al. (<xref ref-type="bibr" rid="CR542">2017</xref>)</td></tr><tr><td align="left" rowspan="2" colspan="1">CYP3A5</td><td align="left" colspan="1" rowspan="1">Antibiotics</td><td align="left" colspan="1" rowspan="1">Rifampicin</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Duodenum</td><td align="left" colspan="1" rowspan="1">Burk et al. (<xref ref-type="bibr" rid="CR54">2004</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Glucocorticoids</td><td align="left" colspan="1" rowspan="1">Topical clobetasol 17-propionate</td><td align="left" colspan="1" rowspan="1">GR</td><td align="left" colspan="1" rowspan="1">Skin</td><td align="left" colspan="1" rowspan="1">Smith et al. (<xref ref-type="bibr" rid="CR430">2006</xref>)</td></tr><tr><td align="left" rowspan="2" colspan="1">CYP3A7 and CYP3A43</td><td align="left" colspan="1" rowspan="1">Antibiotics</td><td align="left" colspan="1" rowspan="1">Rifampicin</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Duodenum</td><td align="left" colspan="1" rowspan="1">Oscarson et al. (<xref ref-type="bibr" rid="CR331">2007</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Antiepileptics</td><td align="left" colspan="1" rowspan="1">Carbamazepine</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (expression)</td><td align="left" colspan="1" rowspan="1">Oscarson et al. (<xref ref-type="bibr" rid="CR330">2006</xref>)</td></tr></tbody></table><table-wrap-foot><p>Only medications currently in clinical use are listed</p><p><sup>a</sup><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202992s010lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202992s010lbl.pdf</ext-link></p><p><sup>b</sup><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211358s000lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211358s000lbl.pdf</ext-link></p></table-wrap-foot></table-wrap><table-wrap id="Tab13" position="float" orientation="portrait"><label>Table&#160;13</label><caption><p>Chemical toxicants and radiation as in vivo inducers of human cytochrome P450 enzymes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Enzyme</th><th align="left" colspan="1" rowspan="1">Class of inducers</th><th align="left" colspan="1" rowspan="1">Compound or exposure</th><th align="left" colspan="1" rowspan="1">Receptor(s) implicated</th><th align="left" colspan="1" rowspan="1">Tissues</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" rowspan="6" colspan="1">CYP1A1</td><td align="left" colspan="1" rowspan="1">Dioxins</td><td align="left" colspan="1" rowspan="1">Various environmental exposures, and a case of massive TCDD poisoning</td><td align="left" colspan="1" rowspan="1">AHR</td><td align="left" colspan="1" rowspan="1">Skin</td><td align="left" colspan="1" rowspan="1">Fabbrocini et al. (<xref ref-type="bibr" rid="CR128">2015</xref>), Saurat et al. (<xref ref-type="bibr" rid="CR408">2012</xref>)</td></tr><tr><td align="left" rowspan="3" colspan="1">PAHs</td><td align="left" colspan="1" rowspan="1">Charbroiled meat</td><td align="left" colspan="1" rowspan="1">AHR</td><td align="left" colspan="1" rowspan="1">Duodenum</td><td align="left" colspan="1" rowspan="1">Fontana et al. (<xref ref-type="bibr" rid="CR141">1999</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Smoking</td><td align="left" colspan="1" rowspan="1">AHR</td><td align="left" colspan="1" rowspan="1">Adipose tissue, lung, oral and pharyngeal mucosa, placenta, uroepithelium, fetal lung, fetal liver</td><td align="left" colspan="1" rowspan="1">Boyle et al. (<xref ref-type="bibr" rid="CR48">2010</xref>), Chi et al. (<xref ref-type="bibr" rid="CR79">2009</xref>), Dorrenhaus et al. (<xref ref-type="bibr" rid="CR115">2007</xref>), Hukkanen et al. (<xref ref-type="bibr" rid="CR192">2002</xref>), Huuskonen et al. (<xref ref-type="bibr" rid="CR198">2008</xref>), McLemore et al. (<xref ref-type="bibr" rid="CR297">1990</xref>), O&#8217;Shaughnessy et al. (<xref ref-type="bibr" rid="CR332">2011</xref>), Pasanen et al. (<xref ref-type="bibr" rid="CR348">1990</xref>), Tsai et al. (<xref ref-type="bibr" rid="CR470">2018</xref>), Ullrich et al. (<xref ref-type="bibr" rid="CR476">1997</xref>), Vyhlidal et al. (<xref ref-type="bibr" rid="CR489">2013</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Topical coal tar</td><td align="left" colspan="1" rowspan="1">AHR</td><td align="left" colspan="1" rowspan="1">Skin, hair follicles</td><td align="left" colspan="1" rowspan="1">Merk et al. (<xref ref-type="bibr" rid="CR300">1987</xref>), Smith et al. (<xref ref-type="bibr" rid="CR430">2006</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Polychlorinated biphenyls</td><td align="left" colspan="1" rowspan="1">Consumption of contaminated rice oil</td><td align="left" colspan="1" rowspan="1">AHR</td><td align="left" colspan="1" rowspan="1">Placenta</td><td align="left" colspan="1" rowspan="1">Lucier et al. (<xref ref-type="bibr" rid="CR276">1987</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Radiation</td><td align="left" colspan="1" rowspan="1">Therapeutic ultraviolet-B radiation</td><td align="left" colspan="1" rowspan="1">AHR</td><td align="left" colspan="1" rowspan="1">Skin</td><td align="left" colspan="1" rowspan="1">Katiyar et al. (<xref ref-type="bibr" rid="CR225">2000</xref>)</td></tr><tr><td align="left" rowspan="7" colspan="1">CYP1A2</td><td align="left" colspan="1" rowspan="1">Dioxins</td><td align="left" colspan="1" rowspan="1">Dioxins, mainly TCDD, from environmental and occupational exposures, an occupational accident, and a case of massive TCDD poisoning</td><td align="left" colspan="1" rowspan="1">AHR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Abraham et al. (<xref ref-type="bibr" rid="CR5">2002</xref>), Chernyak et al. (<xref ref-type="bibr" rid="CR76">2016</xref>), Samer et al. (<xref ref-type="bibr" rid="CR405">2020</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Heterocyclic aromatic amines</td><td align="left" colspan="1" rowspan="1">Pan-fried meat</td><td align="left" colspan="1" rowspan="1">AHR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Sinha et al. (<xref ref-type="bibr" rid="CR425">1994</xref>)</td></tr><tr><td align="left" rowspan="4" colspan="1">PAHs</td><td align="left" colspan="1" rowspan="1">Charbroiled meat</td><td align="left" colspan="1" rowspan="1">AHR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Fontana et al. (<xref ref-type="bibr" rid="CR141">1999</xref>), Kappas et al. (<xref ref-type="bibr" rid="CR222">1978</xref>), Pantuck et al. (<xref ref-type="bibr" rid="CR343">1976</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Coffee</td><td align="left" colspan="1" rowspan="1">AHR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Djordjevic et al. (<xref ref-type="bibr" rid="CR113">2008</xref>), Horn et al. (<xref ref-type="bibr" rid="CR185">1995</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Smoking</td><td align="left" colspan="1" rowspan="1">AHR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping, expression in liver autopsy samples)</td><td align="left" colspan="1" rowspan="1">Baker et al. (<xref ref-type="bibr" rid="CR27">2001</xref>), Hunt et al. (<xref ref-type="bibr" rid="CR195">1976</xref>), Pantuck et al. (<xref ref-type="bibr" rid="CR342">1972</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Topical coal tar</td><td align="left" colspan="1" rowspan="1">AHR</td><td align="left" colspan="1" rowspan="1">Skin</td><td align="left" colspan="1" rowspan="1">Smith et al. (<xref ref-type="bibr" rid="CR430">2006</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Polybrominated and polychlorinated biphenyls</td><td align="left" colspan="1" rowspan="1">Consumption of contaminated fish and farm products</td><td align="left" colspan="1" rowspan="1">AHR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Fitzgerald et al. (<xref ref-type="bibr" rid="CR139">2005</xref>), Lambert et al. (<xref ref-type="bibr" rid="CR254">1990</xref>)</td></tr><tr><td align="left" rowspan="4" colspan="1">CYP1B1</td><td align="left" rowspan="3" colspan="1">PAHs</td><td align="left" colspan="1" rowspan="1">Smoking</td><td align="left" colspan="1" rowspan="1">AHR</td><td align="left" colspan="1" rowspan="1">Adipose tissue, lung, oral mucosa, placenta, white blood cells, whole-blood cells, fetal lung</td><td align="left" colspan="1" rowspan="1">Boyle et al. (<xref ref-type="bibr" rid="CR48">2010</xref>), Chi et al. (<xref ref-type="bibr" rid="CR79">2009</xref>), Hukkanen et al. (<xref ref-type="bibr" rid="CR192">2002</xref>), Huuskonen et al. (<xref ref-type="bibr" rid="CR198">2008</xref>), Lampe et al. (<xref ref-type="bibr" rid="CR255">2004</xref>), Tsai et al. (<xref ref-type="bibr" rid="CR470">2018</xref>), van Leeuwen et al. (<xref ref-type="bibr" rid="CR482">2007</xref>), Vyhlidal et al. (<xref ref-type="bibr" rid="CR489">2013</xref>), Willey et al. (<xref ref-type="bibr" rid="CR511">1997</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Topical coal tar</td><td align="left" colspan="1" rowspan="1">AHR</td><td align="left" colspan="1" rowspan="1">Skin</td><td align="left" colspan="1" rowspan="1">Smith et al. (<xref ref-type="bibr" rid="CR430">2006</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Work in coke ovens and waste incinerators</td><td align="left" colspan="1" rowspan="1">AHR</td><td align="left" colspan="1" rowspan="1">White blood cells</td><td align="left" colspan="1" rowspan="1">Hanaoka et al. (<xref ref-type="bibr" rid="CR171">2002</xref>), Hu et al. (<xref ref-type="bibr" rid="CR189">2006</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Radiation</td><td align="left" colspan="1" rowspan="1">Therapeutic ultraviolet-B radiation</td><td align="left" colspan="1" rowspan="1">AHR</td><td align="left" colspan="1" rowspan="1">Skin</td><td align="left" colspan="1" rowspan="1">Katiyar et al. (<xref ref-type="bibr" rid="CR225">2000</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">CYP2A6</td><td align="left" colspan="1" rowspan="1">Heavy metals</td><td align="left" colspan="1" rowspan="1">Cadmium</td><td align="left" colspan="1" rowspan="1">NRF2</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Satarug et al. (<xref ref-type="bibr" rid="CR406">2004a</xref>, <xref ref-type="bibr" rid="CR407">b</xref>)</td></tr><tr><td align="left" rowspan="3" colspan="1">CYP2E1</td><td align="left" rowspan="3" colspan="1">Benzene derivatives</td><td align="left" colspan="1" rowspan="1">Smoking (cigarette smoke contains both styrene and toluene, see below)</td><td align="left" colspan="1" rowspan="1">Stabilization?</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping), bronchial epithelium</td><td align="left" colspan="1" rowspan="1">Benowitz et al. (<xref ref-type="bibr" rid="CR32">2003</xref>), Oyama et al. (<xref ref-type="bibr" rid="CR335">2007</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Occupational exposure to styrene</td><td align="left" colspan="1" rowspan="1">Stabilization?</td><td align="left" colspan="1" rowspan="1">Blood lymphocytes, whole-blood cells</td><td align="left" colspan="1" rowspan="1">Prieto-Castello et al. (<xref ref-type="bibr" rid="CR370">2010</xref>), Wongvijitsuk et al. (<xref ref-type="bibr" rid="CR516">2011</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Toluene</td><td align="left" colspan="1" rowspan="1">Stabilization?</td><td align="left" colspan="1" rowspan="1">Blood lymphocytes</td><td align="left" colspan="1" rowspan="1">Mendoza-Cantu et al. (<xref ref-type="bibr" rid="CR299">2006</xref>)</td></tr><tr><td align="left" rowspan="3" colspan="1">CYP2S1</td><td align="left" rowspan="2" colspan="1">PAHs</td><td align="left" colspan="1" rowspan="1">Smoking</td><td align="left" colspan="1" rowspan="1">AHR</td><td align="left" colspan="1" rowspan="1">Bronchoalveolar macrophages</td><td align="left" colspan="1" rowspan="1">Thum et al. (<xref ref-type="bibr" rid="CR461">2006</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Topical coal tar</td><td align="left" colspan="1" rowspan="1">AHR</td><td align="left" colspan="1" rowspan="1">Skin</td><td align="left" colspan="1" rowspan="1">Smith et al. (<xref ref-type="bibr" rid="CR429">2003</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Radiation</td><td align="left" colspan="1" rowspan="1">Ultraviolet-B radiation</td><td align="left" colspan="1" rowspan="1">AHR</td><td align="left" colspan="1" rowspan="1">Skin</td><td align="left" colspan="1" rowspan="1">Smith et al. (<xref ref-type="bibr" rid="CR429">2003</xref>)</td></tr><tr><td align="left" rowspan="2" colspan="1">CYP3A4</td><td align="left" rowspan="2" colspan="1">Organochlorine pesticides</td><td align="left" colspan="1" rowspan="1">Dichlorodiphenyltrichloroethane (DDT)</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Petersen et al. (<xref ref-type="bibr" rid="CR359">2007</xref>), Poland et al. (<xref ref-type="bibr" rid="CR364">1970</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Endrin</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Jager (<xref ref-type="bibr" rid="CR205">1970</xref>)</td></tr></tbody></table></table-wrap><table-wrap id="Tab14" position="float" orientation="portrait"><label>Table&#160;14</label><caption><p>Nutritional exposures and herbal remedies as in vivo inducers of human cytochrome P450 enzymes. Some of the studies have been performed with purified compounds in high doses for drug development purposes. Food contaminants and compounds formed during food preparation are listed in Table&#160;<xref rid="Tab13" ref-type="table">13</xref></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Enzyme</th><th align="left" colspan="1" rowspan="1">Compound</th><th align="left" colspan="1" rowspan="1">Examples of sources</th><th align="left" colspan="1" rowspan="1">Receptor(s) implicated</th><th align="left" colspan="1" rowspan="1">Tissues</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">CYP1A2</td><td align="left" colspan="1" rowspan="1">Indole-3-carbinol</td><td align="left" colspan="1" rowspan="1">Cruciferous vegetables</td><td align="left" colspan="1" rowspan="1">AHR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Pantuck et al. (<xref ref-type="bibr" rid="CR344">1979</xref>), Reed et al. (<xref ref-type="bibr" rid="CR385">2005</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Resveratrol</td><td align="left" colspan="1" rowspan="1">Many plants including berries, grapes and peanuts, and red wine</td><td align="left" colspan="1" rowspan="1">AHR indirectly</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping, studied only with a pharmacologic dose)</td><td align="left" colspan="1" rowspan="1">Chow et al. (<xref ref-type="bibr" rid="CR83">2010</xref>)</td></tr><tr><td align="left" rowspan="3" colspan="1">CYP2A6</td><td align="left" colspan="1" rowspan="1">Genistein</td><td align="left" colspan="1" rowspan="1">Legumes such as soybeans</td><td align="left" colspan="1" rowspan="1">ER</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping, studied only with a pharmacologic dose)</td><td align="left" colspan="1" rowspan="1">Chen et al. (<xref ref-type="bibr" rid="CR74">2011</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Sulforaphane</td><td align="left" colspan="1" rowspan="1">Cruciferous vegetables</td><td align="left" colspan="1" rowspan="1">NRF2</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Hakooz and Hamdan (<xref ref-type="bibr" rid="CR169">2007</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Quercetin</td><td align="left" colspan="1" rowspan="1">Tea, many vegetables, fruits, and berries</td><td align="left" colspan="1" rowspan="1">ER</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping, studied only with a pharmacologic dose)</td><td align="left" colspan="1" rowspan="1">Chen et al. (<xref ref-type="bibr" rid="CR72">2009</xref>)</td></tr><tr><td align="left" rowspan="3" colspan="1">CYP2B6</td><td align="left" colspan="1" rowspan="1">Baicalin</td><td align="left" colspan="1" rowspan="1">Baikal skullcap, an herbal remedy</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping, studied only with a pharmacologic dose)</td><td align="left" colspan="1" rowspan="1">Fan et al. (<xref ref-type="bibr" rid="CR131">2009</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Hyperforin</td><td align="left" colspan="1" rowspan="1">St. John&#8217;s wort, an herbal remedy</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Lei et al. (<xref ref-type="bibr" rid="CR264">2010</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Sodium ferulate</td><td align="left" colspan="1" rowspan="1">Several herbal remedies such as <italic toggle="yes">Angelica sinensis, Cimicifuga heracleifolia,</italic> and <italic toggle="yes">Lignsticum chuangxiong</italic></td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping, studied only with a pharmacologic dose)</td><td align="left" colspan="1" rowspan="1">Gao et al. (<xref ref-type="bibr" rid="CR147">2013</xref>, <xref ref-type="bibr" rid="CR146">2012</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">CYP2C9</td><td align="left" colspan="1" rowspan="1">Hyperforin</td><td align="left" colspan="1" rowspan="1">St. John&#8217;s wort</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Jiang et al. (<xref ref-type="bibr" rid="CR211">2004</xref>, <xref ref-type="bibr" rid="CR212">2006</xref>)</td></tr><tr><td align="left" rowspan="2" colspan="1">CYP2C19</td><td align="left" colspan="1" rowspan="1">Baicalin</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Yin Zi Huang</italic>, an herbal remedy with several herbs</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Fan et al. (<xref ref-type="bibr" rid="CR130">2007</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Hyperforin</td><td align="left" colspan="1" rowspan="1">St. John&#8217;s wort</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Wang et al. (<xref ref-type="bibr" rid="CR495">2004a</xref>, <xref ref-type="bibr" rid="CR496">b</xref>)</td></tr><tr><td align="left" rowspan="2" colspan="1">CYP2E1</td><td align="left" colspan="1" rowspan="1">Ethanol</td><td align="left" colspan="1" rowspan="1">Alcoholic drinks</td><td align="left" colspan="1" rowspan="1">Stabilization</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping and expression), blood lymphocytes, esophagus, placenta</td><td align="left" colspan="1" rowspan="1">Girre et al. (<xref ref-type="bibr" rid="CR152">1994</xref>), Millonig et al. (<xref ref-type="bibr" rid="CR307">2011</xref>), Oneta et al. (<xref ref-type="bibr" rid="CR326">2002</xref>), Perrot et al. (<xref ref-type="bibr" rid="CR356">1989</xref>), Rasheed et al. (<xref ref-type="bibr" rid="CR380">1997</xref>), Raucy et al. (<xref ref-type="bibr" rid="CR381">1997</xref>, <xref ref-type="bibr" rid="CR382">1999)</xref>, Takahashi et al. (<xref ref-type="bibr" rid="CR450">1993</xref>), Tsutsumi et al. (<xref ref-type="bibr" rid="CR472">1989</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Unknown compound(s) in St. John&#8217;s wort</td><td align="left" colspan="1" rowspan="1">St. John&#8217;s wort</td><td align="left" colspan="1" rowspan="1">Unknown</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Gurley et al. (<xref ref-type="bibr" rid="CR164">2002</xref>, <xref ref-type="bibr" rid="CR165">2005)</xref></td></tr><tr><td align="left" rowspan="8" colspan="1">CYP3A4</td><td align="left" colspan="1" rowspan="1">Baicalin</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Yin Zi Huang</italic>, an herbal remedy with several herbs</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Fan et al. (<xref ref-type="bibr" rid="CR130">2007</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Unknown compounds in <italic toggle="yes">Echinacea purpurea</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Echinacea purpurea</italic>, an herbal remedy</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Gorski et al. (<xref ref-type="bibr" rid="CR156">2004</xref>), Penzak et al. (<xref ref-type="bibr" rid="CR355">2010</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Ethanol</td><td align="left" colspan="1" rowspan="1">Alcoholic drinks</td><td align="left" colspan="1" rowspan="1">Stabilization</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping and expression), duodenum (phenotyping)</td><td align="left" colspan="1" rowspan="1">Liangpunsakul et al. (<xref ref-type="bibr" rid="CR267">2005</xref>), Luceri et al. (<xref ref-type="bibr" rid="CR275">2001</xref>), Niemela et al. (<xref ref-type="bibr" rid="CR316">2000</xref>), Rahmioglu et al. (<xref ref-type="bibr" rid="CR377">2011</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Genistein</td><td align="left" colspan="1" rowspan="1">Legumes, soybeans, coffee</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping, studied only with a pharmacologic dose)</td><td align="left" colspan="1" rowspan="1">Xiao et al. (<xref ref-type="bibr" rid="CR519">2012</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Ginkgolide A and B</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Ginkgo biloba</italic>, an herbal remedy</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping)</td><td align="left" colspan="1" rowspan="1">Markowitz et al. (<xref ref-type="bibr" rid="CR284">2003</xref>), Robertson et al. (<xref ref-type="bibr" rid="CR392">2008b</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Hyperforin</td><td align="left" colspan="1" rowspan="1">St. John&#8217;s wort</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping), duodenum</td><td align="left" colspan="1" rowspan="1">Durr et al. (<xref ref-type="bibr" rid="CR120">2000</xref>); Piscitelli et al. (<xref ref-type="bibr" rid="CR361">2000</xref>); Roby et al. (<xref ref-type="bibr" rid="CR394">2000</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Quercetin</td><td align="left" colspan="1" rowspan="1">Many vegetables, fruits, and berries (also one of the flavonoids in <italic toggle="yes">Ginkgo biloba</italic>)</td><td align="left" colspan="1" rowspan="1">PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping, studied only with a pharmacologic dose)</td><td align="left" colspan="1" rowspan="1">Duan et al. (<xref ref-type="bibr" rid="CR117">2012</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Tanshinone IIA and cryptotanshinone</td><td align="left" colspan="1" rowspan="1">Danshen (<italic toggle="yes">Salvia miltiorrhiza</italic>), an herbal remedy</td><td align="left" colspan="1" rowspan="1">CAR/PXR</td><td align="left" colspan="1" rowspan="1">Liver (phenotyping), duodenum (phenotyping)</td><td align="left" colspan="1" rowspan="1">Qiu et al. (<xref ref-type="bibr" rid="CR373">2010</xref>), Qiu et al. (<xref ref-type="bibr" rid="CR374">2013</xref>), Zhou et al. (<xref ref-type="bibr" rid="CR548">2018</xref>)</td></tr></tbody></table></table-wrap></p><p id="Par67">The search strategy included searching PubMed with the specific CYPs as keywords (e.g., CYP2B6 and [induction or inducer or induce]). Also searches with the specific probe compounds were performed (e.g., for CYP2B6 &#8220;bupropion and [induction or inducer or induce]&#8221;). The bibliographies of the publications were checked for additional articles. As the clinical and toxicological significance of the induction is often difficult to evaluate, the compounds are listed on the tables with no regard to the consequences or magnitudes of the induction. However, for CYP-inducing TKIs, Table&#160;<xref rid="Tab1" ref-type="table">1</xref> provides the estimates of potency. For the sake of brevity, the following paragraphs do not systematically repeat the data and the references given in Tables&#160;<xref rid="Tab12" ref-type="table">12</xref>, <xref rid="Tab13" ref-type="table">13</xref> and <xref rid="Tab14" ref-type="table">14</xref>.</p><p id="Par68">The most important xenobiotic-activated receptor regulating the induction of enzymes in the CYP1 subfamily is AHR. Several environmental chemicals such as PAHs, dioxins, polychlorinated biphenyls, and heterocyclic aromatic amines induce CYP1A1, CYP1A2, and CYP1B1 enzymes via AHR (Tables&#160;<xref rid="Tab12" ref-type="table">12</xref>, <xref rid="Tab13" ref-type="table">13</xref>, <xref rid="Tab14" ref-type="table">14</xref>). Human in vivo induction of CYP1A1 and CYP1B1 is difficult to study with phenotyping probes owing to their very low or non-existent hepatic expression and overlap with CYP1A2 substrates (Chang et al. <xref ref-type="bibr" rid="CR68">2003</xref>). However, their expression can be measured more easily as these enzymes are widely expressed in various extrahepatic tissues where tissue sampling is more convenient than with liver. Only one medication (omeprazole for CYP1A1 in duodenum and CYP1A2 in liver) (Buchthal et al. <xref ref-type="bibr" rid="CR52">1995</xref>; Diaz et al. <xref ref-type="bibr" rid="CR108">1990</xref>; McDonnell et al. <xref ref-type="bibr" rid="CR296">1992</xref>; Rost et al. <xref ref-type="bibr" rid="CR397">1994</xref>; Rost and Roots <xref ref-type="bibr" rid="CR396">1994</xref>) and one nutritional exposure (indole-3-carbinol present in cruciferous vegetables for hepatic CYP1A2) (Pantuck et al. <xref ref-type="bibr" rid="CR344">1979</xref>; Reed et al. <xref ref-type="bibr" rid="CR385">2005</xref>) are currently known to induce CYP1 enzymes via AHR-mediated pathways. PXR and CAR are not known to directly induce CYP1 enzymes but several CAR/PXR agonists do induce CYP1A2-related activities in vivo. It is quite likely that CAR/PXR agonists induce the expression of AHR and lead to the induction of CYP1 enzymes indirectly (Maglich et al. <xref ref-type="bibr" rid="CR279">2002</xref>; Oscarson et al. <xref ref-type="bibr" rid="CR330">2006</xref>). Recent evidence suggests that teriflunomide, an immunosuppressant, induces CYP1A2 activity as shown with caffeine phenotyping possibly via phenobarbital-like indirect CAR activation (Carazo et al. <xref ref-type="bibr" rid="CR59">2018</xref>).<xref ref-type="fn" rid="Fn3">3</xref></p><p id="Par70">CYP2A6 is induced in humans in vivo by CAR, PXR, ER&#945;, and NRF2 agonists (Tables&#160;<xref rid="Tab12" ref-type="table">12</xref>, <xref rid="Tab13" ref-type="table">13</xref>, <xref rid="Tab14" ref-type="table">14</xref>). The regulation of CYP2A6 by ER&#945; and NRF2 sets it apart as no other CYP enzyme is known to be regulated in vivo by these transcription factors. CYP2A6 is induced through ER&#945; by phytoestrogens such as genistein (in legumes such as soybeans)(Y. Chen et al. <xref ref-type="bibr" rid="CR74">2011</xref>; Mazur <xref ref-type="bibr" rid="CR289">1998</xref>) and quercetin (in tea, vegetables, fruits, and berries) (Chen et al. <xref ref-type="bibr" rid="CR72">2009</xref>; Chun et al. <xref ref-type="bibr" rid="CR87">2012</xref>) as well as ethinyl estradiol of oral contraceptives (Benowitz et al. <xref ref-type="bibr" rid="CR33">2006</xref>; Berlin et al. <xref ref-type="bibr" rid="CR34">2007</xref>; Sinues et al. <xref ref-type="bibr" rid="CR426">2008</xref>). Exposure to cadmium measured as urine cadmium excretion is associated with CYP2A6 activity probed with coumarin 7-hydroxylation but only in non-smokers (Satarug et al. <xref ref-type="bibr" rid="CR406">2004a</xref>, <xref ref-type="bibr" rid="CR407">b</xref>). In smokers, CYP2A6 activity is known to be reduced (inhibition) by an unknown mechanism (Hukkanen et al. <xref ref-type="bibr" rid="CR194">2005</xref>) and as smoking is also an important source of cadmium (induction), it is not surprising that smoking can confound the association between cadmium exposure and CYP2A6 activity. The effect of cadmium on CYP2A6 is most likely mediated by NRF2 as is the induction caused by sulforaphane present in cruciferous vegetables (Abu-Bakar et al. <xref ref-type="bibr" rid="CR6">2004</xref>; Yokota et al. <xref ref-type="bibr" rid="CR527">2011</xref>). All medications known to induce CYP2A6 are combined CAR/PXR activators and it is not known which nuclear receptor is more important for CYP2A6 induction in vivo as there is some evidence for the involvement of both (Itoh et al. <xref ref-type="bibr" rid="CR201">2006</xref>). Rifampicin treatment for 6&#160;days had no effect on CYP2A6 activity measured as coumarin hydroxylation (Rautio et al. <xref ref-type="bibr" rid="CR383">1994</xref>) arguing against the role of PXR in the in vivo regulation.</p><p id="Par71">Several medications with PXR and combined CAR/PXR-activating properties induce CYP2B6 (Table&#160;<xref rid="Tab12" ref-type="table">12</xref>). The mechanism mediating the effect of metamizole, an antipyretic analgesic with spasmolytic properties, on the induction of CYP2B6 is currently unknown (Qin et al. <xref ref-type="bibr" rid="CR372">2012</xref>; Saussele et al. <xref ref-type="bibr" rid="CR409">2007</xref>). It is not acting as a direct ligand of PXR or CAR and an indirect phenobarbital-like mechanism has been suggested (Qin et al. <xref ref-type="bibr" rid="CR372">2012</xref>; Saussele et al. <xref ref-type="bibr" rid="CR409">2007</xref>). No environmental toxicant has been shown to induce CYP2B6 in vivo, but constituents of herbal remedies such as baicalin (CAR/PXR), hyperforin (PXR) of St. John&#8217;s wort, and sodium ferulate (PXR) induce CYP2B6 (Fan et al. <xref ref-type="bibr" rid="CR131">2009</xref>; Gao et al. <xref ref-type="bibr" rid="CR146">2012</xref>, <xref ref-type="bibr" rid="CR147">2013</xref>; Lei et al. <xref ref-type="bibr" rid="CR264">2010</xref>) (Table&#160;<xref rid="Tab14" ref-type="table">14</xref>). The effects of baicalin and sodium ferulate on CYP2B6 were demonstrated only as purified compounds in high doses. Thus, it is not known if dosing as herbal preparations containing <italic toggle="yes">Angelica sinensis</italic>, <italic toggle="yes">Cimicifuga heracleifolia</italic>, or <italic toggle="yes">Lignsticum chuangxiong</italic> (sodium ferulate) or Baikal skullcap (<italic toggle="yes">Scutellaria baicalensis</italic>) (baicalin) induce CYP2B6.</p><p id="Par72">The induction of CYP2C8 has been demonstrated only with a few CAR or PXR-activating pharmaceuticals (Table&#160;<xref rid="Tab12" ref-type="table">12</xref>). No environmental chemicals or constituents of herbal remedies are known to induce CYP2C8 in vivo in humans. Similarly, CYP2C9 is not known to be induced by environmental toxicants and only one herbal preparation, St. John&#8217;s wort, induces CYP2C9-related activities in vivo (Jiang et al. <xref ref-type="bibr" rid="CR211">2004</xref>, <xref ref-type="bibr" rid="CR212">2006</xref>). However, a multitude of medications (PXR agonists and combined CAR/PXR activators) induce CYP2C9 (Table&#160;<xref rid="Tab12" ref-type="table">12</xref>). CYP2C19 induction has been demonstrated with baicalin-containing Chinese multicomponent herbal preparation <italic toggle="yes">Yin Zhi Huang</italic> and hyperforin-containing St. John&#8217;s wort (Fan et al. <xref ref-type="bibr" rid="CR130">2007</xref>; Wang et al. <xref ref-type="bibr" rid="CR495">2004a</xref>, <xref ref-type="bibr" rid="CR496">b</xref>) (Table&#160;<xref rid="Tab14" ref-type="table">14</xref>), while no environmental chemical is known to induce CYP2C19. Several medications with PXR and CAR/PXR-activating properties induce CYP2C19 (Table&#160;<xref rid="Tab12" ref-type="table">12</xref>).</p><p id="Par73">The induction of CYP2E1 is regulated unlike any other CYP enzyme. The stabilization of mRNA and protein by inducing compounds, many of which are also CYP2E1 substrates, is the main mechanism of induction (Cederbaum <xref ref-type="bibr" rid="CR63">2006</xref>). Benzene derivatives such as styrene and toluene encountered by workers in print and plastic industries are known to induce CYP2E1 (Mendoza-Cantu et al. <xref ref-type="bibr" rid="CR299">2006</xref>; Prieto-Castello et al. <xref ref-type="bibr" rid="CR370">2010</xref>; Wongvijitsuk et al. <xref ref-type="bibr" rid="CR516">2011</xref>) and the same compounds may also be responsible for the CYP2E1 induction detected in tobacco smokers (Benowitz et al. <xref ref-type="bibr" rid="CR32">2003</xref>; Oyama et al. <xref ref-type="bibr" rid="CR335">2007</xref>) (Table&#160;<xref rid="Tab13" ref-type="table">13</xref>). The most well-known toxicant inducing CYP2E1 is ethanol (Table&#160;<xref rid="Tab14" ref-type="table">14</xref>). Two medications have been demonstrated to induce CYP2E1, namely isoniazid (stabilization) and oral all-<italic toggle="yes">trans</italic> retinoic acid with RXR agonism as the most likely mode of induction (Gyamfi et al. <xref ref-type="bibr" rid="CR166">2006</xref>) (Table&#160;<xref rid="Tab12" ref-type="table">12</xref>). St John&#8217;s wort induces CYP2E1 in long-term administration (28&#160;days), but the mechanism is unknown (Gurley et al. <xref ref-type="bibr" rid="CR164">2002</xref>, <xref ref-type="bibr" rid="CR165">2005</xref>). It is not known if the well-established PXR agonist hyperforin is involved or if some other St. John&#8217;s wort ingredient is responsible for the induction of CYP2E1.</p><p id="Par74">CYP2S1 is induced in skin and bronchoalveolar macrophages with exposures containing AHR agonists such smoking and topical coal tar (G. Smith et al. <xref ref-type="bibr" rid="CR429">2003</xref>; Thum et al. <xref ref-type="bibr" rid="CR461">2006</xref>) (Table&#160;<xref rid="Tab13" ref-type="table">13</xref>). Ultraviolet-B (UVB) radiation has been demonstrated to induce CYP2S1 in skin with AHR-mediated mechanism which is also involved in the induction of cutaneous CYP1A1 and CYP1B1 by UVB (Katiyar et al. <xref ref-type="bibr" rid="CR225">2000</xref>; Smith et al. <xref ref-type="bibr" rid="CR429">2003</xref>). UVB exposure leads to the formation of 6-formylindolo[3,2-b]carbazole, a tryptophan photoproduct and an endogenous AHR ligand (Fritsche et al. <xref ref-type="bibr" rid="CR142">2007</xref>). The only medication known to induce CYP2S1 expression is topical all-<italic toggle="yes">trans</italic> retinoic acid, possibly via RXR (McNeilly et al. <xref ref-type="bibr" rid="CR298">2012</xref>).</p><p id="Par75">As CYP3A4 is involved in the metabolism of approximately 50% of all marketed medications (Zhou <xref ref-type="bibr" rid="CR546">2008</xref>), its induction is of special importance. There are also numerous pharmaceutical CYP3A4 inducers leading to increased risk of drug&#8211;drug interactions (Table&#160;<xref rid="Tab12" ref-type="table">12</xref>). CAR, GR, and PXR are known to mediate the induction. The mechanism of induction is unknown for antiepileptic rufinamide, stimulants modafinil and its <italic toggle="yes">R</italic>-enantiomer armodafinil, antiherpetic medication amenamevir, and metamizole (Table&#160;<xref rid="Tab12" ref-type="table">12</xref>). Also RXR agonists alitretinoin (9-cis retinoic acid) and bexarotene are known to induce CYP3A4-related activities in phenotyping studies (Padda et al. <xref ref-type="bibr" rid="CR336">2013</xref>; Schmitt-Hoffmann et al. <xref ref-type="bibr" rid="CR413">2011</xref>; Wakelee et al. <xref ref-type="bibr" rid="CR491">2012</xref>).</p><p id="Par76">In addition to CYP3A4-inducing medications, quite many herbal remedies and food ingredients induce CYP3A4 (Table&#160;<xref rid="Tab14" ref-type="table">14</xref>). Also the occupational and environmental exposure to organochlorine pesticides dichlorodiphenyltrichloroethane (DDT) and endrin is associated with the induction of CYP3A4 as measured with urinary 6&#946;-hydroxycortisol (Petersen et al. <xref ref-type="bibr" rid="CR359">2007</xref>; Poland et al. <xref ref-type="bibr" rid="CR364">1970</xref>) (Table&#160;<xref rid="Tab13" ref-type="table">13</xref>). One often neglected CYP3A4 inducer is ethanol. Chronic alcoholics had a higher ratio of urine 6&#946;-hydroxycortisol/cortisol compared with healthy volunteers (Luceri et al. <xref ref-type="bibr" rid="CR275">2001</xref>). Also oral bioavailability of midazolam was significantly lower in subjects with moderate alcohol consumption in comparison with abstaining controls suggesting intestinal CYP3A4 induction (Liangpunsakul et al. <xref ref-type="bibr" rid="CR267">2005</xref>). In a twin study, alcohol consumption was significantly associated with greater St. John&#8217;s wort-induced CYP3A4 activity as assessed with quinine phenotyping (Rahmioglu et al. <xref ref-type="bibr" rid="CR377">2011</xref>). There are also indications that CYP3A4 protein could be induced in liver of the alcoholics with liver disease (Niemela et al. <xref ref-type="bibr" rid="CR316">2000</xref>).</p><p id="Par77">The evaluation of induction phenomena of CYP3A enzymes is complicated by the closely related CYP3A5 enzyme. CYP3A4 and CYP3A5 have widely overlapping substrate specificities and their regulation shares certain features such as crucial role of PXR and CAR (Burk et al. <xref ref-type="bibr" rid="CR54">2004</xref>). A notable difference is the extensive influence of genetics on CYP3A5 expression. The <italic toggle="yes">CYP3A5*3</italic> allele with severely decreased enzymatic activity is more common than the <italic toggle="yes">CYP3A5*1</italic> allele (<italic toggle="yes">CYP3A5*3</italic> allele frequency is&#8201;~&#8201;90% in Caucasians and 50% in African&#8211;Americans) (Lamba et al. <xref ref-type="bibr" rid="CR253">2002</xref>). Thus, most Caucasians do not have a functional CYP3A5 enzyme. The phenotyping studies performed with probes metabolized by CYP3A4 and CYP3A5 are classified here as showing only CYP3A4 induction if there are no enzyme-specific data on CYP3A5 induction. It is conceivable that many of the CYP3A4 inducers are also CYP3A5 inducers in those patients carrying one or two functional <italic toggle="yes">CYP3A5*1</italic> alleles. There are only a few known CYP3A5 in vivo inducers. Rifampicin induced duodenal CYP3A5 mRNA in the subjects carrying a <italic toggle="yes">CYP3A5*1</italic> allele, while no induction was detected in <italic toggle="yes">CYP3A5*3/*3</italic> subjects (Burk et al. <xref ref-type="bibr" rid="CR54">2004</xref>). Topical administration of the glucocorticoid clobetasol 17-propionate induced cutaneous CYP3A5 mRNA (Smith et al. <xref ref-type="bibr" rid="CR430">2006</xref>).</p><p id="Par78">The induction of minor CYP3A forms has also been demonstrated. The use of carbamazepine is associated with the increased expression of hepatic CYP3A7 and CYP3A43 mRNA (Oscarson et al. <xref ref-type="bibr" rid="CR330">2006</xref>). Rifampicin induces intestinal CYP3A7 and CYP3A43 mRNA in healthy volunteers (Oscarson et al. <xref ref-type="bibr" rid="CR331">2007</xref>) (Table&#160;<xref rid="Tab12" ref-type="table">12</xref>).</p></sec><sec id="Sec34"><title>Consequences and relevance of CYP induction</title><p id="Par79">The induction of CYP enzymes as a cause of DDIs, as distinct from the enzyme inhibition, is unique as the induction becomes apparent more slowly and it takes more time for the induction to abate. This is caused by the delay due to the synthesis of new enzymes when the inducer is introduced, and then for the additional enzymes to degrade after the inducer is withdrawn. These effects take usually days to even weeks to fully manifest when concerning rapidly metabolized compounds (Tran et al. <xref ref-type="bibr" rid="CR468">1999</xref>). The time-dependent effects are even slower when dealing with steady-state levels of compounds with long half-lives. Thus, the outcome of adding an inducer to the patient&#8217;s established drug regimen can be difficult to detect in clinical setting if the physician is unaware of the anticipated effect. The effect of the induction is even more difficult to discern when dealing with intermittent exposures as is common with environmental toxicants as both victims and perpetrators of induction. For drugs and toxicants active in their parent form, CYP induction increases the elimination of compounds and decreases therapeutic and toxic effects, respectively. For prodrugs and toxicants that have active metabolites formed by CYP enzymes, enhanced pharmacodynamic and toxic effects could result.</p><p id="Par80">The consequences of CYP induction are even more difficult to evaluate when dealing with mixtures of chemical compounds comprised of all the pharmaceutical, herbal, and environmental chemical exposures encountered by individuals in their daily lives. This is due to newly emerging findings on the combinatorial effects of chemical mixtures as activators of xenobiotic-sensing receptors. This phenomenon has been best demonstrated with PXR. It has been shown that combinations of toxic compounds such as bisphenol A analogs (Sui et al. <xref ref-type="bibr" rid="CR443">2012</xref>), and drugs and toxicants such as the combination of pesticide trans-nonachlor and drug 17&#945;-ethinylestradiol (Delfosse et al. <xref ref-type="bibr" rid="CR106">2015</xref>), potentiate the PXR activation even at the low concentrations incapable to activate PXR by themselves. The science of the combinations is still very much a work in progress.</p></sec><sec id="Sec35"><title>Concluding remarks and lessons learnt</title><p id="Par81">After intense investigation for several decades, the research field of CYP inhibition and induction has reached a rather matured stage. The basic mechanisms of both CYP inhibition and induction are now fairly well understood, although further details continue to be revealed.</p><p id="Par82">The experimental tools to study CYP inhibition and induction in vitro have been well established and adopted in guidelines regulating drug development. The in vitro results can further guide the in vivo experiments. Indeed, we have moved from testing clinically commonly used individual drugs together to the rational design of studies using index drugs and reference inhibitors based on mechanistic understanding of drug&#8211;drug interactions (Tornio et al. <xref ref-type="bibr" rid="CR465">2019</xref>). Further development has been made in the computational tools, and the physiologically based pharmacokinetic modeling can be used to simulate in vivo conditions, extend the knowledge gained from the clinical studies, and even avoid unnecessary clinical studies (Shebley and Einolf <xref ref-type="bibr" rid="CR420">2019</xref>; Venkatakrishnan and Rostami-Hodjegan <xref ref-type="bibr" rid="CR485">2019</xref>). However, human in vivo DDI studies are still needed to definitively demonstrate the consequences of inhibition/induction, especially for the regulatory filings, and it is not likely that these studies would be deemed unnecessary in the near future.</p><p id="Par83">As a result of the methodological developments, the CYP-mediated drug&#8211;drug interactions are identified early in the pharmaceutical development and no longer big surprises appear in the clinical use after approval. The early awareness of the potential CYP-mediated drug&#8211;drug interactions may also guide the drug development process to avoid strong inhibitors and inducers. Thus, especially the number of new inducers has been low among the recently approved drugs. However, there may still be unidentified inducers and inhibitors among the compounds present in our diet and various herbal remedies as well as in the environment as chemical toxicants.</p><p id="Par84">The CYP-mediated interactions are now mastered rather well in the drug development process. The use of different databases and prescription aid tools has also improved application of the interaction data in the clinical practice. The widespread application of these information technology solutions is crucial as the amount of DDI data are too extensive for any individual physician to master. The progress in the pharmaceutical drug development during the recent years has resulted in design of small-molecular drugs with increasing metabolic stability. While this decreases the risk of CYP-mediated drug&#8211;drug interactions, this development may induce other types of interactions such as those mediated by various transporters (Venkatakrishnan and Rostami-Hodjegan <xref ref-type="bibr" rid="CR485">2019</xref>).</p><p id="Par85">Although, in general, there is a good potential for prediction of the CYP inhibition and induction, unusual cases may still continue to provide surprises. For example, it was described that co-binding of two non-activating compounds to the active site of PXR may result in synergistic effect and receptor activation (Delfosse et al. <xref ref-type="bibr" rid="CR106">2015</xref>). This kind of cocktail effect may be possible among drugs, but perhaps more relevant in the toxicological exposure to complex mixtures. Naturally, also drugs and environmental compounds or natural substances could interact or act together. Thus, although much has been learned in the last decades regarding inhibition and induction of CYP enzymes, novel discoveries may still be made by inquiring minds.</p></sec></body><back><fn-group><fn id="Fn1"><label>1</label><p id="Par8">EMA <xref ref-type="bibr" rid="CR1000">2012</xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf">https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf</ext-link>; FDA <xref ref-type="bibr" rid="CR1001">2020</xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/media/134582/download">https://www.fda.gov/media/134582/download</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/media/134581/download">https://www.fda.gov/media/134581/download</ext-link>; MHLW/PMDA <xref ref-type="bibr" rid="CR1003">2018</xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.pmda.go.jp/files/000228122.pdf">https://www.pmda.go.jp/files/000228122.pdf</ext-link>.</p></fn><fn id="Fn2"><label>2</label><p id="Par16"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/media/134581/download">https://www.fda.gov/media/134581/download</ext-link>.</p></fn><fn id="Fn3"><label>3</label><p id="Par69">Summary of Product Characteristics, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202992s010lbl.pdf.</p></fn><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors would like to pay tribute to the late Professor Pertti Neuvonen, a prominent scientist in the field of CYP-mediated drug&#8211;drug interaction, and extensively cited also in this review.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>All authors participated in the literature search, data analysis, and writing of the manuscript. All authors have read and approved the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by University of Oulu including Oulu University Hospital. The original research by the authors is supported by the Academy of Finland (Grants 286743 and 323706) to JHa, Finnish Medical Foundation; the Finnish Foundation for Cardiovascular Research; the Northern Finland Health Care Support Foundation; and the Diabetes Research Foundation to JHu, the Northern Finland Health Care Support to MT.</p></notes><notes notes-type="data-availability"><title>Availability of data and material (data transparency)</title><p>All the data are available in the text and tables of the review.</p></notes><notes notes-type="ethics"><title>Compliance with ethical standards</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par86">The authors declare that they have no conflict of interest.</p></notes><notes id="FPar2"><title>Ethics approval</title><p id="Par87">Not applicable.</p></notes><notes id="FPar3"><title>Consent to participate</title><p id="Par88">Not applicable.</p></notes><notes id="FPar4"><title>Consent for publication</title><p id="Par89">Not applicable.</p></notes><notes id="FPar5"><title>Code availability</title><p id="Par90">Not applicable.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbas</surname><given-names>R</given-names></name><name name-style="western"><surname>Hsyu</surname><given-names>P</given-names></name></person-group><article-title>Clinical pharmacokinetics and pharmacodynamics of bosutinib</article-title><source>Clin Pharmacokinet</source><year>2016</year><volume>55</volume><fpage>1191</fpage><lpage>1204</lpage><pub-id pub-id-type="pmid">27113346</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-016-0391-6</pub-id></element-citation></ref><ref id="CR2"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbas</surname><given-names>R</given-names></name><name name-style="western"><surname>Leister</surname><given-names>C</given-names></name><name name-style="western"><surname>El Gaaloul</surname><given-names>M</given-names></name><name name-style="western"><surname>Chalon</surname><given-names>S</given-names></name><name name-style="western"><surname>Sonnichsen</surname><given-names>D</given-names></name></person-group><article-title>Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects</article-title><source>Clin Ther</source><year>2012</year><volume>34</volume><fpage>2011</fpage><lpage>2019.e1</lpage><pub-id pub-id-type="pmid">22884766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinthera.2012.07.006</pub-id></element-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbas</surname><given-names>R</given-names></name><name name-style="western"><surname>Boni</surname><given-names>J</given-names></name><name name-style="western"><surname>Sonnichsen</surname><given-names>D</given-names></name></person-group><article-title>Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects</article-title><source>Drug Metab Pers Ther</source><year>2015</year><volume>30</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">25803093</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/dmdi-2014-0026</pub-id></element-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abel</surname><given-names>S</given-names></name><name name-style="western"><surname>Back</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Vourvahis</surname><given-names>M</given-names></name></person-group><article-title>Maraviroc: pharmacokinetics and drug interactions</article-title><source>Antivir Ther (Lond)</source><year>2009</year><volume>14</volume><fpage>607</fpage><lpage>618</lpage><pub-id pub-id-type="pmid">19704163</pub-id></element-citation></ref><ref id="CR5"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abraham</surname><given-names>K</given-names></name><name name-style="western"><surname>Geusau</surname><given-names>A</given-names></name><name name-style="western"><surname>Tosun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Helge</surname><given-names>H</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>S</given-names></name><name name-style="western"><surname>Brockmoller</surname><given-names>J</given-names></name></person-group><article-title>Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: insights into the measurement of hepatic cytochrome P450 1A2 induction</article-title><source>Clin Pharmacol Ther</source><year>2002</year><volume>72</volume><fpage>163</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">12189363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2002.126408</pub-id></element-citation></ref><ref id="CR6"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abu-Bakar</surname><given-names>A</given-names></name><name name-style="western"><surname>Satarug</surname><given-names>S</given-names></name><name name-style="western"><surname>Marks</surname><given-names>GC</given-names></name><name name-style="western"><surname>Lang</surname><given-names>MA</given-names></name><name name-style="western"><surname>Moore</surname><given-names>MR</given-names></name></person-group><article-title>Acute cadmium chloride administration induces hepatic and renal CYP2A5 mRNA, protein and activity in the mouse: involvement of transcription factor NRF2</article-title><source>Toxicol Lett</source><year>2004</year><volume>148</volume><fpage>199</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">15041070</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.toxlet.2003.10.029</pub-id></element-citation></ref><ref id="CR7"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abu-Bakar</surname><given-names>A</given-names></name><name name-style="western"><surname>L&#228;ms&#228;</surname><given-names>V</given-names></name><name name-style="western"><surname>Arpiainen</surname><given-names>S</given-names></name><name name-style="western"><surname>Moore</surname><given-names>MR</given-names></name><name name-style="western"><surname>Lang</surname><given-names>MA</given-names></name><name name-style="western"><surname>Hakkola</surname><given-names>J</given-names></name></person-group><article-title>Regulation of CYP2A5 gene by the transcription factor nuclear factor (erythroid-derived 2)-like 2</article-title><source>Drug Metab Dispos</source><year>2007</year><volume>35</volume><fpage>787</fpage><lpage>794</lpage><pub-id pub-id-type="pmid">17303623</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.106.014423</pub-id></element-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abu-Bakar</surname><given-names>A</given-names></name><name name-style="western"><surname>Hakkola</surname><given-names>J</given-names></name><name name-style="western"><surname>Juvonen</surname><given-names>R</given-names></name><name name-style="western"><surname>Rahnasto-Rilla</surname><given-names>M</given-names></name><name name-style="western"><surname>Raunio</surname><given-names>H</given-names></name><name name-style="western"><surname>Lang</surname><given-names>MA</given-names></name></person-group><article-title>Function and regulation of the Cyp2a5/CYP2A6 genes in response to toxic insults in the liver</article-title><source>Curr Drug Metab</source><year>2013</year><volume>14</volume><fpage>137</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">22497566</pub-id></element-citation></ref><ref id="CR9"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adedoyin</surname><given-names>A</given-names></name><name name-style="western"><surname>Stiff</surname><given-names>DD</given-names></name><name name-style="western"><surname>Smith</surname><given-names>DC</given-names></name><name name-style="western"><surname>Romkes</surname><given-names>M</given-names></name><name name-style="western"><surname>Bahnson</surname><given-names>RC</given-names></name><name name-style="western"><surname>Day</surname><given-names>R</given-names></name><name name-style="western"><surname>Hofacker</surname><given-names>J</given-names></name><name name-style="western"><surname>Branch</surname><given-names>RA</given-names></name><name name-style="western"><surname>Trump</surname><given-names>DL</given-names></name></person-group><article-title>All-<italic toggle="yes">trans</italic>-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes</article-title><source>Cancer Chemother Pharmacol</source><year>1998</year><volume>41</volume><fpage>133</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">9443626</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002800050719</pub-id></element-citation></ref><ref id="CR10"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adeloye</surname><given-names>T</given-names></name><name name-style="western"><surname>Sahgal</surname><given-names>O</given-names></name><name name-style="western"><surname>Puri</surname><given-names>A</given-names></name><name name-style="western"><surname>Warrington</surname><given-names>S</given-names></name><name name-style="western"><surname>Endo</surname><given-names>T</given-names></name><name name-style="western"><surname>Dennison</surname><given-names>J</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>A</given-names></name></person-group><article-title>PMC6585933; amenamevir: studies of potential CYP3A-mediated pharmacokinetic interactions with midazolam, cyclosporine, and ritonavir in healthy volunteers</article-title><source>Clin Pharmacol Drug Dev</source><year>2018</year><volume>7</volume><fpage>844</fpage><lpage>859</lpage><pub-id pub-id-type="pmid">30044899</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpdd.586</pub-id><pub-id pub-id-type="pmcid">PMC6585933</pub-id></element-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akiyoshi</surname><given-names>T</given-names></name><name name-style="western"><surname>Ito</surname><given-names>M</given-names></name><name name-style="western"><surname>Murase</surname><given-names>S</given-names></name><name name-style="western"><surname>Miyazaki</surname><given-names>M</given-names></name><name name-style="western"><surname>Guengerich</surname><given-names>FP</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>K</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Ohtani</surname><given-names>H</given-names></name></person-group><article-title>Mechanism-based inhibition profiles of erythromycin and clarithromycin with cytochrome P450 3A4 genetic variants</article-title><source>Drug Metab Pharmacokinet</source><year>2013</year><volume>28</volume><fpage>411</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">23514827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2133/dmpk.dmpk-12-rg-134</pub-id></element-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alam</surname><given-names>C</given-names></name><name name-style="western"><surname>Whyte-Allman</surname><given-names>S</given-names></name><name name-style="western"><surname>Omeragic</surname><given-names>A</given-names></name><name name-style="western"><surname>Bendayan</surname><given-names>R</given-names></name></person-group><article-title>Role and modulation of drug transporters in HIV-1 therapy</article-title><source>Adv Drug Deliv Rev</source><year>2016</year><volume>103</volume><fpage>121</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">27181050</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2016.05.001</pub-id></element-citation></ref><ref id="CR13"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amaya</surname><given-names>GM</given-names></name><name name-style="western"><surname>Durandis</surname><given-names>R</given-names></name><name name-style="western"><surname>Bourgeois</surname><given-names>DS</given-names></name><name name-style="western"><surname>Perkins</surname><given-names>JA</given-names></name><name name-style="western"><surname>Abouda</surname><given-names>AA</given-names></name><name name-style="western"><surname>Wines</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Mohamud</surname><given-names>M</given-names></name><name name-style="western"><surname>Starks</surname><given-names>SA</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>RN</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>KD</given-names></name></person-group><article-title>Cytochromes P450 1A2 and 3A4 catalyze the metabolic activation of sunitinib</article-title><source>Chem Res Toxicol</source><year>2018</year><volume>31</volume><fpage>570</fpage><lpage>584</lpage><pub-id pub-id-type="pmid">29847931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.chemrestox.8b00005</pub-id><pub-id pub-id-type="pmcid">PMC6108078</pub-id></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andreasen</surname><given-names>AH</given-names></name><name name-style="western"><surname>Brosen</surname><given-names>K</given-names></name><name name-style="western"><surname>Damkier</surname><given-names>P</given-names></name></person-group><article-title>A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4</article-title><source>Epilepsia</source><year>2007</year><volume>48</volume><fpage>490</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">17346248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1528-1167.2007.00924.x</pub-id></element-citation></ref><ref id="CR15"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anglicheau</surname><given-names>D</given-names></name><name name-style="western"><surname>Flamant</surname><given-names>M</given-names></name><name name-style="western"><surname>Schlageter</surname><given-names>MH</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>F</given-names></name><name name-style="western"><surname>Cassinat</surname><given-names>B</given-names></name><name name-style="western"><surname>Beaune</surname><given-names>P</given-names></name><name name-style="western"><surname>Legendre</surname><given-names>C</given-names></name><name name-style="western"><surname>Thervet</surname><given-names>E</given-names></name></person-group><article-title>Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation</article-title><source>Nephrol Dial Transplant</source><year>2003</year><volume>18</volume><fpage>2409</fpage><lpage>2414</lpage><pub-id pub-id-type="pmid">14551375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gfg381</pub-id></element-citation></ref><ref id="CR16"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arpiainen</surname><given-names>S</given-names></name><name name-style="western"><surname>Raffalli-Mathieu</surname><given-names>F</given-names></name><name name-style="western"><surname>Lang</surname><given-names>MA</given-names></name><name name-style="western"><surname>Pelkonen</surname><given-names>O</given-names></name><name name-style="western"><surname>Hakkola</surname><given-names>J</given-names></name></person-group><article-title>Regulation of the Cyp2a5 gene involves an aryl hydrocarbon receptor-dependent pathway</article-title><source>Mol Pharmacol</source><year>2005</year><volume>67</volume><fpage>1325</fpage><lpage>1333</lpage><pub-id pub-id-type="pmid">15657367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/mol.104.008078</pub-id></element-citation></ref><ref id="CR17"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asaumi</surname><given-names>R</given-names></name><name name-style="western"><surname>Toshimoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Tobe</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hashizume</surname><given-names>K</given-names></name><name name-style="western"><surname>Nunoya</surname><given-names>K</given-names></name><name name-style="western"><surname>Imawaka</surname><given-names>H</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>Y</given-names></name></person-group><article-title>Comprehensive PBPK Model of rifampicin for quantitative prediction of complex drug&#8211;drug interactions: CYP3A/2C9 induction and OATP inhibition effects</article-title><source>CPT Pharmacomet Syst Pharmacol</source><year>2018</year><volume>7</volume><fpage>186</fpage><lpage>196</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psp4.12275</pub-id><pub-id pub-id-type="pmcid">PMC5869557</pub-id><pub-id pub-id-type="pmid">29368402</pub-id></element-citation></ref><ref id="CR18"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asimus</surname><given-names>S</given-names></name><name name-style="western"><surname>Elsherbiny</surname><given-names>D</given-names></name><name name-style="western"><surname>Hai</surname><given-names>TN</given-names></name><name name-style="western"><surname>Jansson</surname><given-names>B</given-names></name><name name-style="western"><surname>Huong</surname><given-names>NV</given-names></name><name name-style="western"><surname>Petzold</surname><given-names>MG</given-names></name><name name-style="western"><surname>Simonsson</surname><given-names>US</given-names></name><name name-style="western"><surname>Ashton</surname><given-names>M</given-names></name></person-group><article-title>Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects</article-title><source>Fundam Clin Pharmacol</source><year>2007</year><volume>21</volume><fpage>307</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">17521300</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1472-8206.2007.00471.x</pub-id></element-citation></ref><ref id="CR19"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asimus</surname><given-names>S</given-names></name><name name-style="western"><surname>Hai</surname><given-names>TN</given-names></name><name name-style="western"><surname>Van Huong</surname><given-names>N</given-names></name><name name-style="western"><surname>Ashton</surname><given-names>M</given-names></name></person-group><article-title>Artemisinin and CYP2A6 activity in healthy subjects</article-title><source>Eur J Clin Pharmacol</source><year>2008</year><volume>64</volume><fpage>283</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">18064444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-007-0406-1</pub-id></element-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Back</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Bates</surname><given-names>M</given-names></name><name name-style="western"><surname>Bowden</surname><given-names>A</given-names></name><name name-style="western"><surname>Breckenridge</surname><given-names>AM</given-names></name><name name-style="western"><surname>Hall</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Jones</surname><given-names>H</given-names></name><name name-style="western"><surname>MacIver</surname><given-names>M</given-names></name><name name-style="western"><surname>Orme</surname><given-names>M</given-names></name><name name-style="western"><surname>Perucca</surname><given-names>E</given-names></name><name name-style="western"><surname>Richens</surname><given-names>A</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>PH</given-names></name><name name-style="western"><surname>Smith</surname><given-names>E</given-names></name></person-group><article-title>The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy</article-title><source>Contraception</source><year>1980</year><volume>22</volume><fpage>495</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">7471739</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0010-7824(80)90102-x</pub-id></element-citation></ref><ref id="CR21"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Back</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Tjia</surname><given-names>JF</given-names></name><name name-style="western"><surname>Karbwang</surname><given-names>J</given-names></name><name name-style="western"><surname>Colbert</surname><given-names>J</given-names></name></person-group><article-title>In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines</article-title><source>Br J Clin Pharmacol</source><year>1988</year><volume>26</volume><fpage>23</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">3203057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1988.tb03359.x</pub-id><pub-id pub-id-type="pmcid">PMC1386495</pub-id></element-citation></ref><ref id="CR22"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Backman</surname><given-names>JT</given-names></name><name name-style="western"><surname>Granfors</surname><given-names>MT</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name></person-group><article-title>Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine</article-title><source>Eur J Clin Pharmacol</source><year>2006</year><volume>62</volume><fpage>451</fpage><lpage>461</lpage><pub-id pub-id-type="pmid">16758262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-006-0127-x</pub-id></element-citation></ref><ref id="CR23"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Backman</surname><given-names>JT</given-names></name><name name-style="western"><surname>Filppula</surname><given-names>AM</given-names></name><name name-style="western"><surname>Niemi</surname><given-names>M</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name></person-group><article-title>Role of cytochrome P450 2C8 in drug metabolism and interactions</article-title><source>Pharmacol Rev</source><year>2016</year><volume>68</volume><fpage>168</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">26721703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/pr.115.011411</pub-id></element-citation></ref><ref id="CR24"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bae</surname><given-names>SH</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Choi</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>YF</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>KD</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K</given-names></name><name name-style="western"><surname>Bae</surname><given-names>SK</given-names></name></person-group><article-title>Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes</article-title><source>Chem Biol Interact</source><year>2013</year><volume>205</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">23777987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cbi.2013.06.006</pub-id></element-citation></ref><ref id="CR25"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baes</surname><given-names>M</given-names></name><name name-style="western"><surname>Gulick</surname><given-names>T</given-names></name><name name-style="western"><surname>Choi</surname><given-names>HS</given-names></name><name name-style="western"><surname>Martinoli</surname><given-names>MG</given-names></name><name name-style="western"><surname>Simha</surname><given-names>D</given-names></name><name name-style="western"><surname>Moore</surname><given-names>DD</given-names></name></person-group><article-title>A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements</article-title><source>Mol Cell Biol</source><year>1994</year><volume>14</volume><fpage>1544</fpage><lpage>1552</lpage><pub-id pub-id-type="pmid">8114692</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mcb.14.3.1544</pub-id><pub-id pub-id-type="pmcid">PMC358513</pub-id></element-citation></ref><ref id="CR26"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bailey</surname><given-names>DG</given-names></name><name name-style="western"><surname>Dresser</surname><given-names>G</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>JMO</given-names></name></person-group><article-title>Grapefruit-medication interactions: forbidden fruit or avoidable consequences?</article-title><source>CMAJ</source><year>2013</year><volume>185</volume><fpage>309</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">23184849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1503/cmaj.120951</pub-id><pub-id pub-id-type="pmcid">PMC3589309</pub-id></element-citation></ref><ref id="CR27"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>JR</given-names></name><name name-style="western"><surname>Satarug</surname><given-names>S</given-names></name><name name-style="western"><surname>Reilly</surname><given-names>PE</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Ariyoshi</surname><given-names>N</given-names></name><name name-style="western"><surname>Kamataki</surname><given-names>T</given-names></name><name name-style="western"><surname>Moore</surname><given-names>MR</given-names></name><name name-style="western"><surname>Williams</surname><given-names>DJ</given-names></name></person-group><article-title>Relationships between non-occupational cadmium exposure and expression of nine cytochrome P450 forms in human liver and kidney cortex samples</article-title><source>Biochem Pharmacol</source><year>2001</year><volume>62</volume><fpage>713</fpage><lpage>721</lpage><pub-id pub-id-type="pmid">11551516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0006-2952(01)00716-x</pub-id></element-citation></ref><ref id="CR28"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bapiro</surname><given-names>TE</given-names></name><name name-style="western"><surname>Sayi</surname><given-names>J</given-names></name><name name-style="western"><surname>Hasler</surname><given-names>JA</given-names></name><name name-style="western"><surname>Jande</surname><given-names>M</given-names></name><name name-style="western"><surname>Rimoy</surname><given-names>G</given-names></name><name name-style="western"><surname>Masselle</surname><given-names>A</given-names></name><name name-style="western"><surname>Masimirembwa</surname><given-names>CM</given-names></name></person-group><article-title>Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans</article-title><source>Eur J Clin Pharmacol</source><year>2005</year><volume>61</volume><fpage>755</fpage><lpage>761</lpage><pub-id pub-id-type="pmid">16261361</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-005-0037-3</pub-id></element-citation></ref><ref id="CR29"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barditch-Crovo</surname><given-names>P</given-names></name><name name-style="western"><surname>Trapnell</surname><given-names>CB</given-names></name><name name-style="western"><surname>Ette</surname><given-names>E</given-names></name><name name-style="western"><surname>Zacur</surname><given-names>HA</given-names></name><name name-style="western"><surname>Coresh</surname><given-names>J</given-names></name><name name-style="western"><surname>Rocco</surname><given-names>LE</given-names></name><name name-style="western"><surname>Hendrix</surname><given-names>CW</given-names></name><name name-style="western"><surname>Flexner</surname><given-names>C</given-names></name></person-group><article-title>The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive</article-title><source>Clin Pharmacol Ther</source><year>1999</year><volume>65</volume><fpage>428</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">10223781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0009-9236(99)70138-4</pub-id></element-citation></ref><ref id="CR30"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barecki</surname><given-names>ME</given-names></name><name name-style="western"><surname>Casciano</surname><given-names>CN</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>WW</given-names></name><name name-style="western"><surname>Clement</surname><given-names>RP</given-names></name></person-group><article-title>In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes</article-title><source>Drug Metab Dispos</source><year>2001</year><volume>29</volume><fpage>1173</fpage><lpage>1175</lpage><pub-id pub-id-type="pmid">11502723</pub-id></element-citation></ref><ref id="CR31"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belderbos</surname><given-names>BPS</given-names></name><name name-style="western"><surname>Bins</surname><given-names>S</given-names></name><name name-style="western"><surname>van Leeuwen</surname><given-names>RWF</given-names></name><name name-style="western"><surname>Oomen-de Hoop</surname><given-names>E</given-names></name><name name-style="western"><surname>van der Meer</surname><given-names>N</given-names></name><name name-style="western"><surname>de Bruijn</surname><given-names>P</given-names></name><name name-style="western"><surname>Hamberg</surname><given-names>P</given-names></name><name name-style="western"><surname>Overkleeft</surname><given-names>ENM</given-names></name><name name-style="western"><surname>van der Deure</surname><given-names>WM</given-names></name><name name-style="western"><surname>Lolkema</surname><given-names>MP</given-names></name><name name-style="western"><surname>de Wit</surname><given-names>R</given-names></name><name name-style="western"><surname>Mathijssen</surname><given-names>RHJ</given-names></name></person-group><article-title>Influence of enzalutamide on cabazitaxel pharmacokinetics: a drug&#8211;drug interaction study in metastatic castration-resistant prostate cancer (mCRPC) Patients</article-title><source>Clin Cancer Res</source><year>2018</year><volume>24</volume><fpage>541</fpage><lpage>546</lpage><pub-id pub-id-type="pmid">29150561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-17-2336</pub-id></element-citation></ref><ref id="CR32"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benowitz</surname><given-names>NL</given-names></name><name name-style="western"><surname>Peng</surname><given-names>M</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>P</given-names><suffix>III</suffix></name></person-group><article-title>Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism</article-title><source>Clin Pharmacol Ther</source><year>2003</year><volume>74</volume><fpage>468</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">14586387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clpt.2003.07.001</pub-id></element-citation></ref><ref id="CR33"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benowitz</surname><given-names>NL</given-names></name><name name-style="western"><surname>Lessov-Schlaggar</surname><given-names>C</given-names></name><name name-style="western"><surname>Swan</surname><given-names>GE</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>P</given-names><suffix>III</suffix></name></person-group><article-title>Female sex and oral contraceptive use accelerate nicotine metabolism</article-title><source>Clin Pharmacol Ther</source><year>2006</year><volume>79</volume><fpage>480</fpage><lpage>488</lpage><pub-id pub-id-type="pmid">16678549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clpt.2006.01.008</pub-id></element-citation></ref><ref id="CR34"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berlin</surname><given-names>I</given-names></name><name name-style="western"><surname>Gasior</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Moolchan</surname><given-names>ET</given-names></name></person-group><article-title>Sex-based and hormonal contraception effects on the metabolism of nicotine among adolescent tobacco-dependent smokers</article-title><source>Nicotine Tob Res</source><year>2007</year><volume>9</volume><fpage>493</fpage><lpage>498</lpage><pub-id pub-id-type="pmid">17454704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14622200701243193</pub-id></element-citation></ref><ref id="CR35"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berman</surname><given-names>ML</given-names></name><name name-style="western"><surname>Green</surname><given-names>OC</given-names></name></person-group><article-title>Acute stimulation of cortisol metabolism by pentobarbital in man</article-title><source>Anesthesiology</source><year>1971</year><volume>34</volume><fpage>365</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">4926523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000542-197104000-00020</pub-id></element-citation></ref><ref id="CR36"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernasconi</surname><given-names>C</given-names></name><name name-style="western"><surname>Pelkonen</surname><given-names>O</given-names></name><name name-style="western"><surname>Andersson</surname><given-names>TB</given-names></name><name name-style="western"><surname>Strickland</surname><given-names>J</given-names></name><name name-style="western"><surname>Wilk-Zasadna</surname><given-names>I</given-names></name><name name-style="western"><surname>Asturiol</surname><given-names>D</given-names></name><name name-style="western"><surname>Cole</surname><given-names>T</given-names></name><name name-style="western"><surname>Liska</surname><given-names>R</given-names></name><name name-style="western"><surname>Worth</surname><given-names>A</given-names></name><name name-style="western"><surname>M&#252;ller-Vieira</surname><given-names>U</given-names></name><name name-style="western"><surname>Richert</surname><given-names>L</given-names></name><name name-style="western"><surname>Chesne</surname><given-names>C</given-names></name><name name-style="western"><surname>Coecke</surname><given-names>S</given-names></name></person-group><article-title>Validation of in vitro methods for human cytochrome P450 enzyme induction: outcome of a multi-laboratory study</article-title><source>Toxicol In Vitro</source><year>2019</year><volume>60</volume><fpage>212</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">31158489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tiv.2019.05.019</pub-id><pub-id pub-id-type="pmcid">PMC6718736</pub-id></element-citation></ref><ref id="CR37"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Best</surname><given-names>BM</given-names></name><name name-style="western"><surname>Goicoechea</surname><given-names>M</given-names></name></person-group><article-title>Efavirenz-still first-line king?</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2008</year><volume>4</volume><fpage>965</fpage><lpage>972</lpage><pub-id pub-id-type="pmid">18624683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/17425255.4.7.965</pub-id><pub-id pub-id-type="pmcid">PMC5761737</pub-id></element-citation></ref><ref id="CR38"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bilbao-Meseguer</surname><given-names>I</given-names></name><name name-style="western"><surname>Jose</surname><given-names>BS</given-names></name><name name-style="western"><surname>Lopez-Gimenez</surname><given-names>LR</given-names></name><name name-style="western"><surname>Gil</surname><given-names>MA</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>L</given-names></name><name name-style="western"><surname>Casta&#241;o</surname><given-names>M</given-names></name><name name-style="western"><surname>Sautua</surname><given-names>S</given-names></name><name name-style="western"><surname>Basagoiti</surname><given-names>AD</given-names></name><name name-style="western"><surname>Belaustegui</surname><given-names>A</given-names></name><name name-style="western"><surname>Baza</surname><given-names>B</given-names></name><name name-style="western"><surname>Baskaran</surname><given-names>Z</given-names></name><name name-style="western"><surname>Bustinza</surname><given-names>A</given-names></name></person-group><article-title>Drug interactions with sunitinib</article-title><source>J Oncol Pharm Pract</source><year>2015</year><volume>21</volume><fpage>52</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">24403097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1078155213516158</pub-id></element-citation></ref><ref id="CR39"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Birdwell</surname><given-names>KA</given-names></name><name name-style="western"><surname>Decker</surname><given-names>B</given-names></name><name name-style="western"><surname>Barbarino</surname><given-names>JM</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>JF</given-names></name><name name-style="western"><surname>Stein</surname><given-names>CM</given-names></name><name name-style="western"><surname>Sadee</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Vinks</surname><given-names>AA</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Swen</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Leeder</surname><given-names>JS</given-names></name><name name-style="western"><surname>van Schaik</surname><given-names>R</given-names></name><name name-style="western"><surname>Thummel</surname><given-names>KE</given-names></name><name name-style="western"><surname>Klein</surname><given-names>TE</given-names></name><name name-style="western"><surname>Caudle</surname><given-names>KE</given-names></name><name name-style="western"><surname>IaM</surname><given-names>MacPhee</given-names></name></person-group><article-title>Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing</article-title><source>Clin Pharmacol Ther</source><year>2015</year><volume>98</volume><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">25801146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.113</pub-id><pub-id pub-id-type="pmcid">PMC4481158</pub-id></element-citation></ref><ref id="CR40"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Birmingham</surname><given-names>AT</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Orme</surname><given-names>ML</given-names></name><name name-style="western"><surname>Park</surname><given-names>BK</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Short</surname><given-names>AH</given-names></name><name name-style="western"><surname>Southgate</surname><given-names>PJ</given-names></name></person-group><article-title>Antibacterial activity in serum and urine following oral administration in man of DL473 (a cyclopentyl derivative of rifampicin) [proceedings]</article-title><source>Br J Clin Pharmacol</source><year>1978</year><volume>6</volume><fpage>455P</fpage><lpage>456P</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1978.tb04626.x</pub-id><pub-id pub-id-type="pmid">728306</pub-id></element-citation></ref><ref id="CR41"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bledsoe</surname><given-names>T</given-names></name><name name-style="western"><surname>Island</surname><given-names>DP</given-names></name><name name-style="western"><surname>Ney</surname><given-names>RL</given-names></name><name name-style="western"><surname>Liddle</surname><given-names>GW</given-names></name></person-group><article-title>An Effect of O, P&#8217;-Ddd on the extra-adrenal metabolism of cortisol in man</article-title><source>J Clin Endocrinol Metab</source><year>1964</year><volume>24</volume><fpage>1303</fpage><lpage>1311</lpage><pub-id pub-id-type="pmid">14243174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jcem-24-12-1303</pub-id></element-citation></ref><ref id="CR42"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blumberg</surname><given-names>B</given-names></name><name name-style="western"><surname>Sabbagh</surname><given-names>W</given-names></name><name name-style="western"><surname>Juguilon</surname><given-names>H</given-names></name><name name-style="western"><surname>Bolado</surname><given-names>J</given-names></name><name name-style="western"><surname>van Meter</surname><given-names>CM</given-names></name><name name-style="western"><surname>Ong</surname><given-names>ES</given-names></name><name name-style="western"><surname>Evans</surname><given-names>RM</given-names></name></person-group><article-title>SXR, a novel steroid and xenobiotic-sensing nuclear receptor</article-title><source>Genes Dev</source><year>1998</year><volume>12</volume><fpage>3195</fpage><lpage>3205</lpage><pub-id pub-id-type="pmid">9784494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/gad.12.20.3195</pub-id><pub-id pub-id-type="pmcid">PMC317212</pub-id></element-citation></ref><ref id="CR43"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bock</surname><given-names>KW</given-names></name></person-group><article-title>Aryl hydrocarbon receptor (AHR): from selected human target genes and crosstalk with transcription factors to multiple AHR functions</article-title><source>Biochem Pharmacol</source><year>2019</year><volume>168</volume><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">31228464</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2019.06.015</pub-id></element-citation></ref><ref id="CR44"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bodin</surname><given-names>K</given-names></name><name name-style="western"><surname>Bretillon</surname><given-names>L</given-names></name><name name-style="western"><surname>Aden</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bertilsson</surname><given-names>L</given-names></name><name name-style="western"><surname>Broome</surname><given-names>U</given-names></name><name name-style="western"><surname>Einarsson</surname><given-names>C</given-names></name><name name-style="western"><surname>Diczfalusy</surname><given-names>U</given-names></name></person-group><article-title>Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>38685</fpage><lpage>38689</lpage><pub-id pub-id-type="pmid">11514559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M105127200</pub-id></element-citation></ref><ref id="CR45"><mixed-citation publication-type="other">Boehringer-Ingelheim (2005) Tipranavir: Antiviral Drugs Advisory Committee (AVDAC) Briefing Document. NDA 21-814</mixed-citation></ref><ref id="CR46"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bohnert</surname><given-names>T</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A</given-names></name><name name-style="western"><surname>Templeton</surname><given-names>I</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C</given-names></name><name name-style="western"><surname>Lai</surname><given-names>G</given-names></name><name name-style="western"><surname>Leung</surname><given-names>L</given-names></name><name name-style="western"><surname>Tse</surname><given-names>S</given-names></name><name name-style="western"><surname>Einolf</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sinz</surname><given-names>M</given-names></name><name name-style="western"><surname>Stearns</surname><given-names>R</given-names></name><name name-style="western"><surname>Walsky</surname><given-names>R</given-names></name><name name-style="western"><surname>Geng</surname><given-names>W</given-names></name><name name-style="western"><surname>Sudsakorn</surname><given-names>S</given-names></name><name name-style="western"><surname>Moore</surname><given-names>D</given-names></name><name name-style="western"><surname>He</surname><given-names>L</given-names></name><name name-style="western"><surname>Wahlstrom</surname><given-names>J</given-names></name><name name-style="western"><surname>Keirns</surname><given-names>J</given-names></name><name name-style="western"><surname>Narayanan</surname><given-names>R</given-names></name><name name-style="western"><surname>Lang</surname><given-names>D</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name></person-group><article-title>Evaluation of a new molecular entity as a victim of metabolic drug&#8211;drug interactions-an industry perspective</article-title><source>Drug Metab Dispos</source><year>2016</year><volume>44</volume><fpage>1399</fpage><lpage>1423</lpage><pub-id pub-id-type="pmid">27052879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.115.069096</pub-id></element-citation></ref><ref id="CR47"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolton</surname><given-names>AE</given-names></name><name name-style="western"><surname>Peng</surname><given-names>B</given-names></name><name name-style="western"><surname>Hubert</surname><given-names>M</given-names></name><name name-style="western"><surname>Krebs-Brown</surname><given-names>A</given-names></name><name name-style="western"><surname>Capdeville</surname><given-names>R</given-names></name><name name-style="western"><surname>Keller</surname><given-names>U</given-names></name><name name-style="western"><surname>Seiberling</surname><given-names>M</given-names></name></person-group><article-title>Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects</article-title><source>Cancer Chemother Pharmacol</source><year>2004</year><volume>53</volume><fpage>102</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">14605865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-003-0722-9</pub-id></element-citation></ref><ref id="CR48"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyle</surname><given-names>JO</given-names></name><name name-style="western"><surname>Gumus</surname><given-names>ZH</given-names></name><name name-style="western"><surname>Kacker</surname><given-names>A</given-names></name><name name-style="western"><surname>Choksi</surname><given-names>VL</given-names></name><name name-style="western"><surname>Bocker</surname><given-names>JM</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>XK</given-names></name><name name-style="western"><surname>Yantiss</surname><given-names>RK</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>DB</given-names></name><name name-style="western"><surname>Du</surname><given-names>B</given-names></name><name name-style="western"><surname>Judson</surname><given-names>BL</given-names></name><name name-style="western"><surname>Subbaramaiah</surname><given-names>K</given-names></name><name name-style="western"><surname>Dannenberg</surname><given-names>AJ</given-names></name></person-group><article-title>PMC2833216; effects of cigarette smoke on the human oral mucosal transcriptome</article-title><source>Cancer Prev Res (Phila)</source><year>2010</year><volume>3</volume><fpage>266</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">20179299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1940-6207.CAPR-09-0192</pub-id><pub-id pub-id-type="pmcid">PMC2833216</pub-id></element-citation></ref><ref id="CR49"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breckenridge</surname><given-names>A</given-names></name><name name-style="western"><surname>Orme</surname><given-names>M</given-names></name></person-group><article-title>Clinical implications of enzyme induction</article-title><source>Ann N Y Acad Sci</source><year>1971</year><volume>179</volume><fpage>421</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">5285387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1749-6632.1971.tb46919.x</pub-id></element-citation></ref><ref id="CR50"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Britz</surname><given-names>H</given-names></name><name name-style="western"><surname>Hanke</surname><given-names>N</given-names></name><name name-style="western"><surname>Volz</surname><given-names>A</given-names></name><name name-style="western"><surname>Spigset</surname><given-names>O</given-names></name><name name-style="western"><surname>Schwab</surname><given-names>M</given-names></name><name name-style="western"><surname>Eissing</surname><given-names>T</given-names></name><name name-style="western"><surname>Wendl</surname><given-names>T</given-names></name><name name-style="western"><surname>Frechen</surname><given-names>S</given-names></name><name name-style="western"><surname>Lehr</surname><given-names>T</given-names></name></person-group><article-title>Physiologically-based pharmacokinetic models for CYP1A2 drug&#8211;drug interaction prediction: a modeling network of fluvoxamine, theophylline, caffeine, rifampicin, and midazolam</article-title><source>CPT Pharmacomet Syst Pharmacol</source><year>2019</year><volume>8</volume><fpage>296</fpage><lpage>307</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psp4.12397</pub-id><pub-id pub-id-type="pmcid">PMC6539736</pub-id><pub-id pub-id-type="pmid">30762305</pub-id></element-citation></ref><ref id="CR51"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buchman</surname><given-names>CD</given-names></name><name name-style="western"><surname>Chai</surname><given-names>SC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T</given-names></name></person-group><article-title>A current structural perspective on PXR and CAR in drug metabolism</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2018</year><volume>14</volume><fpage>635</fpage><lpage>647</lpage><pub-id pub-id-type="pmid">29757018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17425255.2018.1476488</pub-id><pub-id pub-id-type="pmcid">PMC6002932</pub-id></element-citation></ref><ref id="CR52"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buchthal</surname><given-names>J</given-names></name><name name-style="western"><surname>Grund</surname><given-names>KE</given-names></name><name name-style="western"><surname>Buchmann</surname><given-names>A</given-names></name><name name-style="western"><surname>Schrenk</surname><given-names>D</given-names></name><name name-style="western"><surname>Beaune</surname><given-names>P</given-names></name><name name-style="western"><surname>Bock</surname><given-names>KW</given-names></name></person-group><article-title>Induction of cytochrome P4501A by smoking or omeprazole in comparison with UDP-glucuronosyltransferase in biopsies of human duodenal mucosa</article-title><source>Eur J Clin Pharmacol</source><year>1995</year><volume>47</volume><fpage>431</fpage><lpage>435</lpage><pub-id pub-id-type="pmid">7720765</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00196857</pub-id></element-citation></ref><ref id="CR53"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Budha</surname><given-names>NR</given-names></name><name name-style="western"><surname>Ji</surname><given-names>T</given-names></name><name name-style="western"><surname>Musib</surname><given-names>L</given-names></name><name name-style="western"><surname>Eppler</surname><given-names>S</given-names></name><name name-style="western"><surname>Dresser</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jin</surname><given-names>JY</given-names></name></person-group><article-title>Evaluation of cytochrome P450 3A4-mediated drug&#8211;drug interaction potential for cobimetinib using physiologically based pharmacokinetic modeling and simulation</article-title><source>Clin Pharmacokinet</source><year>2016</year><volume>55</volume><fpage>1435</fpage><lpage>1445</lpage><pub-id pub-id-type="pmid">27225997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-016-0412-5</pub-id></element-citation></ref><ref id="CR54"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burk</surname><given-names>O</given-names></name><name name-style="western"><surname>Koch</surname><given-names>I</given-names></name><name name-style="western"><surname>Raucy</surname><given-names>J</given-names></name><name name-style="western"><surname>Hustert</surname><given-names>E</given-names></name><name name-style="western"><surname>Eichelbaum</surname><given-names>M</given-names></name><name name-style="western"><surname>Brockmoller</surname><given-names>J</given-names></name><name name-style="western"><surname>Zanger</surname><given-names>UM</given-names></name><name name-style="western"><surname>Wojnowski</surname><given-names>L</given-names></name></person-group><article-title>The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR)</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>38379</fpage><lpage>38385</lpage><pub-id pub-id-type="pmid">15252010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M404949200</pub-id></element-citation></ref><ref id="CR55"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burstein</surname><given-names>S</given-names></name><name name-style="western"><surname>Klaiber</surname><given-names>EL</given-names></name></person-group><article-title>Phenobarbital-induced increase in 6-beta-hydroxycortisol excretion: clue to its significance in human urine</article-title><source>J Clin Endocrinol Metab</source><year>1965</year><volume>25</volume><fpage>293</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">14264253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jcem-25-2-293</pub-id></element-citation></ref><ref id="CR56"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cada</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Demaris</surname><given-names>K</given-names></name><name name-style="western"><surname>Levien</surname><given-names>TL</given-names></name><name name-style="western"><surname>Baker</surname><given-names>DE</given-names></name></person-group><article-title>Teriflunomide</article-title><source>Hosp Pharm</source><year>2013</year><volume>48</volume><fpage>231</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">24421467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1310/hpj4803-231</pub-id><pub-id pub-id-type="pmcid">PMC3839508</pub-id></element-citation></ref><ref id="CR57"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>RW</given-names></name><name name-style="western"><surname>Edom</surname><given-names>RW</given-names></name><name name-style="western"><surname>Evans</surname><given-names>DC</given-names></name><name name-style="western"><surname>Shou</surname><given-names>M</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>AD</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Dean</surname><given-names>DC</given-names></name><name name-style="western"><surname>Baillie</surname><given-names>TA</given-names></name></person-group><article-title>Validation of (&#8722;)-<italic toggle="yes">N</italic>-3-benzyl-phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes</article-title><source>Drug Metab Dispos</source><year>2004</year><volume>32</volume><fpage>584</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">15155548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.32.6.584</pub-id></element-citation></ref><ref id="CR58"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caraco</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zylber-Katz</surname><given-names>E</given-names></name><name name-style="western"><surname>Fridlander</surname><given-names>M</given-names></name><name name-style="western"><surname>Admon</surname><given-names>D</given-names></name><name name-style="western"><surname>Levy</surname><given-names>M</given-names></name></person-group><article-title>The effect of short-term dipyrone administration on cyclosporin pharmacokinetics</article-title><source>Eur J Clin Pharmacol</source><year>1999</year><volume>55</volume><fpage>475</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">10492062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002280050659</pub-id></element-citation></ref><ref id="CR59"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carazo</surname><given-names>A</given-names></name><name name-style="western"><surname>Dusek</surname><given-names>J</given-names></name><name name-style="western"><surname>Holas</surname><given-names>O</given-names></name><name name-style="western"><surname>Skoda</surname><given-names>J</given-names></name><name name-style="western"><surname>Hyrsova</surname><given-names>L</given-names></name><name name-style="western"><surname>Smutny</surname><given-names>T</given-names></name><name name-style="western"><surname>Soukup</surname><given-names>T</given-names></name><name name-style="western"><surname>Dosedel</surname><given-names>M</given-names></name><name name-style="western"><surname>P&#225;vek</surname><given-names>P</given-names></name></person-group><article-title>Teriflunomide is an indirect human constitutive androstane receptor (CAR) activator interacting with epidermal growth factor (EGF) signaling</article-title><source>Front Pharmacol</source><year>2018</year><volume>9</volume><fpage>993</fpage><pub-id pub-id-type="pmid">30364229</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2018.00993</pub-id><pub-id pub-id-type="pmcid">PMC6193428</pub-id></element-citation></ref><ref id="CR60"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carroccio</surname><given-names>A</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name><name name-style="western"><surname>Cederbaum</surname><given-names>AI</given-names></name></person-group><article-title>Ethanol increases content and activity of human cytochrome P4502E1 in a transduced HepG2 cell line</article-title><source>Biochem Biophys Res Commun</source><year>1994</year><volume>203</volume><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">8074729</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/bbrc.1994.2242</pub-id></element-citation></ref><ref id="CR61"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cashman</surname><given-names>JR</given-names></name><name name-style="western"><surname>Park</surname><given-names>SB</given-names></name><name name-style="western"><surname>Yang</surname><given-names>ZC</given-names></name><name name-style="western"><surname>Wrighton</surname><given-names>SA</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>P</given-names><suffix>III</suffix></name><name name-style="western"><surname>Benowitz</surname><given-names>NL</given-names></name></person-group><article-title>Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine <italic toggle="yes">N</italic>&#8242;-oxide</article-title><source>Chem Res Toxicol</source><year>1992</year><volume>5</volume><fpage>639</fpage><lpage>646</lpage><pub-id pub-id-type="pmid">1446003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/tx00029a008</pub-id></element-citation></ref><ref id="CR62"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cattaneo</surname><given-names>D</given-names></name><name name-style="western"><surname>Cossu</surname><given-names>MV</given-names></name><name name-style="western"><surname>Rizzardini</surname><given-names>G</given-names></name></person-group><article-title>Pharmacokinetic drug evaluation of ritonavir (versus cobicistat) as adjunctive therapy in the treatment of HIV</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2019</year><volume>15</volume><fpage>927</fpage><lpage>935</lpage><pub-id pub-id-type="pmid">31668105</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17425255.2019.1685495</pub-id></element-citation></ref><ref id="CR63"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cederbaum</surname><given-names>AI</given-names></name></person-group><article-title>CYP2E1-biochemical and toxicological aspects and role in alcohol-induced liver injury</article-title><source>Mt Sinai J Med</source><year>2006</year><volume>73</volume><fpage>657</fpage><lpage>672</lpage><pub-id pub-id-type="pmid">16878272</pub-id></element-citation></ref><ref id="CR64"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chai</surname><given-names>SC</given-names></name><name name-style="western"><surname>Cherian</surname><given-names>MT</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T</given-names></name></person-group><article-title>Small-molecule modulators of PXR and CAR</article-title><source>Biochim Biophys Acta</source><year>2016</year><volume>1859</volume><fpage>1141</fpage><lpage>1154</lpage><pub-id pub-id-type="pmid">26921498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbagrm.2016.02.013</pub-id><pub-id pub-id-type="pmcid">PMC4975625</pub-id></element-citation></ref><ref id="CR65"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>ECY</given-names></name><name name-style="western"><surname>New</surname><given-names>LS</given-names></name><name name-style="western"><surname>Chua</surname><given-names>TB</given-names></name><name name-style="western"><surname>Yap</surname><given-names>CW</given-names></name><name name-style="western"><surname>Ho</surname><given-names>HK</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>SD</given-names></name></person-group><article-title>Interaction of lapatinib with cytochrome P450 3A5</article-title><source>Drug Metab Dispos</source><year>2012</year><volume>40</volume><fpage>1414</fpage><lpage>1422</lpage><pub-id pub-id-type="pmid">22511346</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.112.044958</pub-id></element-citation></ref><ref id="CR66"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>J</given-names></name><name name-style="western"><surname>Oshiro</surname><given-names>T</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S</given-names></name><name name-style="western"><surname>Higa</surname><given-names>A</given-names></name><name name-style="western"><surname>Black</surname><given-names>S</given-names></name><name name-style="western"><surname>Todorovic</surname><given-names>A</given-names></name><name name-style="western"><surname>Elbarbry</surname><given-names>F</given-names></name><name name-style="western"><surname>Harrelson</surname><given-names>JP</given-names></name></person-group><article-title>Inactivation of CYP2A6 by the dietary phenylpropanoid trans-cinnamic aldehyde (Cinnamaldehyde) and estimation of interactions with nicotine and letrozole</article-title><source>Drug Metab Dispos</source><year>2016</year><volume>44</volume><fpage>534</fpage><lpage>543</lpage><pub-id pub-id-type="pmid">26851241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.115.067942</pub-id><pub-id pub-id-type="pmcid">PMC4810772</pub-id></element-citation></ref><ref id="CR67"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>TK</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>WB</given-names></name></person-group><article-title>Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2</article-title><source>J Pharmacol Exp Ther</source><year>2001</year><volume>299</volume><fpage>874</fpage><lpage>882</lpage><pub-id pub-id-type="pmid">11714871</pub-id></element-citation></ref><ref id="CR68"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>TK</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Pillay</surname><given-names>V</given-names></name><name name-style="western"><surname>Ho</surname><given-names>JY</given-names></name><name name-style="western"><surname>Bandiera</surname><given-names>SM</given-names></name></person-group><article-title>Real-time polymerase chain reaction analysis of CYP1B1 gene expression in human liver</article-title><source>Toxicol Sci</source><year>2003</year><volume>71</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">12520071</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/toxsci/71.1.11</pub-id></element-citation></ref><ref id="CR69"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chapron</surname><given-names>B</given-names></name><name name-style="western"><surname>Risler</surname><given-names>L</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>B</given-names></name><name name-style="western"><surname>Collins</surname><given-names>C</given-names></name><name name-style="western"><surname>Thummel</surname><given-names>K</given-names></name><name name-style="western"><surname>Shen</surname><given-names>D</given-names></name></person-group><article-title>Reversible, time-dependent inhibition of CYP3A-mediated metabolism of midazolam and tacrolimus by telaprevir in human liver microsomes</article-title><source>J Pharm Pharm Sci</source><year>2015</year><volume>18</volume><fpage>101</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">25877445</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18433/j3288c</pub-id></element-citation></ref><ref id="CR70"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>GVR</given-names></name></person-group><article-title>CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment</article-title><source>Pharmgenom Pers Med</source><year>2018</year><volume>11</volume><fpage>23</fpage><lpage>33</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/PGPM.S107710</pub-id><pub-id pub-id-type="pmcid">PMC5846312</pub-id><pub-id pub-id-type="pmid">29563827</pub-id></element-citation></ref><ref id="CR71"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>SS</given-names></name><name name-style="western"><surname>Negishi</surname><given-names>M</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>JA</given-names></name></person-group><article-title>Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter</article-title><source>Mol Pharmacol</source><year>2003</year><volume>64</volume><fpage>316</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">12869636</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/mol.64.2.316</pub-id></element-citation></ref><ref id="CR72"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>P</given-names></name><name name-style="western"><surname>Ou-Yang</surname><given-names>D</given-names></name><name name-style="western"><surname>Fan</surname><given-names>L</given-names></name><name name-style="western"><surname>Guo</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>YN</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tu</surname><given-names>JH</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>G</given-names></name><name name-style="western"><surname>Huang</surname><given-names>YF</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>HH</given-names></name></person-group><article-title>Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, <italic toggle="yes">N</italic>-acetyltransferase and xanthine oxidase activity in healthy volunteers</article-title><source>Clin Exp Pharmacol Physiol</source><year>2009</year><volume>36</volume><fpage>828</fpage><lpage>833</lpage><pub-id pub-id-type="pmid">19215233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1440-1681.2009.05158.x</pub-id></element-citation></ref><ref id="CR73"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Wan</surname><given-names>YJ</given-names></name></person-group><article-title>2784018; Retinoids activate RXR/CAR-mediated pathway and induce CYP3A</article-title><source>Biochem Pharmacol</source><year>2010</year><volume>79</volume><fpage>270</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">19686701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2009.08.012</pub-id><pub-id pub-id-type="pmcid">PMC2784018</pub-id></element-citation></ref><ref id="CR74"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>CQ</given-names></name><name name-style="western"><surname>He</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>BL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Tan</surname><given-names>ZR</given-names></name><name name-style="western"><surname>Cao</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>LP</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>HH</given-names></name></person-group><article-title>Genistein alters caffeine exposure in healthy female volunteers</article-title><source>Eur J Clin Pharmacol</source><year>2011</year><volume>67</volume><fpage>347</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">21222115</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-010-0964-5</pub-id></element-citation></ref><ref id="CR75"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name><name name-style="western"><surname>Pawlak</surname><given-names>S</given-names></name><name name-style="western"><surname>James</surname><given-names>LP</given-names></name><name name-style="western"><surname>Peltz</surname><given-names>G</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K</given-names></name><name name-style="western"><surname>Ginman</surname><given-names>K</given-names></name><name name-style="western"><surname>Bergeron</surname><given-names>M</given-names></name><name name-style="western"><surname>Pithavala</surname><given-names>YK</given-names></name></person-group><article-title>The effect of rifampin on the pharmacokinetics and safety of lorlatinib: results of a phase one, open-label, crossover study in healthy participants</article-title><source>Adv Ther</source><year>2020</year><volume>37</volume><fpage>745</fpage><lpage>758</lpage><pub-id pub-id-type="pmid">31863284</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12325-019-01198-9</pub-id></element-citation></ref><ref id="CR76"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chernyak</surname><given-names>YI</given-names></name><name name-style="western"><surname>Merinova</surname><given-names>AP</given-names></name><name name-style="western"><surname>Shelepchikov</surname><given-names>AA</given-names></name><name name-style="western"><surname>Kolesnikov</surname><given-names>SI</given-names></name><name name-style="western"><surname>Grassman</surname><given-names>JA</given-names></name></person-group><article-title>Impact of dioxins on antipyrine metabolism in firefighters</article-title><source>Toxicol Lett</source><year>2016</year><volume>250&#8211;251</volume><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.toxlet.2016.04.006</pub-id><pub-id pub-id-type="pmid">27067104</pub-id></element-citation></ref><ref id="CR77"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chetty</surname><given-names>M</given-names></name><name name-style="western"><surname>Miller</surname><given-names>R</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>MA</given-names></name></person-group><article-title>Phenytoin auto-induction</article-title><source>Ther Drug Monit</source><year>1998</year><volume>20</volume><fpage>60</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">9485556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007691-199802000-00011</pub-id></element-citation></ref><ref id="CR78"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chhun</surname><given-names>S</given-names></name><name name-style="western"><surname>Verstuyft</surname><given-names>C</given-names></name><name name-style="western"><surname>Rizzo-Padoin</surname><given-names>N</given-names></name><name name-style="western"><surname>Simoneau</surname><given-names>G</given-names></name><name name-style="western"><surname>Becquemont</surname><given-names>L</given-names></name><name name-style="western"><surname>Peretti</surname><given-names>I</given-names></name><name name-style="western"><surname>Swaisland</surname><given-names>A</given-names></name><name name-style="western"><surname>Wortelboer</surname><given-names>R</given-names></name><name name-style="western"><surname>Bergmann</surname><given-names>JF</given-names></name><name name-style="western"><surname>Mouly</surname><given-names>S</given-names></name></person-group><article-title>Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers</article-title><source>Br J Clin Pharmacol</source><year>2009</year><volume>68</volume><fpage>226</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">19694743</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2009.03438.x</pub-id><pub-id pub-id-type="pmcid">PMC2767287</pub-id></element-citation></ref><ref id="CR79"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chi</surname><given-names>AC</given-names></name><name name-style="western"><surname>Appleton</surname><given-names>K</given-names></name><name name-style="western"><surname>Henriod</surname><given-names>JB</given-names></name><name name-style="western"><surname>Krayer</surname><given-names>JW</given-names></name><name name-style="western"><surname>Marlow</surname><given-names>NM</given-names></name><name name-style="western"><surname>Bandyopadhyay</surname><given-names>D</given-names></name><name name-style="western"><surname>Sigmon</surname><given-names>RC</given-names></name><name name-style="western"><surname>Kurtz</surname><given-names>DT</given-names></name></person-group><article-title>2764788; differential induction of CYP1A1 and CYP1B1 by benzo[a]pyrene in oral squamous cell carcinoma cell lines and by tobacco smoking in oral mucosa</article-title><source>Oral Oncol</source><year>2009</year><volume>45</volume><fpage>980</fpage><lpage>985</lpage><pub-id pub-id-type="pmid">19576839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.oraloncology.2009.05.562</pub-id><pub-id pub-id-type="pmcid">PMC2764788</pub-id></element-citation></ref><ref id="CR80"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiba</surname><given-names>K</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>K</given-names></name><name name-style="western"><surname>Manabe</surname><given-names>K</given-names></name><name name-style="western"><surname>Tani</surname><given-names>M</given-names></name><name name-style="western"><surname>Kamataki</surname><given-names>T</given-names></name><name name-style="western"><surname>Ishizaki</surname><given-names>T</given-names></name></person-group><article-title>Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with <italic toggle="yes">S</italic>-mephenytoin 4&#8242;-hydroxylation</article-title><source>J Pharmacol Exp Ther</source><year>1993</year><volume>266</volume><fpage>52</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">8331574</pub-id></element-citation></ref><ref id="CR81"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chien</surname><given-names>JY</given-names></name><name name-style="western"><surname>Peter</surname><given-names>RM</given-names></name><name name-style="western"><surname>Nolan</surname><given-names>CM</given-names></name><name name-style="western"><surname>Wartell</surname><given-names>C</given-names></name><name name-style="western"><surname>Slattery</surname><given-names>JT</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>SD</given-names></name><name name-style="western"><surname>Carithers</surname><given-names>RLJ</given-names></name><name name-style="western"><surname>Thummel</surname><given-names>KE</given-names></name></person-group><article-title>Influence of polymorphic <italic toggle="yes">N</italic>-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazid</article-title><source>Clin Pharmacol Ther</source><year>1997</year><volume>61</volume><fpage>24</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">9024171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0009-9236(97)90179-X</pub-id></element-citation></ref><ref id="CR82"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>BC</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D</given-names></name><name name-style="western"><surname>Bearz</surname><given-names>A</given-names></name><name name-style="western"><surname>Laurie</surname><given-names>SA</given-names></name><name name-style="western"><surname>McKeage</surname><given-names>M</given-names></name><name name-style="western"><surname>Borra</surname><given-names>G</given-names></name><name name-style="western"><surname>Park</surname><given-names>K</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Ghosn</surname><given-names>M</given-names></name><name name-style="western"><surname>Ardizzoni</surname><given-names>A</given-names></name><name name-style="western"><surname>Maiello</surname><given-names>E</given-names></name><name name-style="western"><surname>Greystoke</surname><given-names>A</given-names></name><name name-style="western"><surname>Yu</surname><given-names>R</given-names></name><name name-style="western"><surname>Osborne</surname><given-names>K</given-names></name><name name-style="western"><surname>Gu</surname><given-names>W</given-names></name><name name-style="western"><surname>Scott</surname><given-names>JW</given-names></name><name name-style="western"><surname>Passos</surname><given-names>VQ</given-names></name><name name-style="western"><surname>Lau</surname><given-names>YY</given-names></name><name name-style="western"><surname>Wrona</surname><given-names>A</given-names></name></person-group><article-title>ASCEND-8: a randomized phase 1 study of ceritinib, 450&#160;mg or 600&#160;mg, taken with a low-fat meal versus 750&#160;mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC)</article-title><source>J Thorac Oncol</source><year>2017</year><volume>12</volume><fpage>1357</fpage><lpage>1367</lpage><pub-id pub-id-type="pmid">28729021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtho.2017.07.005</pub-id></element-citation></ref><ref id="CR83"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chow</surname><given-names>HH</given-names></name><name name-style="western"><surname>Garland</surname><given-names>LL</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>CH</given-names></name><name name-style="western"><surname>Vining</surname><given-names>DR</given-names></name><name name-style="western"><surname>Chew</surname><given-names>WM</given-names></name><name name-style="western"><surname>Miller</surname><given-names>JA</given-names></name><name name-style="western"><surname>Perloff</surname><given-names>M</given-names></name><name name-style="western"><surname>Crowell</surname><given-names>JA</given-names></name><name name-style="western"><surname>Alberts</surname><given-names>DS</given-names></name></person-group><article-title>PMC2933312; Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study</article-title><source>Cancer Prev Res (Phila)</source><year>2010</year><volume>3</volume><fpage>1168</fpage><lpage>1175</lpage><pub-id pub-id-type="pmid">20716633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1940-6207.CAPR-09-0155</pub-id><pub-id pub-id-type="pmcid">PMC2933312</pub-id></element-citation></ref><ref id="CR84"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christian</surname><given-names>K</given-names></name><name name-style="western"><surname>Lang</surname><given-names>M</given-names></name><name name-style="western"><surname>Maurel</surname><given-names>P</given-names></name><name name-style="western"><surname>Raffalli-Mathieu</surname><given-names>F</given-names></name></person-group><article-title>Interaction of heterogeneous nuclear ribonucleoprotein A1 with cytochrome P450 2A6 mRNA: implications for post-transcriptional regulation of the CYP2A6 gene</article-title><source>Mol Pharmacol</source><year>2004</year><volume>65</volume><fpage>1405</fpage><lpage>1414</lpage><pub-id pub-id-type="pmid">15155834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/mol.65.6.1405</pub-id></element-citation></ref><ref id="CR85"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>X</given-names></name><name name-style="western"><surname>Cai</surname><given-names>X</given-names></name><name name-style="western"><surname>Cui</surname><given-names>D</given-names></name><name name-style="western"><surname>Tang</surname><given-names>C</given-names></name><name name-style="western"><surname>Ghosal</surname><given-names>A</given-names></name><name name-style="western"><surname>Chan</surname><given-names>G</given-names></name><name name-style="western"><surname>Green</surname><given-names>MD</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Maciolek</surname><given-names>CM</given-names></name><name name-style="western"><surname>Palamanda</surname><given-names>J</given-names></name><name name-style="western"><surname>Evers</surname><given-names>R</given-names></name><name name-style="western"><surname>Prueksaritanont</surname><given-names>T</given-names></name></person-group><article-title>In vitro assessment of drug&#8211;drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters</article-title><source>Drug Metab Dispos</source><year>2013</year><volume>41</volume><fpage>668</fpage><lpage>681</lpage><pub-id pub-id-type="pmid">23293300</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.112.049668</pub-id></element-citation></ref><ref id="CR86"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chun</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MY</given-names></name><name name-style="western"><surname>Guengerich</surname><given-names>FP</given-names></name></person-group><article-title>Resveratrol is a selective human cytochrome P450 1A1 inhibitor</article-title><source>Biochem Biophys Res Commun</source><year>1999</year><volume>262</volume><fpage>20</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">10448061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/bbrc.1999.1152</pub-id></element-citation></ref><ref id="CR87"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chun</surname><given-names>OK</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SG</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Vance</surname><given-names>T</given-names></name><name name-style="western"><surname>Song</surname><given-names>WO</given-names></name></person-group><article-title>Estimated flavonoid intake of the elderly in the United States and around the world</article-title><source>J Nutr Gerontol Geriatr</source><year>2012</year><volume>31</volume><fpage>190</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">22888838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21551197.2012.702530</pub-id></element-citation></ref><ref id="CR88"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>JY</given-names></name><name name-style="western"><surname>Cho</surname><given-names>JY</given-names></name><name name-style="western"><surname>Lim</surname><given-names>HS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JR</given-names></name><name name-style="western"><surname>Yu</surname><given-names>KS</given-names></name><name name-style="western"><surname>Lim</surname><given-names>KS</given-names></name><name name-style="western"><surname>Shin</surname><given-names>SG</given-names></name><name name-style="western"><surname>Jang</surname><given-names>IJ</given-names></name></person-group><article-title>Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin</article-title><source>Drug Metab Dispos</source><year>2011</year><volume>39</volume><fpage>92</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">20876786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.110.035246</pub-id></element-citation></ref><ref id="CR89"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cleary</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gertz</surname><given-names>M</given-names></name><name name-style="western"><surname>Morcos</surname><given-names>PN</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><name name-style="western"><surname>Youdim</surname><given-names>K</given-names></name><name name-style="western"><surname>Phipps</surname><given-names>A</given-names></name><name name-style="western"><surname>Fowler</surname><given-names>S</given-names></name><name name-style="western"><surname>Parrott</surname><given-names>N</given-names></name></person-group><article-title>Model-based assessments of CYP-mediated drug&#8211;drug interaction risk of alectinib: physiologically based pharmacokinetic modeling supported clinical development</article-title><source>Clin Pharmacol Ther</source><year>2018</year><volume>104</volume><fpage>505</fpage><lpage>514</lpage><pub-id pub-id-type="pmid">29226313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.956</pub-id></element-citation></ref><ref id="CR90"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collom</surname><given-names>SL</given-names></name><name name-style="western"><surname>Laddusaw</surname><given-names>RM</given-names></name><name name-style="western"><surname>Burch</surname><given-names>AM</given-names></name><name name-style="western"><surname>Kuzmic</surname><given-names>P</given-names></name><name name-style="western"><surname>Perry</surname><given-names>MD</given-names></name><name name-style="western"><surname>Miller</surname><given-names>GP</given-names></name></person-group><article-title>CYP2E1 substrate inhibition. Mechanistic interpretation through an effector site for monocyclic compounds</article-title><source>J Biol Chem</source><year>2008</year><volume>283</volume><fpage>3487</fpage><lpage>3496</lpage><pub-id pub-id-type="pmid">18056994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M707630200</pub-id><pub-id pub-id-type="pmcid">PMC3933162</pub-id></element-citation></ref><ref id="CR91"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooper</surname><given-names>CL</given-names></name><name name-style="western"><surname>van Heeswijk</surname><given-names>RPG</given-names></name><name name-style="western"><surname>Gallicano</surname><given-names>K</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>DW</given-names></name></person-group><article-title>A review of low-dose ritonavir in protease inhibitor combination therapy</article-title><source>Clin Infect Dis</source><year>2003</year><volume>36</volume><fpage>1585</fpage><lpage>1592</lpage><pub-id pub-id-type="pmid">12802760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/375233</pub-id></element-citation></ref><ref id="CR92"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cotreau</surname><given-names>MM</given-names></name><name name-style="western"><surname>Siebers</surname><given-names>NM</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J</given-names></name><name name-style="western"><surname>Strahs</surname><given-names>AL</given-names></name><name name-style="western"><surname>Slichenmyer</surname><given-names>W</given-names></name></person-group><article-title>Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor</article-title><source>Clin Pharmacol Drug Dev</source><year>2015</year><volume>4</volume><fpage>137</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">27128217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpdd.145</pub-id></element-citation></ref><ref id="CR93"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coulet</surname><given-names>M</given-names></name><name name-style="western"><surname>Dacasto</surname><given-names>M</given-names></name><name name-style="western"><surname>Eeckhoutte</surname><given-names>C</given-names></name><name name-style="western"><surname>Larrieu</surname><given-names>G</given-names></name><name name-style="western"><surname>Sutra</surname><given-names>JF</given-names></name><name name-style="western"><surname>Alvinerie</surname><given-names>M</given-names></name><name name-style="western"><surname>Mac&#233;</surname><given-names>K</given-names></name><name name-style="western"><surname>Pfeifer</surname><given-names>AM</given-names></name><name name-style="western"><surname>Galtier</surname><given-names>P</given-names></name></person-group><article-title>Identification of human and rabbit cytochromes P450 1A2 as major isoforms involved in thiabendazole 5-hydroxylation</article-title><source>Fundam Clin Pharmacol</source><year>1998</year><volume>12</volume><fpage>225</fpage><lpage>235</lpage><pub-id pub-id-type="pmid">9565779</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1472-8206.1998.tb00946.x</pub-id></element-citation></ref><ref id="CR94"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crauwels</surname><given-names>H</given-names></name><name name-style="western"><surname>van Heeswijk</surname><given-names>Rolf P G</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>M</given-names></name><name name-style="western"><surname>Buelens</surname><given-names>A</given-names></name><name name-style="western"><surname>Vanveggel</surname><given-names>S</given-names></name><name name-style="western"><surname>Boven</surname><given-names>K</given-names></name><name name-style="western"><surname>Hoetelmans</surname><given-names>R</given-names></name></person-group><article-title>Clinical perspective on drug&#8211;drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine</article-title><source>AIDS Rev</source><year>2013</year><volume>15</volume><fpage>87</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">23681436</pub-id></element-citation></ref><ref id="CR95"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crawford</surname><given-names>P</given-names></name><name name-style="western"><surname>Chadwick</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C</given-names></name><name name-style="western"><surname>Tjia</surname><given-names>J</given-names></name><name name-style="western"><surname>Back</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Orme</surname><given-names>M</given-names></name></person-group><article-title>1368312; the interaction of phenytoin and carbamazepine with combined oral contraceptive steroids</article-title><source>Br J Clin Pharmacol</source><year>1990</year><volume>30</volume><fpage>892</fpage><lpage>896</lpage><pub-id pub-id-type="pmid">2126946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1990.tb05457.x</pub-id><pub-id pub-id-type="pmcid">PMC1368312</pub-id></element-citation></ref><ref id="CR96"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuadrado</surname><given-names>A</given-names></name><name name-style="western"><surname>Rojo</surname><given-names>AI</given-names></name><name name-style="western"><surname>Wells</surname><given-names>G</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>JD</given-names></name><name name-style="western"><surname>Cousin</surname><given-names>SP</given-names></name><name name-style="western"><surname>Rumsey</surname><given-names>WL</given-names></name><name name-style="western"><surname>Attucks</surname><given-names>OC</given-names></name><name name-style="western"><surname>Franklin</surname><given-names>S</given-names></name><name name-style="western"><surname>Levonen</surname><given-names>A</given-names></name><name name-style="western"><surname>Kensler</surname><given-names>TW</given-names></name><name name-style="western"><surname>Dinkova-Kostova</surname><given-names>AT</given-names></name></person-group><article-title>Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases</article-title><source>Nat Rev Drug Discov</source><year>2019</year><volume>18</volume><fpage>295</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">30610225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-018-0008-x</pub-id></element-citation></ref><ref id="CR97"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>W</given-names></name><name name-style="western"><surname>Sun</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X</given-names></name><name name-style="western"><surname>Galeva</surname><given-names>N</given-names></name><name name-style="western"><surname>Williams</surname><given-names>TD</given-names></name><name name-style="western"><surname>Staudinger</surname><given-names>JL</given-names></name></person-group><article-title>A SUMO-acetyl switch in PXR biology</article-title><source>Biochim Biophys Acta</source><year>2016</year><volume>1859</volume><fpage>1170</fpage><lpage>1182</lpage><pub-id pub-id-type="pmid">26883953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbagrm.2016.02.008</pub-id><pub-id pub-id-type="pmcid">PMC4975675</pub-id></element-citation></ref><ref id="CR98"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dahlqvist</surname><given-names>R</given-names></name><name name-style="western"><surname>Steiner</surname><given-names>E</given-names></name><name name-style="western"><surname>Koike</surname><given-names>Y</given-names></name><name name-style="western"><surname>von Bahr</surname><given-names>C</given-names></name><name name-style="western"><surname>Lind</surname><given-names>M</given-names></name><name name-style="western"><surname>Billing</surname><given-names>B</given-names></name></person-group><article-title>Induction of theophylline metabolism by pentobarbital</article-title><source>Ther Drug Monit</source><year>1989</year><volume>11</volume><fpage>408</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">2741188</pub-id></element-citation></ref><ref id="CR99"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dailly</surname><given-names>E</given-names></name><name name-style="western"><surname>Tribut</surname><given-names>O</given-names></name><name name-style="western"><surname>Tattevin</surname><given-names>P</given-names></name><name name-style="western"><surname>Arvieux</surname><given-names>C</given-names></name><name name-style="western"><surname>Perre</surname><given-names>P</given-names></name><name name-style="western"><surname>Raffi</surname><given-names>F</given-names></name><name name-style="western"><surname>Jolliet</surname><given-names>P</given-names></name></person-group><article-title>Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients</article-title><source>Eur J Clin Pharmacol</source><year>2006</year><volume>62</volume><fpage>523</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">16763827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-006-0122-2</pub-id></element-citation></ref><ref id="CR100"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daly</surname><given-names>AK</given-names></name><name name-style="western"><surname>Rettie</surname><given-names>AE</given-names></name><name name-style="western"><surname>Fowler</surname><given-names>DM</given-names></name><name name-style="western"><surname>Miners</surname><given-names>JO</given-names></name></person-group><article-title>Pharmacogenomics of CYP2C9: functional and clinical considerations</article-title><source>J Pers Med</source><year>2017</year><volume>8</volume><issue>1</issue><fpage>1</fpage><pub-id pub-id-type="doi">10.3390/jpm8010001</pub-id><pub-id pub-id-type="pmcid">PMC5872075</pub-id><pub-id pub-id-type="pmid">29283396</pub-id></element-citation></ref><ref id="CR101"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Darwish</surname><given-names>M</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>M</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Hellriegel</surname><given-names>ET</given-names></name></person-group><article-title>Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects</article-title><source>Clin Pharmacokinet</source><year>2008</year><volume>47</volume><fpage>61</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">18076219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-200847010-00006</pub-id></element-citation></ref><ref id="CR102"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Almeida</surname><given-names>NR</given-names></name><name name-style="western"><surname>Conda-Sheridan</surname><given-names>M</given-names></name></person-group><article-title>A review of the molecular design and biological activities of RXR agonists</article-title><source>Med Res Rev</source><year>2019</year><volume>39</volume><fpage>1372</fpage><lpage>1397</lpage><pub-id pub-id-type="pmid">30941786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/med.21578</pub-id><pub-id pub-id-type="pmcid">PMC6565479</pub-id></element-citation></ref><ref id="CR103"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Jong</surname><given-names>J</given-names></name><name name-style="western"><surname>Skee</surname><given-names>D</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>J</given-names></name><name name-style="western"><surname>Sukbuntherng</surname><given-names>J</given-names></name><name name-style="western"><surname>Hellemans</surname><given-names>P</given-names></name><name name-style="western"><surname>Smit</surname><given-names>J</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>R</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Snoeys</surname><given-names>J</given-names></name><name name-style="western"><surname>Mannaert</surname><given-names>E</given-names></name></person-group><article-title>Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants</article-title><source>Pharmacol Res Perspect</source><year>2015</year><volume>3</volume><fpage>e00156</fpage><pub-id pub-id-type="pmid">26171235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/prp2.156</pub-id><pub-id pub-id-type="pmcid">PMC4492731</pub-id></element-citation></ref><ref id="CR104"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de la Torre</surname><given-names>BG</given-names></name><name name-style="western"><surname>Albericio</surname><given-names>F</given-names></name></person-group><article-title>The Pharmaceutical Industry in 2019. An analysis of FDA drug approvals from the perspective of molecules</article-title><source>Molecules</source><year>2020</year><volume>25</volume><issue>3</issue><fpage>745</fpage><pub-id pub-id-type="doi">10.3390/molecules25030745</pub-id><pub-id pub-id-type="pmcid">PMC7037960</pub-id><pub-id pub-id-type="pmid">32050446</pub-id></element-citation></ref><ref id="CR105"><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Dean</surname><given-names>L</given-names></name></person-group><person-group person-group-type="editor"><name name-style="western"><surname>Pratt</surname><given-names>VM</given-names></name><name name-style="western"><surname>McLeod</surname><given-names>HL</given-names></name><name name-style="western"><surname>Rubinstein</surname><given-names>WS</given-names></name><name name-style="western"><surname>Scott</surname><given-names>SA</given-names></name><name name-style="western"><surname>Dean</surname><given-names>LC</given-names></name><name name-style="western"><surname>Kattman</surname><given-names>BL</given-names></name><name name-style="western"><surname>Malheiro</surname><given-names>AJ</given-names></name></person-group><article-title>Propafenone therapy and CYP2D6 genotype</article-title><source>Medical genetics summaries</source><year>2012</year><publisher-loc>Bethesda</publisher-loc><publisher-name>National Center for Biotechnology Information (US)</publisher-name><pub-id pub-id-type="pmid">28520383</pub-id></element-citation></ref><ref id="CR106"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delfosse</surname><given-names>V</given-names></name><name name-style="western"><surname>Dendele</surname><given-names>B</given-names></name><name name-style="western"><surname>Huet</surname><given-names>T</given-names></name><name name-style="western"><surname>Grimaldi</surname><given-names>M</given-names></name><name name-style="western"><surname>Boulahtouf</surname><given-names>A</given-names></name><name name-style="western"><surname>Gerbal-Chaloin</surname><given-names>S</given-names></name><name name-style="western"><surname>Beucher</surname><given-names>B</given-names></name><name name-style="western"><surname>Roecklin</surname><given-names>D</given-names></name><name name-style="western"><surname>Muller</surname><given-names>C</given-names></name><name name-style="western"><surname>Rahmani</surname><given-names>R</given-names></name><name name-style="western"><surname>Cavailles</surname><given-names>V</given-names></name><name name-style="western"><surname>Daujat-Chavanieu</surname><given-names>M</given-names></name><name name-style="western"><surname>Vivat</surname><given-names>V</given-names></name><name name-style="western"><surname>Pascussi</surname><given-names>JM</given-names></name><name name-style="western"><surname>Balaguer</surname><given-names>P</given-names></name><name name-style="western"><surname>Bourguet</surname><given-names>W</given-names></name></person-group><article-title>PMC4569708; synergistic activation of human pregnane X receptor by binary cocktails of pharmaceutical and environmental compounds</article-title><source>Nat Commun</source><year>2015</year><volume>6</volume><fpage>8089</fpage><pub-id pub-id-type="pmid">26333997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms9089</pub-id><pub-id pub-id-type="pmcid">PMC4569708</pub-id></element-citation></ref><ref id="CR107"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Depre</surname><given-names>M</given-names></name><name name-style="western"><surname>Van Hecken</surname><given-names>A</given-names></name><name name-style="western"><surname>Oeyen</surname><given-names>M</given-names></name><name name-style="western"><surname>De Lepeleire</surname><given-names>I</given-names></name><name name-style="western"><surname>Laethem</surname><given-names>T</given-names></name><name name-style="western"><surname>Rothenberg</surname><given-names>P</given-names></name><name name-style="western"><surname>Petty</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Majumdar</surname><given-names>A</given-names></name><name name-style="western"><surname>Crumley</surname><given-names>T</given-names></name><name name-style="western"><surname>Panebianco</surname><given-names>D</given-names></name><name name-style="western"><surname>Bergman</surname><given-names>A</given-names></name><name name-style="western"><surname>de Hoon</surname><given-names>JN</given-names></name></person-group><article-title>Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin</article-title><source>Eur J Clin Pharmacol</source><year>2005</year><volume>61</volume><fpage>341</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">15983826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-005-0907-8</pub-id></element-citation></ref><ref id="CR108"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diaz</surname><given-names>D</given-names></name><name name-style="western"><surname>Fabre</surname><given-names>I</given-names></name><name name-style="western"><surname>Daujat</surname><given-names>M</given-names></name><name name-style="western"><surname>Saint Aubert</surname><given-names>B</given-names></name><name name-style="western"><surname>Bories</surname><given-names>P</given-names></name><name name-style="western"><surname>Michel</surname><given-names>H</given-names></name><name name-style="western"><surname>Maurel</surname><given-names>P</given-names></name></person-group><article-title>Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450</article-title><source>Gastroenterology</source><year>1990</year><volume>99</volume><fpage>737</fpage><lpage>747</lpage><pub-id pub-id-type="pmid">2136526</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0016-5085(90)90963-2</pub-id></element-citation></ref><ref id="CR109"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dickinson</surname><given-names>RG</given-names></name><name name-style="western"><surname>Hooper</surname><given-names>WD</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>M</given-names></name><name name-style="western"><surname>Eadie</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Maguire</surname><given-names>B</given-names></name></person-group><article-title>Extent of urinary excretion of <italic toggle="yes">p</italic>-hydroxyphenytoin in healthy subjects given phenytoin</article-title><source>Ther Drug Monit</source><year>1985</year><volume>7</volume><fpage>283</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">4049465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007691-198507030-00008</pub-id></element-citation></ref><ref id="CR110"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dickinson</surname><given-names>L</given-names></name><name name-style="western"><surname>Boffito</surname><given-names>M</given-names></name><name name-style="western"><surname>Back</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Khoo</surname><given-names>SH</given-names></name><name name-style="western"><surname>Pozniak</surname><given-names>AL</given-names></name><name name-style="western"><surname>Mugyenyi</surname><given-names>P</given-names></name><name name-style="western"><surname>Merry</surname><given-names>C</given-names></name><name name-style="western"><surname>Autar</surname><given-names>RS</given-names></name><name name-style="western"><surname>Burger</surname><given-names>DM</given-names></name><name name-style="western"><surname>Aarons</surname><given-names>LJ</given-names></name></person-group><article-title>Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals</article-title><source>J Antimicrob Chemother</source><year>2008</year><volume>62</volume><fpage>1344</fpage><lpage>1355</lpage><pub-id pub-id-type="pmid">18824460</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/dkn399</pub-id><pub-id pub-id-type="pmcid">PMC3597129</pub-id></element-citation></ref><ref id="CR111"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dingemanse</surname><given-names>J</given-names></name><name name-style="western"><surname>Schaarschmidt</surname><given-names>D</given-names></name><name name-style="western"><surname>van Giersbergen</surname><given-names>PL</given-names></name></person-group><article-title>Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin</article-title><source>Clin Pharmacokinet</source><year>2003</year><volume>42</volume><fpage>293</fpage><lpage>301</lpage><pub-id pub-id-type="pmid">12603176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-200342030-00004</pub-id></element-citation></ref><ref id="CR112"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dirix</surname><given-names>L</given-names></name><name name-style="western"><surname>Swaisland</surname><given-names>H</given-names></name><name name-style="western"><surname>Verheul</surname><given-names>HMW</given-names></name><name name-style="western"><surname>Rottey</surname><given-names>S</given-names></name><name name-style="western"><surname>Leunen</surname><given-names>K</given-names></name><name name-style="western"><surname>Jerusalem</surname><given-names>G</given-names></name><name name-style="western"><surname>Rolfo</surname><given-names>C</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>D</given-names></name><name name-style="western"><surname>Molife</surname><given-names>LR</given-names></name><name name-style="western"><surname>Kristeleit</surname><given-names>R</given-names></name><name name-style="western"><surname>Vos-Geelen</surname><given-names>Jd</given-names></name><name name-style="western"><surname>Mau-S&#248;rensen</surname><given-names>M</given-names></name><name name-style="western"><surname>Soetekouw</surname><given-names>P</given-names></name><name name-style="western"><surname>van Herpen</surname><given-names>C</given-names></name><name name-style="western"><surname>Fielding</surname><given-names>A</given-names></name><name name-style="western"><surname>So</surname><given-names>K</given-names></name><name name-style="western"><surname>Bannister</surname><given-names>W</given-names></name><name name-style="western"><surname>Plummer</surname><given-names>R</given-names></name></person-group><article-title>Effect of itraconazole and rifampin on the pharmacokinetics of olaparib in patients with advanced solid tumors: results of two phase I open-label studies</article-title><source>Clin Ther</source><year>2016</year><volume>38</volume><fpage>2286</fpage><lpage>2299</lpage><pub-id pub-id-type="pmid">27745744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinthera.2016.08.010</pub-id></element-citation></ref><ref id="CR113"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Djordjevic</surname><given-names>N</given-names></name><name name-style="western"><surname>Ghotbi</surname><given-names>R</given-names></name><name name-style="western"><surname>Bertilsson</surname><given-names>L</given-names></name><name name-style="western"><surname>Jankovic</surname><given-names>S</given-names></name><name name-style="western"><surname>Aklillu</surname><given-names>E</given-names></name></person-group><article-title>Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes</article-title><source>Eur J Clin Pharmacol</source><year>2008</year><volume>64</volume><fpage>381</fpage><lpage>385</lpage><pub-id pub-id-type="pmid">18157525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-007-0438-6</pub-id></element-citation></ref><ref id="CR114"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dolwick</surname><given-names>KM</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>JV</given-names></name><name name-style="western"><surname>Carver</surname><given-names>LA</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>HI</given-names></name><name name-style="western"><surname>Bradfield</surname><given-names>CA</given-names></name></person-group><article-title>Cloning and expression of a human Ah receptor cDNA</article-title><source>Mol Pharmacol</source><year>1993</year><volume>44</volume><fpage>911</fpage><lpage>917</lpage><pub-id pub-id-type="pmid">8246913</pub-id></element-citation></ref><ref id="CR115"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorrenhaus</surname><given-names>A</given-names></name><name name-style="western"><surname>Muller</surname><given-names>T</given-names></name><name name-style="western"><surname>Roos</surname><given-names>PH</given-names></name></person-group><article-title>Increased CYP1A1 expression in human exfoliated urothelial cells of cigarette smokers compared to non-smokers</article-title><source>Arch Toxicol</source><year>2007</year><volume>81</volume><fpage>19</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">16947004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00204-006-0134-9</pub-id></element-citation></ref><ref id="CR116"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>QQ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>ZJ</given-names></name><name name-style="western"><surname>He</surname><given-names>L</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>XH</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>PXR polymorphisms and their impact on pharmacokinetics/pharmacodynamics of repaglinide in healthy Chinese volunteers</article-title><source>Eur J Clin Pharmacol</source><year>2013</year><volume>69</volume><issue>11</issue><fpage>1917</fpage><lpage>1925</lpage><pub-id pub-id-type="doi">10.1007/s00228-013-1552-2</pub-id><pub-id pub-id-type="pmid">23807564</pub-id></element-citation></ref><ref id="CR117"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>KM</given-names></name><name name-style="western"><surname>Wang</surname><given-names>SY</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>W</given-names></name><name name-style="western"><surname>Mao</surname><given-names>YM</given-names></name><name name-style="western"><surname>Yang</surname><given-names>LJ</given-names></name></person-group><article-title>Effect of quercetin on CYP3A activity in Chinese healthy participants</article-title><source>J Clin Pharmacol</source><year>2012</year><volume>52</volume><fpage>940</fpage><lpage>946</lpage><pub-id pub-id-type="pmid">21680781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0091270011406278</pub-id></element-citation></ref><ref id="CR118"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dumond</surname><given-names>JB</given-names></name><name name-style="western"><surname>Vourvahis</surname><given-names>M</given-names></name><name name-style="western"><surname>Rezk</surname><given-names>NL</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>KB</given-names></name><name name-style="western"><surname>Tien</surname><given-names>HC</given-names></name><name name-style="western"><surname>White</surname><given-names>N</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>SH</given-names></name><name name-style="western"><surname>Choi</surname><given-names>SO</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>MJ</given-names></name><name name-style="western"><surname>La-Beck</surname><given-names>N</given-names></name><name name-style="western"><surname>Drulak</surname><given-names>M</given-names></name><name name-style="western"><surname>Sabo</surname><given-names>JP</given-names></name><name name-style="western"><surname>Castles</surname><given-names>MA</given-names></name><name name-style="western"><surname>Macgregor</surname><given-names>TR</given-names></name><name name-style="western"><surname>Kashuba</surname><given-names>AD</given-names></name></person-group><article-title>2882206; A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir</article-title><source>Clin Pharmacol Ther</source><year>2010</year><volume>87</volume><fpage>735</fpage><lpage>742</lpage><pub-id pub-id-type="pmid">20147896</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2009.253</pub-id><pub-id pub-id-type="pmcid">PMC2882206</pub-id></element-citation></ref><ref id="CR119"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duran</surname><given-names>I</given-names></name><name name-style="western"><surname>Carles</surname><given-names>J</given-names></name><name name-style="western"><surname>Bulat</surname><given-names>I</given-names></name><name name-style="western"><surname>Hellemans</surname><given-names>P</given-names></name><name name-style="western"><surname>Mitselos</surname><given-names>A</given-names></name><name name-style="western"><surname>Ward</surname><given-names>P</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>J</given-names></name><name name-style="western"><surname>Armas</surname><given-names>D</given-names></name><name name-style="western"><surname>Chien</surname><given-names>C</given-names></name></person-group><article-title>Pharmacokinetic drug-drug interaction of apalutamide, part 1: clinical studies in healthy men and patients with castration-resistant prostate cancer</article-title><source>Clin Pharmacokinet</source><year>2020</year><volume>59</volume><issue>9</issue><fpage>1135</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1007/s40262-020-00882-2</pub-id><pub-id pub-id-type="pmid">32338345</pub-id></element-citation></ref><ref id="CR120"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Durr</surname><given-names>D</given-names></name><name name-style="western"><surname>Stieger</surname><given-names>B</given-names></name><name name-style="western"><surname>Kullak-Ublick</surname><given-names>G</given-names></name><name name-style="western"><surname>Rentsch</surname><given-names>KM</given-names></name><name name-style="western"><surname>Steinert</surname><given-names>HC</given-names></name><name name-style="western"><surname>Meier</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Fattinger</surname><given-names>K</given-names></name></person-group><article-title>St John&#8217;s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4</article-title><source>Clin Pharmacol Ther</source><year>2000</year><volume>68</volume><fpage>598</fpage><lpage>604</lpage><pub-id pub-id-type="pmid">11180019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2000.112240</pub-id></element-citation></ref><ref id="CR121"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dutreix</surname><given-names>C</given-names></name><name name-style="western"><surname>Peng</surname><given-names>B</given-names></name><name name-style="western"><surname>Mehring</surname><given-names>G</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>M</given-names></name><name name-style="western"><surname>Capdeville</surname><given-names>R</given-names></name><name name-style="western"><surname>Pokorny</surname><given-names>R</given-names></name><name name-style="western"><surname>Seiberling</surname><given-names>M</given-names></name></person-group><article-title>Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects</article-title><source>Cancer Chemother Pharmacol</source><year>2004</year><volume>54</volume><fpage>290</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">15138710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-004-0832-z</pub-id></element-citation></ref><ref id="CR122"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dutreix</surname><given-names>C</given-names></name><name name-style="western"><surname>Munarini</surname><given-names>F</given-names></name><name name-style="western"><surname>Lorenzo</surname><given-names>S</given-names></name><name name-style="western"><surname>Roesel</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Investigation into CYP3A4-mediated drug&#8211;drug interactions on midostaurin in healthy volunteers</article-title><source>Cancer Chemother Pharmacol</source><year>2013</year><volume>72</volume><fpage>1223</fpage><lpage>1234</lpage><pub-id pub-id-type="pmid">24085261</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-013-2287-6</pub-id><pub-id pub-id-type="pmcid">PMC3834177</pub-id></element-citation></ref><ref id="CR123"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eagling</surname><given-names>VA</given-names></name><name name-style="western"><surname>Wiltshire</surname><given-names>H</given-names></name><name name-style="western"><surname>Whitcombe</surname><given-names>IWA</given-names></name><name name-style="western"><surname>Back</surname><given-names>DJ</given-names></name></person-group><article-title>CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro</article-title><source>Xenobiotica</source><year>2002</year><volume>32</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">11824416</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/00498250110085845</pub-id></element-citation></ref><ref id="CR124"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elsby</surname><given-names>R</given-names></name><name name-style="western"><surname>Hare</surname><given-names>V</given-names></name><name name-style="western"><surname>Neal</surname><given-names>H</given-names></name><name name-style="western"><surname>Outteridge</surname><given-names>S</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>C</given-names></name><name name-style="western"><surname>Plant</surname><given-names>K</given-names></name><name name-style="western"><surname>Gill</surname><given-names>RU</given-names></name><name name-style="western"><surname>Butler</surname><given-names>P</given-names></name><name name-style="western"><surname>Riley</surname><given-names>RJ</given-names></name></person-group><article-title>Mechanistic in vitro studies indicate that the clinical drug&#8211;drug interaction between telithromycin and simvastatin acid is driven by time-dependent inhibition of CYP3A4 with minimal effect on OATP1B1</article-title><source>Drug Metab Dispos</source><year>2019</year><volume>47</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">30348903</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.118.083832</pub-id></element-citation></ref><ref id="CR125"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elsherbiny</surname><given-names>DA</given-names></name><name name-style="western"><surname>Asimus</surname><given-names>SA</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>MO</given-names></name><name name-style="western"><surname>Ashton</surname><given-names>M</given-names></name><name name-style="western"><surname>Simonsson</surname><given-names>US</given-names></name></person-group><article-title>A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens</article-title><source>J Pharmacokinet Pharmacodyn</source><year>2008</year><volume>35</volume><issue>2</issue><fpage>203</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1007/s10928-008-9084-6</pub-id><pub-id pub-id-type="pmid">18350255</pub-id></element-citation></ref><ref id="CR1000"><mixed-citation publication-type="other">EMA (2012) Guideline on the investigation of drug interactions. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf">https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf</ext-link></mixed-citation></ref><ref id="CR126"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ena</surname><given-names>J</given-names></name><name name-style="western"><surname>Amador</surname><given-names>C</given-names></name><name name-style="western"><surname>Benito</surname><given-names>C</given-names></name><name name-style="western"><surname>Pasquau</surname><given-names>F</given-names></name></person-group><article-title>Pharmacological and clinical evidence of nevirapine immediate- and extended-release formulations</article-title><source>HIV AIDS (Auckl)</source><year>2012</year><volume>4</volume><fpage>169</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">23172991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/HIV.S35564</pub-id><pub-id pub-id-type="pmcid">PMC3501953</pub-id></element-citation></ref><ref id="CR127"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ernstg&#229;rd</surname><given-names>L</given-names></name><name name-style="western"><surname>Warholm</surname><given-names>M</given-names></name><name name-style="western"><surname>Johanson</surname><given-names>G</given-names></name></person-group><article-title>Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity</article-title><source>Br J Clin Pharmacol</source><year>2004</year><volume>58</volume><fpage>190</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">15255802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2004.02132.x</pub-id><pub-id pub-id-type="pmcid">PMC1884585</pub-id></element-citation></ref><ref id="CR128"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fabbrocini</surname><given-names>G</given-names></name><name name-style="western"><surname>Kaya</surname><given-names>G</given-names></name><name name-style="western"><surname>Caseiro Silverio</surname><given-names>P</given-names></name><name name-style="western"><surname>De Vita</surname><given-names>V</given-names></name><name name-style="western"><surname>Kaya</surname><given-names>A</given-names></name><name name-style="western"><surname>Fontao</surname><given-names>F</given-names></name><name name-style="western"><surname>Sorg</surname><given-names>O</given-names></name><name name-style="western"><surname>Saurat</surname><given-names>JH</given-names></name></person-group><article-title>Aryl hydrocarbon receptor activation in acne vulgaris skin: a case series from the region of Naples, Italy</article-title><source>Dermatology</source><year>2015</year><volume>231</volume><fpage>334</fpage><lpage>338</lpage><pub-id pub-id-type="pmid">26440531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000439402</pub-id></element-citation></ref><ref id="CR129"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faber</surname><given-names>MS</given-names></name><name name-style="western"><surname>Jetter</surname><given-names>A</given-names></name><name name-style="western"><surname>Fuhr</surname><given-names>U</given-names></name></person-group><article-title>Assessment of CYP1A2 activity in clinical practice: why, how, and when?</article-title><source>Basic Clin Pharmacol Toxicol</source><year>2005</year><volume>97</volume><fpage>125</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">16128905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1742-7843.2005.pto_973160.x</pub-id></element-citation></ref><ref id="CR130"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>LS</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Huang</surname><given-names>YF</given-names></name><name name-style="western"><surname>Huang</surname><given-names>RX</given-names></name><name name-style="western"><surname>Hu</surname><given-names>DL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>HH</given-names></name></person-group><article-title>Herbal medicine yin zhi huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole</article-title><source>Acta Pharmacol Sin</source><year>2007</year><volume>28</volume><fpage>1685</fpage><lpage>1692</lpage><pub-id pub-id-type="pmid">17883958</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1745-7254.2007.00617.x</pub-id></element-citation></ref><ref id="CR131"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JC</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>F</given-names></name><name name-style="western"><surname>Tan</surname><given-names>ZR</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Lei</surname><given-names>HP</given-names></name><name name-style="western"><surname>Hu</surname><given-names>DL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>HH</given-names></name></person-group><article-title>Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation</article-title><source>Eur J Clin Pharmacol</source><year>2009</year><volume>65</volume><fpage>403</fpage><lpage>409</lpage><pub-id pub-id-type="pmid">19066872</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-008-0594-3</pub-id></element-citation></ref><ref id="CR132"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>M</given-names></name><name name-style="western"><surname>Pan</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Deng</surname><given-names>K</given-names></name><name name-style="western"><surname>He</surname><given-names>F</given-names></name></person-group><article-title>A new similarity method for assessment of pharmacokinetic interaction between flucloxacillin and midazolam</article-title><source>Pharmazie</source><year>2019</year><volume>74</volume><fpage>397</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">31288895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1691/ph.2019.9016</pub-id></element-citation></ref><ref id="CR1001"><mixed-citation publication-type="other">FDA (2020) In vitro drug interaction studies&#8212;cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/media/134582/download">https://www.fda.gov/media/134582/download</ext-link></mixed-citation></ref><ref id="CR133"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fellay</surname><given-names>J</given-names></name><name name-style="western"><surname>Marzolini</surname><given-names>C</given-names></name><name name-style="western"><surname>Decosterd</surname><given-names>L</given-names></name><name name-style="western"><surname>Golay</surname><given-names>KP</given-names></name><name name-style="western"><surname>Baumann</surname><given-names>P</given-names></name><name name-style="western"><surname>Buclin</surname><given-names>T</given-names></name><name name-style="western"><surname>Telenti</surname><given-names>A</given-names></name><name name-style="western"><surname>Eap</surname><given-names>CB</given-names></name></person-group><article-title>Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients</article-title><source>Eur J Clin Pharmacol</source><year>2005</year><volume>60</volume><fpage>865</fpage><lpage>873</lpage><pub-id pub-id-type="pmid">15657782</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-004-0855-8</pub-id></element-citation></ref><ref id="CR134"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Huang</surname><given-names>SL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>HH</given-names></name></person-group><article-title>1873992; the induction effect of rifampicin on activity of mephenytoin 4&#8242;-hydroxylase related to M1 mutation of CYP2C19 and gene dose</article-title><source>Br J Clin Pharmacol</source><year>1998</year><volume>45</volume><fpage>27</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">9489590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2125.1998.00643.x</pub-id><pub-id pub-id-type="pmcid">PMC1873992</pub-id></element-citation></ref><ref id="CR135"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fenner</surname><given-names>KS</given-names></name><name name-style="western"><surname>Troutman</surname><given-names>MD</given-names></name><name name-style="western"><surname>Kempshall</surname><given-names>S</given-names></name><name name-style="western"><surname>Cook</surname><given-names>JA</given-names></name><name name-style="western"><surname>Ware</surname><given-names>JA</given-names></name><name name-style="western"><surname>Smith</surname><given-names>DA</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CA</given-names></name></person-group><article-title>Drug&#8211;drug interactions mediated through P-glycoprotein: clinical relevance and in vitro&#8211;in vivo correlation using digoxin as a probe drug</article-title><source>Clin Pharmacol Ther</source><year>2009</year><volume>85</volume><fpage>173</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">18987624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2008.195</pub-id></element-citation></ref><ref id="CR136"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferguson</surname><given-names>SS</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>LeCluyse</surname><given-names>EL</given-names></name><name name-style="western"><surname>Negishi</surname><given-names>M</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>JA</given-names></name></person-group><article-title>Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha</article-title><source>Mol Pharmacol</source><year>2005</year><volume>68</volume><fpage>747</fpage><lpage>757</lpage><pub-id pub-id-type="pmid">15933212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/mol.105.013169</pub-id></element-citation></ref><ref id="CR137"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filppula</surname><given-names>AM</given-names></name><name name-style="western"><surname>Mustonen</surname><given-names>TM</given-names></name><name name-style="western"><surname>Backman</surname><given-names>JT</given-names></name></person-group><article-title>In vitro screening of six protein kinase inhibitors for time-dependent inhibition of CYP2C8 and CYP3A4: possible implications with regard to drug&#8211;drug interactions</article-title><source>Basic Clin Pharmacol Toxicol</source><year>2018</year><volume>123</volume><fpage>739</fpage><lpage>748</lpage><pub-id pub-id-type="pmid">29956478</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcpt.13088</pub-id></element-citation></ref><ref id="CR138"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filppula</surname><given-names>AM</given-names></name><name name-style="western"><surname>Parvizi</surname><given-names>R</given-names></name><name name-style="western"><surname>Mateus</surname><given-names>A</given-names></name><name name-style="western"><surname>Baranczewski</surname><given-names>P</given-names></name><name name-style="western"><surname>Artursson</surname><given-names>P</given-names></name></person-group><article-title>Improved predictions of time-dependent drug&#8211;drug interactions by determination of cytosolic drug concentrations</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><fpage>5850</fpage><pub-id pub-id-type="pmid">30971754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-019-42051-x</pub-id><pub-id pub-id-type="pmcid">PMC6458156</pub-id></element-citation></ref><ref id="CR139"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fitzgerald</surname><given-names>EF</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>SA</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>G</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>M</given-names></name><name name-style="western"><surname>Tarbell</surname><given-names>A</given-names></name></person-group><article-title>1253751; PCB exposure and in vivo CYP1A2 activity among Native Americans</article-title><source>Environ Health Perspect</source><year>2005</year><volume>113</volume><fpage>272</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">15743714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1289/ehp.7370</pub-id><pub-id pub-id-type="pmcid">PMC1253751</pub-id></element-citation></ref><ref id="CR140"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flaherty</surname><given-names>KT</given-names></name><name name-style="western"><surname>Lathia</surname><given-names>C</given-names></name><name name-style="western"><surname>Frye</surname><given-names>RF</given-names></name><name name-style="western"><surname>Schuchter</surname><given-names>L</given-names></name><name name-style="western"><surname>Redlinger</surname><given-names>M</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>M</given-names></name><name name-style="western"><surname>O&#8217;Dwyer</surname><given-names>PJ</given-names></name></person-group><article-title>Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study</article-title><source>Cancer Chemother Pharmacol</source><year>2011</year><volume>68</volume><fpage>1111</fpage><lpage>1118</lpage><pub-id pub-id-type="pmid">21350850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-011-1585-0</pub-id></element-citation></ref><ref id="CR141"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fontana</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Lown</surname><given-names>KS</given-names></name><name name-style="western"><surname>Paine</surname><given-names>MF</given-names></name><name name-style="western"><surname>Fortlage</surname><given-names>L</given-names></name><name name-style="western"><surname>Santella</surname><given-names>RM</given-names></name><name name-style="western"><surname>Felton</surname><given-names>JS</given-names></name><name name-style="western"><surname>Knize</surname><given-names>MG</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>A</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>PB</given-names></name></person-group><article-title>Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers</article-title><source>Gastroenterology</source><year>1999</year><volume>117</volume><fpage>89</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">10381914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0016-5085(99)70554-8</pub-id></element-citation></ref><ref id="CR142"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fritsche</surname><given-names>E</given-names></name><name name-style="western"><surname>Schafer</surname><given-names>C</given-names></name><name name-style="western"><surname>Calles</surname><given-names>C</given-names></name><name name-style="western"><surname>Bernsmann</surname><given-names>T</given-names></name><name name-style="western"><surname>Bernshausen</surname><given-names>T</given-names></name><name name-style="western"><surname>Wurm</surname><given-names>M</given-names></name><name name-style="western"><surname>Hubenthal</surname><given-names>U</given-names></name><name name-style="western"><surname>Cline</surname><given-names>JE</given-names></name><name name-style="western"><surname>Hajimiragha</surname><given-names>H</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>P</given-names></name><name name-style="western"><surname>Klotz</surname><given-names>LO</given-names></name><name name-style="western"><surname>Rannug</surname><given-names>A</given-names></name><name name-style="western"><surname>Furst</surname><given-names>P</given-names></name><name name-style="western"><surname>Hanenberg</surname><given-names>H</given-names></name><name name-style="western"><surname>Abel</surname><given-names>J</given-names></name><name name-style="western"><surname>Krutmann</surname><given-names>J</given-names></name></person-group><article-title>1885591; lightening up the UV response by identification of the arylhydrocarbon receptor as a cytoplasmatic target for ultraviolet B radiation</article-title><source>Proc Natl Acad Sci USA</source><year>2007</year><volume>104</volume><fpage>8851</fpage><lpage>8856</lpage><pub-id pub-id-type="pmid">17502624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0701764104</pub-id><pub-id pub-id-type="pmcid">PMC1885591</pub-id></element-citation></ref><ref id="CR143"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Funck-Brentano</surname><given-names>C</given-names></name><name name-style="western"><surname>Becquemont</surname><given-names>L</given-names></name><name name-style="western"><surname>Lenevu</surname><given-names>A</given-names></name><name name-style="western"><surname>Roux</surname><given-names>A</given-names></name><name name-style="western"><surname>Jaillon</surname><given-names>P</given-names></name><name name-style="western"><surname>Beaune</surname><given-names>P</given-names></name></person-group><article-title>Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments</article-title><source>J Pharmacol Exp Ther</source><year>1997</year><volume>280</volume><fpage>730</fpage><lpage>738</lpage><pub-id pub-id-type="pmid">9023285</pub-id></element-citation></ref><ref id="CR144"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallant</surname><given-names>JE</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>M</given-names></name><name name-style="western"><surname>DeJesus</surname><given-names>E</given-names></name><name name-style="western"><surname>Voskuhl</surname><given-names>GW</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>White</surname><given-names>K</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>A</given-names></name><name name-style="western"><surname>Quirk</surname><given-names>E</given-names></name><name name-style="western"><surname>Martin</surname><given-names>H</given-names></name></person-group><article-title>Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-infected adults</article-title><source>J Acquir Immune Defic Syndr</source><year>2017</year><volume>75</volume><fpage>61</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">28196003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/QAI.0000000000001306</pub-id><pub-id pub-id-type="pmcid">PMC5389589</pub-id></element-citation></ref><ref id="CR145"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gangadhar</surname><given-names>TC</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>EEW</given-names></name><name name-style="western"><surname>Wu</surname><given-names>K</given-names></name><name name-style="western"><surname>Janisch</surname><given-names>L</given-names></name><name name-style="western"><surname>Geary</surname><given-names>D</given-names></name><name name-style="western"><surname>Kocherginsky</surname><given-names>M</given-names></name><name name-style="western"><surname>House</surname><given-names>LK</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>J</given-names></name><name name-style="western"><surname>Undevia</surname><given-names>SD</given-names></name><name name-style="western"><surname>Maitland</surname><given-names>ML</given-names></name><name name-style="western"><surname>Fleming</surname><given-names>GF</given-names></name><name name-style="western"><surname>Ratain</surname><given-names>MJ</given-names></name></person-group><article-title>Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies</article-title><source>Clin Cancer Res</source><year>2011</year><volume>17</volume><fpage>1956</fpage><lpage>1963</lpage><pub-id pub-id-type="pmid">21447721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-10-2061</pub-id><pub-id pub-id-type="pmcid">PMC3077032</pub-id></element-citation></ref><ref id="CR146"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>LC</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Tan</surname><given-names>ZR</given-names></name><name name-style="western"><surname>Fan</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>HH</given-names></name></person-group><article-title>The effects of sodium ferulate on the pharmacokinetics of bupropion and its active metabolite in healthy men</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2012</year><volume>16</volume><fpage>1192</fpage><lpage>1196</lpage><pub-id pub-id-type="pmid">23047502</pub-id></element-citation></ref><ref id="CR147"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>L</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yin</surname><given-names>J</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>D</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name></person-group><article-title>PMC3686783; genetic variants of pregnane X receptor (PXR) and CYP2B6 affect the induction of bupropion hydroxylation by sodium ferulate</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e62489</fpage><pub-id pub-id-type="pmid">23840296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0062489</pub-id><pub-id pub-id-type="pmcid">PMC3686783</pub-id></element-citation></ref><ref id="CR148"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gay</surname><given-names>C</given-names></name><name name-style="western"><surname>Toulet</surname><given-names>D</given-names></name><name name-style="western"><surname>Le Corre</surname><given-names>P</given-names></name></person-group><article-title>Pharmacokinetic drug&#8211;drug interactions of tyrosine kinase inhibitors: a focus on cytochrome P450, transporters, and acid suppression therapy</article-title><source>Hematol Oncol</source><year>2017</year><volume>35</volume><fpage>259</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">27925256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hon.2335</pub-id></element-citation></ref><ref id="CR149"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerbal-Chaloin</surname><given-names>S</given-names></name><name name-style="western"><surname>Daujat</surname><given-names>M</given-names></name><name name-style="western"><surname>Pascussi</surname><given-names>JM</given-names></name><name name-style="western"><surname>Pichard-Garcia</surname><given-names>L</given-names></name><name name-style="western"><surname>Vilarem</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Maurel</surname><given-names>P</given-names></name></person-group><article-title>Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>209</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">11679585</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M107228200</pub-id></element-citation></ref><ref id="CR150"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gibbons</surname><given-names>JA</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>M</given-names></name><name name-style="western"><surname>Krauwinkel</surname><given-names>W</given-names></name><name name-style="western"><surname>Ohtsu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Noukens</surname><given-names>J</given-names></name><name name-style="western"><surname>van der Walt</surname><given-names>JS</given-names></name><name name-style="western"><surname>Mol</surname><given-names>R</given-names></name><name name-style="western"><surname>Mordenti</surname><given-names>J</given-names></name><name name-style="western"><surname>Ouatas</surname><given-names>T</given-names></name></person-group><article-title>PMC4580724; pharmacokinetic drug interaction studies with enzalutamide</article-title><source>Clin Pharmacokinet</source><year>2015</year><volume>54</volume><fpage>1057</fpage><lpage>1069</lpage><pub-id pub-id-type="pmid">25929560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-015-0283-1</pub-id><pub-id pub-id-type="pmcid">PMC4580724</pub-id></element-citation></ref><ref id="CR151"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gillen</surname><given-names>M</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>D</given-names></name><name name-style="western"><surname>Valdez</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>B</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Z</given-names></name></person-group><article-title>Evaluation of pharmacokinetic interactions between lesinurad, a new selective urate reabsorption inhibitor, and CYP enzyme substrates sildenafil, amlodipine, tolbutamide, and repaglinide</article-title><source>Clin Pharmacol Drug Dev</source><year>2017</year><volume>6</volume><fpage>363</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">28067999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpdd.324</pub-id></element-citation></ref><ref id="CR152"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Girre</surname><given-names>C</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>D</given-names></name><name name-style="western"><surname>Hispard</surname><given-names>E</given-names></name><name name-style="western"><surname>Menez</surname><given-names>C</given-names></name><name name-style="western"><surname>Dally</surname><given-names>S</given-names></name><name name-style="western"><surname>Menez</surname><given-names>JF</given-names></name></person-group><article-title>Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics</article-title><source>Biochem Pharmacol</source><year>1994</year><volume>47</volume><fpage>1503</fpage><lpage>1508</lpage><pub-id pub-id-type="pmid">7910460</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0006-2952(94)90524-x</pub-id></element-citation></ref><ref id="CR153"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giuliano</surname><given-names>C</given-names></name><name name-style="western"><surname>Lovati</surname><given-names>E</given-names></name><name name-style="western"><surname>Funk</surname><given-names>C</given-names></name><name name-style="western"><surname>Potthast</surname><given-names>M</given-names></name><name name-style="western"><surname>Pietra</surname><given-names>C</given-names></name></person-group><article-title>In vitro drug&#8211;drug interaction studies with the antiemetic drug netupitant and its major metabolites M1 and M2, involving several human cytochrome P450 isoenzymes</article-title><source>Ann Oncol</source><year>2012</year><volume>23</volume><issue>suppl 9</issue><fpage>ix520</fpage></element-citation></ref><ref id="CR154"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glaeser</surname><given-names>H</given-names></name><name name-style="western"><surname>Drescher</surname><given-names>S</given-names></name><name name-style="western"><surname>Eichelbaum</surname><given-names>M</given-names></name><name name-style="western"><surname>Fromm</surname><given-names>MF</given-names></name></person-group><article-title>Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes</article-title><source>Br J Clin Pharmacol</source><year>2005</year><volume>59</volume><fpage>199</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">15676042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2004.02265.x</pub-id><pub-id pub-id-type="pmcid">PMC1884745</pub-id></element-citation></ref><ref id="CR155"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldberg</surname><given-names>MR</given-names></name><name name-style="western"><surname>Lo</surname><given-names>MW</given-names></name><name name-style="western"><surname>Deutsch</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>SE</given-names></name><name name-style="western"><surname>McWilliams</surname><given-names>EJ</given-names></name><name name-style="western"><surname>McCrea</surname><given-names>JB</given-names></name></person-group><article-title>Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174</article-title><source>Clin Pharmacol Ther</source><year>1996</year><volume>59</volume><fpage>268</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">8653989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0009-9236(96)80004-X</pub-id></element-citation></ref><ref id="CR156"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorski</surname><given-names>JC</given-names></name><name name-style="western"><surname>Huang</surname><given-names>SM</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>A</given-names></name><name name-style="western"><surname>Hamman</surname><given-names>MA</given-names></name><name name-style="western"><surname>Hilligoss</surname><given-names>JK</given-names></name><name name-style="western"><surname>Zaheer</surname><given-names>NA</given-names></name><name name-style="western"><surname>Desai</surname><given-names>M</given-names></name><name name-style="western"><surname>Miller</surname><given-names>M</given-names></name><name name-style="western"><surname>Hall</surname><given-names>SD</given-names></name></person-group><article-title>The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo</article-title><source>Clin Pharmacol Ther</source><year>2004</year><volume>75</volume><fpage>89</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">14749695</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clpt.2003.09.013</pub-id></element-citation></ref><ref id="CR157"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Granfors</surname><given-names>MT</given-names></name><name name-style="western"><surname>Backman</surname><given-names>JT</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>M</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name></person-group><article-title>Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism</article-title><source>Clin Pharmacol Ther</source><year>2004</year><volume>76</volume><fpage>598</fpage><lpage>606</lpage><pub-id pub-id-type="pmid">15592331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clpt.2004.08.018</pub-id></element-citation></ref><ref id="CR158"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Granfors</surname><given-names>MT</given-names></name><name name-style="western"><surname>Backman</surname><given-names>JT</given-names></name><name name-style="western"><surname>Laitila</surname><given-names>J</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name></person-group><article-title>Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2</article-title><source>Clin Pharmacol Ther</source><year>2005</year><volume>78</volume><fpage>400</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">16198659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clpt.2005.06.009</pub-id></element-citation></ref><ref id="CR159"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greiner</surname><given-names>B</given-names></name><name name-style="western"><surname>Eichelbaum</surname><given-names>M</given-names></name><name name-style="western"><surname>Fritz</surname><given-names>P</given-names></name><name name-style="western"><surname>Kreichgauer</surname><given-names>HP</given-names></name><name name-style="western"><surname>von Richter</surname><given-names>O</given-names></name><name name-style="western"><surname>Zundler</surname><given-names>J</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>HK</given-names></name></person-group><article-title>PMC408477; the role of intestinal P-glycoprotein in the interaction of digoxin and rifampin</article-title><source>J Clin Investig</source><year>1999</year><volume>104</volume><fpage>147</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">10411543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI6663</pub-id><pub-id pub-id-type="pmcid">PMC408477</pub-id></element-citation></ref><ref id="CR160"><mixed-citation publication-type="other">Groll AH, Townsend R, Desai A, Azie N, Jones M, Engelhardt M, Schmitt-Hoffman AH, Br&#252;ggemann RJM (2017) Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. Transpl Infect Dis 19(5). 10.1111/tid.12751<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/tid.12751</pub-id><pub-id pub-id-type="pmid">28722255</pub-id></mixed-citation></ref><ref id="CR161"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>H</given-names></name><name name-style="western"><surname>Dutreix</surname><given-names>C</given-names></name><name name-style="western"><surname>Rebello</surname><given-names>S</given-names></name><name name-style="western"><surname>Ouatas</surname><given-names>T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Chun</surname><given-names>DY</given-names></name><name name-style="western"><surname>Einolf</surname><given-names>HJ</given-names></name><name name-style="western"><surname>He</surname><given-names>H</given-names></name></person-group><article-title>Simultaneous physiologically based pharmacokinetic (PBPK) modeling of parent and active metabolites to investigate complex CYP3A4 drug&#8211;drug interaction potential: a case example of midostaurin</article-title><source>Drug Metab Dispos</source><year>2018</year><volume>46</volume><fpage>109</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">29117990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.117.078006</pub-id></element-citation></ref><ref id="CR162"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lucksiri</surname><given-names>A</given-names></name><name name-style="western"><surname>Dickinson</surname><given-names>GL</given-names></name><name name-style="western"><surname>Vuppalanchi</surname><given-names>RK</given-names></name><name name-style="western"><surname>Hilligoss</surname><given-names>JK</given-names></name><name name-style="western"><surname>Hall</surname><given-names>SD</given-names></name></person-group><article-title>Quantitative prediction of CYP3A4- and CYP3A5-mediated drug interactions</article-title><source>Clin Pharmacol Ther</source><year>2020</year><volume>107</volume><fpage>246</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">31356678</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.1596</pub-id><pub-id pub-id-type="pmcid">PMC6925622</pub-id></element-citation></ref><ref id="CR163"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>N</given-names></name><name name-style="western"><surname>Hanley</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Venkatakrishnan</surname><given-names>K</given-names></name><name name-style="western"><surname>Bessudo</surname><given-names>A</given-names></name><name name-style="western"><surname>Rasco</surname><given-names>DW</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S</given-names></name><name name-style="western"><surname>O&#8217;Neil</surname><given-names>BH</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Ke</surname><given-names>A</given-names></name><name name-style="western"><surname>Patel</surname><given-names>C</given-names></name><name name-style="western"><surname>Rowland Yeo</surname><given-names>K</given-names></name><name name-style="western"><surname>Xia</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Esseltine</surname><given-names>D</given-names></name><name name-style="western"><surname>Nemunaitis</surname><given-names>J</given-names></name></person-group><article-title>Effects of strong CYP3A inhibition and induction on the pharmacokinetics of ixazomib, an oral proteasome inhibitor: results of drug&#8211;drug interaction studies in patients with advanced solid tumors or lymphoma and a physiologically based pharmacokinetic analysis</article-title><source>J Clin Pharmacol</source><year>2018</year><volume>58</volume><fpage>180</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">28800141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcph.988</pub-id><pub-id pub-id-type="pmcid">PMC5811830</pub-id></element-citation></ref><ref id="CR164"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gurley</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>SF</given-names></name><name name-style="western"><surname>Hubbard</surname><given-names>MA</given-names></name><name name-style="western"><surname>Williams</surname><given-names>DK</given-names></name><name name-style="western"><surname>Gentry</surname><given-names>WB</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ang</surname><given-names>CY</given-names></name></person-group><article-title>Cytochrome P450 phenotypic ratios for predicting herb&#8211;drug interactions in humans</article-title><source>Clin Pharmacol Ther</source><year>2002</year><volume>72</volume><fpage>276</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">12235448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2002.126913</pub-id></element-citation></ref><ref id="CR165"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gurley</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>SF</given-names></name><name name-style="western"><surname>Hubbard</surname><given-names>MA</given-names></name><name name-style="western"><surname>Williams</surname><given-names>DK</given-names></name><name name-style="western"><surname>Gentry</surname><given-names>WB</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ang</surname><given-names>CY</given-names></name></person-group><article-title>Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John&#8217;s wort, garlic oil, Panax ginseng and Ginkgo biloba</article-title><source>Drugs Aging</source><year>2005</year><volume>22</volume><fpage>525</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">15974642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00002512-200522060-00006</pub-id><pub-id pub-id-type="pmcid">PMC1858666</pub-id></element-citation></ref><ref id="CR166"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gyamfi</surname><given-names>MA</given-names></name><name name-style="western"><surname>Kocsis</surname><given-names>MG</given-names></name><name name-style="western"><surname>He</surname><given-names>L</given-names></name><name name-style="western"><surname>Dai</surname><given-names>G</given-names></name><name name-style="western"><surname>Mendy</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Wan</surname><given-names>YJ</given-names></name></person-group><article-title>The role of retinoid X receptor alpha in regulating alcohol metabolism</article-title><source>J Pharmacol Exp Ther</source><year>2006</year><volume>319</volume><fpage>360</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">16829625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.106.108175</pub-id></element-citation></ref><ref id="CR167"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ha-Duong</surname><given-names>NT</given-names></name><name name-style="western"><surname>Dijols</surname><given-names>S</given-names></name><name name-style="western"><surname>Macherey</surname><given-names>AC</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>JA</given-names></name><name name-style="western"><surname>Dansette</surname><given-names>PM</given-names></name><name name-style="western"><surname>Mansuy</surname><given-names>D</given-names></name></person-group><article-title>Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19</article-title><source>Biochemistry</source><year>2001</year><volume>40</volume><fpage>12112</fpage><lpage>12122</lpage><pub-id pub-id-type="pmid">11580286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/bi010254c</pub-id></element-citation></ref><ref id="CR168"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hakkola</surname><given-names>J</given-names></name><name name-style="western"><surname>Bernasconi</surname><given-names>C</given-names></name><name name-style="western"><surname>Coecke</surname><given-names>S</given-names></name><name name-style="western"><surname>Richert</surname><given-names>L</given-names></name><name name-style="western"><surname>Andersson</surname><given-names>TB</given-names></name><name name-style="western"><surname>Pelkonen</surname><given-names>O</given-names></name></person-group><article-title>Cytochrome P450 induction and xeno-sensing receptors pregnane X receptor, constitutive androstane receptor, aryl hydrocarbon receptor and peroxisome proliferator-activated receptor &#945; at the crossroads of toxicokinetics and toxicodynamics</article-title><source>Basic Clin Pharmacol Toxicol</source><year>2018</year><volume>123</volume><issue>Suppl 5</issue><fpage>42</fpage><lpage>50</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcpt.13004</pub-id><pub-id pub-id-type="pmid">29527807</pub-id></element-citation></ref><ref id="CR169"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hakooz</surname><given-names>N</given-names></name><name name-style="western"><surname>Hamdan</surname><given-names>I</given-names></name></person-group><article-title>Effects of dietary broccoli on human in vivo caffeine metabolism: a pilot study on a group of Jordanian volunteers</article-title><source>Curr Drug Metab</source><year>2007</year><volume>8</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">17266520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/138920007779315080</pub-id></element-citation></ref><ref id="CR170"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamilton</surname><given-names>M</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>JL</given-names></name><name name-style="western"><surname>Drolet</surname><given-names>DW</given-names></name><name name-style="western"><surname>Fettner</surname><given-names>SH</given-names></name><name name-style="western"><surname>Rakhit</surname><given-names>AK</given-names></name><name name-style="western"><surname>Witt</surname><given-names>K</given-names></name><name name-style="western"><surname>Lum</surname><given-names>BL</given-names></name></person-group><article-title>The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects</article-title><source>Cancer Chemother Pharmacol</source><year>2014</year><volume>73</volume><fpage>613</fpage><lpage>621</lpage><pub-id pub-id-type="pmid">24474302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-014-2390-3</pub-id></element-citation></ref><ref id="CR171"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanaoka</surname><given-names>T</given-names></name><name name-style="western"><surname>Yamano</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pan</surname><given-names>G</given-names></name><name name-style="western"><surname>Hara</surname><given-names>K</given-names></name><name name-style="western"><surname>Ichiba</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>K</given-names></name><name name-style="western"><surname>Kagawa</surname><given-names>J</given-names></name><name name-style="western"><surname>Tsugane</surname><given-names>S</given-names></name></person-group><article-title>Cytochrome P450 1B1 mRNA levels in peripheral blood cells and exposure to polycyclic aromatic hydrocarbons in Chinese coke oven workers</article-title><source>Sci Total Environ</source><year>2002</year><volume>296</volume><fpage>27</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">12398325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0048-9697(02)00070-0</pub-id></element-citation></ref><ref id="CR172"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanley</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Cancalon</surname><given-names>P</given-names></name><name name-style="western"><surname>Widmer</surname><given-names>WW</given-names></name><name name-style="western"><surname>Greenblatt</surname><given-names>DJ</given-names></name></person-group><article-title>The effect of grapefruit juice on drug disposition</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2011</year><volume>7</volume><fpage>267</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">21254874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/17425255.2011.553189</pub-id><pub-id pub-id-type="pmcid">PMC3071161</pub-id></element-citation></ref><ref id="CR173"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Havens</surname><given-names>JP</given-names></name><name name-style="western"><surname>Podany</surname><given-names>AT</given-names></name><name name-style="western"><surname>Scarsi</surname><given-names>KK</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>CV</given-names></name></person-group><article-title>Clinical pharmacokinetics and pharmacodynamics of etravirine: an updated review</article-title><source>Clin Pharmacokinet</source><year>2020</year><volume>59</volume><fpage>137</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">31679131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-019-00830-9</pub-id><pub-id pub-id-type="pmcid">PMC7034776</pub-id></element-citation></ref><ref id="CR174"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hedrich</surname><given-names>WD</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>HE</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name></person-group><article-title>Insights into CYP2B6-mediated drug&#8211;drug interactions</article-title><source>Acta Pharm Sin B</source><year>2016</year><volume>6</volume><fpage>413</fpage><lpage>425</lpage><pub-id pub-id-type="pmid">27709010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2016.07.016</pub-id><pub-id pub-id-type="pmcid">PMC5045548</pub-id></element-citation></ref><ref id="CR175"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heimark</surname><given-names>LD</given-names></name><name name-style="western"><surname>Wienkers</surname><given-names>L</given-names></name><name name-style="western"><surname>Kunze</surname><given-names>K</given-names></name><name name-style="western"><surname>Gibaldi</surname><given-names>M</given-names></name><name name-style="western"><surname>Eddy</surname><given-names>AC</given-names></name><name name-style="western"><surname>Trager</surname><given-names>WF</given-names></name><name name-style="western"><surname>O&#8217;Reilly</surname><given-names>RA</given-names></name><name name-style="western"><surname>Goulart</surname><given-names>DA</given-names></name></person-group><article-title>The mechanism of the interaction between amiodarone and warfarin in humans</article-title><source>Clin Pharmacol Ther</source><year>1992</year><volume>51</volume><fpage>398</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">1563209</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.1992.39</pub-id></element-citation></ref><ref id="CR176"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heinemeyer</surname><given-names>G</given-names></name><name name-style="western"><surname>Gramm</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Simgen</surname><given-names>W</given-names></name><name name-style="western"><surname>Dennhardt</surname><given-names>R</given-names></name><name name-style="western"><surname>Roots</surname><given-names>I</given-names></name></person-group><article-title>Kinetics of hexobarbital and dipyrone in critical care patients receiving high-dose pentobarbital</article-title><source>Eur J Clin Pharmacol</source><year>1987</year><volume>32</volume><fpage>273</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">3595700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00607575</pub-id></element-citation></ref><ref id="CR177"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herman</surname><given-names>D</given-names></name><name name-style="western"><surname>Locatelli</surname><given-names>I</given-names></name><name name-style="western"><surname>Grabnar</surname><given-names>I</given-names></name><name name-style="western"><surname>Peternel</surname><given-names>P</given-names></name><name name-style="western"><surname>Stegnar</surname><given-names>M</given-names></name><name name-style="western"><surname>Lainscak</surname><given-names>M</given-names></name><name name-style="western"><surname>Mrhar</surname><given-names>A</given-names></name><name name-style="western"><surname>Breskvar</surname><given-names>K</given-names></name><name name-style="western"><surname>Dolzan</surname><given-names>V</given-names></name></person-group><article-title>The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose</article-title><source>Eur J Clin Pharmacol</source><year>2006</year><volume>62</volume><fpage>291</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">16552506</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-006-0104-4</pub-id></element-citation></ref><ref id="CR178"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hermann</surname><given-names>R</given-names></name><name name-style="western"><surname>von Richter</surname><given-names>O</given-names></name></person-group><article-title>Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions</article-title><source>Planta Med</source><year>2012</year><volume>78</volume><fpage>1458</fpage><lpage>1477</lpage><pub-id pub-id-type="pmid">22855269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0032-1315117</pub-id></element-citation></ref><ref id="CR179"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hesse</surname><given-names>LM</given-names></name><name name-style="western"><surname>Venkatakrishnan</surname><given-names>K</given-names></name><name name-style="western"><surname>Court</surname><given-names>MH</given-names></name><name name-style="western"><surname>von Moltke</surname><given-names>LL</given-names></name><name name-style="western"><surname>Duan</surname><given-names>SX</given-names></name><name name-style="western"><surname>Shader</surname><given-names>RI</given-names></name><name name-style="western"><surname>Greenblatt</surname><given-names>DJ</given-names></name></person-group><article-title>CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants</article-title><source>Drug Metab Dispos</source><year>2000</year><volume>28</volume><fpage>1176</fpage><lpage>1183</lpage><pub-id pub-id-type="pmid">10997936</pub-id></element-citation></ref><ref id="CR180"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Higashi</surname><given-names>E</given-names></name><name name-style="western"><surname>Fukami</surname><given-names>T</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>M</given-names></name><name name-style="western"><surname>Kyo</surname><given-names>S</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>M</given-names></name><name name-style="western"><surname>Yokoi</surname><given-names>T</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>M</given-names></name></person-group><article-title>Human CYP2A6 is induced by estrogen via estrogen receptor</article-title><source>Drug Metab Dispos</source><year>2007</year><volume>35</volume><fpage>1935</fpage><lpage>1941</lpage><pub-id pub-id-type="pmid">17646279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.107.016568</pub-id></element-citation></ref><ref id="CR181"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>MF</given-names></name><name name-style="western"><surname>Preissner</surname><given-names>SC</given-names></name><name name-style="western"><surname>Nickel</surname><given-names>J</given-names></name><name name-style="western"><surname>Dunkel</surname><given-names>M</given-names></name><name name-style="western"><surname>Preissner</surname><given-names>R</given-names></name><name name-style="western"><surname>Preissner</surname><given-names>S</given-names></name></person-group><article-title>The transformer database: biotransformation of xenobiotics</article-title><source>Nucleic Acids Res</source><year>2014</year><volume>42</volume><fpage>1113</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkt1246</pub-id><pub-id pub-id-type="pmcid">PMC3965107</pub-id><pub-id pub-id-type="pmid">24334957</pub-id></element-citation></ref><ref id="CR182"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hofman</surname><given-names>J</given-names></name><name name-style="western"><surname>Sorf</surname><given-names>A</given-names></name><name name-style="western"><surname>Vagiannis</surname><given-names>D</given-names></name><name name-style="western"><surname>Sucha</surname><given-names>S</given-names></name><name name-style="western"><surname>Novotna</surname><given-names>E</given-names></name><name name-style="western"><surname>Kammerer</surname><given-names>S</given-names></name><name name-style="western"><surname>K&#252;pper</surname><given-names>J</given-names></name><name name-style="western"><surname>Ceckova</surname><given-names>M</given-names></name><name name-style="western"><surname>Staud</surname><given-names>F</given-names></name></person-group><article-title>Interactions of alectinib with human ATP-binding cassette drug efflux transporters and cytochrome P450 biotransformation enzymes: effect on pharmacokinetic multidrug resistance</article-title><source>Drug Metab Dispos</source><year>2019</year><volume>47</volume><fpage>699</fpage><lpage>709</lpage><pub-id pub-id-type="pmid">31068367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.119.086975</pub-id></element-citation></ref><ref id="CR183"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chia</surname><given-names>YMF</given-names></name><name name-style="western"><surname>Yeo</surname><given-names>RH</given-names></name><name name-style="western"><surname>Venkatesan</surname><given-names>G</given-names></name><name name-style="western"><surname>Koh</surname><given-names>SK</given-names></name><name name-style="western"><surname>Chai</surname><given-names>CLL</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Kojodjojo</surname><given-names>P</given-names></name><name name-style="western"><surname>Chan</surname><given-names>ECY</given-names></name></person-group><article-title>Inactivation of human cytochrome P450 3A4 and 3A5 by dronedarone and <italic toggle="yes">N</italic>-desbutyl dronedarone</article-title><source>Mol Pharmacol</source><year>2016</year><volume>89</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">26490246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/mol.115.100891</pub-id></element-citation></ref><ref id="CR184"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honkakoski</surname><given-names>P</given-names></name><name name-style="western"><surname>Zelko</surname><given-names>I</given-names></name><name name-style="western"><surname>Sueyoshi</surname><given-names>T</given-names></name><name name-style="western"><surname>Negishi</surname><given-names>M</given-names></name></person-group><article-title>The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene</article-title><source>Mol Cell Biol</source><year>1998</year><volume>18</volume><fpage>5652</fpage><lpage>5658</lpage><pub-id pub-id-type="pmid">9742082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mcb.18.10.5652</pub-id><pub-id pub-id-type="pmcid">PMC109151</pub-id></element-citation></ref><ref id="CR185"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horn</surname><given-names>EP</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>MA</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>G</given-names></name><name name-style="western"><surname>Silverman</surname><given-names>D</given-names></name><name name-style="western"><surname>Zametkin</surname><given-names>D</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>R</given-names></name><name name-style="western"><surname>Hartge</surname><given-names>T</given-names></name><name name-style="western"><surname>Landi</surname><given-names>MT</given-names></name><name name-style="western"><surname>Caporaso</surname><given-names>NE</given-names></name></person-group><article-title>A study of gender-based cytochrome P4501A2 variability: a possible mechanism for the male excess of bladder cancer</article-title><source>Cancer Epidemiol Biomark Prev</source><year>1995</year><volume>4</volume><fpage>529</fpage><lpage>533</lpage><pub-id pub-id-type="pmid">7549810</pub-id></element-citation></ref><ref id="CR186"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hossain</surname><given-names>MA</given-names></name><name name-style="western"><surname>Tran</surname><given-names>T</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T</given-names></name><name name-style="western"><surname>Mikus</surname><given-names>G</given-names></name><name name-style="western"><surname>Greenblatt</surname><given-names>DJ</given-names></name></person-group><article-title>Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat</article-title><source>J Pharm Pharmacol</source><year>2017</year><volume>69</volume><fpage>1786</fpage><lpage>1793</lpage><pub-id pub-id-type="pmid">28960344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jphp.12820</pub-id></element-citation></ref><ref id="CR187"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>A</given-names></name><name name-style="western"><surname>Granneman</surname><given-names>GR</given-names></name><name name-style="western"><surname>Witt</surname><given-names>G</given-names></name><name name-style="western"><surname>Locke</surname><given-names>C</given-names></name><name name-style="western"><surname>Denissen</surname><given-names>J</given-names></name><name name-style="western"><surname>Molla</surname><given-names>A</given-names></name><name name-style="western"><surname>Valdes</surname><given-names>J</given-names></name><name name-style="western"><surname>Smith</surname><given-names>J</given-names></name><name name-style="western"><surname>Erdman</surname><given-names>K</given-names></name><name name-style="western"><surname>Lyons</surname><given-names>N</given-names></name><name name-style="western"><surname>Niu</surname><given-names>P</given-names></name><name name-style="western"><surname>Decourt</surname><given-names>JP</given-names></name><name name-style="western"><surname>Fourtillan</surname><given-names>JB</given-names></name><name name-style="western"><surname>Girault</surname><given-names>J</given-names></name><name name-style="western"><surname>Leonard</surname><given-names>JM</given-names></name></person-group><article-title>163822; multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects</article-title><source>Antimicrob Agents Chemother</source><year>1997</year><volume>41</volume><fpage>898</fpage><lpage>905</lpage><pub-id pub-id-type="pmid">9145841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aac.41.5.898</pub-id><pub-id pub-id-type="pmcid">PMC163822</pub-id></element-citation></ref><ref id="CR188"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>A</given-names></name><name name-style="western"><surname>Granneman</surname><given-names>GR</given-names></name><name name-style="western"><surname>Bertz</surname><given-names>RJ</given-names></name></person-group><article-title>Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents</article-title><source>Clin Pharmacokinet</source><year>1998</year><volume>35</volume><fpage>275</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">9812178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-199835040-00002</pub-id></element-citation></ref><ref id="CR189"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>SW</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CC</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>CY</given-names></name><name name-style="western"><surname>Lin</surname><given-names>WH</given-names></name><name name-style="western"><surname>Lin</surname><given-names>P</given-names></name></person-group><article-title>Increased cytochrome P4501B1 gene expression in peripheral leukocytes of municipal waste incinerator workers</article-title><source>Toxicol Lett</source><year>2006</year><volume>160</volume><fpage>112</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">16098693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.toxlet.2005.06.015</pub-id></element-citation></ref><ref id="CR190"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name><name name-style="western"><surname>Lan</surname><given-names>T</given-names></name><name name-style="western"><surname>Dai</surname><given-names>D</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cai</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>G</given-names></name></person-group><article-title>Evaluation of 24 CYP2D6 variants on the metabolism of nebivolol in vitro</article-title><source>Drug Metab Dispos</source><year>2016</year><volume>44</volume><fpage>1828</fpage><lpage>1831</lpage><pub-id pub-id-type="pmid">27538917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.116.071811</pub-id></element-citation></ref><ref id="CR191"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hukkanen</surname><given-names>J</given-names></name></person-group><article-title>Induction of CYP enzymes: a view on human in vivo findings</article-title><source>Expert Rev Clin Pharmacol</source><year>2012</year><volume>5</volume><fpage>569</fpage><lpage>585</lpage><pub-id pub-id-type="pmid">23121279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/ecp.12.39</pub-id></element-citation></ref><ref id="CR192"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hukkanen</surname><given-names>J</given-names></name><name name-style="western"><surname>Pelkonen</surname><given-names>O</given-names></name><name name-style="western"><surname>Hakkola</surname><given-names>J</given-names></name><name name-style="western"><surname>Raunio</surname><given-names>H</given-names></name></person-group><article-title>Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung</article-title><source>Crit Rev Toxicol</source><year>2002</year><volume>32</volume><fpage>391</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">12389869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/20024091064273</pub-id></element-citation></ref><ref id="CR193"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hukkanen</surname><given-names>J</given-names></name><name name-style="western"><surname>Vaisanen</surname><given-names>T</given-names></name><name name-style="western"><surname>Lassila</surname><given-names>A</given-names></name><name name-style="western"><surname>Piipari</surname><given-names>R</given-names></name><name name-style="western"><surname>Anttila</surname><given-names>S</given-names></name><name name-style="western"><surname>Pelkonen</surname><given-names>O</given-names></name><name name-style="western"><surname>Raunio</surname><given-names>H</given-names></name><name name-style="western"><surname>Hakkola</surname><given-names>J</given-names></name></person-group><article-title>Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells</article-title><source>J Pharmacol Exp Ther</source><year>2003</year><volume>304</volume><fpage>745</fpage><lpage>752</lpage><pub-id pub-id-type="pmid">12538830</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.102.038208</pub-id></element-citation></ref><ref id="CR194"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hukkanen</surname><given-names>J</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>P</given-names><suffix>III</suffix></name><name name-style="western"><surname>Benowitz</surname><given-names>NL</given-names></name></person-group><article-title>Metabolism and disposition kinetics of nicotine</article-title><source>Pharmacol Rev</source><year>2005</year><volume>57</volume><fpage>79</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">15734728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/pr.57.1.3</pub-id></element-citation></ref><ref id="CR195"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hunt</surname><given-names>SN</given-names></name><name name-style="western"><surname>Jusko</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Yurchak</surname><given-names>AM</given-names></name></person-group><article-title>Effect of smoking on theophylline disposition</article-title><source>Clin Pharmacol Ther</source><year>1976</year><volume>19</volume><fpage>546</fpage><lpage>551</lpage><pub-id pub-id-type="pmid">1277710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt1976195part1546</pub-id></element-citation></ref><ref id="CR196"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hussaarts</surname><given-names>KGAM</given-names></name><name name-style="western"><surname>Veerman</surname><given-names>GDM</given-names></name><name name-style="western"><surname>Jansman</surname><given-names>FGA</given-names></name><name name-style="western"><surname>van Gelder</surname><given-names>T</given-names></name><name name-style="western"><surname>Mathijssen</surname><given-names>RHJ</given-names></name><name name-style="western"><surname>van Leeuwen</surname><given-names>RWF</given-names></name></person-group><article-title>Clinically relevant drug interactions with multikinase inhibitors: a review</article-title><source>Ther Adv Med Oncol</source><year>2019</year><volume>11</volume><fpage>1758835918818347</fpage><pub-id pub-id-type="pmid">30643582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1758835918818347</pub-id><pub-id pub-id-type="pmcid">PMC6322107</pub-id></element-citation></ref><ref id="CR197"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hutzler</surname><given-names>JM</given-names></name><name name-style="western"><surname>Balogh</surname><given-names>LM</given-names></name><name name-style="western"><surname>Zientek</surname><given-names>M</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>V</given-names></name><name name-style="western"><surname>Tracy</surname><given-names>TS</given-names></name></person-group><article-title>Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+/&#8722;)-suprofen: a comparison of kinetics and probe substrate selection</article-title><source>Drug Metab Dispos</source><year>2009</year><volume>37</volume><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">18838506</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.108.023358</pub-id><pub-id pub-id-type="pmcid">PMC2610245</pub-id></element-citation></ref><ref id="CR198"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huuskonen</surname><given-names>P</given-names></name><name name-style="western"><surname>Storvik</surname><given-names>M</given-names></name><name name-style="western"><surname>Reinisalo</surname><given-names>M</given-names></name><name name-style="western"><surname>Honkakoski</surname><given-names>P</given-names></name><name name-style="western"><surname>Rysa</surname><given-names>J</given-names></name><name name-style="western"><surname>Hakkola</surname><given-names>J</given-names></name><name name-style="western"><surname>Pasanen</surname><given-names>M</given-names></name></person-group><article-title>Microarray analysis of the global alterations in the gene expression in the placentas from cigarette-smoking mothers</article-title><source>Clin Pharmacol Ther</source><year>2008</year><volume>83</volume><fpage>542</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">17928820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.clpt.6100376</pub-id></element-citation></ref><ref id="CR199"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iga</surname><given-names>K</given-names></name></person-group><article-title>Dynamic and static simulations of fluvoxamine-perpetrated drug&#8211;drug interactions using multiple cytochrome P450 inhibition modeling, and determination of perpetrator-specific CYP isoform inhibition constants and fractional CYP isoform contributions to victim clearance</article-title><source>J Pharm Sci</source><year>2016</year><volume>105</volume><fpage>1307</fpage><lpage>1317</lpage><pub-id pub-id-type="pmid">26886336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xphs.2015.11.044</pub-id></element-citation></ref><ref id="CR200"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Indra</surname><given-names>R</given-names></name><name name-style="western"><surname>Pompach</surname><given-names>P</given-names></name><name name-style="western"><surname>Mart&#237;nek</surname><given-names>V</given-names></name><name name-style="western"><surname>Tak&#225;csov&#225;</surname><given-names>P</given-names></name><name name-style="western"><surname>Vavrov&#225;</surname><given-names>K</given-names></name><name name-style="western"><surname>Heger</surname><given-names>Z</given-names></name><name name-style="western"><surname>Adam</surname><given-names>V</given-names></name><name name-style="western"><surname>Eckschlager</surname><given-names>T</given-names></name><name name-style="western"><surname>Kope&#269;kov&#225;</surname><given-names>K</given-names></name><name name-style="western"><surname>Arlt</surname><given-names>VM</given-names></name><name name-style="western"><surname>Stiborov&#225;</surname><given-names>M</given-names></name></person-group><article-title>Identification of human enzymes oxidizing the anti-thyroid-cancer drug vandetanib and explanation of the high efficiency of cytochrome P450 3A4 in its oxidation</article-title><source>Int J Mol Sci</source><year>2019</year><volume>20</volume><issue>14</issue><fpage>3392</fpage><pub-id pub-id-type="doi">10.3390/ijms20143392</pub-id><pub-id pub-id-type="pmcid">PMC6679423</pub-id><pub-id pub-id-type="pmid">31295928</pub-id></element-citation></ref><ref id="CR201"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Itoh</surname><given-names>M</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>M</given-names></name><name name-style="western"><surname>Higashi</surname><given-names>E</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>R</given-names></name><name name-style="western"><surname>Nagata</surname><given-names>K</given-names></name><name name-style="western"><surname>Yamazoe</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yokoi</surname><given-names>T</given-names></name></person-group><article-title>Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-gamma coactivator 1alpha</article-title><source>J Pharmacol Exp Ther</source><year>2006</year><volume>319</volume><fpage>693</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">16857725</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.106.107573</pub-id></element-citation></ref><ref id="CR202"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Izzo</surname><given-names>AA</given-names></name><name name-style="western"><surname>Ernst</surname><given-names>E</given-names></name></person-group><article-title>Interactions between herbal medicines and prescribed drugs: an updated systematic review</article-title><source>Drugs</source><year>2009</year><volume>69</volume><fpage>1777</fpage><lpage>1798</lpage><pub-id pub-id-type="pmid">19719333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/11317010-000000000-00000</pub-id></element-citation></ref><ref id="CR203"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaakkola</surname><given-names>T</given-names></name><name name-style="western"><surname>Backman</surname><given-names>JT</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>M</given-names></name><name name-style="western"><surname>Laitila</surname><given-names>J</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name></person-group><article-title>Effect of rifampicin on the pharmacokinetics of pioglitazone</article-title><source>Br J Clin Pharmacol</source><year>2006</year><volume>61</volume><fpage>70</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">16390353</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2005.02515.x</pub-id><pub-id pub-id-type="pmcid">PMC1884976</pub-id></element-citation></ref><ref id="CR204"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>KD</given-names></name><name name-style="western"><surname>Durandis</surname><given-names>R</given-names></name><name name-style="western"><surname>Vergne</surname><given-names>MJ</given-names></name></person-group><article-title>Role of cytochrome P450 enzymes in the metabolic activation of tyrosine kinase inhibitors</article-title><source>Int J Mol Sci</source><year>2018</year><volume>19</volume><issue>8</issue><fpage>2367</fpage><pub-id pub-id-type="doi">10.3390/ijms19082367</pub-id><pub-id pub-id-type="pmcid">PMC6121577</pub-id><pub-id pub-id-type="pmid">30103502</pub-id></element-citation></ref><ref id="CR205"><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Jager</surname><given-names>KW</given-names></name></person-group><source>Aldrin, Dieldrin, Endrin and Telodrin: an epidemiological and toxicological study of long term occupational exposure</source><year>1970</year><publisher-loc>Amsterdam</publisher-loc><publisher-name>Elsevier</publisher-name></element-citation></ref><ref id="CR206"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>James</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Smith</surname><given-names>CC</given-names></name><name name-style="western"><surname>Litzow</surname><given-names>M</given-names></name><name name-style="western"><surname>Perl</surname><given-names>AE</given-names></name><name name-style="western"><surname>Altman</surname><given-names>JK</given-names></name><name name-style="western"><surname>Shepard</surname><given-names>D</given-names></name><name name-style="western"><surname>Kadokura</surname><given-names>T</given-names></name><name name-style="western"><surname>Souda</surname><given-names>K</given-names></name><name name-style="western"><surname>Patton</surname><given-names>M</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Moy</surname><given-names>S</given-names></name><name name-style="western"><surname>Levis</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Bahceci</surname><given-names>E</given-names></name></person-group><article-title>Pharmacokinetic profile of gilteritinib: a novel FLT-3 tyrosine kinase inhibitor</article-title><source>Clin Pharmacokinet</source><year>2020</year><volume>59</volume><issue>10</issue><fpage>1273</fpage><lpage>1290</lpage><pub-id pub-id-type="doi">10.1007/s40262-020-00888-w</pub-id><pub-id pub-id-type="pmid">32304015</pub-id><pub-id pub-id-type="pmcid">PMC7550323</pub-id></element-citation></ref><ref id="CR207"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jao</surname><given-names>JY</given-names></name><name name-style="western"><surname>Jusko</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>JL</given-names></name></person-group><article-title>Phenobarbital effects on cyclophosphamide pharmacokinetics in man</article-title><source>Cancer Res</source><year>1972</year><volume>32</volume><fpage>2761</fpage><lpage>2764</lpage><pub-id pub-id-type="pmid">4678592</pub-id></element-citation></ref><ref id="CR208"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>S</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>PD</given-names></name><name name-style="western"><surname>Desta</surname><given-names>Z</given-names></name></person-group><article-title>Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A</article-title><source>Antimicrob Agents Chemother</source><year>2009</year><volume>53</volume><fpage>541</fpage><lpage>551</lpage><pub-id pub-id-type="pmid">19029318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.01123-08</pub-id><pub-id pub-id-type="pmcid">PMC2630638</pub-id></element-citation></ref><ref id="CR209"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>S</given-names></name><name name-style="western"><surname>Woo</surname><given-names>MM</given-names></name><name name-style="western"><surname>Flockhart</surname><given-names>DA</given-names></name><name name-style="western"><surname>Desta</surname><given-names>Z</given-names></name></person-group><article-title>Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4&#8242;-methanol-bisbenzonitrile in vitro</article-title><source>Cancer Chemother Pharmacol</source><year>2009</year><volume>64</volume><fpage>867</fpage><lpage>875</lpage><pub-id pub-id-type="pmid">19198839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-009-0935-7</pub-id><pub-id pub-id-type="pmcid">PMC2774495</pub-id></element-citation></ref><ref id="CR210"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>P</given-names></name><name name-style="western"><surname>Damle</surname><given-names>B</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J</given-names></name><name name-style="western"><surname>Unger</surname><given-names>SE</given-names></name><name name-style="western"><surname>Grasela</surname><given-names>DM</given-names></name><name name-style="western"><surname>Kaul</surname><given-names>S</given-names></name></person-group><article-title>Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects</article-title><source>J Clin Pharmacol</source><year>2008</year><volume>48</volume><fpage>948</fpage><lpage>956</lpage><pub-id pub-id-type="pmid">18519918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0091270008319792</pub-id></element-citation></ref><ref id="CR211"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>X</given-names></name><name name-style="western"><surname>Williams</surname><given-names>KM</given-names></name><name name-style="western"><surname>Liauw</surname><given-names>WS</given-names></name><name name-style="western"><surname>Ammit</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Roufogalis</surname><given-names>BD</given-names></name><name name-style="western"><surname>Duke</surname><given-names>CC</given-names></name><name name-style="western"><surname>Day</surname><given-names>RO</given-names></name><name name-style="western"><surname>McLachlan</surname><given-names>AJ</given-names></name></person-group><article-title>Effect of St John&#8217;s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects</article-title><source>Br J Clin Pharmacol</source><year>2004</year><volume>57</volume><fpage>592</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">15089812</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2003.02051.x</pub-id><pub-id pub-id-type="pmcid">PMC1884493</pub-id></element-citation></ref><ref id="CR212"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>X</given-names></name><name name-style="western"><surname>Blair</surname><given-names>EY</given-names></name><name name-style="western"><surname>McLachlan</surname><given-names>AJ</given-names></name></person-group><article-title>Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach</article-title><source>J Clin Pharmacol</source><year>2006</year><volume>46</volume><fpage>1370</fpage><lpage>1378</lpage><pub-id pub-id-type="pmid">17050802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0091270006292124</pub-id></element-citation></ref><ref id="CR213"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johansson</surname><given-names>S</given-names></name><name name-style="western"><surname>Read</surname><given-names>J</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>S</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lisbon</surname><given-names>E</given-names></name><name name-style="western"><surname>Mathews</surname><given-names>D</given-names></name><name name-style="western"><surname>Leese</surname><given-names>PT</given-names></name><name name-style="western"><surname>Martin</surname><given-names>P</given-names></name></person-group><article-title>Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine</article-title><source>Clin Pharmacokinet</source><year>2014</year><volume>53</volume><fpage>837</fpage><lpage>847</lpage><pub-id pub-id-type="pmid">25117183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-014-0161-2</pub-id></element-citation></ref><ref id="CR214"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>FM</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>S</given-names></name><name name-style="western"><surname>Burris</surname><given-names>H</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>L</given-names></name><name name-style="western"><surname>Dhillon</surname><given-names>N</given-names></name><name name-style="western"><surname>Hong</surname><given-names>D</given-names></name><name name-style="western"><surname>Blackwood-Chirchir</surname><given-names>A</given-names></name><name name-style="western"><surname>Luo</surname><given-names>FR</given-names></name><name name-style="western"><surname>Sy</surname><given-names>O</given-names></name><name name-style="western"><surname>Kaul</surname><given-names>S</given-names></name><name name-style="western"><surname>Chiappori</surname><given-names>AA</given-names></name></person-group><article-title>Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors</article-title><source>Cancer</source><year>2010</year><volume>116</volume><fpage>1582</fpage><lpage>1591</lpage><pub-id pub-id-type="pmid">20108303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.24927</pub-id></element-citation></ref><ref id="CR215"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>JP</given-names></name><name name-style="western"><surname>Joswig-Jones</surname><given-names>CA</given-names></name><name name-style="western"><surname>Hebner</surname><given-names>M</given-names></name><name name-style="western"><surname>Chu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Koop</surname><given-names>DR</given-names></name></person-group><article-title>The effects of nitrogen-heme-iron coordination on substrate affinities for cytochrome P450 2E1</article-title><source>Chem Biol Interact</source><year>2011</year><volume>193</volume><fpage>50</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">21600194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cbi.2011.05.001</pub-id><pub-id pub-id-type="pmcid">PMC3129366</pub-id></element-citation></ref><ref id="CR216"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jushchyshyn</surname><given-names>MI</given-names></name><name name-style="western"><surname>Wahlstrom</surname><given-names>JL</given-names></name><name name-style="western"><surname>Hollenberg</surname><given-names>PF</given-names></name><name name-style="western"><surname>Wienkers</surname><given-names>LC</given-names></name></person-group><article-title>Mechanism of inactivation of human cytochrome P450 2B6 by phencyclidine</article-title><source>Drug Metab Dispos</source><year>2006</year><volume>34</volume><fpage>1523</fpage><lpage>1529</lpage><pub-id pub-id-type="pmid">16782764</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.106.010579</pub-id></element-citation></ref><ref id="CR217"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Justesen</surname><given-names>US</given-names></name><name name-style="western"><surname>Klitgaard</surname><given-names>NA</given-names></name><name name-style="western"><surname>Brosen</surname><given-names>K</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>C</given-names></name></person-group><article-title>Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers</article-title><source>Br J Clin Pharmacol</source><year>2003</year><volume>55</volume><fpage>100</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">12534646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2125.2003.01734.x</pub-id><pub-id pub-id-type="pmcid">PMC1884187</pub-id></element-citation></ref><ref id="CR218"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kahma</surname><given-names>H</given-names></name><name name-style="western"><surname>Filppula</surname><given-names>AM</given-names></name><name name-style="western"><surname>Launiainen</surname><given-names>T</given-names></name><name name-style="western"><surname>Viinam&#228;ki</surname><given-names>J</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>M</given-names></name><name name-style="western"><surname>Evangelista</surname><given-names>EA</given-names></name><name name-style="western"><surname>Totah</surname><given-names>RA</given-names></name><name name-style="western"><surname>Backman</surname><given-names>JT</given-names></name></person-group><article-title>Critical differences between enzyme sources in sensitivity to detect time-dependent inactivation of CYP2C8</article-title><source>Drug Metab Dispos</source><year>2019</year><volume>47</volume><fpage>436</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">30709838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.118.085498</pub-id><pub-id pub-id-type="pmcid">PMC11022894</pub-id></element-citation></ref><ref id="CR219"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kakuda</surname><given-names>TN</given-names></name><name name-style="western"><surname>Van Solingen-Ristea</surname><given-names>RM</given-names></name><name name-style="western"><surname>Onkelinx</surname><given-names>J</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>T</given-names></name><name name-style="western"><surname>Aharchi</surname><given-names>F</given-names></name><name name-style="western"><surname>De Smedt</surname><given-names>G</given-names></name><name name-style="western"><surname>Peeters</surname><given-names>M</given-names></name><name name-style="western"><surname>Leopold</surname><given-names>L</given-names></name><name name-style="western"><surname>Hoetelmans</surname><given-names>RM</given-names></name></person-group><article-title>The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects</article-title><source>J Clin Pharmacol</source><year>2014</year><volume>54</volume><fpage>422</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">24165884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcph.214</pub-id></element-citation></ref><ref id="CR220"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanamitsu</surname><given-names>S</given-names></name><name name-style="western"><surname>Ito</surname><given-names>K</given-names></name><name name-style="western"><surname>Green</surname><given-names>CE</given-names></name><name name-style="western"><surname>Tyson</surname><given-names>CA</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>N</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>Y</given-names></name></person-group><article-title>Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4</article-title><source>Pharm Res</source><year>2000</year><volume>17</volume><fpage>419</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">10870985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1007572803027</pub-id></element-citation></ref><ref id="CR221"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kandel</surname><given-names>CE</given-names></name><name name-style="western"><surname>Walmsley</surname><given-names>SL</given-names></name></person-group><article-title>Dolutegravir&#8212;a review of the pharmacology, efficacy, and safety in the treatment of HIV</article-title><source>Drug Des Dev Ther</source><year>2015</year><volume>9</volume><fpage>3547</fpage><lpage>3555</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DDDT.S84850</pub-id><pub-id pub-id-type="pmcid">PMC4500604</pub-id><pub-id pub-id-type="pmid">26185421</pub-id></element-citation></ref><ref id="CR222"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kappas</surname><given-names>A</given-names></name><name name-style="western"><surname>Alvares</surname><given-names>AP</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>KE</given-names></name><name name-style="western"><surname>Pantuck</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Pantuck</surname><given-names>CB</given-names></name><name name-style="western"><surname>Chang</surname><given-names>R</given-names></name><name name-style="western"><surname>Conney</surname><given-names>AH</given-names></name></person-group><article-title>Effect of charcoal-broiled beef on antipyrine and theophylline metabolism</article-title><source>Clin Pharmacol Ther</source><year>1978</year><volume>23</volume><fpage>445</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">630792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt1978234445</pub-id></element-citation></ref><ref id="CR223"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karjalainen</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Backman</surname><given-names>JT</given-names></name></person-group><article-title>In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions</article-title><source>Basic Clin Pharmacol Toxicol</source><year>2008</year><volume>103</volume><fpage>157</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">18816299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1742-7843.2008.00252.x</pub-id></element-citation></ref><ref id="CR224"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kashuba</surname><given-names>AD</given-names></name><name name-style="western"><surname>Tierney</surname><given-names>C</given-names></name><name name-style="western"><surname>Downey</surname><given-names>GF</given-names></name><name name-style="western"><surname>Acosta</surname><given-names>EP</given-names></name><name name-style="western"><surname>Vergis</surname><given-names>EN</given-names></name><name name-style="western"><surname>Klingman</surname><given-names>K</given-names></name><name name-style="western"><surname>Mellors</surname><given-names>JW</given-names></name><name name-style="western"><surname>Eshleman</surname><given-names>SH</given-names></name><name name-style="western"><surname>Scott</surname><given-names>TR</given-names></name><name name-style="western"><surname>Collier</surname><given-names>AC</given-names></name></person-group><article-title>Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: aCTG protocol A5143 results</article-title><source>AIDS</source><year>2005</year><volume>19</volume><fpage>145</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">15668539</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00002030-200501280-00006</pub-id></element-citation></ref><ref id="CR225"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katiyar</surname><given-names>SK</given-names></name><name name-style="western"><surname>Matsui</surname><given-names>MS</given-names></name><name name-style="western"><surname>Mukhtar</surname><given-names>H</given-names></name></person-group><article-title>Ultraviolet-B exposure of human skin induces cytochromes P450 1A1 and 1B1</article-title><source>J Investig Dermatol</source><year>2000</year><volume>114</volume><fpage>328</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">10651994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1523-1747.2000.00876.x</pub-id></element-citation></ref><ref id="CR226"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kato</surname><given-names>H</given-names></name></person-group><article-title>Computational prediction of cytochrome P450 inhibition and induction</article-title><source>Drug Metab Pharmacokinet</source><year>2020</year><volume>35</volume><fpage>30</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">31902468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dmpk.2019.11.006</pub-id></element-citation></ref><ref id="CR227"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawajiri</surname><given-names>K</given-names></name><name name-style="western"><surname>Fujii-Kuriyama</surname><given-names>Y</given-names></name></person-group><article-title>The aryl hydrocarbon receptor: a multifunctional chemical sensor for host defense and homeostatic maintenance</article-title><source>Exp Anim</source><year>2017</year><volume>66</volume><fpage>75</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">27980293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1538/expanim.16-0092</pub-id><pub-id pub-id-type="pmcid">PMC5411294</pub-id></element-citation></ref><ref id="CR228"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kellogg</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Paine</surname><given-names>MF</given-names></name><name name-style="western"><surname>McCune</surname><given-names>JS</given-names></name><name name-style="western"><surname>Oberlies</surname><given-names>NH</given-names></name><name name-style="western"><surname>Cech</surname><given-names>NB</given-names></name></person-group><article-title>Selection and characterization of botanical natural products for research studies: a NaPDI center recommended approach</article-title><source>Nat Prod Rep</source><year>2019</year><volume>36</volume><fpage>1196</fpage><lpage>1221</lpage><pub-id pub-id-type="pmid">30681109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c8np00065d</pub-id><pub-id pub-id-type="pmcid">PMC6658353</pub-id></element-citation></ref><ref id="CR229"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kenny</surname><given-names>JR</given-names></name><name name-style="western"><surname>Mukadam</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Tay</surname><given-names>S</given-names></name><name name-style="western"><surname>Collins</surname><given-names>C</given-names></name><name name-style="western"><surname>Galetin</surname><given-names>A</given-names></name><name name-style="western"><surname>Khojasteh</surname><given-names>SC</given-names></name></person-group><article-title>Drug&#8211;drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug&#8211;drug interaction prediction</article-title><source>Pharm Res</source><year>2012</year><volume>29</volume><fpage>1960</fpage><lpage>1976</lpage><pub-id pub-id-type="pmid">22415140</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-012-0724-6</pub-id></element-citation></ref><ref id="CR230"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ketter</surname><given-names>TA</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>JB</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>DH</given-names></name><name name-style="western"><surname>Pazzaglia</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Marangell</surname><given-names>LB</given-names></name><name name-style="western"><surname>George</surname><given-names>MS</given-names></name><name name-style="western"><surname>Callahan</surname><given-names>AM</given-names></name><name name-style="western"><surname>Hinton</surname><given-names>ML</given-names></name><name name-style="western"><surname>Chao</surname><given-names>J</given-names></name><name name-style="western"><surname>Post</surname><given-names>RM</given-names></name></person-group><article-title>Carbamazepine but not valproate induces bupropion metabolism</article-title><source>J Clin Psychopharmacol</source><year>1995</year><volume>15</volume><fpage>327</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">8830063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00004714-199510000-00004</pub-id></element-citation></ref><ref id="CR231"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalilieh</surname><given-names>SG</given-names></name><name name-style="western"><surname>Yee</surname><given-names>KL</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>RI</given-names></name><name name-style="western"><surname>Fan</surname><given-names>L</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>MS</given-names></name><name name-style="western"><surname>Sura</surname><given-names>M</given-names></name><name name-style="western"><surname>Laethem</surname><given-names>T</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>S</given-names></name><name name-style="western"><surname>van Bortel</surname><given-names>L</given-names></name><name name-style="western"><surname>van Lancker</surname><given-names>G</given-names></name><name name-style="western"><surname>Iwamoto</surname><given-names>M</given-names></name></person-group><article-title>Doravirine and the potential for cyp3a-mediated drug-drug interactions</article-title><source>Antimicrob Agents Chemother</source><year>2019</year><volume>63</volume><issue>5</issue><fpage>e02016</fpage><lpage>e02018</lpage><pub-id pub-id-type="doi">10.1128/AAC.02016-18</pub-id><pub-id pub-id-type="pmid">30783000</pub-id><pub-id pub-id-type="pmcid">PMC6496093</pub-id></element-citation></ref><ref id="CR232"><mixed-citation publication-type="other">Kharasch ED, Mitchell D, Coles R, Blanco R (2008) Rapid clinical induction of hepatic cytochrome P4502B6 (CYP2B6) activity by ritonavir. Antimicrob Agents Chemother<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.01600-07</pub-id><pub-id pub-id-type="pmcid">PMC2346649</pub-id><pub-id pub-id-type="pmid">18285471</pub-id></mixed-citation></ref><ref id="CR233"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kharasch</surname><given-names>ED</given-names></name><name name-style="western"><surname>Whittington</surname><given-names>D</given-names></name><name name-style="western"><surname>Ensign</surname><given-names>D</given-names></name><name name-style="western"><surname>Hoffer</surname><given-names>C</given-names></name><name name-style="western"><surname>Bedynek</surname><given-names>PS</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>S</given-names></name><name name-style="western"><surname>Stubbert</surname><given-names>K</given-names></name><name name-style="western"><surname>Crafford</surname><given-names>A</given-names></name><name name-style="western"><surname>London</surname><given-names>A</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T</given-names></name></person-group><article-title>Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics</article-title><source>Clin Pharmacol Ther</source><year>2012</year><volume>91</volume><issue>4</issue><fpage>673</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1038/clpt.2011.276</pub-id><pub-id pub-id-type="pmid">22398970</pub-id><pub-id pub-id-type="pmcid">PMC3600645</pub-id></element-citation></ref><ref id="CR234"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>KY</given-names></name><name name-style="western"><surname>Frey</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Epplen</surname><given-names>K</given-names></name><name name-style="western"><surname>Foruhari</surname><given-names>F</given-names></name></person-group><article-title>Interaction between warfarin and nafcillin: case report and review of the literature</article-title><source>Pharmacotherapy</source><year>2007</year><volume>27</volume><fpage>1467</fpage><lpage>1470</lpage><pub-id pub-id-type="pmid">17896903</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1592/phco.27.10.1467</pub-id></element-citation></ref><ref id="CR235"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>King</surname><given-names>CA</given-names></name><name name-style="western"><surname>Babcock</surname><given-names>KM</given-names></name><name name-style="western"><surname>Godios</surname><given-names>RJ</given-names></name><name name-style="western"><surname>King</surname><given-names>BS</given-names></name></person-group><article-title>PMC6243422; significant drug&#8211;drug interaction between warfarin and nafcillin</article-title><source>Ther Adv Drug Saf</source><year>2018</year><volume>9</volume><fpage>667</fpage><lpage>671</lpage><pub-id pub-id-type="pmid">30479741</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2042098618796186</pub-id><pub-id pub-id-type="pmcid">PMC6243422</pub-id></element-citation></ref><ref id="CR236"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirby</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Collier</surname><given-names>AC</given-names></name><name name-style="western"><surname>Kharasch</surname><given-names>ED</given-names></name><name name-style="western"><surname>Whittington</surname><given-names>D</given-names></name><name name-style="western"><surname>Thummel</surname><given-names>KE</given-names></name><name name-style="western"><surname>Unadkat</surname><given-names>JD</given-names></name></person-group><article-title>Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir</article-title><source>Drug Metab Dispos</source><year>2011</year><volume>39</volume><fpage>1070</fpage><lpage>1078</lpage><pub-id pub-id-type="pmid">21406602</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.110.037523</pub-id><pub-id pub-id-type="pmcid">PMC3100903</pub-id></element-citation></ref><ref id="CR237"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirby</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Collier</surname><given-names>AC</given-names></name><name name-style="western"><surname>Kharasch</surname><given-names>ED</given-names></name><name name-style="western"><surname>Dixit</surname><given-names>V</given-names></name><name name-style="western"><surname>Desai</surname><given-names>P</given-names></name><name name-style="western"><surname>Whittington</surname><given-names>D</given-names></name><name name-style="western"><surname>Thummel</surname><given-names>KE</given-names></name><name name-style="western"><surname>Unadkat</surname><given-names>JD</given-names></name></person-group><article-title>Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro-to-in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir</article-title><source>Drug Metab Dispos</source><year>2011</year><volume>39</volume><fpage>2329</fpage><lpage>2337</lpage><pub-id pub-id-type="pmid">21930825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.111.038646</pub-id><pub-id pub-id-type="pmcid">PMC3226381</pub-id></element-citation></ref><ref id="CR238"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kliewer</surname><given-names>SA</given-names></name><name name-style="western"><surname>Moore</surname><given-names>JT</given-names></name><name name-style="western"><surname>Wade</surname><given-names>L</given-names></name><name name-style="western"><surname>Staudinger</surname><given-names>JL</given-names></name><name name-style="western"><surname>Watson</surname><given-names>MA</given-names></name><name name-style="western"><surname>Jones</surname><given-names>SA</given-names></name><name name-style="western"><surname>McKee</surname><given-names>DD</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>BB</given-names></name><name name-style="western"><surname>Willson</surname><given-names>TM</given-names></name><name name-style="western"><surname>Zetterstr&#246;m</surname><given-names>RH</given-names></name><name name-style="western"><surname>Perlmann</surname><given-names>T</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>JM</given-names></name></person-group><article-title>An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway</article-title><source>Cell</source><year>1998</year><volume>92</volume><fpage>73</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">9489701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0092-8674(00)80900-9</pub-id></element-citation></ref><ref id="CR239"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klosterskov Jensen</surname><given-names>P</given-names></name><name name-style="western"><surname>Saano</surname><given-names>V</given-names></name><name name-style="western"><surname>Haring</surname><given-names>P</given-names></name><name name-style="western"><surname>Svenstrup</surname><given-names>B</given-names></name><name name-style="western"><surname>Menge</surname><given-names>GP</given-names></name></person-group><article-title>Possible interaction between oxcarbazepine and an oral contraceptive</article-title><source>Epilepsia</source><year>1992</year><volume>33</volume><fpage>1149</fpage><lpage>1152</lpage><pub-id pub-id-type="pmid">1464278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1528-1157.1992.tb01773.x</pub-id></element-citation></ref><ref id="CR240"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ko</surname><given-names>JW</given-names></name><name name-style="western"><surname>Desta</surname><given-names>Z</given-names></name><name name-style="western"><surname>Soukhova</surname><given-names>NV</given-names></name><name name-style="western"><surname>Tracy</surname><given-names>T</given-names></name><name name-style="western"><surname>Flockhart</surname><given-names>DA</given-names></name></person-group><article-title>In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6</article-title><source>Br J Clin Pharmacol</source><year>2000</year><volume>49</volume><fpage>343</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">10759690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2125.2000.00175.x</pub-id><pub-id pub-id-type="pmcid">PMC2014930</pub-id></element-citation></ref><ref id="CR241"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>K</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Honkakoski</surname><given-names>P</given-names></name><name name-style="western"><surname>Negishi</surname><given-names>M</given-names></name></person-group><article-title>Regulation of gene expression by CAR: an update</article-title><source>Arch Toxicol</source><year>2015</year><volume>89</volume><fpage>1045</fpage><lpage>1055</lpage><pub-id pub-id-type="pmid">25975989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00204-015-1522-9</pub-id></element-citation></ref><ref id="CR242"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>K&#246;hle</surname><given-names>C</given-names></name><name name-style="western"><surname>Bock</surname><given-names>KW</given-names></name></person-group><article-title>Coordinate regulation of Phase I and II xenobiotic metabolisms by the Ah receptor and Nrf2</article-title><source>Biochem Pharmacol</source><year>2007</year><volume>73</volume><fpage>1853</fpage><lpage>1862</lpage><pub-id pub-id-type="pmid">17266942</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2007.01.009</pub-id></element-citation></ref><ref id="CR243"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolars</surname><given-names>JC</given-names></name><name name-style="western"><surname>Schmiedlin-Ren</surname><given-names>P</given-names></name><name name-style="western"><surname>Schuetz</surname><given-names>JD</given-names></name><name name-style="western"><surname>Fang</surname><given-names>C</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>PB</given-names></name></person-group><article-title>PMC443248; Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes</article-title><source>J Clin Investig</source><year>1992</year><volume>90</volume><fpage>1871</fpage><lpage>1878</lpage><pub-id pub-id-type="pmid">1430211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI116064</pub-id><pub-id pub-id-type="pmcid">PMC443248</pub-id></element-citation></ref><ref id="CR244"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>LM</given-names></name><name name-style="western"><surname>Xu</surname><given-names>SY</given-names></name><name name-style="western"><surname>Hu</surname><given-names>HH</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>HD</given-names></name><name name-style="western"><surname>Yu</surname><given-names>LS</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>S</given-names></name></person-group><article-title>Identification of CYP2C19 inhibitors from phytochemicals using the recombinant human enzyme model</article-title><source>Pharmazie</source><year>2014</year><volume>69</volume><fpage>362</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">24855828</pub-id></element-citation></ref><ref id="CR245"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korzekwa</surname><given-names>K</given-names></name><name name-style="western"><surname>Tweedie</surname><given-names>D</given-names></name><name name-style="western"><surname>Argikar</surname><given-names>UA</given-names></name><name name-style="western"><surname>Whitcher-Johnstone</surname><given-names>A</given-names></name><name name-style="western"><surname>Bell</surname><given-names>L</given-names></name><name name-style="western"><surname>Bickford</surname><given-names>S</given-names></name><name name-style="western"><surname>Nagar</surname><given-names>S</given-names></name></person-group><article-title>A numerical method for analysis of in vitro time-dependent inhibition data. Part 2. Application to experimental data</article-title><source>Drug Metab Dispos</source><year>2014</year><volume>42</volume><fpage>1587</fpage><lpage>1595</lpage><pub-id pub-id-type="pmid">24939653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.114.058297</pub-id><pub-id pub-id-type="pmcid">PMC4152872</pub-id></element-citation></ref><ref id="CR246"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krauwinkel</surname><given-names>W</given-names></name><name name-style="western"><surname>Dickinson</surname><given-names>J</given-names></name><name name-style="western"><surname>Schaddelee</surname><given-names>M</given-names></name><name name-style="western"><surname>Meijer</surname><given-names>J</given-names></name><name name-style="western"><surname>Tretter</surname><given-names>R</given-names></name><name name-style="western"><surname>van de Wetering</surname><given-names>J</given-names></name><name name-style="western"><surname>Strabach</surname><given-names>G</given-names></name><name name-style="western"><surname>van Gelderen</surname><given-names>M</given-names></name></person-group><article-title>The effect of mirabegron, a potent and selective &#946;3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol</article-title><source>Eur J Drug Metab Pharmacokinet</source><year>2014</year><volume>39</volume><fpage>43</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">23728524</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13318-013-0133-1</pub-id></element-citation></ref><ref id="CR247"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishna</surname><given-names>G</given-names></name><name name-style="western"><surname>Moton</surname><given-names>A</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>Savant</surname><given-names>I</given-names></name><name name-style="western"><surname>Martinho</surname><given-names>M</given-names></name><name name-style="western"><surname>Seiberling</surname><given-names>M</given-names></name><name name-style="western"><surname>McLeod</surname><given-names>J</given-names></name></person-group><article-title>Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers</article-title><source>Clin Ther</source><year>2009</year><volume>31</volume><fpage>286</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">19302901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinthera.2009.02.022</pub-id></element-citation></ref><ref id="CR248"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kunze</surname><given-names>KL</given-names></name><name name-style="western"><surname>Wienkers</surname><given-names>LC</given-names></name><name name-style="western"><surname>Thummel</surname><given-names>KE</given-names></name><name name-style="western"><surname>Trager</surname><given-names>WF</given-names></name></person-group><article-title>Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies</article-title><source>Drug Metab Dispos</source><year>1996</year><volume>24</volume><fpage>414</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">8801056</pub-id></element-citation></ref><ref id="CR249"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kusawake</surname><given-names>T</given-names></name><name name-style="western"><surname>den Adel</surname><given-names>M</given-names></name><name name-style="western"><surname>Groenendaal-van de Meent</surname><given-names>D</given-names></name><name name-style="western"><surname>Garcia-Hernandez</surname><given-names>A</given-names></name><name name-style="western"><surname>Takada</surname><given-names>A</given-names></name><name name-style="western"><surname>Kato</surname><given-names>K</given-names></name><name name-style="western"><surname>Ohtsu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Katashima</surname><given-names>M</given-names></name></person-group><article-title>PMC5702381; pharmacokinetic evaluation of the interactions of amenamevir (ASP2151) with ketoconazole, rifampicin, midazolam, and warfarin in healthy adults</article-title><source>Adv Ther</source><year>2017</year><volume>34</volume><fpage>2466</fpage><lpage>2480</lpage><pub-id pub-id-type="pmid">29076107</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12325-017-0634-4</pub-id><pub-id pub-id-type="pmcid">PMC5702381</pub-id></element-citation></ref><ref id="CR250"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuypers</surname><given-names>DR</given-names></name><name name-style="western"><surname>Claes</surname><given-names>K</given-names></name><name name-style="western"><surname>Evenepoel</surname><given-names>P</given-names></name><name name-style="western"><surname>Maes</surname><given-names>B</given-names></name><name name-style="western"><surname>Coosemans</surname><given-names>W</given-names></name><name name-style="western"><surname>Pirenne</surname><given-names>J</given-names></name><name name-style="western"><surname>Vanrenterghem</surname><given-names>Y</given-names></name></person-group><article-title>Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients</article-title><source>Clin Pharmacokinet</source><year>2004</year><volume>43</volume><fpage>741</fpage><lpage>762</lpage><pub-id pub-id-type="pmid">15301578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-200443110-00005</pub-id></element-citation></ref><ref id="CR251"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kyerematen</surname><given-names>GA</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>M</given-names></name><name name-style="western"><surname>Warner</surname><given-names>G</given-names></name><name name-style="western"><surname>Martin</surname><given-names>LF</given-names></name><name name-style="western"><surname>Vesell</surname><given-names>ES</given-names></name></person-group><article-title>Metabolism of nicotine by hepatocytes</article-title><source>Biochem Pharmacol</source><year>1990</year><volume>40</volume><fpage>1747</fpage><lpage>1756</lpage><pub-id pub-id-type="pmid">2242011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0006-2952(90)90351-k</pub-id></element-citation></ref><ref id="CR252"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>ML</given-names></name><name name-style="western"><surname>Lin</surname><given-names>TS</given-names></name><name name-style="western"><surname>Huang</surname><given-names>JD</given-names></name></person-group><article-title>Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin</article-title><source>Eur J Clin Pharmacol</source><year>1992</year><volume>43</volume><fpage>201</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">1425879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF01740672</pub-id></element-citation></ref><ref id="CR253"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamba</surname><given-names>JK</given-names></name><name name-style="western"><surname>Lin</surname><given-names>YS</given-names></name><name name-style="western"><surname>Schuetz</surname><given-names>EG</given-names></name><name name-style="western"><surname>Thummel</surname><given-names>KE</given-names></name></person-group><article-title>Genetic contribution to variable human CYP3A-mediated metabolism</article-title><source>Adv Drug Deliv Rev</source><year>2002</year><volume>54</volume><fpage>1271</fpage><lpage>1294</lpage><pub-id pub-id-type="pmid">12406645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0169-409x(02)00066-2</pub-id></element-citation></ref><ref id="CR254"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambert</surname><given-names>GH</given-names></name><name name-style="western"><surname>Schoeller</surname><given-names>DA</given-names></name><name name-style="western"><surname>Humphrey</surname><given-names>HE</given-names></name><name name-style="western"><surname>Kotake</surname><given-names>AN</given-names></name><name name-style="western"><surname>Lietz</surname><given-names>H</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>M</given-names></name><name name-style="western"><surname>Kalow</surname><given-names>W</given-names></name><name name-style="western"><surname>Spielberg</surname><given-names>SP</given-names></name><name name-style="western"><surname>Budd</surname><given-names>M</given-names></name></person-group><article-title>1567793; the caffeine breath test and caffeine urinary metabolite ratios in the Michigan cohort exposed to polybrominated biphenyls: a preliminary study</article-title><source>Environ Health Perspect</source><year>1990</year><volume>89</volume><fpage>175</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">1965165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1289/ehp.9089175</pub-id><pub-id pub-id-type="pmcid">PMC1567793</pub-id></element-citation></ref><ref id="CR255"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lampe</surname><given-names>JW</given-names></name><name name-style="western"><surname>Stepaniants</surname><given-names>SB</given-names></name><name name-style="western"><surname>Mao</surname><given-names>M</given-names></name><name name-style="western"><surname>Radich</surname><given-names>JP</given-names></name><name name-style="western"><surname>Dai</surname><given-names>H</given-names></name><name name-style="western"><surname>Linsley</surname><given-names>PS</given-names></name><name name-style="western"><surname>Friend</surname><given-names>SH</given-names></name><name name-style="western"><surname>Potter</surname><given-names>JD</given-names></name></person-group><article-title>Signatures of environmental exposures using peripheral leukocyte gene expression: tobacco smoke</article-title><source>Cancer Epidemiol Biomark Prev</source><year>2004</year><volume>13</volume><fpage>445</fpage><lpage>453</lpage><pub-id pub-id-type="pmid">15006922</pub-id></element-citation></ref><ref id="CR256"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#228;ms&#228;</surname><given-names>V</given-names></name><name name-style="western"><surname>Levonen</surname><given-names>A</given-names></name><name name-style="western"><surname>Leinonen</surname><given-names>H</given-names></name><name name-style="western"><surname>Yl&#228;-Herttuala</surname><given-names>S</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Hakkola</surname><given-names>J</given-names></name></person-group><article-title>Cytochrome P450 2A5 constitutive expression and induction by heavy metals is dependent on redox-sensitive transcription factor Nrf2 in liver</article-title><source>Chem Res Toxicol</source><year>2010</year><volume>23</volume><fpage>977</fpage><lpage>985</lpage><pub-id pub-id-type="pmid">20402460</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/tx100084c</pub-id></element-citation></ref><ref id="CR257"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Landay</surname><given-names>RA</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>MA</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>JC</given-names></name></person-group><article-title>Effect of phenobarbital on theophylline disposition</article-title><source>J Allergy Clin Immunol</source><year>1978</year><volume>62</volume><fpage>27</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">659737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0091-6749(78)90068-4</pub-id></element-citation></ref><ref id="CR258"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lang</surname><given-names>CC</given-names></name><name name-style="western"><surname>Jamal</surname><given-names>SK</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>Z</given-names></name><name name-style="western"><surname>Mustafa</surname><given-names>MR</given-names></name><name name-style="western"><surname>Mustafa</surname><given-names>AM</given-names></name><name name-style="western"><surname>Lee</surname><given-names>TC</given-names></name></person-group><article-title>1884262; evidence of an interaction between nifedipine and nafcillin in humans</article-title><source>Br J Clin Pharmacol</source><year>2003</year><volume>55</volume><fpage>588</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">12814453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2125.2003.01789.x</pub-id><pub-id pub-id-type="pmcid">PMC1884262</pub-id></element-citation></ref><ref id="CR259"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawrence</surname><given-names>SK</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>D</given-names></name><name name-style="western"><surname>Bowen</surname><given-names>C</given-names></name><name name-style="western"><surname>Richards-Peterson</surname><given-names>L</given-names></name><name name-style="western"><surname>Skordos</surname><given-names>KW</given-names></name></person-group><article-title>The metabolic drug&#8211;drug interaction profile of Dabrafenib: in vitro investigations and quantitative extrapolation of the P450-mediated DDI risk</article-title><source>Drug Metab Dispos</source><year>2014</year><volume>42</volume><fpage>1180</fpage><lpage>1190</lpage><pub-id pub-id-type="pmid">24748562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.114.057778</pub-id></element-citation></ref><ref id="CR260"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lecamwasam</surname><given-names>DS</given-names></name><name name-style="western"><surname>Franklin</surname><given-names>C</given-names></name><name name-style="western"><surname>Turner</surname><given-names>P</given-names></name></person-group><article-title>Effect of phenobarbitone on hepatic drug-metabolizing enzymes and urinary <sc>d</sc>-glucaric acid excretion in man</article-title><source>Br J Clin Pharmacol</source><year>1975</year><volume>2</volume><fpage>257</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">1234506</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1975.tb01584.x</pub-id><pub-id pub-id-type="pmcid">PMC1402570</pub-id></element-citation></ref><ref id="CR261"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JSF</given-names></name><name name-style="western"><surname>Calmy</surname><given-names>A</given-names></name><name name-style="western"><surname>Andrieux-Meyer</surname><given-names>I</given-names></name><name name-style="western"><surname>Ford</surname><given-names>N</given-names></name></person-group><article-title>Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings</article-title><source>HIV AIDS (Auckl)</source><year>2012</year><volume>4</volume><fpage>5</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">22347806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/HIV.S20993</pub-id><pub-id pub-id-type="pmcid">PMC3280623</pub-id></element-citation></ref><ref id="CR262"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lefebvre</surname><given-names>J</given-names></name><name name-style="western"><surname>Poirier</surname><given-names>L</given-names></name><name name-style="western"><surname>Poirier</surname><given-names>P</given-names></name><name name-style="western"><surname>Turgeon</surname><given-names>J</given-names></name><name name-style="western"><surname>Lacourciere</surname><given-names>Y</given-names></name></person-group><article-title>The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension</article-title><source>Br J Clin Pharmacol</source><year>2007</year><volume>63</volume><fpage>575</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">17094780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2006.02796.x</pub-id><pub-id pub-id-type="pmcid">PMC2000751</pub-id></element-citation></ref><ref id="CR263"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lehmann</surname><given-names>JM</given-names></name><name name-style="western"><surname>McKee</surname><given-names>DD</given-names></name><name name-style="western"><surname>Watson</surname><given-names>MA</given-names></name><name name-style="western"><surname>Willson</surname><given-names>TM</given-names></name><name name-style="western"><surname>Moore</surname><given-names>JT</given-names></name><name name-style="western"><surname>Kliewer</surname><given-names>SA</given-names></name></person-group><article-title>The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions</article-title><source>J Clin Investig</source><year>1998</year><volume>102</volume><fpage>1016</fpage><lpage>1023</lpage><pub-id pub-id-type="pmid">9727070</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI3703</pub-id><pub-id pub-id-type="pmcid">PMC508967</pub-id></element-citation></ref><ref id="CR264"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>HP</given-names></name><name name-style="western"><surname>Yu</surname><given-names>XY</given-names></name><name name-style="western"><surname>Xie</surname><given-names>HT</given-names></name><name name-style="western"><surname>Li</surname><given-names>HH</given-names></name><name name-style="western"><surname>Fan</surname><given-names>L</given-names></name><name name-style="western"><surname>Dai</surname><given-names>LL</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>HH</given-names></name></person-group><article-title>Effect of St. John&#8217;s wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers</article-title><source>Xenobiotica</source><year>2010</year><volume>40</volume><fpage>275</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">20102294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/00498250903509383</pub-id></element-citation></ref><ref id="CR265"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>CH</given-names></name><name name-style="western"><surname>Koenig</surname><given-names>M</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>MD</given-names></name><name name-style="western"><surname>Vojkovsky</surname><given-names>T</given-names></name></person-group><article-title>Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways</article-title><source>Drug Metab Dispos</source><year>2009</year><volume>37</volume><fpage>1242</fpage><lpage>1250</lpage><pub-id pub-id-type="pmid">19282395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.108.025932</pub-id><pub-id pub-id-type="pmcid">PMC3202349</pub-id></element-citation></ref><ref id="CR266"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>AC</given-names></name><name name-style="western"><surname>Yu</surname><given-names>E</given-names></name><name name-style="western"><surname>Ring</surname><given-names>SC</given-names></name><name name-style="western"><surname>Chovan</surname><given-names>JP</given-names></name></person-group><article-title>Structural identification of imatinib cyanide adducts by mass spectrometry and elucidation of bioactivation pathway</article-title><source>Rapid Commun Mass Spectrom</source><year>2014</year><volume>28</volume><fpage>123</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">24285397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/rcm.6758</pub-id></element-citation></ref><ref id="CR267"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liangpunsakul</surname><given-names>S</given-names></name><name name-style="western"><surname>Kolwankar</surname><given-names>D</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>A</given-names></name><name name-style="western"><surname>Gorski</surname><given-names>JC</given-names></name><name name-style="western"><surname>Hall</surname><given-names>SD</given-names></name><name name-style="western"><surname>Chalasani</surname><given-names>N</given-names></name></person-group><article-title>Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: a comparison with nonalcoholics</article-title><source>Hepatology</source><year>2005</year><volume>41</volume><fpage>1144</fpage><lpage>1150</lpage><pub-id pub-id-type="pmid">15841467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.20673</pub-id></element-citation></ref><ref id="CR268"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>ML</given-names></name><name name-style="western"><surname>Min</surname><given-names>SS</given-names></name><name name-style="western"><surname>Eron</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Bertz</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>M</given-names></name><name name-style="western"><surname>Gaedigk</surname><given-names>A</given-names></name><name name-style="western"><surname>Kashuba</surname><given-names>AD</given-names></name></person-group><article-title>Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction</article-title><source>J Acquir Immune Defic Syndr</source><year>2004</year><volume>36</volume><fpage>1034</fpage><lpage>1040</lpage><pub-id pub-id-type="pmid">15247556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00126334-200408150-00006</pub-id></element-citation></ref><ref id="CR269"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>D</given-names></name><name name-style="western"><surname>Kostov</surname><given-names>R</given-names></name><name name-style="western"><surname>Huang</surname><given-names>JT-</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>CR</given-names></name></person-group><article-title>Novel pathways of ponatinib disposition catalyzed by CYP1A1 involving generation of potentially toxic metabolites</article-title><source>J Pharmacol Exp Ther</source><year>2017</year><volume>363</volume><fpage>12</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">28882992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.117.243246</pub-id><pub-id pub-id-type="pmcid">PMC5596814</pub-id></element-citation></ref><ref id="CR270"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loboz</surname><given-names>KK</given-names></name><name name-style="western"><surname>Gross</surname><given-names>AS</given-names></name><name name-style="western"><surname>Williams</surname><given-names>KM</given-names></name><name name-style="western"><surname>Liauw</surname><given-names>WS</given-names></name><name name-style="western"><surname>Day</surname><given-names>RO</given-names></name><name name-style="western"><surname>Blievernicht</surname><given-names>JK</given-names></name><name name-style="western"><surname>Zanger</surname><given-names>UM</given-names></name><name name-style="western"><surname>McLachlan</surname><given-names>AJ</given-names></name></person-group><article-title>Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity</article-title><source>Clin Pharmacol Ther</source><year>2006</year><volume>80</volume><fpage>75</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">16815319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clpt.2006.03.010</pub-id></element-citation></ref><ref id="CR271"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lolodi</surname><given-names>O</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wright</surname><given-names>WC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T</given-names></name></person-group><article-title>Differential regulation of CYP3A4 and CYP3A5 and its implication in drug discovery</article-title><source>Curr Drug Metab</source><year>2017</year><volume>18</volume><fpage>1095</fpage><lpage>1105</lpage><pub-id pub-id-type="pmid">28558634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1389200218666170531112038</pub-id><pub-id pub-id-type="pmcid">PMC5709240</pub-id></element-citation></ref><ref id="CR272"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez-Cortes</surname><given-names>L</given-names></name><name name-style="western"><surname>Ruiz-Valderas</surname><given-names>R</given-names></name><name name-style="western"><surname>Viciana</surname><given-names>P</given-names></name><name name-style="western"><surname>Alarcon-Gonzalez</surname><given-names>A</given-names></name><name name-style="western"><surname>Gomez-Mateos</surname><given-names>J</given-names></name><name name-style="western"><surname>Leon-Jimenez</surname><given-names>E</given-names></name><name name-style="western"><surname>Sarasanacenta</surname><given-names>M</given-names></name><name name-style="western"><surname>Lopez-Pua</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pachon</surname><given-names>J</given-names></name></person-group><article-title>Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis</article-title><source>Clin Pharmacokinet</source><year>2002</year><volume>41</volume><fpage>681</fpage><lpage>690</lpage><pub-id pub-id-type="pmid">12126459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-200241090-00004</pub-id></element-citation></ref><ref id="CR273"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>C</given-names></name><name name-style="western"><surname>Di</surname><given-names>L</given-names></name></person-group><article-title>In vitro and in vivo methods to assess pharmacokinetic drug&#8211;drug interactions in drug discovery and development</article-title><source>Biopharm Drug Dispos</source><year>2020</year><volume>41</volume><fpage>3</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">31778578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bdd.2212</pub-id></element-citation></ref><ref id="CR274"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lucas</surname><given-names>RA</given-names></name><name name-style="western"><surname>Gilfillan</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Bergstrom</surname><given-names>RF</given-names></name></person-group><article-title>A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism</article-title><source>Eur J Clin Pharmacol</source><year>1998</year><volume>54</volume><fpage>639</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">9860152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002280050527</pub-id></element-citation></ref><ref id="CR275"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luceri</surname><given-names>F</given-names></name><name name-style="western"><surname>Fattori</surname><given-names>S</given-names></name><name name-style="western"><surname>Luceri</surname><given-names>C</given-names></name><name name-style="western"><surname>Zorn</surname><given-names>M</given-names></name><name name-style="western"><surname>Mannaioni</surname><given-names>P</given-names></name><name name-style="western"><surname>Messeri</surname><given-names>G</given-names></name></person-group><article-title>Gas chromatography-mass spectrometry measurement of 6beta-OH-cortisol/cortisol ratio in human urine: a specific marker of enzymatic induction</article-title><source>Clin Chem Lab Med</source><year>2001</year><volume>39</volume><fpage>1234</fpage><lpage>1239</lpage><pub-id pub-id-type="pmid">11798083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/CCLM.2001.198</pub-id></element-citation></ref><ref id="CR276"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lucier</surname><given-names>GW</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>KG</given-names></name><name name-style="western"><surname>Everson</surname><given-names>RB</given-names></name><name name-style="western"><surname>Wong</surname><given-names>TK</given-names></name><name name-style="western"><surname>Philpot</surname><given-names>RM</given-names></name><name name-style="western"><surname>Tiernan</surname><given-names>T</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>M</given-names></name><name name-style="western"><surname>Sunahara</surname><given-names>GI</given-names></name></person-group><article-title>1474460; placental markers of human exposure to polychlorinated biphenyls and polychlorinated dibenzofurans</article-title><source>Environ Health Perspect</source><year>1987</year><volume>76</volume><fpage>79</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">2834196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1289/ehp.877679</pub-id><pub-id pub-id-type="pmcid">PMC1474460</pub-id></element-citation></ref><ref id="CR277"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lutz</surname><given-names>JD</given-names></name><name name-style="western"><surname>Isoherranen</surname><given-names>N</given-names></name></person-group><article-title>In vitro-to-in vivo predictions of drug&#8211;drug interactions involving multiple reversible inhibitors</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2012</year><volume>8</volume><fpage>449</fpage><lpage>466</lpage><pub-id pub-id-type="pmid">22384784</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/17425255.2012.667801</pub-id></element-citation></ref><ref id="CR278"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lutz</surname><given-names>JD</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Song</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ling</surname><given-names>J</given-names></name><name name-style="western"><surname>Massetto</surname><given-names>B</given-names></name><name name-style="western"><surname>Worth</surname><given-names>A</given-names></name><name name-style="western"><surname>Kearney</surname><given-names>BP</given-names></name><name name-style="western"><surname>Mathias</surname><given-names>A</given-names></name></person-group><article-title>PMC6282692; cytochrome P450 3A induction predicts P-glycoprotein induction; part 2: prediction of decreased substrate exposure after rifabutin or carbamazepine</article-title><source>Clin Pharmacol Ther</source><year>2018</year><volume>104</volume><fpage>1191</fpage><lpage>1198</lpage><pub-id pub-id-type="pmid">29569712</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.1072</pub-id><pub-id pub-id-type="pmcid">PMC6282692</pub-id></element-citation></ref><ref id="CR279"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maglich</surname><given-names>JM</given-names></name><name name-style="western"><surname>Stoltz</surname><given-names>CM</given-names></name><name name-style="western"><surname>Goodwin</surname><given-names>B</given-names></name><name name-style="western"><surname>Hawkins-Brown</surname><given-names>D</given-names></name><name name-style="western"><surname>Moore</surname><given-names>JT</given-names></name><name name-style="western"><surname>Kliewer</surname><given-names>SA</given-names></name></person-group><article-title>Nuclear pregnane X receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification</article-title><source>Mol Pharmacol</source><year>2002</year><volume>62</volume><fpage>638</fpage><lpage>646</lpage><pub-id pub-id-type="pmid">12181440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/mol.62.3.638</pub-id></element-citation></ref><ref id="CR280"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malhi</surname><given-names>V</given-names></name><name name-style="western"><surname>Colburn</surname><given-names>D</given-names></name><name name-style="western"><surname>Williams</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Hop</surname><given-names>CECA</given-names></name><name name-style="western"><surname>Dresser</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Chandra</surname><given-names>P</given-names></name><name name-style="western"><surname>Graham</surname><given-names>RA</given-names></name></person-group><article-title>A clinical drug&#8211;drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib</article-title><source>Cancer Chemother Pharmacol</source><year>2016</year><volume>78</volume><fpage>41</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">27154174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-016-3020-z</pub-id><pub-id pub-id-type="pmcid">PMC4921109</pub-id></element-citation></ref><ref id="CR281"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manikandan</surname><given-names>P</given-names></name><name name-style="western"><surname>Nagini</surname><given-names>S</given-names></name></person-group><article-title>Cytochrome P450 structure, function and clinical significance: a review</article-title><source>Curr Drug Targets</source><year>2018</year><volume>19</volume><fpage>38</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">28124606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1389450118666170125144557</pub-id></element-citation></ref><ref id="CR282"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manosuthi</surname><given-names>W</given-names></name><name name-style="western"><surname>Sukasem</surname><given-names>C</given-names></name><name name-style="western"><surname>Lueangniyomkul</surname><given-names>A</given-names></name><name name-style="western"><surname>Mankatitham</surname><given-names>W</given-names></name><name name-style="western"><surname>Thongyen</surname><given-names>S</given-names></name><name name-style="western"><surname>Nilkamhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Manosuthi</surname><given-names>S</given-names></name><name name-style="western"><surname>Sungkanuparph</surname><given-names>S</given-names></name></person-group><article-title>Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug&#8211;drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients</article-title><source>Antimicrob Agents Chemother</source><year>2013</year><volume>57</volume><fpage>1019</fpage><lpage>1024</lpage><pub-id pub-id-type="pmid">23254426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.02023-12</pub-id><pub-id pub-id-type="pmcid">PMC3553682</pub-id></element-citation></ref><ref id="CR283"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>J</given-names></name><name name-style="western"><surname>Tay</surname><given-names>S</given-names></name><name name-style="western"><surname>Khojasteh</surname><given-names>CS</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hop</surname><given-names>CECA</given-names></name><name name-style="western"><surname>Kenny</surname><given-names>JR</given-names></name></person-group><article-title>Evaluation of time dependent inhibition assays for marketed oncology drugs: comparison of human hepatocytes and liver microsomes in the presence and absence of human plasma</article-title><source>Pharm Res</source><year>2016</year><volume>33</volume><fpage>1204</fpage><lpage>1219</lpage><pub-id pub-id-type="pmid">26869174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-016-1865-9</pub-id></element-citation></ref><ref id="CR284"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Markowitz</surname><given-names>JS</given-names></name><name name-style="western"><surname>Donovan</surname><given-names>JL</given-names></name><name name-style="western"><surname>Lindsay DeVane</surname><given-names>C</given-names></name><name name-style="western"><surname>Sipkes</surname><given-names>L</given-names></name><name name-style="western"><surname>Chavin</surname><given-names>KD</given-names></name></person-group><article-title>Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers</article-title><source>J Clin Psychopharmacol</source><year>2003</year><volume>23</volume><fpage>576</fpage><lpage>581</lpage><pub-id pub-id-type="pmid">14624188</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.jcp.0000095340.32154.c6</pub-id></element-citation></ref><ref id="CR285"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marschall</surname><given-names>HU</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>M</given-names></name><name name-style="western"><surname>Zollner</surname><given-names>G</given-names></name><name name-style="western"><surname>Fickert</surname><given-names>P</given-names></name><name name-style="western"><surname>Diczfalusy</surname><given-names>U</given-names></name><name name-style="western"><surname>Gumhold</surname><given-names>J</given-names></name><name name-style="western"><surname>Silbert</surname><given-names>D</given-names></name><name name-style="western"><surname>Fuchsbichler</surname><given-names>A</given-names></name><name name-style="western"><surname>Benthin</surname><given-names>L</given-names></name><name name-style="western"><surname>Grundstrom</surname><given-names>R</given-names></name><name name-style="western"><surname>Gustafsson</surname><given-names>U</given-names></name><name name-style="western"><surname>Sahlin</surname><given-names>S</given-names></name><name name-style="western"><surname>Einarsson</surname><given-names>C</given-names></name><name name-style="western"><surname>Trauner</surname><given-names>M</given-names></name></person-group><article-title>Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans</article-title><source>Gastroenterology</source><year>2005</year><volume>129</volume><fpage>476</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">16083704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gastro.2005.05.009</pub-id></element-citation></ref><ref id="CR286"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>P</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>S</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>J</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>S</given-names></name><name name-style="western"><surname>Read</surname><given-names>J</given-names></name><name name-style="western"><surname>Duvauchelle</surname><given-names>T</given-names></name></person-group><article-title>Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole</article-title><source>Drugs R D</source><year>2011</year><volume>11</volume><fpage>37</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">21410294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/11586980-000000000-00000</pub-id><pub-id pub-id-type="pmcid">PMC3586143</pub-id></element-citation></ref><ref id="CR287"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marzolini</surname><given-names>C</given-names></name><name name-style="western"><surname>Rajoli</surname><given-names>R</given-names></name><name name-style="western"><surname>Battegay</surname><given-names>M</given-names></name><name name-style="western"><surname>Elzi</surname><given-names>L</given-names></name><name name-style="western"><surname>Back</surname><given-names>D</given-names></name><name name-style="western"><surname>Siccardi</surname><given-names>M</given-names></name></person-group><article-title>Physiologically based pharmacokinetic modeling to predict drug&#8211;drug interactions with efavirenz involving simultaneous inducing and inhibitory effects on cytochromes</article-title><source>Clin Pharmacokinet</source><year>2017</year><volume>56</volume><fpage>409</fpage><lpage>420</lpage><pub-id pub-id-type="pmid">27599706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-016-0447-7</pub-id></element-citation></ref><ref id="CR288"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsunaga</surname><given-names>T</given-names></name><name name-style="western"><surname>Maruyama</surname><given-names>M</given-names></name><name name-style="western"><surname>Harada</surname><given-names>E</given-names></name><name name-style="western"><surname>Katsuyama</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sugihara</surname><given-names>N</given-names></name><name name-style="western"><surname>Ise</surname><given-names>H</given-names></name><name name-style="western"><surname>Negishi</surname><given-names>N</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>U</given-names></name><name name-style="western"><surname>Ohmori</surname><given-names>S</given-names></name></person-group><article-title>Expression and induction of CYP3As in human fetal hepatocytes</article-title><source>Biochem Biophys Res Commun</source><year>2004</year><volume>318</volume><fpage>428</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">15120618</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2004.04.041</pub-id></element-citation></ref><ref id="CR289"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazur</surname><given-names>W</given-names></name></person-group><article-title>Phytoestrogen content in foods</article-title><source>Baillieres Clin Endocrinol Metab</source><year>1998</year><volume>12</volume><fpage>729</fpage><lpage>742</lpage><pub-id pub-id-type="pmid">10384822</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0950-351x(98)80013-x</pub-id></element-citation></ref><ref id="CR290"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazze</surname><given-names>RI</given-names></name><name name-style="western"><surname>Woodruff</surname><given-names>RE</given-names></name><name name-style="western"><surname>Heerdt</surname><given-names>ME</given-names></name></person-group><article-title>Isoniazid-induced enflurane defluorination in humans</article-title><source>Anesthesiology</source><year>1982</year><volume>57</volume><fpage>5</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">7091722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000542-198207000-00002</pub-id></element-citation></ref><ref id="CR291"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McAllister</surname><given-names>WA</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Al-Habet</surname><given-names>S</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>HJ</given-names></name></person-group><article-title>1547305; rifampicin reduces effectiveness and bioavailability of prednisolone</article-title><source>Br Med J (Clin Res Ed)</source><year>1983</year><volume>286</volume><fpage>923</fpage><lpage>925</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.286.6369.923</pub-id><pub-id pub-id-type="pmcid">PMC1547305</pub-id><pub-id pub-id-type="pmid">6403136</pub-id></element-citation></ref><ref id="CR292"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCormick</surname><given-names>A</given-names></name><name name-style="western"><surname>Swaisland</surname><given-names>H</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>VP</given-names></name><name name-style="western"><surname>Learoyd</surname><given-names>M</given-names></name><name name-style="western"><surname>Scarfe</surname><given-names>G</given-names></name></person-group><article-title>In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450</article-title><source>Xenobiotica</source><year>2018</year><volume>48</volume><fpage>555</fpage><lpage>564</lpage><pub-id pub-id-type="pmid">28657402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/00498254.2017.1346332</pub-id></element-citation></ref><ref id="CR293"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCune</surname><given-names>JS</given-names></name><name name-style="western"><surname>Hawke</surname><given-names>RL</given-names></name><name name-style="western"><surname>LeCluyse</surname><given-names>EL</given-names></name><name name-style="western"><surname>Gillenwater</surname><given-names>HH</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>G</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>J</given-names></name><name name-style="western"><surname>Lindley</surname><given-names>C</given-names></name></person-group><article-title>In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone</article-title><source>Clin Pharmacol Ther</source><year>2000</year><volume>68</volume><fpage>356</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">11061575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2000.110215</pub-id></element-citation></ref><ref id="CR294"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McDonagh</surname><given-names>EM</given-names></name><name name-style="western"><surname>Lau</surname><given-names>JL</given-names></name><name name-style="western"><surname>Alvarellos</surname><given-names>ML</given-names></name><name name-style="western"><surname>Altman</surname><given-names>RB</given-names></name><name name-style="western"><surname>Klein</surname><given-names>TE</given-names></name></person-group><article-title>PharmGKB summary: efavirenz pathway, pharmacokinetics</article-title><source>Pharmacogenet Genom</source><year>2015</year><volume>25</volume><fpage>363</fpage><lpage>376</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FPC.0000000000000145</pub-id><pub-id pub-id-type="pmcid">PMC4461466</pub-id><pub-id pub-id-type="pmid">25966836</pub-id></element-citation></ref><ref id="CR295"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McDonald</surname><given-names>MG</given-names></name><name name-style="western"><surname>Au</surname><given-names>NT</given-names></name><name name-style="western"><surname>Rettie</surname><given-names>AE</given-names></name></person-group><article-title>P450-based drug&#8211;drug interactions of amiodarone and its metabolites: diversity of inhibitory mechanisms</article-title><source>Drug Metab Dispos</source><year>2015</year><volume>43</volume><fpage>1661</fpage><lpage>1669</lpage><pub-id pub-id-type="pmid">26296708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.115.065623</pub-id><pub-id pub-id-type="pmcid">PMC4613947</pub-id></element-citation></ref><ref id="CR296"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McDonnell</surname><given-names>WM</given-names></name><name name-style="western"><surname>Scheiman</surname><given-names>JM</given-names></name><name name-style="western"><surname>Traber</surname><given-names>PG</given-names></name></person-group><article-title>Induction of cytochrome P450IA genes (CYP1A) by omeprazole in the human alimentary tract</article-title><source>Gastroenterology</source><year>1992</year><volume>103</volume><fpage>1509</fpage><lpage>1516</lpage><pub-id pub-id-type="pmid">1426869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0016-5085(92)91171-y</pub-id></element-citation></ref><ref id="CR297"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McLemore</surname><given-names>TL</given-names></name><name name-style="western"><surname>Adelberg</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>MC</given-names></name><name name-style="western"><surname>McMahon</surname><given-names>NA</given-names></name><name name-style="western"><surname>Yu</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Hubbard</surname><given-names>WC</given-names></name><name name-style="western"><surname>Czerwinski</surname><given-names>M</given-names></name><name name-style="western"><surname>Wood</surname><given-names>TG</given-names></name><name name-style="western"><surname>Storeng</surname><given-names>R</given-names></name><name name-style="western"><surname>Lubet</surname><given-names>RA</given-names></name></person-group><article-title>Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas</article-title><source>J Natl Cancer Inst</source><year>1990</year><volume>82</volume><fpage>1333</fpage><lpage>1339</lpage><pub-id pub-id-type="pmid">2380990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/82.16.1333</pub-id></element-citation></ref><ref id="CR298"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McNeilly</surname><given-names>AD</given-names></name><name name-style="western"><surname>Woods</surname><given-names>JA</given-names></name><name name-style="western"><surname>Ibbotson</surname><given-names>SH</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>CR</given-names></name><name name-style="western"><surname>Smith</surname><given-names>G</given-names></name></person-group><article-title>Characterization of a human keratinocyte HaCaT cell line model to study the regulation of CYP2S1</article-title><source>Drug Metab Dispos</source><year>2012</year><volume>40</volume><fpage>283</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">22039172</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.111.042085</pub-id></element-citation></ref><ref id="CR299"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendoza-Cantu</surname><given-names>A</given-names></name><name name-style="western"><surname>Castorena-Torres</surname><given-names>F</given-names></name><name name-style="western"><surname>Bermudez de Leon</surname><given-names>M</given-names></name><name name-style="western"><surname>Cisneros</surname><given-names>B</given-names></name><name name-style="western"><surname>Lopez-Carrillo</surname><given-names>L</given-names></name><name name-style="western"><surname>Rojas-Garcia</surname><given-names>A</given-names></name><name name-style="western"><surname>Aguilar-Salinas</surname><given-names>A</given-names></name><name name-style="western"><surname>Manno</surname><given-names>M</given-names></name><name name-style="western"><surname>Albores</surname><given-names>A</given-names></name></person-group><article-title>1440770; occupational toluene exposure induces cytochrome P450 2E1 mRNA expression in peripheral lymphocytes</article-title><source>Environ Health Perspect</source><year>2006</year><volume>114</volume><fpage>494</fpage><lpage>499</lpage><pub-id pub-id-type="pmid">16581535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1289/ehp.8192</pub-id><pub-id pub-id-type="pmcid">PMC1440770</pub-id></element-citation></ref><ref id="CR300"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merk</surname><given-names>HF</given-names></name><name name-style="western"><surname>Mukhtar</surname><given-names>H</given-names></name><name name-style="western"><surname>Kaufmann</surname><given-names>I</given-names></name><name name-style="western"><surname>Das</surname><given-names>M</given-names></name><name name-style="western"><surname>Bickers</surname><given-names>DR</given-names></name></person-group><article-title>Human hair follicle benzo[a]pyrene and benzo[a]pyrene 7,8-diol metabolism: effect of exposure to a coal tar-containing shampoo</article-title><source>J Investig Dermatol</source><year>1987</year><volume>88</volume><fpage>71</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">3794390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1523-1747.ep12465053</pub-id></element-citation></ref><ref id="CR301"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metzger</surname><given-names>IF</given-names></name><name name-style="western"><surname>Dave</surname><given-names>N</given-names></name><name name-style="western"><surname>Kreutz</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>JBL</given-names></name><name name-style="western"><surname>Galinsky</surname><given-names>RE</given-names></name><name name-style="western"><surname>Desta</surname><given-names>Z</given-names></name></person-group><article-title>PMC6853154; CYP2B6 genotype-dependent inhibition of CYP1A2 and induction of CYP2A6 by the antiretroviral drug efavirenz in healthy volunteers</article-title><source>Clin Transl Sci</source><year>2019</year><volume>12</volume><fpage>657</fpage><lpage>666</lpage><pub-id pub-id-type="pmid">31339646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cts.12671</pub-id><pub-id pub-id-type="pmcid">PMC6853154</pub-id></element-citation></ref><ref id="CR302"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meyer zu Schwabedissen</surname><given-names>HE</given-names></name><name name-style="western"><surname>Oswald</surname><given-names>S</given-names></name><name name-style="western"><surname>Bresser</surname><given-names>C</given-names></name><name name-style="western"><surname>Nassif</surname><given-names>A</given-names></name><name name-style="western"><surname>Modess</surname><given-names>C</given-names></name><name name-style="western"><surname>Desta</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ogburn</surname><given-names>ET</given-names></name><name name-style="western"><surname>Marinova</surname><given-names>M</given-names></name><name name-style="western"><surname>Lutjohann</surname><given-names>D</given-names></name><name name-style="western"><surname>Spielhagen</surname><given-names>C</given-names></name><name name-style="western"><surname>Nauck</surname><given-names>M</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>HK</given-names></name><name name-style="western"><surname>Siegmund</surname><given-names>W</given-names></name></person-group><article-title>PMC3667667; compartment-specific gene regulation of the CAR inducer efavirenz in vivo</article-title><source>Clin Pharmacol Ther</source><year>2012</year><volume>92</volume><fpage>103</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">22588604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2012.34</pub-id><pub-id pub-id-type="pmcid">PMC3667667</pub-id></element-citation></ref><ref id="CR303"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michaud</surname><given-names>V</given-names></name><name name-style="western"><surname>Ogburn</surname><given-names>E</given-names></name><name name-style="western"><surname>Thong</surname><given-names>N</given-names></name><name name-style="western"><surname>Aregbe</surname><given-names>AO</given-names></name><name name-style="western"><surname>Quigg</surname><given-names>TC</given-names></name><name name-style="western"><surname>Flockhart</surname><given-names>DA</given-names></name><name name-style="western"><surname>Desta</surname><given-names>Z</given-names></name></person-group><article-title>Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers</article-title><source>Clin Pharmacol Ther</source><year>2012</year><volume>91</volume><issue>3</issue><fpage>475</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1038/clpt.2011.249</pub-id><pub-id pub-id-type="pmid">22318618</pub-id><pub-id pub-id-type="pmcid">PMC3667659</pub-id></element-citation></ref><ref id="CR304"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mihara</surname><given-names>K</given-names></name><name name-style="western"><surname>Svensson</surname><given-names>US</given-names></name><name name-style="western"><surname>Tybring</surname><given-names>G</given-names></name><name name-style="western"><surname>Hai</surname><given-names>TN</given-names></name><name name-style="western"><surname>Bertilsson</surname><given-names>L</given-names></name><name name-style="western"><surname>Ashton</surname><given-names>M</given-names></name></person-group><article-title>Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19</article-title><source>Fundam Clin Pharmacol</source><year>1999</year><volume>13</volume><fpage>671</fpage><lpage>675</lpage><pub-id pub-id-type="pmid">10626755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1472-8206.1999.tb00379.x</pub-id></element-citation></ref><ref id="CR305"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mildvan</surname><given-names>D</given-names></name><name name-style="western"><surname>Yarrish</surname><given-names>R</given-names></name><name name-style="western"><surname>Marshak</surname><given-names>A</given-names></name><name name-style="western"><surname>Hutman</surname><given-names>HW</given-names></name><name name-style="western"><surname>McDonough</surname><given-names>M</given-names></name><name name-style="western"><surname>Lamson</surname><given-names>M</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>P</given-names></name></person-group><article-title>Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women</article-title><source>J Acquir Immune Defic Syndr</source><year>2002</year><volume>29</volume><fpage>471</fpage><lpage>477</lpage><pub-id pub-id-type="pmid">11981363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00126334-200204150-00007</pub-id></element-citation></ref><ref id="CR306"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>M</given-names></name><name name-style="western"><surname>Cosgriff</surname><given-names>J</given-names></name><name name-style="western"><surname>Kwong</surname><given-names>T</given-names></name><name name-style="western"><surname>Morken</surname><given-names>DA</given-names></name></person-group><article-title>Influence of phenytoin on theophylline clearance</article-title><source>Clin Pharmacol Ther</source><year>1984</year><volume>35</volume><fpage>666</fpage><lpage>669</lpage><pub-id pub-id-type="pmid">6713777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.1984.92</pub-id></element-citation></ref><ref id="CR307"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Millonig</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Homann</surname><given-names>N</given-names></name><name name-style="western"><surname>Bernhardt</surname><given-names>F</given-names></name><name name-style="western"><surname>Qin</surname><given-names>H</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>S</given-names></name><name name-style="western"><surname>Bartsch</surname><given-names>H</given-names></name><name name-style="western"><surname>Seitz</surname><given-names>HK</given-names></name></person-group><article-title>Ethanol-mediated carcinogenesis in the human esophagus implicates CYP2E1 induction and the generation of carcinogenic DNA-lesions</article-title><source>Int J Cancer</source><year>2011</year><volume>128</volume><fpage>533</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">20715111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.25604</pub-id></element-citation></ref><ref id="CR308"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Min</surname><given-names>JS</given-names></name><name name-style="western"><surname>Bae</surname><given-names>SK</given-names></name></person-group><article-title>Prediction of drug&#8211;drug interaction potential using physiologically based pharmacokinetic modeling</article-title><source>Arch Pharm Res</source><year>2017</year><volume>40</volume><fpage>1356</fpage><lpage>1379</lpage><pub-id pub-id-type="pmid">29079968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12272-017-0976-0</pub-id></element-citation></ref><ref id="CR309"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morcos</surname><given-names>PN</given-names></name><name name-style="western"><surname>Cleary</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guerini</surname><given-names>E</given-names></name><name name-style="western"><surname>Dall</surname><given-names>G</given-names></name><name name-style="western"><surname>Bogman</surname><given-names>K</given-names></name><name name-style="western"><surname>De Petris</surname><given-names>L</given-names></name><name name-style="western"><surname>Viteri</surname><given-names>S</given-names></name><name name-style="western"><surname>Bordogna</surname><given-names>W</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><name name-style="western"><surname>Martin-Facklam</surname><given-names>M</given-names></name><name name-style="western"><surname>Phipps</surname><given-names>A</given-names></name></person-group><article-title>Clinical drug&#8211;drug interactions through cytochrome P450 3A (CYP3A) for the selective ALK inhibitor alectinib</article-title><source>Clin Pharmacol Drug Dev</source><year>2017</year><volume>6</volume><fpage>280</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">27545757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpdd.298</pub-id></element-citation></ref><ref id="CR310"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreland</surname><given-names>TA</given-names></name><name name-style="western"><surname>Park</surname><given-names>BK</given-names></name><name name-style="western"><surname>Rylance</surname><given-names>GW</given-names></name></person-group><article-title>1427548; microsomal enzyme induction in children: the influence of carbamazepine treatment on antipyrine kinetics, 6 beta-hydroxycortisol excretion and plasma gamma-glutamyltranspeptidase activity</article-title><source>Br J Clin Pharmacol</source><year>1982</year><volume>14</volume><fpage>861</fpage><lpage>865</lpage><pub-id pub-id-type="pmid">6129885</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1982.tb02050.x</pub-id><pub-id pub-id-type="pmcid">PMC1427548</pub-id></element-citation></ref><ref id="CR311"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mouly</surname><given-names>S</given-names></name><name name-style="western"><surname>Lown</surname><given-names>KS</given-names></name><name name-style="western"><surname>Kornhauser</surname><given-names>D</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>JL</given-names></name><name name-style="western"><surname>Fiske</surname><given-names>WD</given-names></name><name name-style="western"><surname>Benedek</surname><given-names>IH</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>PB</given-names></name></person-group><article-title>Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans</article-title><source>Clin Pharmacol Ther</source><year>2002</year><volume>72</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12151999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2002.124519</pub-id></element-citation></ref><ref id="CR1003"><mixed-citation publication-type="other">MHLW/PMDA (2018) Pharmaceuticals and medical devices safety information. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.pmda.go.jp/english/safety/info-services/drugs/medical-safety-information/0016.html">https://www.pmda.go.jp/english/safety/info-services/drugs/medical-safety-information/0016.html</ext-link>. Accessed 20 June 2020</mixed-citation></ref><ref id="CR312"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Narasimhan</surname><given-names>NI</given-names></name><name name-style="western"><surname>Dorer</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Niland</surname><given-names>K</given-names></name><name name-style="western"><surname>Haluska</surname><given-names>F</given-names></name><name name-style="western"><surname>Sonnichsen</surname><given-names>D</given-names></name></person-group><article-title>Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects</article-title><source>J Clin Pharmacol</source><year>2013</year><volume>53</volume><fpage>974</fpage><lpage>981</lpage><pub-id pub-id-type="pmid">23801357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcph.109</pub-id><pub-id pub-id-type="pmcid">PMC3781849</pub-id></element-citation></ref><ref id="CR313"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nebert</surname><given-names>DW</given-names></name></person-group><article-title>Aryl hydrocarbon receptor (AHR): &#8220;pioneer member&#8221; of the basic-helix/loop/helix per-Arnt-sim (bHLH/PAS) family of &#8220;sensors&#8221; of foreign and endogenous signals</article-title><source>Prog Lipid Res</source><year>2017</year><volume>67</volume><fpage>38</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">28606467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.plipres.2017.06.001</pub-id><pub-id pub-id-type="pmcid">PMC5568781</pub-id></element-citation></ref><ref id="CR314"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ngaimisi</surname><given-names>E</given-names></name><name name-style="western"><surname>Mugusi</surname><given-names>S</given-names></name><name name-style="western"><surname>Minzi</surname><given-names>OM</given-names></name><name name-style="western"><surname>Sasi</surname><given-names>P</given-names></name><name name-style="western"><surname>Riedel</surname><given-names>KD</given-names></name><name name-style="western"><surname>Suda</surname><given-names>A</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>N</given-names></name><name name-style="western"><surname>Janabi</surname><given-names>M</given-names></name><name name-style="western"><surname>Mugusi</surname><given-names>F</given-names></name><name name-style="western"><surname>Haefeli</surname><given-names>WE</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J</given-names></name><name name-style="western"><surname>Aklillu</surname><given-names>E</given-names></name></person-group><article-title>Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients</article-title><source>Clin Pharmacol Ther</source><year>2010</year><volume>88</volume><fpage>676</fpage><lpage>684</lpage><pub-id pub-id-type="pmid">20881953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2010.172</pub-id></element-citation></ref><ref id="CR315"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>L</given-names></name><name name-style="western"><surname>Holland</surname><given-names>J</given-names></name><name name-style="western"><surname>Miles</surname><given-names>D</given-names></name><name name-style="western"><surname>Engel</surname><given-names>C</given-names></name><name name-style="western"><surname>Benrimoh</surname><given-names>N</given-names></name><name name-style="western"><surname>O&#8217;Reilly</surname><given-names>T</given-names></name><name name-style="western"><surname>Lacy</surname><given-names>S</given-names></name></person-group><article-title>Pharmacokinetic (PK) drug interaction studies of cabozantinib: effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK</article-title><source>J Clin Pharmacol</source><year>2015</year><volume>55</volume><fpage>1012</fpage><lpage>1023</lpage><pub-id pub-id-type="pmid">25854986</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcph.510</pub-id></element-citation></ref><ref id="CR316"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niemela</surname><given-names>O</given-names></name><name name-style="western"><surname>Parkkila</surname><given-names>S</given-names></name><name name-style="western"><surname>Juvonen</surname><given-names>RO</given-names></name><name name-style="western"><surname>Viitala</surname><given-names>K</given-names></name><name name-style="western"><surname>Gelboin</surname><given-names>HV</given-names></name><name name-style="western"><surname>Pasanen</surname><given-names>M</given-names></name></person-group><article-title>Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases</article-title><source>J Hepatol</source><year>2000</year><volume>33</volume><fpage>893</fpage><lpage>901</lpage><pub-id pub-id-type="pmid">11131450</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0168-8278(00)80120-8</pub-id></element-citation></ref><ref id="CR317"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niemi</surname><given-names>M</given-names></name><name name-style="western"><surname>Backman</surname><given-names>JT</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>M</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Kivisto</surname><given-names>KT</given-names></name></person-group><article-title>Rifampin decreases the plasma concentrations and effects of repaglinide</article-title><source>Clin Pharmacol Ther</source><year>2000</year><volume>68</volume><fpage>495</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">11103752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2000.111183</pub-id></element-citation></ref><ref id="CR318"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niemi</surname><given-names>M</given-names></name><name name-style="western"><surname>Backman</surname><given-names>JT</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name></person-group><article-title>Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone</article-title><source>Clin Pharmacol Ther</source><year>2004</year><volume>76</volume><fpage>239</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">15371985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clpt.2004.05.001</pub-id></element-citation></ref><ref id="CR319"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niu</surname><given-names>B</given-names></name><name name-style="western"><surname>Coslo</surname><given-names>DM</given-names></name><name name-style="western"><surname>Bataille</surname><given-names>AR</given-names></name><name name-style="western"><surname>Albert</surname><given-names>I</given-names></name><name name-style="western"><surname>Pugh</surname><given-names>BF</given-names></name><name name-style="western"><surname>Omiecinski</surname><given-names>CJ</given-names></name></person-group><article-title>In vivo genome-wide binding interactions of mouse and human constitutive androstane receptors reveal novel gene targets</article-title><source>Nucleic Acids Res</source><year>2018</year><volume>46</volume><fpage>8385</fpage><lpage>8403</lpage><pub-id pub-id-type="pmid">30102401</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gky692</pub-id><pub-id pub-id-type="pmcid">PMC6144799</pub-id></element-citation></ref><ref id="CR320"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niwa</surname><given-names>T</given-names></name><name name-style="western"><surname>Shiraga</surname><given-names>T</given-names></name><name name-style="western"><surname>Takagi</surname><given-names>A</given-names></name></person-group><article-title>Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes</article-title><source>Biol Pharm Bull</source><year>2005</year><volume>28</volume><fpage>1805</fpage><lpage>1808</lpage><pub-id pub-id-type="pmid">16141567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1248/bpb.28.1805</pub-id></element-citation></ref><ref id="CR321"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Brien</surname><given-names>SG</given-names></name><name name-style="western"><surname>Meinhardt</surname><given-names>P</given-names></name><name name-style="western"><surname>Bond</surname><given-names>E</given-names></name><name name-style="western"><surname>Beck</surname><given-names>J</given-names></name><name name-style="western"><surname>Peng</surname><given-names>B</given-names></name><name name-style="western"><surname>Dutreix</surname><given-names>C</given-names></name><name name-style="western"><surname>Mehring</surname><given-names>G</given-names></name><name name-style="western"><surname>Milosavljev</surname><given-names>S</given-names></name><name name-style="western"><surname>Huber</surname><given-names>C</given-names></name><name name-style="western"><surname>Capdeville</surname><given-names>R</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>T</given-names></name></person-group><article-title>Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia</article-title><source>Br J Cancer</source><year>2003</year><volume>89</volume><fpage>1855</fpage><lpage>1859</lpage><pub-id pub-id-type="pmid">14612892</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bjc.6601152</pub-id><pub-id pub-id-type="pmcid">PMC2394453</pub-id></element-citation></ref><ref id="CR322"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohnhaus</surname><given-names>EE</given-names></name><name name-style="western"><surname>Park</surname><given-names>BK</given-names></name></person-group><article-title>Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin</article-title><source>Eur J Clin Pharmacol</source><year>1979</year><volume>15</volume><fpage>139</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">35353</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00609878</pub-id></element-citation></ref><ref id="CR323"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohyama</surname><given-names>K</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>M</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>M</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>N</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>H</given-names></name><name name-style="western"><surname>Yokoi</surname><given-names>T</given-names></name></person-group><article-title>Inhibitory effects of amiodarone and its <italic toggle="yes">N</italic>-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions</article-title><source>Br J Clin Pharmacol</source><year>2000</year><volume>49</volume><fpage>244</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">10718780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2125.2000.00134.x</pub-id><pub-id pub-id-type="pmcid">PMC2014912</pub-id></element-citation></ref><ref id="CR324"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okeke</surname><given-names>NL</given-names></name><name name-style="western"><surname>Hicks</surname><given-names>C</given-names></name></person-group><article-title>Role of raltegravir in the management of HIV-1 infection</article-title><source>HIV AIDS (Auckl)</source><year>2011</year><volume>3</volume><fpage>81</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">22096410</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/HIV.S13985</pub-id><pub-id pub-id-type="pmcid">PMC3218709</pub-id></element-citation></ref><ref id="CR325"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oladimeji</surname><given-names>P</given-names></name><name name-style="western"><surname>Cui</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T</given-names></name></person-group><article-title>PMC4992434; regulation of PXR and CAR by protein&#8211;protein interaction and signaling crosstalk</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2016</year><volume>12</volume><fpage>997</fpage><lpage>1010</lpage><pub-id pub-id-type="pmid">27295009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17425255.2016.1201069</pub-id><pub-id pub-id-type="pmcid">PMC4992434</pub-id></element-citation></ref><ref id="CR326"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oneta</surname><given-names>CM</given-names></name><name name-style="western"><surname>Lieber</surname><given-names>CS</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Ruttimann</surname><given-names>S</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>B</given-names></name><name name-style="western"><surname>Lattmann</surname><given-names>J</given-names></name><name name-style="western"><surname>Rosman</surname><given-names>AS</given-names></name><name name-style="western"><surname>Seitz</surname><given-names>HK</given-names></name></person-group><article-title>Dynamics of cytochrome P4502E1 activity in man: induction by ethanol and disappearance during withdrawal phase</article-title><source>J Hepatol</source><year>2002</year><volume>36</volume><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">11804663</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0168-8278(01)00223-9</pub-id></element-citation></ref><ref id="CR327"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Reilly</surname><given-names>RA</given-names></name></person-group><article-title>Interaction of sodium warfarin and rifampin. Studies in man</article-title><source>Ann Intern Med</source><year>1974</year><volume>81</volume><fpage>337</fpage><lpage>340</lpage><pub-id pub-id-type="pmid">4852505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-81-3-337</pub-id></element-citation></ref><ref id="CR328"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Reilly</surname><given-names>RA</given-names></name><name name-style="western"><surname>Trager</surname><given-names>WF</given-names></name><name name-style="western"><surname>Motley</surname><given-names>CH</given-names></name><name name-style="western"><surname>Howald</surname><given-names>W</given-names></name></person-group><article-title>Interaction of secobarbital with warfarin pseudoracemates</article-title><source>Clin Pharmacol Ther</source><year>1980</year><volume>28</volume><fpage>187</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">7398186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.1980.149</pub-id></element-citation></ref><ref id="CR329"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orme</surname><given-names>M</given-names></name><name name-style="western"><surname>Breckenridge</surname><given-names>A</given-names></name></person-group><article-title>Enantiomers of warfarin and phenobarbital</article-title><source>N Engl J Med</source><year>1976</year><volume>295</volume><fpage>1482</fpage><lpage>1483</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/nejm197612232952613</pub-id><pub-id pub-id-type="pmid">995149</pub-id></element-citation></ref><ref id="CR330"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oscarson</surname><given-names>M</given-names></name><name name-style="western"><surname>Zanger</surname><given-names>UM</given-names></name><name name-style="western"><surname>Rifki</surname><given-names>OF</given-names></name><name name-style="western"><surname>Klein</surname><given-names>K</given-names></name><name name-style="western"><surname>Eichelbaum</surname><given-names>M</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>UA</given-names></name></person-group><article-title>Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine</article-title><source>Clin Pharmacol Ther</source><year>2006</year><volume>80</volume><fpage>440</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">17112801</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clpt.2006.08.013</pub-id></element-citation></ref><ref id="CR331"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oscarson</surname><given-names>M</given-names></name><name name-style="western"><surname>Burk</surname><given-names>O</given-names></name><name name-style="western"><surname>Winter</surname><given-names>S</given-names></name><name name-style="western"><surname>Schwab</surname><given-names>M</given-names></name><name name-style="western"><surname>Wolbold</surname><given-names>R</given-names></name><name name-style="western"><surname>Dippon</surname><given-names>J</given-names></name><name name-style="western"><surname>Eichelbaum</surname><given-names>M</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>UA</given-names></name></person-group><article-title>Effects of rifampicin on global gene expression in human small intestine</article-title><source>Pharmacogenet Genom</source><year>2007</year><volume>17</volume><fpage>907</fpage><lpage>918</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FPC.0b013e3280143dfc</pub-id><pub-id pub-id-type="pmid">18075461</pub-id></element-citation></ref><ref id="CR332"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Shaughnessy</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Monteiro</surname><given-names>A</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>S</given-names></name><name name-style="western"><surname>Fowler</surname><given-names>PA</given-names></name></person-group><article-title>Maternal smoking and fetal sex significantly affect metabolic enzyme expression in the human fetal liver</article-title><source>J Clin Endocrinol Metab</source><year>2011</year><volume>96</volume><fpage>2851</fpage><lpage>2860</lpage><pub-id pub-id-type="pmid">21715529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2011-1437</pub-id></element-citation></ref><ref id="CR333"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Shea</surname><given-names>D</given-names></name><name name-style="western"><surname>Kim</surname><given-names>RB</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>GR</given-names></name></person-group><article-title>Modulation of CYP2E1 activity by isoniazid in rapid and slow <italic toggle="yes">N</italic>-acetylators</article-title><source>Br J Clin Pharmacol</source><year>1997</year><volume>43</volume><fpage>99</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">9056059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1997.tb00039.x</pub-id></element-citation></ref><ref id="CR334"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ouellet</surname><given-names>D</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>A</given-names></name><name name-style="western"><surname>Qian</surname><given-names>J</given-names></name><name name-style="western"><surname>Locke</surname><given-names>CS</given-names></name><name name-style="western"><surname>Eason</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Cavanaugh</surname><given-names>JH</given-names></name><name name-style="western"><surname>Leonard</surname><given-names>JM</given-names></name><name name-style="western"><surname>Granneman</surname><given-names>GR</given-names></name></person-group><article-title>Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers</article-title><source>Br J Clin Pharmacol</source><year>1998</year><volume>46</volume><fpage>111</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">9723818</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2125.1998.00749.x</pub-id><pub-id pub-id-type="pmcid">PMC1873670</pub-id></element-citation></ref><ref id="CR335"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oyama</surname><given-names>T</given-names></name><name name-style="western"><surname>Sugio</surname><given-names>K</given-names></name><name name-style="western"><surname>Uramoto</surname><given-names>H</given-names></name><name name-style="western"><surname>Iwata</surname><given-names>T</given-names></name><name name-style="western"><surname>Onitsuka</surname><given-names>T</given-names></name><name name-style="western"><surname>Isse</surname><given-names>T</given-names></name><name name-style="western"><surname>Nozoe</surname><given-names>T</given-names></name><name name-style="western"><surname>Kagawa</surname><given-names>N</given-names></name><name name-style="western"><surname>Yasumoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Kawamoto</surname><given-names>T</given-names></name></person-group><article-title>Increased cytochrome P450 and aryl hydrocarbon receptor in bronchial epithelium of heavy smokers with non-small cell lung carcinoma carries a poor prognosis</article-title><source>Front Biosci</source><year>2007</year><volume>12</volume><fpage>4497</fpage><lpage>4503</lpage><pub-id pub-id-type="pmid">17485391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2741/2404</pub-id></element-citation></ref><ref id="CR336"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Padda</surname><given-names>SK</given-names></name><name name-style="western"><surname>Chhatwani</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>CD</given-names></name><name name-style="western"><surname>Lopez-Anaya</surname><given-names>A</given-names></name><name name-style="western"><surname>Wakelee</surname><given-names>HA</given-names></name></person-group><article-title>Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report</article-title><source>Anticancer Drugs</source><year>2013</year><volume>24</volume><fpage>731</fpage><lpage>735</lpage><pub-id pub-id-type="pmid">23552470</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CAD.0b013e32836100d7</pub-id></element-citation></ref><ref id="CR337"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paine</surname><given-names>MF</given-names></name><name name-style="western"><surname>Roe</surname><given-names>AL</given-names></name></person-group><article-title>&#8220;Green Medicine&#8221;: the past, present, and future of botanicals</article-title><source>Clin Pharmacol Ther</source><year>2018</year><volume>104</volume><fpage>410</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">30151884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.1168</pub-id></element-citation></ref><ref id="CR338"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paine</surname><given-names>MF</given-names></name><name name-style="western"><surname>Shen</surname><given-names>DD</given-names></name><name name-style="western"><surname>McCune</surname><given-names>JS</given-names></name></person-group><article-title>Recommended approaches for pharmacokinetic natural product-drug interaction research: a NaPDI Center Commentary</article-title><source>Drug Metab Dispos</source><year>2018</year><volume>46</volume><fpage>1041</fpage><lpage>1045</lpage><pub-id pub-id-type="pmid">29735755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.117.079962</pub-id><pub-id pub-id-type="pmcid">PMC6003437</pub-id></element-citation></ref><ref id="CR339"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pakkir Maideen</surname><given-names>NM</given-names></name><name name-style="western"><surname>Manavalan</surname><given-names>G</given-names></name><name name-style="western"><surname>Balasubramanian</surname><given-names>K</given-names></name></person-group><article-title>Drug interactions of meglitinide antidiabetics involving CYP enzymes and OATP1B1 transporter</article-title><source>Ther Adv Endocrinol Metab</source><year>2018</year><volume>9</volume><fpage>259</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">30181852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2042018818767220</pub-id><pub-id pub-id-type="pmcid">PMC6116761</pub-id></element-citation></ref><ref id="CR340"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palacharla</surname><given-names>RC</given-names></name><name name-style="western"><surname>Nirogi</surname><given-names>R</given-names></name><name name-style="western"><surname>Uthukam</surname><given-names>V</given-names></name><name name-style="western"><surname>Manoharan</surname><given-names>A</given-names></name><name name-style="western"><surname>Ponnamaneni</surname><given-names>RK</given-names></name><name name-style="western"><surname>Kalaikadhiban</surname><given-names>I</given-names></name></person-group><article-title>Quantitative in vitro phenotyping and prediction of drug interaction potential of CYP2B6 substrates as victims</article-title><source>Xenobiotica</source><year>2018</year><volume>48</volume><fpage>663</fpage><lpage>675</lpage><pub-id pub-id-type="pmid">28737446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/00498254.2017.1354267</pub-id></element-citation></ref><ref id="CR341"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paladino</surname><given-names>JA</given-names></name><name name-style="western"><surname>Blumer</surname><given-names>NA</given-names></name><name name-style="western"><surname>Maddox</surname><given-names>RR</given-names></name></person-group><article-title>Effect of secobarbital on theophylline clearance</article-title><source>Ther Drug Monit</source><year>1983</year><volume>5</volume><fpage>135</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">6845397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007691-198303000-00016</pub-id></element-citation></ref><ref id="CR5000"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palovaara</surname><given-names>S</given-names></name><name name-style="western"><surname>Kivist&#246;</surname><given-names>KT</given-names></name><name name-style="western"><surname>Tapanainen</surname><given-names>P</given-names></name><name name-style="western"><surname>Manninen</surname><given-names>P</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Laine</surname><given-names>K</given-names></name></person-group><article-title>Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation</article-title><source>Br J Clin Pharmacol</source><year>2000</year><volume>50</volume><issue>4</issue><fpage>333</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2125.2000.00271.x</pub-id><pub-id pub-id-type="pmid">11012556</pub-id><pub-id pub-id-type="pmcid">PMC2015005</pub-id></element-citation></ref><ref id="CR342"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pantuck</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Kuntzman</surname><given-names>R</given-names></name><name name-style="western"><surname>Conney</surname><given-names>AH</given-names></name></person-group><article-title>Decreased concentration of phenacetin in plasma of cigarette smokers</article-title><source>Science</source><year>1972</year><volume>175</volume><fpage>1248</fpage><lpage>1250</lpage><pub-id pub-id-type="pmid">5061244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.175.4027.1248</pub-id></element-citation></ref><ref id="CR343"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pantuck</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>KC</given-names></name><name name-style="western"><surname>Conney</surname><given-names>AH</given-names></name><name name-style="western"><surname>Garland</surname><given-names>WA</given-names></name><name name-style="western"><surname>Kappas</surname><given-names>A</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>KE</given-names></name><name name-style="western"><surname>Alvares</surname><given-names>AP</given-names></name></person-group><article-title>Effect of charcoal-broiled beef on phenacetin metabolism in man</article-title><source>Science</source><year>1976</year><volume>194</volume><fpage>1055</fpage><lpage>1057</lpage><pub-id pub-id-type="pmid">982059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.982059</pub-id></element-citation></ref><ref id="CR344"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pantuck</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Pantuck</surname><given-names>CB</given-names></name><name name-style="western"><surname>Garland</surname><given-names>WA</given-names></name><name name-style="western"><surname>Min</surname><given-names>BH</given-names></name><name name-style="western"><surname>Wattenberg</surname><given-names>LW</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>KE</given-names></name><name name-style="western"><surname>Kappas</surname><given-names>A</given-names></name><name name-style="western"><surname>Conney</surname><given-names>AH</given-names></name></person-group><article-title>Stimulatory effect of brussels sprouts and cabbage on human drug metabolism</article-title><source>Clin Pharmacol Ther</source><year>1979</year><volume>25</volume><fpage>88</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">758247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt197925188</pub-id></element-citation></ref><ref id="CR345"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>JY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KA</given-names></name><name name-style="western"><surname>Kang</surname><given-names>MH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SL</given-names></name><name name-style="western"><surname>Shin</surname><given-names>JG</given-names></name></person-group><article-title>Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects</article-title><source>Clin Pharmacol Ther</source><year>2004</year><volume>75</volume><fpage>157</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">15001966</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clpt.2003.10.003</pub-id></element-citation></ref><ref id="CR346"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parker</surname><given-names>AC</given-names></name><name name-style="western"><surname>Pritchard</surname><given-names>P</given-names></name><name name-style="western"><surname>Preston</surname><given-names>T</given-names></name><name name-style="western"><surname>Choonara</surname><given-names>I</given-names></name></person-group><article-title>Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test</article-title><source>Br J Clin Pharmacol</source><year>1998</year><volume>45</volume><fpage>176</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">9491835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2125.1998.00684.x</pub-id><pub-id pub-id-type="pmcid">PMC1873361</pub-id></element-citation></ref><ref id="CR347"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parmentier</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pothier</surname><given-names>C</given-names></name><name name-style="western"><surname>Delmas</surname><given-names>A</given-names></name><name name-style="western"><surname>Caradec</surname><given-names>F</given-names></name><name name-style="western"><surname>Trancart</surname><given-names>M</given-names></name><name name-style="western"><surname>Guillet</surname><given-names>F</given-names></name><name name-style="western"><surname>Bouaita</surname><given-names>B</given-names></name><name name-style="western"><surname>Chesne</surname><given-names>C</given-names></name><name name-style="western"><surname>Brian Houston</surname><given-names>J</given-names></name><name name-style="western"><surname>Walther</surname><given-names>B</given-names></name></person-group><article-title>Direct and quantitative evaluation of the human CYP3A4 contribution (fm) to drug clearance using the in vitro SILENSOMES model</article-title><source>Xenobiotica</source><year>2017</year><volume>47</volume><fpage>562</fpage><lpage>575</lpage><pub-id pub-id-type="pmid">27485383</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/00498254.2016.1208854</pub-id></element-citation></ref><ref id="CR348"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasanen</surname><given-names>M</given-names></name><name name-style="western"><surname>Haaparanta</surname><given-names>T</given-names></name><name name-style="western"><surname>Sundin</surname><given-names>M</given-names></name><name name-style="western"><surname>Sivonen</surname><given-names>P</given-names></name><name name-style="western"><surname>Vakakangas</surname><given-names>K</given-names></name><name name-style="western"><surname>Raunio</surname><given-names>H</given-names></name><name name-style="western"><surname>Hines</surname><given-names>R</given-names></name><name name-style="western"><surname>Gustafsson</surname><given-names>JA</given-names></name><name name-style="western"><surname>Pelkonen</surname><given-names>O</given-names></name></person-group><article-title>Immunochemical and molecular biological studies on human placental cigarette smoke-inducible cytochrome P-450-dependent monooxygenase activities</article-title><source>Toxicology</source><year>1990</year><volume>62</volume><fpage>175</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">1693794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0300-483x(90)90108-s</pub-id></element-citation></ref><ref id="CR349"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pascussi</surname><given-names>JM</given-names></name><name name-style="western"><surname>Drocourt</surname><given-names>L</given-names></name><name name-style="western"><surname>Gerbal-Chaloin</surname><given-names>S</given-names></name><name name-style="western"><surname>Fabre</surname><given-names>JM</given-names></name><name name-style="western"><surname>Maurel</surname><given-names>P</given-names></name><name name-style="western"><surname>Vilarem</surname><given-names>MJ</given-names></name></person-group><article-title>Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor</article-title><source>Eur J Biochem</source><year>2001</year><volume>268</volume><fpage>6346</fpage><lpage>6358</lpage><pub-id pub-id-type="pmid">11737189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.0014-2956.2001.02540.x</pub-id></element-citation></ref><ref id="CR350"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pascussi</surname><given-names>JM</given-names></name><name name-style="western"><surname>Busson-Le Coniat</surname><given-names>M</given-names></name><name name-style="western"><surname>Maurel</surname><given-names>P</given-names></name><name name-style="western"><surname>Vilarem</surname><given-names>M</given-names></name></person-group><article-title>Transcriptional analysis of the orphan nuclear receptor constitutive androstane receptor (NR1I3) gene promoter: identification of a distal glucocorticoid response element</article-title><source>Mol Endocrinol</source><year>2003</year><volume>17</volume><fpage>42</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">12511605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/me.2002-0244</pub-id></element-citation></ref><ref id="CR351"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pavek</surname><given-names>P</given-names></name></person-group><article-title>Pregnane X receptor (PXR)-mediated gene repression and cross-talk of PXR with other nuclear receptors via coactivator interactions</article-title><source>Front Pharmacol</source><year>2016</year><volume>7</volume><fpage>456</fpage><pub-id pub-id-type="pmid">27932985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2016.00456</pub-id><pub-id pub-id-type="pmcid">PMC5122737</pub-id></element-citation></ref><ref id="CR352"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pelkonen</surname><given-names>O</given-names></name><name name-style="western"><surname>Turpeinen</surname><given-names>M</given-names></name><name name-style="western"><surname>Hakkola</surname><given-names>J</given-names></name><name name-style="western"><surname>Honkakoski</surname><given-names>P</given-names></name><name name-style="western"><surname>Hukkanen</surname><given-names>J</given-names></name><name name-style="western"><surname>Raunio</surname><given-names>H</given-names></name></person-group><article-title>Inhibition and induction of human cytochrome P450 enzymes: current status</article-title><source>Arch Toxicol</source><year>2008</year><volume>82</volume><fpage>667</fpage><lpage>715</lpage><pub-id pub-id-type="pmid">18618097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00204-008-0332-8</pub-id></element-citation></ref><ref id="CR353"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pelkonen</surname><given-names>O</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Fan</surname><given-names>T</given-names></name></person-group><article-title>Why is research on herbal medicinal products important and how can we improve its quality?</article-title><source>J Tradit Complement Med</source><year>2014</year><volume>4</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">24872927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/2225-4110.124323</pub-id><pub-id pub-id-type="pmcid">PMC4032837</pub-id></element-citation></ref><ref id="CR354"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Penzak</surname><given-names>SR</given-names></name><name name-style="western"><surname>Hon</surname><given-names>YY</given-names></name><name name-style="western"><surname>Lawhorn</surname><given-names>WD</given-names></name><name name-style="western"><surname>Shirley</surname><given-names>KL</given-names></name><name name-style="western"><surname>Spratlin</surname><given-names>V</given-names></name><name name-style="western"><surname>Jann</surname><given-names>MW</given-names></name></person-group><article-title>Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers</article-title><source>J Clin Psychopharmacol</source><year>2002</year><volume>22</volume><fpage>366</fpage><lpage>370</lpage><pub-id pub-id-type="pmid">12172335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00004714-200208000-00006</pub-id></element-citation></ref><ref id="CR355"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Penzak</surname><given-names>SR</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>SM</given-names></name><name name-style="western"><surname>Hunt</surname><given-names>JD</given-names></name><name name-style="western"><surname>Chairez</surname><given-names>C</given-names></name><name name-style="western"><surname>Malati</surname><given-names>CY</given-names></name><name name-style="western"><surname>Alfaro</surname><given-names>RM</given-names></name><name name-style="western"><surname>Stevenson</surname><given-names>JM</given-names></name><name name-style="western"><surname>Kovacs</surname><given-names>JA</given-names></name></person-group><article-title>PMC3407958; echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir&#8211;ritonavir exposure in healthy subjects</article-title><source>Pharmacotherapy</source><year>2010</year><volume>30</volume><fpage>797</fpage><lpage>805</lpage><pub-id pub-id-type="pmid">20653355</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1592/phco.30.8.797</pub-id><pub-id pub-id-type="pmcid">PMC3407958</pub-id></element-citation></ref><ref id="CR356"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perrot</surname><given-names>N</given-names></name><name name-style="western"><surname>Nalpas</surname><given-names>B</given-names></name><name name-style="western"><surname>Yang</surname><given-names>CS</given-names></name><name name-style="western"><surname>Beaune</surname><given-names>PH</given-names></name></person-group><article-title>Modulation of cytochrome P450 isozymes in human liver, by ethanol and drug intake</article-title><source>Eur J Clin Investig</source><year>1989</year><volume>19</volume><fpage>549</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">2515975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2362.1989.tb00273.x</pub-id></element-citation></ref><ref id="CR357"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perucca</surname><given-names>E</given-names></name><name name-style="western"><surname>Grimaldi</surname><given-names>R</given-names></name><name name-style="western"><surname>Frigo</surname><given-names>GM</given-names></name><name name-style="western"><surname>Sardi</surname><given-names>A</given-names></name><name name-style="western"><surname>Monig</surname><given-names>H</given-names></name><name name-style="western"><surname>Ohnhaus</surname><given-names>EE</given-names></name></person-group><article-title>Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects</article-title><source>Eur J Clin Pharmacol</source><year>1988</year><volume>34</volume><fpage>595</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">2901960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00615223</pub-id></element-citation></ref><ref id="CR358"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perucca</surname><given-names>E</given-names></name><name name-style="western"><surname>Cloyd</surname><given-names>J</given-names></name><name name-style="western"><surname>Critchley</surname><given-names>D</given-names></name><name name-style="western"><surname>Fuseau</surname><given-names>E</given-names></name></person-group><article-title>Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy</article-title><source>Epilepsia</source><year>2008</year><volume>49</volume><fpage>1123</fpage><lpage>1141</lpage><pub-id pub-id-type="pmid">18503564</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1528-1167.2008.01665.x</pub-id></element-citation></ref><ref id="CR359"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petersen</surname><given-names>MS</given-names></name><name name-style="western"><surname>Halling</surname><given-names>J</given-names></name><name name-style="western"><surname>Damkier</surname><given-names>P</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>F</given-names></name><name name-style="western"><surname>Grandjean</surname><given-names>P</given-names></name><name name-style="western"><surname>Weihe</surname><given-names>P</given-names></name><name name-style="western"><surname>Brosen</surname><given-names>K</given-names></name></person-group><article-title>Polychlorinated biphenyl (PCB) induction of CYP3A4 enzyme activity in healthy Faroese adults</article-title><source>Toxicol Appl Pharmacol</source><year>2007</year><volume>224</volume><fpage>202</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">17692354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.taap.2007.07.002</pub-id></element-citation></ref><ref id="CR360"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pilla Reddy</surname><given-names>V</given-names></name><name name-style="western"><surname>Walker</surname><given-names>M</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P</given-names></name><name name-style="western"><surname>Ballard</surname><given-names>P</given-names></name><name name-style="western"><surname>Vishwanathan</surname><given-names>K</given-names></name></person-group><article-title>Development, verification, and prediction of osimertinib drug&#8211;drug interactions using PBPK modeling approach to inform drug label</article-title><source>CPT Pharmacomet Syst Pharmacol</source><year>2018</year><volume>7</volume><fpage>321</fpage><lpage>330</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psp4.12289</pub-id><pub-id pub-id-type="pmcid">PMC5980577</pub-id><pub-id pub-id-type="pmid">29468841</pub-id></element-citation></ref><ref id="CR361"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piscitelli</surname><given-names>SC</given-names></name><name name-style="western"><surname>Burstein</surname><given-names>AH</given-names></name><name name-style="western"><surname>Chaitt</surname><given-names>D</given-names></name><name name-style="western"><surname>Alfaro</surname><given-names>RM</given-names></name><name name-style="western"><surname>Falloon</surname><given-names>J</given-names></name></person-group><article-title>Indinavir concentrations and St John&#8217;s wort</article-title><source>Lancet</source><year>2000</year><volume>355</volume><fpage>547</fpage><lpage>548</lpage><pub-id pub-id-type="pmid">10683007</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(99)05712-8</pub-id></element-citation></ref><ref id="CR362"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pithavala</surname><given-names>YK</given-names></name><name name-style="western"><surname>Tortorici</surname><given-names>M</given-names></name><name name-style="western"><surname>Toh</surname><given-names>M</given-names></name><name name-style="western"><surname>Garrett</surname><given-names>M</given-names></name><name name-style="western"><surname>Hee</surname><given-names>B</given-names></name><name name-style="western"><surname>Kuruganti</surname><given-names>U</given-names></name><name name-style="western"><surname>Ni</surname><given-names>G</given-names></name><name name-style="western"><surname>Klamerus</surname><given-names>KJ</given-names></name></person-group><article-title>Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers</article-title><source>Cancer Chemother Pharmacol</source><year>2010</year><volume>65</volume><fpage>563</fpage><lpage>570</lpage><pub-id pub-id-type="pmid">19603168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-009-1065-y</pub-id><pub-id pub-id-type="pmcid">PMC2797436</pub-id></element-citation></ref><ref id="CR363"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pithavala</surname><given-names>YK</given-names></name><name name-style="western"><surname>Tong</surname><given-names>W</given-names></name><name name-style="western"><surname>Mount</surname><given-names>J</given-names></name><name name-style="western"><surname>Rahavendran</surname><given-names>SV</given-names></name><name name-style="western"><surname>Garrett</surname><given-names>M</given-names></name><name name-style="western"><surname>Hee</surname><given-names>B</given-names></name><name name-style="western"><surname>Selaru</surname><given-names>P</given-names></name><name name-style="western"><surname>Sarapa</surname><given-names>N</given-names></name><name name-style="western"><surname>Klamerus</surname><given-names>KJ</given-names></name></person-group><article-title>Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers</article-title><source>Investig New Drugs</source><year>2012</year><volume>30</volume><fpage>273</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">20740300</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10637-010-9511-6</pub-id><pub-id pub-id-type="pmcid">PMC3256319</pub-id></element-citation></ref><ref id="CR364"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poland</surname><given-names>A</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D</given-names></name><name name-style="western"><surname>Kuntzman</surname><given-names>R</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>M</given-names></name><name name-style="western"><surname>Conney</surname><given-names>AH</given-names></name></person-group><article-title>Effect of intensive occupational exposure to DDT on phenylbutazone and cortisol metabolism in human subjects</article-title><source>Clin Pharmacol Ther</source><year>1970</year><volume>11</volume><fpage>724</fpage><lpage>732</lpage><pub-id pub-id-type="pmid">5455634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt1970115724</pub-id></element-citation></ref><ref id="CR365"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poland</surname><given-names>A</given-names></name><name name-style="western"><surname>Glover</surname><given-names>E</given-names></name><name name-style="western"><surname>Kende</surname><given-names>AS</given-names></name></person-group><article-title>Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-<italic toggle="yes">p</italic>-dioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase</article-title><source>J Biol Chem</source><year>1976</year><volume>251</volume><fpage>4936</fpage><lpage>4946</lpage><pub-id pub-id-type="pmid">956169</pub-id></element-citation></ref><ref id="CR1002"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polasek</surname><given-names>TM</given-names></name><name name-style="western"><surname>Elliot</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>BC</given-names></name><name name-style="western"><surname>Miners</surname><given-names>JO</given-names></name></person-group><article-title>Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro</article-title><source>J Pharmacol Exp Ther</source><year>2004</year><volume>311</volume><issue>3</issue><fpage>996</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.1124/jpet.104.071803</pub-id><pub-id pub-id-type="pmid">15304522</pub-id></element-citation></ref><ref id="CR366"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Posada</surname><given-names>MM</given-names></name><name name-style="western"><surname>Morse</surname><given-names>BL</given-names></name><name name-style="western"><surname>Turner</surname><given-names>PK</given-names></name><name name-style="western"><surname>Kulanthaivel</surname><given-names>P</given-names></name><name name-style="western"><surname>Hall</surname><given-names>SD</given-names></name><name name-style="western"><surname>Dickinson</surname><given-names>GL</given-names></name></person-group><article-title>Predicting clinical effects of CYP3A4 modulators on abemaciclib and active metabolites exposure using physiologically based pharmacokinetic modeling</article-title><source>J Clin Pharmacol</source><year>2020</year><volume>60</volume><fpage>915</fpage><lpage>930</lpage><pub-id pub-id-type="pmid">32080863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcph.1584</pub-id><pub-id pub-id-type="pmcid">PMC7318171</pub-id></element-citation></ref><ref id="CR367"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pratt-Hyatt</surname><given-names>M</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H</given-names></name><name name-style="western"><surname>Hollenberg</surname><given-names>PF</given-names></name></person-group><article-title>Mechanism-based inactivation of human CYP2E1 by diethyldithocarbamate</article-title><source>Drug Metab Dispos</source><year>2010</year><volume>38</volume><fpage>2286</fpage><lpage>2292</lpage><pub-id pub-id-type="pmid">20826547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.110.034710</pub-id><pub-id pub-id-type="pmcid">PMC2993453</pub-id></element-citation></ref><ref id="CR368"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Preissner</surname><given-names>S</given-names></name><name name-style="western"><surname>Kroll</surname><given-names>K</given-names></name><name name-style="western"><surname>Dunkel</surname><given-names>M</given-names></name><name name-style="western"><surname>Senger</surname><given-names>C</given-names></name><name name-style="western"><surname>Goldsobel</surname><given-names>G</given-names></name><name name-style="western"><surname>Kuzman</surname><given-names>D</given-names></name><name name-style="western"><surname>Guenther</surname><given-names>S</given-names></name><name name-style="western"><surname>Winnenburg</surname><given-names>R</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>M</given-names></name><name name-style="western"><surname>Preissner</surname><given-names>R</given-names></name></person-group><article-title>SuperCYP: a comprehensive database on cytochrome P450 enzymes including a tool for analysis of CYP&#8211;drug interactions</article-title><source>Nucleic Acids Res</source><year>2010</year><volume>38</volume><fpage>237</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkp970</pub-id><pub-id pub-id-type="pmcid">PMC2808967</pub-id><pub-id pub-id-type="pmid">19934256</pub-id></element-citation></ref><ref id="CR369"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Press</surname><given-names>RR</given-names></name><name name-style="western"><surname>Ploeger</surname><given-names>BA</given-names></name><name name-style="western"><surname>den Hartigh</surname><given-names>J</given-names></name><name name-style="western"><surname>van der Straaten</surname><given-names>T</given-names></name><name name-style="western"><surname>van Pelt</surname><given-names>H</given-names></name><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><name name-style="western"><surname>de Fijter</surname><given-names>H</given-names></name><name name-style="western"><surname>Guchelaar</surname><given-names>HJ</given-names></name></person-group><article-title>2868991; explaining variability in ciclosporin exposure in adult kidney transplant recipients</article-title><source>Eur J Clin Pharmacol</source><year>2010</year><volume>66</volume><fpage>579</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">20354687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-010-0810-9</pub-id><pub-id pub-id-type="pmcid">PMC2868991</pub-id></element-citation></ref><ref id="CR370"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prieto-Castello</surname><given-names>M</given-names></name><name name-style="western"><surname>Cardona</surname><given-names>A</given-names></name><name name-style="western"><surname>Marhuenda</surname><given-names>D</given-names></name><name name-style="western"><surname>Roel</surname><given-names>JM</given-names></name><name name-style="western"><surname>Corno</surname><given-names>A</given-names></name></person-group><article-title>Use of the CYP2E1 genotype and phenotype for the biological monitoring of occupational exposure to styrene</article-title><source>Toxicol Lett</source><year>2010</year><volume>192</volume><fpage>34</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">20117323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.toxlet.2009.01.011</pub-id></element-citation></ref><ref id="CR371"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pursche</surname><given-names>S</given-names></name><name name-style="western"><surname>Schleyer</surname><given-names>E</given-names></name><name name-style="western"><surname>von Bonin</surname><given-names>M</given-names></name><name name-style="western"><surname>Ehninger</surname><given-names>G</given-names></name><name name-style="western"><surname>Said</surname><given-names>SM</given-names></name><name name-style="western"><surname>Prondzinsky</surname><given-names>R</given-names></name><name name-style="western"><surname>Illmer</surname><given-names>T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hosius</surname><given-names>C</given-names></name><name name-style="western"><surname>Nikolova</surname><given-names>Z</given-names></name><name name-style="western"><surname>Bornh&#228;user</surname><given-names>M</given-names></name><name name-style="western"><surname>Dresemann</surname><given-names>G</given-names></name></person-group><article-title>Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients</article-title><source>Curr Clin Pharmacol</source><year>2008</year><volume>3</volume><fpage>198</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">18781906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/157488408785747656</pub-id><pub-id pub-id-type="pmcid">PMC2748699</pub-id></element-citation></ref><ref id="CR372"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>ZQ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>XP</given-names></name><name name-style="western"><surname>Tan</surname><given-names>ZR</given-names></name><name name-style="western"><surname>Hu</surname><given-names>DL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Fan</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>HH</given-names></name></person-group><article-title>PMC3522813; Rapid clinical induction of bupropion hydroxylation by metamizole in healthy Chinese men</article-title><source>Br J Clin Pharmacol</source><year>2012</year><volume>74</volume><fpage>999</fpage><lpage>1004</lpage><pub-id pub-id-type="pmid">22519658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2012.04304.x</pub-id><pub-id pub-id-type="pmcid">PMC3522813</pub-id></element-citation></ref><ref id="CR373"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name></person-group><article-title>PMC2883758; Effect of danshen extract on the activity of CYP3A4 in healthy volunteers</article-title><source>Br J Clin Pharmacol</source><year>2010</year><volume>69</volume><fpage>656</fpage><lpage>662</lpage><pub-id pub-id-type="pmid">20565457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2010.03624.x</pub-id><pub-id pub-id-type="pmcid">PMC2883758</pub-id></element-citation></ref><ref id="CR374"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>F</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>He</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Miao</surname><given-names>P</given-names></name></person-group><article-title>PMC3816049; opposite effects of single-dose and multidose administration of the ethanol extract of danshen on CYP3A in healthy volunteers</article-title><source>Evid Based Complement Altern Med</source><year>2013</year><volume>2013</volume><fpage>730734</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2013/730734</pub-id><pub-id pub-id-type="pmcid">PMC3816049</pub-id><pub-id pub-id-type="pmid">24223062</pub-id></element-citation></ref><ref id="CR375"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quattrochi</surname><given-names>LC</given-names></name><name name-style="western"><surname>Tukey</surname><given-names>RH</given-names></name></person-group><article-title>Nuclear uptake of the Ah (dioxin) receptor in response to omeprazole: transcriptional activation of the human CYP1A1 gene</article-title><source>Mol Pharmacol</source><year>1993</year><volume>43</volume><fpage>504</fpage><lpage>508</lpage><pub-id pub-id-type="pmid">8386305</pub-id></element-citation></ref><ref id="CR376"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raaska</surname><given-names>K</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name></person-group><article-title>Ciprofloxacin increases serum clozapine and <italic toggle="yes">N</italic>-desmethylclozapine: a study in patients with schizophrenia</article-title><source>Eur J Clin Pharmacol</source><year>2000</year><volume>56</volume><fpage>585</fpage><lpage>589</lpage><pub-id pub-id-type="pmid">11151749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002280000192</pub-id></element-citation></ref><ref id="CR377"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahmioglu</surname><given-names>N</given-names></name><name name-style="western"><surname>Heaton</surname><given-names>J</given-names></name><name name-style="western"><surname>Clement</surname><given-names>G</given-names></name><name name-style="western"><surname>Gill</surname><given-names>R</given-names></name><name name-style="western"><surname>Surdulescu</surname><given-names>G</given-names></name><name name-style="western"><surname>Zlobecka</surname><given-names>K</given-names></name><name name-style="western"><surname>Hodgkiss</surname><given-names>D</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hider</surname><given-names>RC</given-names></name><name name-style="western"><surname>Smith</surname><given-names>NW</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>KR</given-names></name></person-group><article-title>Genetic epidemiology of induced CYP3A4 activity</article-title><source>Pharmacogenet Genom</source><year>2011</year><volume>21</volume><fpage>642</fpage><lpage>651</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FPC.0b013e3283498ecf</pub-id><pub-id pub-id-type="pmid">21750469</pub-id></element-citation></ref><ref id="CR378"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramanathan</surname><given-names>S</given-names></name><name name-style="western"><surname>Jin</surname><given-names>F</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S</given-names></name><name name-style="western"><surname>Kearney</surname><given-names>BP</given-names></name></person-group><article-title>Clinical Pharmacokinetic and pharmacodynamic profile of idelalisib</article-title><source>Clin Pharmacokinet</source><year>2016</year><volume>55</volume><fpage>33</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">26242379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-015-0304-0</pub-id></element-citation></ref><ref id="CR379"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>PSS</given-names></name><name name-style="western"><surname>Midde</surname><given-names>NM</given-names></name><name name-style="western"><surname>Miller</surname><given-names>DD</given-names></name><name name-style="western"><surname>Chauhan</surname><given-names>S</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name></person-group><article-title>Diallyl sulfide: potential use in novel therapeutic interventions in alcohol, drugs, and disease mediated cellular toxicity by targeting cytochrome P450 2E1</article-title><source>Curr Drug Metab</source><year>2015</year><volume>16</volume><fpage>486</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">26264202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1389200216666150812123554</pub-id><pub-id pub-id-type="pmcid">PMC4663692</pub-id></element-citation></ref><ref id="CR380"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rasheed</surname><given-names>A</given-names></name><name name-style="western"><surname>Hines</surname><given-names>RN</given-names></name><name name-style="western"><surname>McCarver-May</surname><given-names>D</given-names></name></person-group><article-title>Variation in induction of human placental CYP2E1: possible role in susceptibility to fetal alcohol syndrome?</article-title><source>Toxicol Appl Pharmacol</source><year>1997</year><volume>144</volume><fpage>396</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">9194424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/taap.1997.8152</pub-id></element-citation></ref><ref id="CR381"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raucy</surname><given-names>JL</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>ED</given-names></name><name name-style="western"><surname>Wester</surname><given-names>MR</given-names></name><name name-style="western"><surname>Arora</surname><given-names>S</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>DE</given-names></name><name name-style="western"><surname>Omdahl</surname><given-names>JL</given-names></name><name name-style="western"><surname>Carpenter</surname><given-names>SP</given-names></name></person-group><article-title>Human lymphocyte cytochrome P450 2E1, a putative marker for alcohol-mediated changes in hepatic chlorzoxazone activity</article-title><source>Drug Metab Dispos</source><year>1997</year><volume>25</volume><fpage>1429</fpage><lpage>1435</lpage><pub-id pub-id-type="pmid">9394034</pub-id></element-citation></ref><ref id="CR382"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raucy</surname><given-names>JL</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>ED</given-names></name><name name-style="western"><surname>Kearins</surname><given-names>MC</given-names></name><name name-style="western"><surname>Arora</surname><given-names>S</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>DE</given-names></name><name name-style="western"><surname>Omdahl</surname><given-names>JL</given-names></name><name name-style="western"><surname>Eckmann</surname><given-names>L</given-names></name><name name-style="western"><surname>Carpenter</surname><given-names>SP</given-names></name></person-group><article-title>CYP2E1 expression in human lymphocytes from various ethnic populations</article-title><source>Alcohol Clin Exp Res</source><year>1999</year><volume>23</volume><fpage>1868</fpage><lpage>1874</lpage><pub-id pub-id-type="pmid">10630604</pub-id></element-citation></ref><ref id="CR383"><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Rautio</surname><given-names>A</given-names></name><name name-style="western"><surname>Salmela</surname><given-names>E</given-names></name><name name-style="western"><surname>Arvela</surname><given-names>P</given-names></name><name name-style="western"><surname>Pelkonen</surname><given-names>O</given-names></name><name name-style="western"><surname>Sotaniemi</surname><given-names>EA</given-names></name></person-group><person-group person-group-type="editor"><name name-style="western"><surname>Lechner</surname><given-names>MC</given-names></name></person-group><article-title>Assessment of CYP2A6 and CYP3A4 activities in vivo in different diseases in man</article-title><source>Cytochrome P450: biochemistry, biophysics and molecular biology</source><year>1994</year><publisher-loc>Paris</publisher-loc><publisher-name>John Libbey Eurotext</publisher-name><fpage>519</fpage><lpage>521</lpage></element-citation></ref><ref id="CR384"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reardon</surname><given-names>DA</given-names></name><name name-style="western"><surname>Vredenburgh</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Desjardins</surname><given-names>A</given-names></name><name name-style="western"><surname>Peters</surname><given-names>K</given-names></name><name name-style="western"><surname>Gururangan</surname><given-names>S</given-names></name><name name-style="western"><surname>Sampson</surname><given-names>JH</given-names></name><name name-style="western"><surname>Marcello</surname><given-names>J</given-names></name><name name-style="western"><surname>Herndon</surname><given-names>JE</given-names></name><name name-style="western"><surname>McLendon</surname><given-names>RE</given-names></name><name name-style="western"><surname>Janney</surname><given-names>D</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>AH</given-names></name><name name-style="western"><surname>Bigner</surname><given-names>DD</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>HS</given-names></name></person-group><article-title>Effect of CYP3A-inducing antiepileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma</article-title><source>J Neurooncol</source><year>2011</year><volume>101</volume><fpage>57</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">20443129</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11060-010-0217-6</pub-id><pub-id pub-id-type="pmcid">PMC3102498</pub-id></element-citation></ref><ref id="CR385"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reed</surname><given-names>GA</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>KS</given-names></name><name name-style="western"><surname>Smith</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Gray</surname><given-names>JC</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>DK</given-names></name><name name-style="western"><surname>Mayo</surname><given-names>MS</given-names></name><name name-style="western"><surname>Crowell</surname><given-names>JA</given-names></name><name name-style="western"><surname>Hurwitz</surname><given-names>A</given-names></name></person-group><article-title>A phase I study of indole-3-carbinol in women: tolerability and effects</article-title><source>Cancer Epidemiol Biomark Prev</source><year>2005</year><volume>14</volume><fpage>1953</fpage><lpage>1960</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1055-9965.EPI-05-0121</pub-id><pub-id pub-id-type="pmid">16103443</pub-id></element-citation></ref><ref id="CR386"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reese</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Wurm</surname><given-names>RM</given-names></name><name name-style="western"><surname>Muir</surname><given-names>KT</given-names></name><name name-style="western"><surname>Generaux</surname><given-names>GT</given-names></name><name name-style="western"><surname>St John-Williams</surname><given-names>L</given-names></name><name name-style="western"><surname>McConn</surname><given-names>DJ</given-names></name></person-group><article-title>An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug&#8211;drug interaction</article-title><source>Drug Metab Dispos</source><year>2008</year><volume>36</volume><fpage>1198</fpage><lpage>1201</lpage><pub-id pub-id-type="pmid">18420781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.107.020198</pub-id></element-citation></ref><ref id="CR387"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richter</surname><given-names>E</given-names></name><name name-style="western"><surname>Breimer</surname><given-names>DD</given-names></name><name name-style="western"><surname>Zilly</surname><given-names>W</given-names></name></person-group><article-title>Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents</article-title><source>Eur J Clin Pharmacol</source><year>1980</year><volume>17</volume><fpage>197</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">7363932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00561900</pub-id></element-citation></ref><ref id="CR388"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Rollins</surname><given-names>KD</given-names></name><name name-style="western"><surname>Kashuba</surname><given-names>AD</given-names></name><name name-style="western"><surname>Paine</surname><given-names>MF</given-names></name><name name-style="western"><surname>Nelsen</surname><given-names>AC</given-names></name><name name-style="western"><surname>Williams</surname><given-names>EE</given-names></name><name name-style="western"><surname>Moran</surname><given-names>C</given-names></name><name name-style="western"><surname>Lamba</surname><given-names>JK</given-names></name><name name-style="western"><surname>Schuetz</surname><given-names>EG</given-names></name><name name-style="western"><surname>Hawke</surname><given-names>RL</given-names></name></person-group><article-title>2770345; the influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans</article-title><source>Drug Metab Dispos</source><year>2008</year><volume>36</volume><fpage>1465</fpage><lpage>1469</lpage><pub-id pub-id-type="pmid">18490434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.107.020065</pub-id><pub-id pub-id-type="pmcid">PMC2770345</pub-id></element-citation></ref><ref id="CR389"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robertson</surname><given-names>P</given-names></name><name name-style="western"><surname>DeCory</surname><given-names>HH</given-names></name><name name-style="western"><surname>Madan</surname><given-names>A</given-names></name><name name-style="western"><surname>Parkinson</surname><given-names>A</given-names></name></person-group><article-title>In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil</article-title><source>Drug Metab Dispos</source><year>2000</year><volume>28</volume><fpage>664</fpage><lpage>671</lpage><pub-id pub-id-type="pmid">10820139</pub-id></element-citation></ref><ref id="CR390"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robertson</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Hellriegel</surname><given-names>ET</given-names></name><name name-style="western"><surname>Arora</surname><given-names>S</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>M</given-names></name></person-group><article-title>Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers</article-title><source>Clin Pharmacol Ther</source><year>2002</year><volume>71</volume><fpage>46</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">11823757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2002.121217</pub-id></element-citation></ref><ref id="CR391"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robertson</surname><given-names>SM</given-names></name><name name-style="western"><surname>Maldarelli</surname><given-names>F</given-names></name><name name-style="western"><surname>Natarajan</surname><given-names>V</given-names></name><name name-style="western"><surname>Formentini</surname><given-names>E</given-names></name><name name-style="western"><surname>Alfaro</surname><given-names>RM</given-names></name><name name-style="western"><surname>Penzak</surname><given-names>SR</given-names></name></person-group><article-title>Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects</article-title><source>J Acquir Immune Defic Syndr</source><year>2008</year><volume>49</volume><fpage>513</fpage><lpage>519</lpage><pub-id pub-id-type="pmid">18989234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/QAI.0b013e318183a425</pub-id><pub-id pub-id-type="pmcid">PMC9036313</pub-id></element-citation></ref><ref id="CR392"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robertson</surname><given-names>SM</given-names></name><name name-style="western"><surname>Davey</surname><given-names>RT</given-names></name><name name-style="western"><surname>Voell</surname><given-names>J</given-names></name><name name-style="western"><surname>Formentini</surname><given-names>E</given-names></name><name name-style="western"><surname>Alfaro</surname><given-names>RM</given-names></name><name name-style="western"><surname>Penzak</surname><given-names>SR</given-names></name></person-group><article-title>Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects</article-title><source>Curr Med Res Opin</source><year>2008</year><volume>24</volume><fpage>591</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">18205997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1185/030079908x260871</pub-id></element-citation></ref><ref id="CR393"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robson</surname><given-names>RA</given-names></name><name name-style="western"><surname>Miners</surname><given-names>JO</given-names></name><name name-style="western"><surname>Wing</surname><given-names>LM</given-names></name><name name-style="western"><surname>Birkett</surname><given-names>DJ</given-names></name></person-group><article-title>1463637; theophylline-rifampicin interaction: non-selective induction of theophylline metabolic pathways</article-title><source>Br J Clin Pharmacol</source><year>1984</year><volume>18</volume><fpage>445</fpage><lpage>448</lpage><pub-id pub-id-type="pmid">6487483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1984.tb02487.x</pub-id><pub-id pub-id-type="pmcid">PMC1463637</pub-id></element-citation></ref><ref id="CR394"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roby</surname><given-names>CA</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>GD</given-names></name><name name-style="western"><surname>Kantor</surname><given-names>E</given-names></name><name name-style="western"><surname>Dryer</surname><given-names>DA</given-names></name><name name-style="western"><surname>Burstein</surname><given-names>AH</given-names></name></person-group><article-title>St John&#8217;s Wort: effect on CYP3A4 activity</article-title><source>Clin Pharmacol Ther</source><year>2000</year><volume>67</volume><fpage>451</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">10824623</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2000.106793</pub-id></element-citation></ref><ref id="CR395"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenfeld</surname><given-names>WE</given-names></name><name name-style="western"><surname>Doose</surname><given-names>DR</given-names></name><name name-style="western"><surname>Walker</surname><given-names>SA</given-names></name><name name-style="western"><surname>Nayak</surname><given-names>RK</given-names></name></person-group><article-title>Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy</article-title><source>Epilepsia</source><year>1997</year><volume>38</volume><fpage>317</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">9070594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1528-1157.1997.tb01123.x</pub-id></element-citation></ref><ref id="CR396"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rost</surname><given-names>KL</given-names></name><name name-style="western"><surname>Roots</surname><given-names>I</given-names></name></person-group><article-title>Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test</article-title><source>Clin Pharmacol Ther</source><year>1994</year><volume>55</volume><fpage>402</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">8162667</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.1994.49</pub-id></element-citation></ref><ref id="CR397"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rost</surname><given-names>KL</given-names></name><name name-style="western"><surname>Brosicke</surname><given-names>H</given-names></name><name name-style="western"><surname>Heinemeyer</surname><given-names>G</given-names></name><name name-style="western"><surname>Roots</surname><given-names>I</given-names></name></person-group><article-title>Specific and dose-dependent enzyme induction by omeprazole in human beings</article-title><source>Hepatology</source><year>1994</year><volume>20</volume><fpage>1204</fpage><lpage>1212</lpage><pub-id pub-id-type="pmid">7927253</pub-id></element-citation></ref><ref id="CR398"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rothhammer</surname><given-names>V</given-names></name><name name-style="western"><surname>Quintana</surname><given-names>FJ</given-names></name></person-group><article-title>The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease</article-title><source>Nat Rev Immunol</source><year>2019</year><volume>19</volume><fpage>184</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">30718831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-019-0125-8</pub-id></element-citation></ref><ref id="CR399"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rowland</surname><given-names>A</given-names></name><name name-style="western"><surname>van Dyk</surname><given-names>M</given-names></name><name name-style="western"><surname>Warncken</surname><given-names>D</given-names></name><name name-style="western"><surname>Mangoni</surname><given-names>AA</given-names></name><name name-style="western"><surname>Sorich</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Rowland</surname><given-names>A</given-names></name></person-group><article-title>Evaluation of modafinil as a perpetrator of metabolic drug&#8211;drug interactions using a model informed cocktail reaction phenotyping trial protocol</article-title><source>Br J Clin Pharmacol</source><year>2018</year><volume>84</volume><fpage>501</fpage><lpage>509</lpage><pub-id pub-id-type="pmid">29178272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.13478</pub-id><pub-id pub-id-type="pmcid">PMC5809348</pub-id></element-citation></ref><ref id="CR400"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryu</surname><given-names>JY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HU</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SY</given-names></name></person-group><article-title>Deep learning improves prediction of drug&#8211;drug and drug&#8211;food interactions</article-title><source>Proc Natl Acad Sci USA</source><year>2018</year><volume>115</volume><fpage>E4304</fpage><lpage>E4311</lpage><pub-id pub-id-type="pmid">29666228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1803294115</pub-id><pub-id pub-id-type="pmcid">PMC5939113</pub-id></element-citation></ref><ref id="CR401"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saarikoski</surname><given-names>ST</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>SP</given-names></name><name name-style="western"><surname>Hankinson</surname><given-names>O</given-names></name><name name-style="western"><surname>Husgafvel-Pursiainen</surname><given-names>K</given-names></name></person-group><article-title>CYP2S1: a short review</article-title><source>Toxicol Appl Pharmacol</source><year>2005</year><volume>207</volume><fpage>62</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">16054184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.taap.2004.12.027</pub-id></element-citation></ref><ref id="CR402"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saccar</surname><given-names>CL</given-names></name><name name-style="western"><surname>Danish</surname><given-names>M</given-names></name><name name-style="western"><surname>Ragni</surname><given-names>MC</given-names></name><name name-style="western"><surname>Rocci</surname><given-names>MLJ</given-names></name><name name-style="western"><surname>Greene</surname><given-names>J</given-names></name><name name-style="western"><surname>Yaffe</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Mansmann</surname><given-names>HCJ</given-names></name></person-group><article-title>The effect of phenobarbital on theophylline disposition in children with asthma</article-title><source>J Allergy Clin Immunol</source><year>1985</year><volume>75</volume><fpage>716</fpage><lpage>719</lpage><pub-id pub-id-type="pmid">4008801</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0091-6749(85)90099-5</pub-id></element-citation></ref><ref id="CR403"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sager</surname><given-names>JE</given-names></name><name name-style="western"><surname>Tripathy</surname><given-names>S</given-names></name><name name-style="western"><surname>Price</surname><given-names>LSL</given-names></name><name name-style="western"><surname>Nath</surname><given-names>A</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J</given-names></name><name name-style="western"><surname>Stephenson-Famy</surname><given-names>A</given-names></name><name name-style="western"><surname>Isoherranen</surname><given-names>N</given-names></name></person-group><article-title>In vitro to in vivo extrapolation of the complex drug&#8211;drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation</article-title><source>Biochem Pharmacol</source><year>2017</year><volume>123</volume><fpage>85</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">27836670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2016.11.007</pub-id><pub-id pub-id-type="pmcid">PMC5164944</pub-id></element-citation></ref><ref id="CR404"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sale</surname><given-names>M</given-names></name><name name-style="western"><surname>Sadler</surname><given-names>BM</given-names></name><name name-style="western"><surname>Stein</surname><given-names>DS</given-names></name></person-group><article-title>Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir</article-title><source>Antimicrob Agents Chemother</source><year>2002</year><volume>46</volume><fpage>746</fpage><lpage>754</lpage><pub-id pub-id-type="pmid">11850257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.46.3.746-754.2002</pub-id><pub-id pub-id-type="pmcid">PMC127459</pub-id></element-citation></ref><ref id="CR405"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samer</surname><given-names>CF</given-names></name><name name-style="western"><surname>Gloor</surname><given-names>Y</given-names></name><name name-style="western"><surname>Rollason</surname><given-names>V</given-names></name><name name-style="western"><surname>Guessous</surname><given-names>I</given-names></name><name name-style="western"><surname>Doffey-Lazeyras</surname><given-names>F</given-names></name><name name-style="western"><surname>Saurat</surname><given-names>JH</given-names></name><name name-style="western"><surname>Sorg</surname><given-names>O</given-names></name><name name-style="western"><surname>Desmeules</surname><given-names>J</given-names></name><name name-style="western"><surname>Daali</surname><given-names>Y</given-names></name></person-group><article-title>Cytochrome P450 1A2 activity and incidence of thyroid disease and cancer after chronic or acute exposure to dioxins</article-title><source>Basic Clin Pharmacol Toxicol</source><year>2020</year><volume>126</volume><issue>3</issue><fpage>296</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1111/bcpt.13339</pub-id><pub-id pub-id-type="pmid">31608602</pub-id></element-citation></ref><ref id="CR406"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Satarug</surname><given-names>S</given-names></name><name name-style="western"><surname>Ujjin</surname><given-names>P</given-names></name><name name-style="western"><surname>Vanavanitkun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nishijo</surname><given-names>M</given-names></name><name name-style="western"><surname>Baker</surname><given-names>JR</given-names></name><name name-style="western"><surname>Moore</surname><given-names>MR</given-names></name></person-group><article-title>Effects of cigarette smoking and exposure to cadmium and lead on phenotypic variability of hepatic CYP2A6 and renal function biomarkers in men</article-title><source>Toxicology</source><year>2004</year><volume>204</volume><fpage>161</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">15388242</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tox.2004.06.022</pub-id></element-citation></ref><ref id="CR407"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Satarug</surname><given-names>S</given-names></name><name name-style="western"><surname>Nishijo</surname><given-names>M</given-names></name><name name-style="western"><surname>Ujjin</surname><given-names>P</given-names></name><name name-style="western"><surname>Vanavanitkun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Baker</surname><given-names>JR</given-names></name><name name-style="western"><surname>Moore</surname><given-names>MR</given-names></name></person-group><article-title>Effects of chronic exposure to low-level cadmium on renal tubular function and CYP2A6-mediated coumarin metabolism in healthy human subjects</article-title><source>Toxicol Lett</source><year>2004</year><volume>148</volume><fpage>187</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">15041069</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.toxlet.2003.10.028</pub-id></element-citation></ref><ref id="CR408"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saurat</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kaya</surname><given-names>G</given-names></name><name name-style="western"><surname>Saxer-Sekulic</surname><given-names>N</given-names></name><name name-style="western"><surname>Pardo</surname><given-names>B</given-names></name><name name-style="western"><surname>Becker</surname><given-names>M</given-names></name><name name-style="western"><surname>Fontao</surname><given-names>L</given-names></name><name name-style="western"><surname>Mottu</surname><given-names>F</given-names></name><name name-style="western"><surname>Carraux</surname><given-names>P</given-names></name><name name-style="western"><surname>Pham</surname><given-names>XC</given-names></name><name name-style="western"><surname>Barde</surname><given-names>C</given-names></name><name name-style="western"><surname>Fontao</surname><given-names>F</given-names></name><name name-style="western"><surname>Zennegg</surname><given-names>M</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>P</given-names></name><name name-style="western"><surname>Schaad</surname><given-names>O</given-names></name><name name-style="western"><surname>Descombes</surname><given-names>P</given-names></name><name name-style="western"><surname>Sorg</surname><given-names>O</given-names></name></person-group><article-title>The cutaneous lesions of dioxin exposure: lessons from the poisoning of Victor Yushchenko</article-title><source>Toxicol Sci</source><year>2012</year><volume>125</volume><fpage>310</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">21998131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/toxsci/kfr223</pub-id></element-citation></ref><ref id="CR409"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saussele</surname><given-names>T</given-names></name><name name-style="western"><surname>Burk</surname><given-names>O</given-names></name><name name-style="western"><surname>Blievernicht</surname><given-names>JK</given-names></name><name name-style="western"><surname>Klein</surname><given-names>K</given-names></name><name name-style="western"><surname>Nussler</surname><given-names>A</given-names></name><name name-style="western"><surname>Nussler</surname><given-names>N</given-names></name><name name-style="western"><surname>Hengstler</surname><given-names>JG</given-names></name><name name-style="western"><surname>Eichelbaum</surname><given-names>M</given-names></name><name name-style="western"><surname>Schwab</surname><given-names>M</given-names></name><name name-style="western"><surname>Zanger</surname><given-names>UM</given-names></name></person-group><article-title>Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole</article-title><source>Clin Pharmacol Ther</source><year>2007</year><volume>82</volume><fpage>265</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">17344806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.clpt.6100138</pub-id></element-citation></ref><ref id="CR410"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sax</surname><given-names>PE</given-names></name><name name-style="western"><surname>DeJesus</surname><given-names>E</given-names></name><name name-style="western"><surname>Crofoot</surname><given-names>G</given-names></name><name name-style="western"><surname>Ward</surname><given-names>D</given-names></name><name name-style="western"><surname>Benson</surname><given-names>P</given-names></name><name name-style="western"><surname>Dretler</surname><given-names>R</given-names></name><name name-style="western"><surname>Mills</surname><given-names>A</given-names></name><name name-style="western"><surname>Brinson</surname><given-names>C</given-names></name><name name-style="western"><surname>Peloquin</surname><given-names>J</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X</given-names></name><name name-style="western"><surname>White</surname><given-names>K</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>A</given-names></name><name name-style="western"><surname>Martin</surname><given-names>H</given-names></name><name name-style="western"><surname>Quirk</surname><given-names>E</given-names></name></person-group><article-title>Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial</article-title><source>Lancet HIV</source><year>2017</year><volume>4</volume><fpage>e154</fpage><lpage>e160</lpage><pub-id pub-id-type="pmid">28219610</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2352-3018(17)30016-4</pub-id></element-citation></ref><ref id="CR411"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheer</surname><given-names>N</given-names></name><name name-style="western"><surname>Ross</surname><given-names>J</given-names></name><name name-style="western"><surname>Rode</surname><given-names>A</given-names></name><name name-style="western"><surname>Zevnik</surname><given-names>B</given-names></name><name name-style="western"><surname>Niehaves</surname><given-names>S</given-names></name><name name-style="western"><surname>Faust</surname><given-names>N</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>CR</given-names></name></person-group><article-title>A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response</article-title><source>J Clin Investig</source><year>2008</year><volume>118</volume><fpage>3228</fpage><lpage>3239</lpage><pub-id pub-id-type="pmid">18677425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI35483</pub-id><pub-id pub-id-type="pmcid">PMC2493444</pub-id></element-citation></ref><ref id="CR412"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schellens</surname><given-names>JH</given-names></name><name name-style="western"><surname>van der Wart</surname><given-names>JH</given-names></name><name name-style="western"><surname>Brugman</surname><given-names>M</given-names></name><name name-style="western"><surname>Breimer</surname><given-names>DD</given-names></name></person-group><article-title>Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a &#8220;cocktail&#8221; study design</article-title><source>J Pharmacol Exp Ther</source><year>1989</year><volume>249</volume><fpage>638</fpage><lpage>645</lpage><pub-id pub-id-type="pmid">2724144</pub-id></element-citation></ref><ref id="CR413"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmitt-Hoffmann</surname><given-names>A</given-names></name><name name-style="western"><surname>Roos</surname><given-names>B</given-names></name><name name-style="western"><surname>Sauer</surname><given-names>J</given-names></name><name name-style="western"><surname>Spickermann</surname><given-names>J</given-names></name><name name-style="western"><surname>Maares</surname><given-names>J</given-names></name><name name-style="western"><surname>Schoetzau</surname><given-names>A</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>I</given-names></name></person-group><article-title>Pharmacokinetic interactions between alitretinoin and ketoconazole or simvastatin or ciclosporin A</article-title><source>Clin Exp Dermatol</source><year>2011</year><volume>36</volume><issue>Suppl 2</issue><fpage>24</fpage><lpage>28</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2230.2011.04034.x</pub-id><pub-id pub-id-type="pmid">21443601</pub-id></element-citation></ref><ref id="CR414"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scholler-Gyure</surname><given-names>M</given-names></name><name name-style="western"><surname>Kakuda</surname><given-names>TN</given-names></name><name name-style="western"><surname>Raoof</surname><given-names>A</given-names></name><name name-style="western"><surname>De Smedt</surname><given-names>G</given-names></name><name name-style="western"><surname>Hoetelmans</surname><given-names>RM</given-names></name></person-group><article-title>Clinical pharmacokinetics and pharmacodynamics of etravirine</article-title><source>Clin Pharmacokinet</source><year>2009</year><volume>48</volume><fpage>561</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">19725591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/10895940-000000000-00000</pub-id></element-citation></ref><ref id="CR415"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulz</surname><given-names>M</given-names></name><name name-style="western"><surname>Iwersen-Bergmann</surname><given-names>S</given-names></name><name name-style="western"><surname>Andresen</surname><given-names>H</given-names></name><name name-style="western"><surname>Schmoldt</surname><given-names>A</given-names></name></person-group><article-title>Therapeutic and toxic blood concentrations of nearly 1000 drugs and other xenobiotics</article-title><source>Crit Care</source><year>2012</year><volume>16</volume><fpage>R136</fpage><pub-id pub-id-type="pmid">22835221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/cc11441</pub-id><pub-id pub-id-type="pmcid">PMC3580721</pub-id></element-citation></ref><ref id="CR416"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulz</surname><given-names>M</given-names></name><name name-style="western"><surname>Schmoldt</surname><given-names>A</given-names></name><name name-style="western"><surname>Andresen-Streichert</surname><given-names>H</given-names></name><name name-style="western"><surname>Iwersen-Bergmann</surname><given-names>S</given-names></name></person-group><article-title>Revisited: therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics</article-title><source>Crit Care</source><year>2020</year><volume>24</volume><fpage>195</fpage><pub-id pub-id-type="pmid">32375836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-020-02915-5</pub-id><pub-id pub-id-type="pmcid">PMC7201985</pub-id></element-citation></ref><ref id="CR417"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwartzberg</surname><given-names>LS</given-names></name><name name-style="western"><surname>Yardley</surname><given-names>DA</given-names></name><name name-style="western"><surname>Elias</surname><given-names>AD</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M</given-names></name><name name-style="western"><surname>LoRusso</surname><given-names>P</given-names></name><name name-style="western"><surname>Burris</surname><given-names>HA</given-names></name><name name-style="western"><surname>Gucalp</surname><given-names>A</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>AC</given-names></name><name name-style="western"><surname>Blaney</surname><given-names>ME</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>JL</given-names></name><name name-style="western"><surname>Gibbons</surname><given-names>JA</given-names></name><name name-style="western"><surname>Traina</surname><given-names>TA</given-names></name></person-group><article-title>A phase I/Ib study of enzalutamide alone and in combination with endocrine therapies in women with advanced breast cancer</article-title><source>Clin Cancer Res</source><year>2017</year><volume>23</volume><fpage>4046</fpage><lpage>4054</lpage><pub-id pub-id-type="pmid">28280092</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-16-2339</pub-id></element-citation></ref><ref id="CR418"><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Sevior</surname><given-names>D</given-names></name><name name-style="western"><surname>Ahokas</surname><given-names>JT</given-names></name></person-group><person-group person-group-type="editor"><name name-style="western"><surname>Pelkonen</surname><given-names>O</given-names></name><name name-style="western"><surname>Duez</surname><given-names>P</given-names></name><name name-style="western"><surname>Vuorela</surname><given-names>H</given-names></name></person-group><article-title>Chapter 5: interactions between conventional and herbal medicinal products</article-title><source>Toxicology of herbal products</source><year>2017</year><publisher-loc>Switzerland</publisher-loc><publisher-name>Springer International Publishing</publisher-name><fpage>81</fpage><lpage>99</lpage></element-citation></ref><ref id="CR419"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shadle</surname><given-names>CR</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y</given-names></name><name name-style="western"><surname>Majumdar</surname><given-names>AK</given-names></name><name name-style="western"><surname>Petty</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Gargano</surname><given-names>C</given-names></name><name name-style="western"><surname>Bradstreet</surname><given-names>TE</given-names></name><name name-style="western"><surname>Evans</surname><given-names>JK</given-names></name><name name-style="western"><surname>Blum</surname><given-names>RA</given-names></name></person-group><article-title>Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity</article-title><source>J Clin Pharmacol</source><year>2004</year><volume>44</volume><fpage>215</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">14973304</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0091270003262950</pub-id></element-citation></ref><ref id="CR420"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shebley</surname><given-names>M</given-names></name><name name-style="western"><surname>Einolf</surname><given-names>HJ</given-names></name></person-group><article-title>Practical assessment of clinical drug&#8211;drug interactions in drug development using physiologically based pharmacokinetics modeling</article-title><source>Clin Pharmacol Ther</source><year>2019</year><volume>105</volume><fpage>1326</fpage><lpage>1328</lpage><pub-id pub-id-type="pmid">30893473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.1394</pub-id></element-citation></ref><ref id="CR421"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherman</surname><given-names>EM</given-names></name><name name-style="western"><surname>Worley</surname><given-names>MV</given-names></name><name name-style="western"><surname>Unger</surname><given-names>NR</given-names></name><name name-style="western"><surname>Gauthier</surname><given-names>TP</given-names></name><name name-style="western"><surname>Schafer</surname><given-names>JJ</given-names></name></person-group><article-title>Cobicistat: review of a pharmacokinetic enhancer for HIV infection</article-title><source>Clin Ther</source><year>2015</year><volume>37</volume><fpage>1876</fpage><lpage>1893</lpage><pub-id pub-id-type="pmid">26319088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinthera.2015.07.022</pub-id></element-citation></ref><ref id="CR422"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>JG</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Emm</surname><given-names>T</given-names></name><name name-style="western"><surname>Scherle</surname><given-names>PA</given-names></name><name name-style="western"><surname>McGee</surname><given-names>RF</given-names></name><name name-style="western"><surname>Lo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Landman</surname><given-names>RR</given-names></name><name name-style="western"><surname>McKeever</surname><given-names>EG</given-names></name><name name-style="western"><surname>Punwani</surname><given-names>NG</given-names></name><name name-style="western"><surname>Williams</surname><given-names>WV</given-names></name><name name-style="western"><surname>Yeleswaram</surname><given-names>S</given-names></name></person-group><article-title>The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers</article-title><source>J Clin Pharmacol</source><year>2012</year><volume>52</volume><fpage>809</fpage><lpage>818</lpage><pub-id pub-id-type="pmid">21602517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0091270011405663</pub-id></element-citation></ref><ref id="CR423"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shukla</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Sakamuru</surname><given-names>S</given-names></name><name name-style="western"><surname>Huang</surname><given-names>R</given-names></name><name name-style="western"><surname>Moeller</surname><given-names>TA</given-names></name><name name-style="western"><surname>Shinn</surname><given-names>P</given-names></name><name name-style="western"><surname>Vanleer</surname><given-names>D</given-names></name><name name-style="western"><surname>Auld</surname><given-names>DS</given-names></name><name name-style="western"><surname>Austin</surname><given-names>CP</given-names></name><name name-style="western"><surname>Xia</surname><given-names>M</given-names></name></person-group><article-title>Identification of clinically used drugs that activate pregnane X receptors</article-title><source>Drug Metab Dispos</source><year>2011</year><volume>39</volume><fpage>151</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">20966043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.110.035105</pub-id><pub-id pub-id-type="pmcid">PMC3014269</pub-id></element-citation></ref><ref id="CR424"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simonsson</surname><given-names>US</given-names></name><name name-style="western"><surname>Jansson</surname><given-names>B</given-names></name><name name-style="western"><surname>Hai</surname><given-names>TN</given-names></name><name name-style="western"><surname>Huong</surname><given-names>DX</given-names></name><name name-style="western"><surname>Tybring</surname><given-names>G</given-names></name><name name-style="western"><surname>Ashton</surname><given-names>M</given-names></name></person-group><article-title>Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9</article-title><source>Clin Pharmacol Ther</source><year>2003</year><volume>74</volume><fpage>32</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">12844133</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0009-9236(03)00092-4</pub-id></element-citation></ref><ref id="CR425"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinha</surname><given-names>R</given-names></name><name name-style="western"><surname>Rothman</surname><given-names>N</given-names></name><name name-style="western"><surname>Brown</surname><given-names>ED</given-names></name><name name-style="western"><surname>Mark</surname><given-names>SD</given-names></name><name name-style="western"><surname>Hoover</surname><given-names>RN</given-names></name><name name-style="western"><surname>Caporaso</surname><given-names>NE</given-names></name><name name-style="western"><surname>Levander</surname><given-names>OA</given-names></name><name name-style="western"><surname>Knize</surname><given-names>MG</given-names></name><name name-style="western"><surname>Lang</surname><given-names>NP</given-names></name><name name-style="western"><surname>Kadlubar</surname><given-names>FF</given-names></name></person-group><article-title>Pan-fried meat containing high levels of heterocyclic aromatic amines but low levels of polycyclic aromatic hydrocarbons induces cytochrome P4501A2 activity in humans</article-title><source>Cancer Res</source><year>1994</year><volume>54</volume><fpage>6154</fpage><lpage>6159</lpage><pub-id pub-id-type="pmid">7954461</pub-id></element-citation></ref><ref id="CR426"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinues</surname><given-names>B</given-names></name><name name-style="western"><surname>Fanlo</surname><given-names>A</given-names></name><name name-style="western"><surname>Mayayo</surname><given-names>E</given-names></name><name name-style="western"><surname>Carcas</surname><given-names>C</given-names></name><name name-style="western"><surname>Vicente</surname><given-names>J</given-names></name><name name-style="western"><surname>Arenaz</surname><given-names>I</given-names></name><name name-style="western"><surname>Cebollada</surname><given-names>A</given-names></name></person-group><article-title>CYP2A6 activity in a healthy Spanish population: effect of age, sex, smoking, and oral contraceptives</article-title><source>Hum Exp Toxicol</source><year>2008</year><volume>27</volume><fpage>367</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">18715882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0960327107082224</pub-id></element-citation></ref><ref id="CR427"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skerjanec</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Maren</surname><given-names>K</given-names></name><name name-style="western"><surname>Rojkjaer</surname><given-names>L</given-names></name></person-group><article-title>Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers</article-title><source>J Clin Pharmacol</source><year>2010</year><volume>50</volume><fpage>205</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">19940232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0091270009340418</pub-id></element-citation></ref><ref id="CR428"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slattery</surname><given-names>JT</given-names></name><name name-style="western"><surname>Kalhorn</surname><given-names>TF</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>GB</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>K</given-names></name><name name-style="western"><surname>Buckner</surname><given-names>CD</given-names></name><name name-style="western"><surname>Bensinger</surname><given-names>WI</given-names></name><name name-style="western"><surname>Anasetti</surname><given-names>C</given-names></name><name name-style="western"><surname>Appelbaum</surname><given-names>FR</given-names></name></person-group><article-title>Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients</article-title><source>J Clin Oncol</source><year>1996</year><volume>14</volume><fpage>1484</fpage><lpage>1494</lpage><pub-id pub-id-type="pmid">8622062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.1996.14.5.1484</pub-id></element-citation></ref><ref id="CR429"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>G</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>CR</given-names></name><name name-style="western"><surname>Deeni</surname><given-names>YY</given-names></name><name name-style="western"><surname>Dawe</surname><given-names>RS</given-names></name><name name-style="western"><surname>Evans</surname><given-names>AT</given-names></name><name name-style="western"><surname>Comrie</surname><given-names>MM</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>J</given-names></name><name name-style="western"><surname>Ibbotson</surname><given-names>SH</given-names></name></person-group><article-title>Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases</article-title><source>Lancet</source><year>2003</year><volume>361</volume><fpage>1336</fpage><lpage>1343</lpage><pub-id pub-id-type="pmid">12711469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(03)13081-4</pub-id></element-citation></ref><ref id="CR430"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>G</given-names></name><name name-style="western"><surname>Ibbotson</surname><given-names>SH</given-names></name><name name-style="western"><surname>Comrie</surname><given-names>MM</given-names></name><name name-style="western"><surname>Dawe</surname><given-names>RS</given-names></name><name name-style="western"><surname>Bryden</surname><given-names>A</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>J</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>CR</given-names></name></person-group><article-title>Regulation of cutaneous drug-metabolizing enzymes and cytoprotective gene expression by topical drugs in human skin in vivo</article-title><source>Br J Dermatol</source><year>2006</year><volume>155</volume><fpage>275</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">16882163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2006.07317.x</pub-id></element-citation></ref><ref id="CR431"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>DA</given-names></name><name name-style="western"><surname>Koch</surname><given-names>KM</given-names></name><name name-style="western"><surname>Arya</surname><given-names>N</given-names></name><name name-style="western"><surname>Bowen</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Herendeen</surname><given-names>JM</given-names></name><name name-style="western"><surname>Beelen</surname><given-names>A</given-names></name></person-group><article-title>Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects</article-title><source>Br J Clin Pharmacol</source><year>2009</year><volume>67</volume><fpage>421</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">19371315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2009.03370.x</pub-id><pub-id pub-id-type="pmcid">PMC2679105</pub-id></element-citation></ref><ref id="CR432"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>NF</given-names></name><name name-style="western"><surname>Mani</surname><given-names>S</given-names></name><name name-style="western"><surname>Schuetz</surname><given-names>EG</given-names></name><name name-style="western"><surname>Yasuda</surname><given-names>K</given-names></name><name name-style="western"><surname>Sissung</surname><given-names>TM</given-names></name><name name-style="western"><surname>Bates</surname><given-names>SE</given-names></name><name name-style="western"><surname>Figg</surname><given-names>WD</given-names></name><name name-style="western"><surname>Sparreboom</surname><given-names>A</given-names></name></person-group><article-title>3100585; Induction of CYP3A4 by vinblastine: role of the nuclear receptor NR1I2</article-title><source>Ann Pharmacother</source><year>2010</year><volume>44</volume><fpage>1709</fpage><lpage>1717</lpage><pub-id pub-id-type="pmid">20959500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1345/aph.1P354</pub-id><pub-id pub-id-type="pmcid">PMC3100585</pub-id></element-citation></ref><ref id="CR433"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>RP</given-names></name><name name-style="western"><surname>Eckalbar</surname><given-names>WL</given-names></name><name name-style="western"><surname>Morrissey</surname><given-names>KM</given-names></name><name name-style="western"><surname>Luizon</surname><given-names>MR</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Jones</surname><given-names>SL</given-names></name><name name-style="western"><surname>Force Aldred</surname><given-names>S</given-names></name><name name-style="western"><surname>Ramamoorthy</surname><given-names>A</given-names></name><name name-style="western"><surname>Desta</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Skaar</surname><given-names>TC</given-names></name><name name-style="western"><surname>Trinklein</surname><given-names>ND</given-names></name><name name-style="western"><surname>Giacomini</surname><given-names>KM</given-names></name><name name-style="western"><surname>Ahituv</surname><given-names>N</given-names></name></person-group><article-title>Genome-wide discovery of drug-dependent human liver regulatory elements</article-title><source>PLoS Genet</source><year>2014</year><volume>10</volume><fpage>e1004648</fpage><pub-id pub-id-type="pmid">25275310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pgen.1004648</pub-id><pub-id pub-id-type="pmcid">PMC4183418</pub-id></element-citation></ref><ref id="CR434"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smutny</surname><given-names>T</given-names></name><name name-style="western"><surname>Mani</surname><given-names>S</given-names></name><name name-style="western"><surname>Pavek</surname><given-names>P</given-names></name></person-group><article-title>Post-translational and post-transcriptional modifications of pregnane X receptor (PXR) in regulation of the cytochrome P450 superfamily</article-title><source>Curr Drug Metab</source><year>2013</year><volume>14</volume><fpage>1059</fpage><lpage>1069</lpage><pub-id pub-id-type="pmid">24329114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1389200214666131211153307</pub-id><pub-id pub-id-type="pmcid">PMC3914715</pub-id></element-citation></ref><ref id="CR435"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solas</surname><given-names>C</given-names></name><name name-style="western"><surname>Poizot-Martin</surname><given-names>I</given-names></name><name name-style="western"><surname>Drogoul</surname><given-names>MP</given-names></name><name name-style="western"><surname>Ravaux</surname><given-names>I</given-names></name><name name-style="western"><surname>Dhiver</surname><given-names>C</given-names></name><name name-style="western"><surname>Lafeuillade</surname><given-names>A</given-names></name><name name-style="western"><surname>Allegre</surname><given-names>T</given-names></name><name name-style="western"><surname>Mokhtari</surname><given-names>M</given-names></name><name name-style="western"><surname>Moreau</surname><given-names>J</given-names></name><name name-style="western"><surname>Lepeu</surname><given-names>G</given-names></name><name name-style="western"><surname>Petit</surname><given-names>N</given-names></name><name name-style="western"><surname>Durand</surname><given-names>A</given-names></name><name name-style="western"><surname>Lacarelle</surname><given-names>B</given-names></name></person-group><article-title>Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor</article-title><source>Br J Clin Pharmacol</source><year>2004</year><volume>57</volume><fpage>436</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">15025741</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2125.2003.02020.x</pub-id><pub-id pub-id-type="pmcid">PMC1884480</pub-id></element-citation></ref><ref id="CR436"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Veech</surname><given-names>RL</given-names></name><name name-style="western"><surname>Park</surname><given-names>SS</given-names></name><name name-style="western"><surname>Gelboin</surname><given-names>HV</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>FJ</given-names></name></person-group><article-title>Induction of rat hepatic <italic toggle="yes">N</italic>-nitrosodimethylamine demethylase by acetone is due to protein stabilization</article-title><source>J Biol Chem</source><year>1989</year><volume>264</volume><fpage>3568</fpage><lpage>3572</lpage><pub-id pub-id-type="pmid">2914964</pub-id></element-citation></ref><ref id="CR437"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sorf</surname><given-names>A</given-names></name><name name-style="western"><surname>Hofman</surname><given-names>J</given-names></name><name name-style="western"><surname>Ku&#269;era</surname><given-names>R</given-names></name><name name-style="western"><surname>Staud</surname><given-names>F</given-names></name><name name-style="western"><surname>Ceckova</surname><given-names>M</given-names></name></person-group><article-title>Ribociclib shows potential for pharmacokinetic drug&#8211;drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro</article-title><source>Biochem Pharmacol</source><year>2018</year><volume>154</volume><fpage>10</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">29673999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2018.04.013</pub-id></element-citation></ref><ref id="CR438"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stage</surname><given-names>TB</given-names></name><name name-style="western"><surname>Graff</surname><given-names>M</given-names></name><name name-style="western"><surname>Wong</surname><given-names>S</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>LL</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>F</given-names></name><name name-style="western"><surname>Pottegard</surname><given-names>A</given-names></name><name name-style="western"><surname>Brosen</surname><given-names>K</given-names></name><name name-style="western"><surname>Kroetz</surname><given-names>DL</given-names></name><name name-style="western"><surname>Khojasteh</surname><given-names>SC</given-names></name><name name-style="western"><surname>Damkier</surname><given-names>P</given-names></name></person-group><article-title>PMC5809358; Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro</article-title><source>Br J Clin Pharmacol</source><year>2018</year><volume>84</volume><fpage>510</fpage><lpage>519</lpage><pub-id pub-id-type="pmid">29105855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.13467</pub-id><pub-id pub-id-type="pmcid">PMC5809358</pub-id></element-citation></ref><ref id="CR439"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Staudinger</surname><given-names>JL</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Biswas</surname><given-names>A</given-names></name><name name-style="western"><surname>Mani</surname><given-names>S</given-names></name></person-group><article-title>Post-translational modification of pregnane X receptor</article-title><source>Pharmacol Res</source><year>2011</year><volume>64</volume><fpage>4</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">21397695</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2011.02.011</pub-id><pub-id pub-id-type="pmcid">PMC3111031</pub-id></element-citation></ref><ref id="CR440"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stresser</surname><given-names>DM</given-names></name><name name-style="western"><surname>Broudy</surname><given-names>MI</given-names></name><name name-style="western"><surname>Ho</surname><given-names>T</given-names></name><name name-style="western"><surname>Cargill</surname><given-names>CE</given-names></name><name name-style="western"><surname>Blanchard</surname><given-names>AP</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>R</given-names></name><name name-style="western"><surname>Dandeneau</surname><given-names>AA</given-names></name><name name-style="western"><surname>Goodwin</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Turner</surname><given-names>SD</given-names></name><name name-style="western"><surname>Erve</surname><given-names>JCL</given-names></name><name name-style="western"><surname>Patten</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Dehal</surname><given-names>SS</given-names></name><name name-style="western"><surname>Crespi</surname><given-names>CL</given-names></name></person-group><article-title>Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible</article-title><source>Drug Metab Dispos</source><year>2004</year><volume>32</volume><fpage>105</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">14709627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.32.1.105</pub-id></element-citation></ref><ref id="CR441"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stresser</surname><given-names>DM</given-names></name><name name-style="western"><surname>Perloff</surname><given-names>ES</given-names></name><name name-style="western"><surname>Mason</surname><given-names>AK</given-names></name><name name-style="western"><surname>Blanchard</surname><given-names>AP</given-names></name><name name-style="western"><surname>Dehal</surname><given-names>SS</given-names></name><name name-style="western"><surname>Creegan</surname><given-names>TP</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R</given-names></name><name name-style="western"><surname>Gangl</surname><given-names>ET</given-names></name></person-group><article-title>Selective time- and NADPH-dependent inhibition of human CYP2E1 by clomethiazole</article-title><source>Drug Metab Dispos</source><year>2016</year><volume>44</volume><fpage>1424</fpage><lpage>1430</lpage><pub-id pub-id-type="pmid">27149898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.116.070193</pub-id></element-citation></ref><ref id="CR442"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sugiyama</surname><given-names>M</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>K</given-names></name><name name-style="western"><surname>Murayama</surname><given-names>N</given-names></name><name name-style="western"><surname>Akiyama</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>H</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>Y</given-names></name></person-group><article-title>Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1&#8242;-hydroxylation</article-title><source>Drug Metab Dispos</source><year>2011</year><volume>39</volume><fpage>757</fpage><lpage>762</lpage><pub-id pub-id-type="pmid">21266595</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.110.037853</pub-id></element-citation></ref><ref id="CR443"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sui</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ai</surname><given-names>N</given-names></name><name name-style="western"><surname>Park</surname><given-names>SH</given-names></name><name name-style="western"><surname>Rios-Pilier</surname><given-names>J</given-names></name><name name-style="western"><surname>Perkins</surname><given-names>JT</given-names></name><name name-style="western"><surname>Welsh</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C</given-names></name></person-group><article-title>3295358; bisphenol A and its analogues activate human pregnane X receptor</article-title><source>Environ Health Perspect</source><year>2012</year><volume>120</volume><fpage>399</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">22214767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1289/ehp.1104426</pub-id><pub-id pub-id-type="pmcid">PMC3295358</pub-id></element-citation></ref><ref id="CR444"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suttle</surname><given-names>AB</given-names></name><name name-style="western"><surname>Grossmann</surname><given-names>KF</given-names></name><name name-style="western"><surname>Ouellet</surname><given-names>D</given-names></name><name name-style="western"><surname>Richards-Peterson</surname><given-names>L</given-names></name><name name-style="western"><surname>Aktan</surname><given-names>G</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>MS</given-names></name><name name-style="western"><surname>LoRusso</surname><given-names>PM</given-names></name><name name-style="western"><surname>Infante</surname><given-names>JR</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S</given-names></name><name name-style="western"><surname>Kendra</surname><given-names>K</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M</given-names></name><name name-style="western"><surname>Pant</surname><given-names>S</given-names></name><name name-style="western"><surname>Arkenau</surname><given-names>HT</given-names></name><name name-style="western"><surname>Middleton</surname><given-names>MR</given-names></name><name name-style="western"><surname>Blackman</surname><given-names>SC</given-names></name><name name-style="western"><surname>Botbyl</surname><given-names>J</given-names></name><name name-style="western"><surname>Carson</surname><given-names>SW</given-names></name></person-group><article-title>Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib</article-title><source>J Clin Pharmacol</source><year>2015</year><volume>55</volume><fpage>392</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">25449654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcph.437</pub-id></element-citation></ref><ref id="CR445"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name></person-group><article-title>Molecular basis of the Keap1-Nrf2 system</article-title><source>Free Radic Biol Med</source><year>2015</year><volume>88</volume><fpage>93</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">26117331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.freeradbiomed.2015.06.006</pub-id></element-citation></ref><ref id="CR446"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>H</given-names></name><name name-style="western"><surname>Kneller</surname><given-names>MB</given-names></name><name name-style="western"><surname>Haining</surname><given-names>RL</given-names></name><name name-style="western"><surname>Trager</surname><given-names>WF</given-names></name><name name-style="western"><surname>Rettie</surname><given-names>AE</given-names></name></person-group><article-title>(+)-<italic toggle="yes">N</italic>-3-benzyl-nirvanol and (&#8722;)-<italic toggle="yes">N</italic>-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19</article-title><source>Drug Metab Dispos</source><year>2002</year><volume>30</volume><fpage>235</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">11854139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.30.3.235</pub-id></element-citation></ref><ref id="CR447"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Svedberg</surname><given-names>A</given-names></name><name name-style="western"><surname>Vikingsson</surname><given-names>S</given-names></name><name name-style="western"><surname>Vikstrom</surname><given-names>A</given-names></name><name name-style="western"><surname>Hornstra</surname><given-names>N</given-names></name><name name-style="western"><surname>Kentson</surname><given-names>M</given-names></name><name name-style="western"><surname>Branden</surname><given-names>E</given-names></name><name name-style="western"><surname>Koyi</surname><given-names>H</given-names></name><name name-style="western"><surname>Bergman</surname><given-names>B</given-names></name><name name-style="western"><surname>Green</surname><given-names>H</given-names></name></person-group><article-title>Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients</article-title><source>Br J Clin Pharmacol</source><year>2019</year><volume>85</volume><fpage>1704</fpage><lpage>1709</lpage><pub-id pub-id-type="pmid">30945322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.13953</pub-id><pub-id pub-id-type="pmcid">PMC6624433</pub-id></element-citation></ref><ref id="CR448"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Svensson</surname><given-names>US</given-names></name><name name-style="western"><surname>Ashton</surname><given-names>M</given-names></name><name name-style="western"><surname>Trinh</surname><given-names>NH</given-names></name><name name-style="western"><surname>Bertilsson</surname><given-names>L</given-names></name><name name-style="western"><surname>Dinh</surname><given-names>XH</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>VH</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>TN</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>DS</given-names></name><name name-style="western"><surname>Lykkesfeldt</surname><given-names>J</given-names></name><name name-style="western"><surname>Le</surname><given-names>DC</given-names></name></person-group><article-title>Artemisinin induces omeprazole metabolism in human beings</article-title><source>Clin Pharmacol Ther</source><year>1998</year><volume>64</volume><fpage>160</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">9728896</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0009-9236(98)90149-7</pub-id></element-citation></ref><ref id="CR449"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swaisland</surname><given-names>HC</given-names></name><name name-style="western"><surname>Ranson</surname><given-names>M</given-names></name><name name-style="western"><surname>Smith</surname><given-names>RP</given-names></name><name name-style="western"><surname>Leadbetter</surname><given-names>J</given-names></name><name name-style="western"><surname>Laight</surname><given-names>A</given-names></name><name name-style="western"><surname>McKillop</surname><given-names>D</given-names></name><name name-style="western"><surname>Wild</surname><given-names>MJ</given-names></name></person-group><article-title>Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol</article-title><source>Clin Pharmacokinet</source><year>2005</year><volume>44</volume><fpage>1067</fpage><lpage>1081</lpage><pub-id pub-id-type="pmid">16176119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-200544100-00005</pub-id></element-citation></ref><ref id="CR450"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takahashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Lasker</surname><given-names>JM</given-names></name><name name-style="western"><surname>Rosman</surname><given-names>AS</given-names></name><name name-style="western"><surname>Lieber</surname><given-names>CS</given-names></name></person-group><article-title>Induction of cytochrome P-4502E1 in the human liver by ethanol is caused by a corresponding increase in encoding messenger RNA</article-title><source>Hepatology</source><year>1993</year><volume>17</volume><fpage>236</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">8428720</pub-id></element-citation></ref><ref id="CR451"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takakusa</surname><given-names>H</given-names></name><name name-style="western"><surname>Wahlin</surname><given-names>MD</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>KL</given-names></name><name name-style="western"><surname>New</surname><given-names>LS</given-names></name><name name-style="western"><surname>Chan</surname><given-names>ECY</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>SD</given-names></name></person-group><article-title>Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib</article-title><source>Drug Metab Dispos</source><year>2011</year><volume>39</volume><fpage>1022</fpage><lpage>1030</lpage><pub-id pub-id-type="pmid">21363997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.110.037531</pub-id><pub-id pub-id-type="pmcid">PMC3100900</pub-id></element-citation></ref><ref id="CR452"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takusagawa</surname><given-names>S</given-names></name><name name-style="western"><surname>Miyashita</surname><given-names>A</given-names></name><name name-style="western"><surname>Iwatsubo</surname><given-names>T</given-names></name><name name-style="western"><surname>Usui</surname><given-names>T</given-names></name></person-group><article-title>In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective &#946;3-adrenoceptor agonist</article-title><source>Xenobiotica</source><year>2012</year><volume>42</volume><fpage>1187</fpage><lpage>1196</lpage><pub-id pub-id-type="pmid">22834478</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/00498254.2012.700140</pub-id></element-citation></ref><ref id="CR453"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>AR</given-names></name><name name-style="western"><surname>Gibbon</surname><given-names>DG</given-names></name><name name-style="western"><surname>Stein</surname><given-names>MN</given-names></name><name name-style="western"><surname>Lindquist</surname><given-names>D</given-names></name><name name-style="western"><surname>Edenfield</surname><given-names>JW</given-names></name><name name-style="western"><surname>Martin</surname><given-names>JC</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>C</given-names></name><name name-style="western"><surname>Suttle</surname><given-names>AB</given-names></name><name name-style="western"><surname>Tada</surname><given-names>H</given-names></name><name name-style="western"><surname>Botbyl</surname><given-names>J</given-names></name><name name-style="western"><surname>Stephenson</surname><given-names>JJ</given-names></name></person-group><article-title>Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors</article-title><source>Cancer Chemother Pharmacol</source><year>2013</year><volume>71</volume><fpage>1635</fpage><lpage>1643</lpage><pub-id pub-id-type="pmid">23636448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-013-2164-3</pub-id></element-citation></ref><ref id="CR454"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>C</given-names></name></person-group><article-title>Clinical pharmacology of deferasirox</article-title><source>Clin Pharmacokinet</source><year>2014</year><volume>53</volume><fpage>679</fpage><lpage>694</lpage><pub-id pub-id-type="pmid">24996374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-014-0151-4</pub-id></element-citation></ref><ref id="CR455"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>C</given-names></name><name name-style="western"><surname>Yin</surname><given-names>OQP</given-names></name><name name-style="western"><surname>Smith</surname><given-names>T</given-names></name><name name-style="western"><surname>Sethuraman</surname><given-names>V</given-names></name><name name-style="western"><surname>Grouss</surname><given-names>K</given-names></name><name name-style="western"><surname>Galitz</surname><given-names>L</given-names></name><name name-style="western"><surname>Harrell</surname><given-names>R</given-names></name><name name-style="western"><surname>Schran</surname><given-names>H</given-names></name></person-group><article-title>Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants</article-title><source>J Clin Pharmacol</source><year>2011</year><volume>51</volume><fpage>75</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">20702754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0091270010367428</pub-id></element-citation></ref><ref id="CR456"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanner</surname><given-names>JA</given-names></name><name name-style="western"><surname>Tyndale</surname><given-names>RF</given-names></name></person-group><article-title>Variation in CYP2A6 activity and personalized medicine</article-title><source>J Pers Med</source><year>2017</year><volume>7</volume><issue>4</issue><fpage>18</fpage><pub-id pub-id-type="doi">10.3390/jpm7040018</pub-id><pub-id pub-id-type="pmcid">PMC5748630</pub-id><pub-id pub-id-type="pmid">29194389</pub-id></element-citation></ref><ref id="CR457"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tassaneeyakul</surname><given-names>W</given-names></name><name name-style="western"><surname>Guo</surname><given-names>LQ</given-names></name><name name-style="western"><surname>Fukuda</surname><given-names>K</given-names></name><name name-style="western"><surname>Ohta</surname><given-names>T</given-names></name><name name-style="western"><surname>Yamazoe</surname><given-names>Y</given-names></name></person-group><article-title>Inhibition selectivity of grapefruit juice components on human cytochromes P450</article-title><source>Arch Biochem Biophys</source><year>2000</year><volume>378</volume><fpage>356</fpage><lpage>363</lpage><pub-id pub-id-type="pmid">10860553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/abbi.2000.1835</pub-id></element-citation></ref><ref id="CR458"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teng</surname><given-names>WC</given-names></name><name name-style="western"><surname>Oh</surname><given-names>JW</given-names></name><name name-style="western"><surname>New</surname><given-names>LS</given-names></name><name name-style="western"><surname>Wahlin</surname><given-names>MD</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>SD</given-names></name><name name-style="western"><surname>Ho</surname><given-names>HK</given-names></name><name name-style="western"><surname>Chan</surname><given-names>ECY</given-names></name></person-group><article-title>Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib</article-title><source>Mol Pharmacol</source><year>2010</year><volume>78</volume><fpage>693</fpage><lpage>703</lpage><pub-id pub-id-type="pmid">20624855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/mol.110.065839</pub-id></element-citation></ref><ref id="CR459"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thelingwani</surname><given-names>RS</given-names></name><name name-style="western"><surname>Zvada</surname><given-names>SP</given-names></name><name name-style="western"><surname>Dolgos</surname><given-names>H</given-names></name><name name-style="western"><surname>Ungell</surname><given-names>AB</given-names></name><name name-style="western"><surname>Masimirembwa</surname><given-names>CM</given-names></name></person-group><article-title>In vitro and in silico identification and characterization of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug&#8211;drug interactions</article-title><source>Drug Metab Dispos</source><year>2009</year><volume>37</volume><fpage>1286</fpage><lpage>1294</lpage><pub-id pub-id-type="pmid">19299526</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.108.024604</pub-id></element-citation></ref><ref id="CR460"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thorn</surname><given-names>CF</given-names></name><name name-style="western"><surname>Aklillu</surname><given-names>E</given-names></name><name name-style="western"><surname>McDonagh</surname><given-names>EM</given-names></name><name name-style="western"><surname>Klein</surname><given-names>TE</given-names></name><name name-style="western"><surname>Altman</surname><given-names>RB</given-names></name></person-group><article-title>PharmGKB summary: caffeine pathway</article-title><source>Pharmacogenet Genom</source><year>2012</year><volume>22</volume><fpage>389</fpage><lpage>395</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FPC.0b013e3283505d5e</pub-id><pub-id pub-id-type="pmcid">PMC3381939</pub-id><pub-id pub-id-type="pmid">22293536</pub-id></element-citation></ref><ref id="CR461"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thum</surname><given-names>T</given-names></name><name name-style="western"><surname>Erpenbeck</surname><given-names>VJ</given-names></name><name name-style="western"><surname>Moeller</surname><given-names>J</given-names></name><name name-style="western"><surname>Hohlfeld</surname><given-names>JM</given-names></name><name name-style="western"><surname>Krug</surname><given-names>N</given-names></name><name name-style="western"><surname>Borlak</surname><given-names>J</given-names></name></person-group><article-title>Expression of xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers</article-title><source>Environ Health Perspect</source><year>2006</year><volume>114</volume><fpage>1655</fpage><lpage>1661</lpage><pub-id pub-id-type="pmid">17107849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1289/ehp.8861</pub-id><pub-id pub-id-type="pmcid">PMC1665420</pub-id></element-citation></ref><ref id="CR462"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thummel</surname><given-names>KE</given-names></name><name name-style="western"><surname>Shen</surname><given-names>DD</given-names></name><name name-style="western"><surname>Podoll</surname><given-names>TD</given-names></name><name name-style="western"><surname>Kunze</surname><given-names>KL</given-names></name><name name-style="western"><surname>Trager</surname><given-names>WF</given-names></name><name name-style="western"><surname>Hartwell</surname><given-names>PS</given-names></name><name name-style="western"><surname>Raisys</surname><given-names>VA</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>CL</given-names></name><name name-style="western"><surname>McVicar</surname><given-names>JP</given-names></name><name name-style="western"><surname>Barr</surname><given-names>DM</given-names></name></person-group><article-title>Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients</article-title><source>J Pharmacol Exp Ther</source><year>1994</year><volume>271</volume><fpage>549</fpage><lpage>556</lpage><pub-id pub-id-type="pmid">7965755</pub-id></element-citation></ref><ref id="CR463"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Heimbach</surname><given-names>T</given-names></name><name name-style="western"><surname>He</surname><given-names>H</given-names></name><name name-style="western"><surname>Buchbinder</surname><given-names>A</given-names></name><name name-style="western"><surname>Aghoghovbia</surname><given-names>M</given-names></name><name name-style="western"><surname>Hourcade-Potelleret</surname><given-names>F</given-names></name></person-group><article-title>Clinical pharmacokinetic and pharmacodynamic overview of nilotinib, a selective tyrosine kinase inhibitor</article-title><source>J Clin Pharmacol</source><year>2018</year><volume>58</volume><fpage>1533</fpage><lpage>1540</lpage><pub-id pub-id-type="pmid">30179260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcph.1312</pub-id></element-citation></ref><ref id="CR464"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tornio</surname><given-names>A</given-names></name><name name-style="western"><surname>Filppula</surname><given-names>AM</given-names></name><name name-style="western"><surname>Kailari</surname><given-names>O</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>M</given-names></name><name name-style="western"><surname>Nyr&#246;nen</surname><given-names>TH</given-names></name><name name-style="western"><surname>Tapaninen</surname><given-names>T</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Niemi</surname><given-names>M</given-names></name><name name-style="western"><surname>Backman</surname><given-names>JT</given-names></name></person-group><article-title>Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug&#8211;drug interactions</article-title><source>Clin Pharmacol Ther</source><year>2014</year><volume>96</volume><fpage>498</fpage><lpage>507</lpage><pub-id pub-id-type="pmid">24971633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2014.141</pub-id></element-citation></ref><ref id="CR465"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tornio</surname><given-names>A</given-names></name><name name-style="western"><surname>Filppula</surname><given-names>AM</given-names></name><name name-style="western"><surname>Niemi</surname><given-names>M</given-names></name><name name-style="western"><surname>Backman</surname><given-names>JT</given-names></name></person-group><article-title>Clinical studies on drug&#8211;drug interactions involving metabolism and transport: methodology, pitfalls, and interpretation</article-title><source>Clin Pharmacol Ther</source><year>2019</year><volume>105</volume><fpage>1345</fpage><lpage>1361</lpage><pub-id pub-id-type="pmid">30916389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.1435</pub-id><pub-id pub-id-type="pmcid">PMC6563007</pub-id></element-citation></ref><ref id="CR466"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Townsend</surname><given-names>R</given-names></name><name name-style="western"><surname>Dietz</surname><given-names>A</given-names></name><name name-style="western"><surname>Hale</surname><given-names>C</given-names></name><name name-style="western"><surname>Akhtar</surname><given-names>S</given-names></name><name name-style="western"><surname>Kowalski</surname><given-names>D</given-names></name><name name-style="western"><surname>Lademacher</surname><given-names>C</given-names></name><name name-style="western"><surname>Lasseter</surname><given-names>K</given-names></name><name name-style="western"><surname>Pearlman</surname><given-names>H</given-names></name><name name-style="western"><surname>Rammelsberg</surname><given-names>D</given-names></name><name name-style="western"><surname>Schmitt-Hoffmann</surname><given-names>A</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>T</given-names></name><name name-style="western"><surname>Desai</surname><given-names>A</given-names></name></person-group><article-title>Pharmacokinetic evaluation of CYP3A4-mediated drug&#8211;drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol/norethindrone in healthy adults</article-title><source>Clin Pharmacol Drug Dev</source><year>2017</year><volume>6</volume><fpage>44</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">27273461</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpdd.285</pub-id><pub-id pub-id-type="pmcid">PMC5298035</pub-id></element-citation></ref><ref id="CR467"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>A</given-names></name><name name-style="western"><surname>Rey</surname><given-names>E</given-names></name><name name-style="western"><surname>Pons</surname><given-names>G</given-names></name><name name-style="western"><surname>Rousseau</surname><given-names>M</given-names></name><name name-style="western"><surname>d&#8217;Athis</surname><given-names>P</given-names></name><name name-style="western"><surname>Olive</surname><given-names>G</given-names></name><name name-style="western"><surname>Mather</surname><given-names>GG</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>FE</given-names></name><name name-style="western"><surname>Wurden</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Labroo</surname><given-names>R</given-names></name><name name-style="western"><surname>Trager</surname><given-names>WF</given-names></name><name name-style="western"><surname>Kunze</surname><given-names>KL</given-names></name><name name-style="western"><surname>Thummel</surname><given-names>KE</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>JC</given-names></name><name name-style="western"><surname>Gillardin</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lepage</surname><given-names>F</given-names></name><name name-style="western"><surname>Levy</surname><given-names>RH</given-names></name></person-group><article-title>Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants</article-title><source>Clin Pharmacol Ther</source><year>1997</year><volume>62</volume><fpage>490</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">9390105</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0009-9236(97)90044-8</pub-id></element-citation></ref><ref id="CR468"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>JQ</given-names></name><name name-style="western"><surname>Kovacs</surname><given-names>SJ</given-names></name><name name-style="western"><surname>McIntosh</surname><given-names>TS</given-names></name><name name-style="western"><surname>Davis</surname><given-names>HM</given-names></name><name name-style="western"><surname>Martin</surname><given-names>DE</given-names></name></person-group><article-title>Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction</article-title><source>J Clin Pharmacol</source><year>1999</year><volume>39</volume><fpage>487</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">10234596</pub-id></element-citation></ref><ref id="CR469"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>JQ</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>C</given-names></name><name name-style="western"><surname>Garrett</surname><given-names>M</given-names></name><name name-style="western"><surname>Hee</surname><given-names>B</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>BM</given-names></name></person-group><article-title>Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir</article-title><source>Clin Pharmacol Ther</source><year>2002</year><volume>72</volume><fpage>615</fpage><lpage>626</lpage><pub-id pub-id-type="pmid">12496743</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2002.128868</pub-id></element-citation></ref><ref id="CR470"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>PC</given-names></name><name name-style="western"><surname>Glastonbury</surname><given-names>CA</given-names></name><name name-style="western"><surname>Eliot</surname><given-names>MN</given-names></name><name name-style="western"><surname>Bollepalli</surname><given-names>S</given-names></name><name name-style="western"><surname>Yet</surname><given-names>I</given-names></name><name name-style="western"><surname>Castillo-Fernandez</surname><given-names>J</given-names></name><name name-style="western"><surname>Carnero-Montoro</surname><given-names>E</given-names></name><name name-style="western"><surname>Hardiman</surname><given-names>T</given-names></name><name name-style="western"><surname>Martin</surname><given-names>TC</given-names></name><name name-style="western"><surname>Vickers</surname><given-names>A</given-names></name><name name-style="western"><surname>Mangino</surname><given-names>M</given-names></name><name name-style="western"><surname>Ward</surname><given-names>K</given-names></name><name name-style="western"><surname>Pietilainen</surname><given-names>KH</given-names></name><name name-style="western"><surname>Deloukas</surname><given-names>P</given-names></name><name name-style="western"><surname>Spector</surname><given-names>TD</given-names></name><name name-style="western"><surname>Vinuela</surname><given-names>A</given-names></name><name name-style="western"><surname>Loucks</surname><given-names>EB</given-names></name><name name-style="western"><surname>Ollikainen</surname><given-names>M</given-names></name><name name-style="western"><surname>Kelsey</surname><given-names>KT</given-names></name><name name-style="western"><surname>Small</surname><given-names>KS</given-names></name><name name-style="western"><surname>Bell</surname><given-names>JT</given-names></name></person-group><article-title>PMC6196025; Smoking induces coordinated DNA methylation and gene expression changes in adipose tissue with consequences for metabolic health</article-title><source>Clin Epigenet</source><year>2018</year><volume>10</volume><fpage>126</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13148-018-0558-0</pub-id><pub-id pub-id-type="pmcid">PMC6196025</pub-id><pub-id pub-id-type="pmid">30342560</pub-id></element-citation></ref><ref id="CR471"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tseng</surname><given-names>A</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>CA</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Seet</surname><given-names>J</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>EJ</given-names></name></person-group><article-title>Cobicistat versus ritonavir: similar pharmacokinetic enhancers but some important differences</article-title><source>Ann Pharmacother</source><year>2017</year><volume>51</volume><fpage>1008</fpage><lpage>1022</lpage><pub-id pub-id-type="pmid">28627229</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1060028017717018</pub-id><pub-id pub-id-type="pmcid">PMC5702580</pub-id></element-citation></ref><ref id="CR472"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsutsumi</surname><given-names>M</given-names></name><name name-style="western"><surname>Lasker</surname><given-names>JM</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>M</given-names></name><name name-style="western"><surname>Rosman</surname><given-names>AS</given-names></name><name name-style="western"><surname>Lieber</surname><given-names>CS</given-names></name></person-group><article-title>The intralobular distribution of ethanol-inducible P450IIE1 in rat and human liver</article-title><source>Hepatology</source><year>1989</year><volume>10</volume><fpage>437</fpage><lpage>446</lpage><pub-id pub-id-type="pmid">2673969</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.1840100407</pub-id></element-citation></ref><ref id="CR473"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tugnait</surname><given-names>M</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>N</given-names></name><name name-style="western"><surname>Hanley</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Sonnichsen</surname><given-names>D</given-names></name><name name-style="western"><surname>Kerstein</surname><given-names>D</given-names></name><name name-style="western"><surname>Dorer</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Venkatakrishnan</surname><given-names>K</given-names></name><name name-style="western"><surname>Narasimhan</surname><given-names>N</given-names></name></person-group><article-title>Effects of Strong CYP2C8 or CYP3A inhibition and CYP3A induction on the pharmacokinetics of brigatinib, an oral anaplastic lymphoma kinase inhibitor, in healthy volunteers</article-title><source>Clin Pharmacol Drug Dev</source><year>2020</year><volume>9</volume><fpage>214</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">31287236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpdd.723</pub-id><pub-id pub-id-type="pmcid">PMC7027746</pub-id></element-citation></ref><ref id="CR474"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turpeinen</surname><given-names>M</given-names></name><name name-style="western"><surname>Raunio</surname><given-names>H</given-names></name><name name-style="western"><surname>Pelkonen</surname><given-names>O</given-names></name></person-group><article-title>The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico</article-title><source>Curr Drug Metab</source><year>2006</year><volume>7</volume><fpage>705</fpage><lpage>714</lpage><pub-id pub-id-type="pmid">17073575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/138920006778520633</pub-id></element-citation></ref><ref id="CR475"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Udall</surname><given-names>JA</given-names></name></person-group><article-title>Clinical implications of warfarin interactions with five sedatives</article-title><source>Am J Cardiol</source><year>1975</year><volume>35</volume><fpage>67</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">1109248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0002-9149(75)90560-3</pub-id></element-citation></ref><ref id="CR476"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ullrich</surname><given-names>D</given-names></name><name name-style="western"><surname>Munzel</surname><given-names>PA</given-names></name><name name-style="western"><surname>Beck-Gschaidmeier</surname><given-names>S</given-names></name><name name-style="western"><surname>Schroder</surname><given-names>M</given-names></name><name name-style="western"><surname>Bock</surname><given-names>KW</given-names></name></person-group><article-title>Drug-metabolizing enzymes in pharyngeal mucosa and in oropharyngeal cancer tissue</article-title><source>Biochem Pharmacol</source><year>1997</year><volume>54</volume><fpage>1159</fpage><lpage>1162</lpage><pub-id pub-id-type="pmid">9464459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0006-2952(97)00347-x</pub-id></element-citation></ref><ref id="CR477"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Booven</surname><given-names>D</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>S</given-names></name><name name-style="western"><surname>McLeod</surname><given-names>H</given-names></name><name name-style="western"><surname>Carrillo</surname><given-names>MW</given-names></name><name name-style="western"><surname>Sangkuhl</surname><given-names>K</given-names></name><name name-style="western"><surname>Klein</surname><given-names>TE</given-names></name><name name-style="western"><surname>Altman</surname><given-names>RB</given-names></name></person-group><article-title>Cytochrome P450 2C9-CYP2C9</article-title><source>Pharmacogenet Genom</source><year>2010</year><volume>20</volume><fpage>277</fpage><lpage>281</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FPC.0b013e3283349e84</pub-id><pub-id pub-id-type="pmcid">PMC3201766</pub-id><pub-id pub-id-type="pmid">20150829</pub-id></element-citation></ref><ref id="CR478"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van den Bent</surname><given-names>Martin J</given-names></name><name name-style="western"><surname>Brandes</surname><given-names>AA</given-names></name><name name-style="western"><surname>Rampling</surname><given-names>R</given-names></name><name name-style="western"><surname>Kouwenhoven</surname><given-names>MCM</given-names></name><name name-style="western"><surname>Kros</surname><given-names>JM</given-names></name><name name-style="western"><surname>Carpentier</surname><given-names>AF</given-names></name><name name-style="western"><surname>Clement</surname><given-names>PM</given-names></name><name name-style="western"><surname>Frenay</surname><given-names>M</given-names></name><name name-style="western"><surname>Campone</surname><given-names>M</given-names></name><name name-style="western"><surname>Baurain</surname><given-names>J</given-names></name><name name-style="western"><surname>Armand</surname><given-names>J</given-names></name><name name-style="western"><surname>Taphoorn</surname><given-names>MJB</given-names></name><name name-style="western"><surname>Tosoni</surname><given-names>A</given-names></name><name name-style="western"><surname>Kletzl</surname><given-names>H</given-names></name><name name-style="western"><surname>Klughammer</surname><given-names>B</given-names></name><name name-style="western"><surname>Lacombe</surname><given-names>D</given-names></name><name name-style="western"><surname>Gorlia</surname><given-names>T</given-names></name></person-group><article-title>Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>1268</fpage><lpage>1274</lpage><pub-id pub-id-type="pmid">19204207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2008.17.5984</pub-id><pub-id pub-id-type="pmcid">PMC2667826</pub-id></element-citation></ref><ref id="CR479"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Duijnhoven</surname><given-names>EM</given-names></name><name name-style="western"><surname>Boots</surname><given-names>JM</given-names></name><name name-style="western"><surname>Christiaans</surname><given-names>MH</given-names></name><name name-style="western"><surname>Stolk</surname><given-names>LM</given-names></name><name name-style="western"><surname>Undre</surname><given-names>NA</given-names></name><name name-style="western"><surname>van Hooff</surname><given-names>JP</given-names></name></person-group><article-title>Increase in tacrolimus trough levels after steroid withdrawal</article-title><source>Transpl Int</source><year>2003</year><volume>16</volume><fpage>721</fpage><lpage>725</lpage><pub-id pub-id-type="pmid">12827231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00147-003-0615-1</pub-id></element-citation></ref><ref id="CR480"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Erp</surname><given-names>NP</given-names></name><name name-style="western"><surname>Guchelaar</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Ploeger</surname><given-names>BA</given-names></name><name name-style="western"><surname>Romijn</surname><given-names>JA</given-names></name><name name-style="western"><surname>Hartigh</surname><given-names>J</given-names></name><name name-style="western"><surname>Gelderblom</surname><given-names>H</given-names></name></person-group><article-title>Mitotane has a strong and a durable inducing effect on CYP3A4 activity</article-title><source>Eur J Endocrinol</source><year>2011</year><volume>164</volume><fpage>621</fpage><lpage>626</lpage><pub-id pub-id-type="pmid">21220434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1530/EJE-10-0956</pub-id></element-citation></ref><ref id="CR481"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Giersbergen</surname><given-names>PL</given-names></name><name name-style="western"><surname>Treiber</surname><given-names>A</given-names></name><name name-style="western"><surname>Clozel</surname><given-names>M</given-names></name><name name-style="western"><surname>Bodin</surname><given-names>F</given-names></name><name name-style="western"><surname>Dingemanse</surname><given-names>J</given-names></name></person-group><article-title>In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide</article-title><source>Clin Pharmacol Ther</source><year>2002</year><volume>71</volume><fpage>253</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">11956508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2002.122473</pub-id></element-citation></ref><ref id="CR482"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Leeuwen</surname><given-names>DM</given-names></name><name name-style="western"><surname>van Agen</surname><given-names>E</given-names></name><name name-style="western"><surname>Gottschalk</surname><given-names>RW</given-names></name><name name-style="western"><surname>Vlietinck</surname><given-names>R</given-names></name><name name-style="western"><surname>Gielen</surname><given-names>M</given-names></name><name name-style="western"><surname>van Herwijnen</surname><given-names>MH</given-names></name><name name-style="western"><surname>Maas</surname><given-names>LM</given-names></name><name name-style="western"><surname>Kleinjans</surname><given-names>JC</given-names></name><name name-style="western"><surname>van Delft</surname><given-names>JH</given-names></name></person-group><article-title>Cigarette smoke-induced differential gene expression in blood cells from monozygotic twin pairs</article-title><source>Carcinogenesis</source><year>2007</year><volume>28</volume><fpage>691</fpage><lpage>697</lpage><pub-id pub-id-type="pmid">17056606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/carcin/bgl199</pub-id></element-citation></ref><ref id="CR483"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Leeuwen</surname><given-names>RWF</given-names></name><name name-style="western"><surname>van Gelder</surname><given-names>T</given-names></name><name name-style="western"><surname>Mathijssen</surname><given-names>RHJ</given-names></name><name name-style="western"><surname>Jansman</surname><given-names>FGA</given-names></name></person-group><article-title>Drug&#8211;drug interactions with tyrosine-kinase inhibitors: a clinical perspective</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><fpage>315</fpage><pub-id pub-id-type="pmid">24988935</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(13)70579-5</pub-id></element-citation></ref><ref id="CR484"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varma</surname><given-names>MV</given-names></name><name name-style="western"><surname>Pang</surname><given-names>KS</given-names></name><name name-style="western"><surname>Isoherranen</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>P</given-names></name></person-group><article-title>Dealing with the complex drug&#8211;drug interactions: towards mechanistic models</article-title><source>Biopharm Drug Dispos</source><year>2015</year><volume>36</volume><fpage>71</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">25545151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bdd.1934</pub-id></element-citation></ref><ref id="CR485"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venkatakrishnan</surname><given-names>K</given-names></name><name name-style="western"><surname>Rostami-Hodjegan</surname><given-names>A</given-names></name></person-group><article-title>Come dance with me: transformative changes in the&#160;science and practice of drug&#8211;drug interactions</article-title><source>Clin Pharmacol Ther</source><year>2019</year><volume>105</volume><fpage>1272</fpage><lpage>1278</lpage><pub-id pub-id-type="pmid">31004453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.1433</pub-id></element-citation></ref><ref id="CR486"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villikka</surname><given-names>K</given-names></name><name name-style="western"><surname>Varis</surname><given-names>T</given-names></name><name name-style="western"><surname>Backman</surname><given-names>JT</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Kivisto</surname><given-names>KT</given-names></name></person-group><article-title>Effect of methylprednisolone on CYP3A4-mediated drug metabolism in vivo</article-title><source>Eur J Clin Pharmacol</source><year>2001</year><volume>57</volume><fpage>457</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">11699609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002280100340</pub-id></element-citation></ref><ref id="CR487"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vishwanathan</surname><given-names>K</given-names></name><name name-style="western"><surname>So</surname><given-names>K</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>K</given-names></name><name name-style="western"><surname>Bramley</surname><given-names>A</given-names></name><name name-style="western"><surname>English</surname><given-names>S</given-names></name><name name-style="western"><surname>Collier</surname><given-names>J</given-names></name></person-group><article-title>Absolute bioavailability of osimertinib in healthy adults</article-title><source>Clin Pharmacol Drug Dev</source><year>2019</year><volume>8</volume><fpage>198</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">29683562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpdd.467</pub-id></element-citation></ref><ref id="CR488"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vital Durand</surname><given-names>D</given-names></name><name name-style="western"><surname>Hampden</surname><given-names>C</given-names></name><name name-style="western"><surname>Boobis</surname><given-names>AR</given-names></name><name name-style="western"><surname>Park</surname><given-names>BK</given-names></name><name name-style="western"><surname>Davies</surname><given-names>DS</given-names></name></person-group><article-title>1400797; Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative</article-title><source>Br J Clin Pharmacol</source><year>1986</year><volume>21</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">3947503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1986.tb02816.x</pub-id><pub-id pub-id-type="pmcid">PMC1400797</pub-id></element-citation></ref><ref id="CR489"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vyhlidal</surname><given-names>CA</given-names></name><name name-style="western"><surname>Riffel</surname><given-names>AK</given-names></name><name name-style="western"><surname>Haley</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S</given-names></name><name name-style="western"><surname>Dai</surname><given-names>H</given-names></name><name name-style="western"><surname>Tantisira</surname><given-names>KG</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>ST</given-names></name><name name-style="western"><surname>Leeder</surname><given-names>JS</given-names></name></person-group><article-title>PMC3558855; Cotinine in human placenta predicts induction of gene expression in fetal tissues</article-title><source>Drug Metab Dispos</source><year>2013</year><volume>41</volume><fpage>305</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">23209192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.112.049999</pub-id><pub-id pub-id-type="pmcid">PMC3558855</pub-id></element-citation></ref><ref id="CR490"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>P</given-names></name><name name-style="western"><surname>Arya</surname><given-names>V</given-names></name><name name-style="western"><surname>Mullick</surname><given-names>C</given-names></name><name name-style="western"><surname>Struble</surname><given-names>K</given-names></name><name name-style="western"><surname>Au</surname><given-names>S</given-names></name></person-group><article-title>Physiologically Based pharmacokinetic modeling for predicting the effect of intrinsic and extrinsic factors on darunavir or lopinavir exposure coadministered with ritonavir</article-title><source>J Clin Pharmacol</source><year>2017</year><volume>57</volume><fpage>1295</fpage><lpage>1304</lpage><pub-id pub-id-type="pmid">28569994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcph.936</pub-id><pub-id pub-id-type="pmcid">PMC5591066</pub-id></element-citation></ref><ref id="CR491"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wakelee</surname><given-names>HA</given-names></name><name name-style="western"><surname>Takimoto</surname><given-names>CH</given-names></name><name name-style="western"><surname>Lopez-Anaya</surname><given-names>A</given-names></name><name name-style="western"><surname>Chu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Middleton</surname><given-names>G</given-names></name><name name-style="western"><surname>Dunlop</surname><given-names>D</given-names></name><name name-style="western"><surname>Ramlau</surname><given-names>R</given-names></name><name name-style="western"><surname>Leighl</surname><given-names>N</given-names></name><name name-style="western"><surname>Rowinsky</surname><given-names>EK</given-names></name><name name-style="western"><surname>Hao</surname><given-names>D</given-names></name><name name-style="western"><surname>Zatloukal</surname><given-names>P</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>CD</given-names></name><name name-style="western"><surname>Rodon</surname><given-names>J</given-names></name></person-group><article-title>The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer</article-title><source>Cancer Chemother Pharmacol</source><year>2012</year><volume>69</volume><fpage>563</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">22057855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-011-1772-z</pub-id></element-citation></ref><ref id="CR492"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsky</surname><given-names>RL</given-names></name><name name-style="western"><surname>Obach</surname><given-names>RS</given-names></name></person-group><article-title>A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1,1&#8242;,1&#8243;-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6</article-title><source>Drug Metab Dispos</source><year>2007</year><volume>35</volume><fpage>2053</fpage><lpage>2059</lpage><pub-id pub-id-type="pmid">17682072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.107.015883</pub-id></element-citation></ref><ref id="CR493"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walubo</surname><given-names>A</given-names></name><name name-style="western"><surname>Coetsee</surname><given-names>C</given-names></name><name name-style="western"><surname>Arti</surname><given-names>D</given-names></name><name name-style="western"><surname>Du Plessis</surname><given-names>JB</given-names></name></person-group><article-title>The effect of isoniazid containing regimen on CYP2E1 during antituberculosis therapy</article-title><source>Res Commun Mol Pathol Pharmacol</source><year>2005</year><volume>117&#8211;118</volume><fpage>137</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">18426085</pub-id></element-citation></ref><ref id="CR494"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name></person-group><article-title>Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development</article-title><source>Curr Med Chem</source><year>2009</year><volume>16</volume><fpage>4066</fpage><lpage>4218</lpage><pub-id pub-id-type="pmid">19754423</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/092986709789378198</pub-id></element-citation></ref><ref id="CR495"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>LS</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>B</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JG</given-names></name><name name-style="western"><surname>Abd El-Aty</surname><given-names>AM</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>TL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>XY</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>HH</given-names></name></person-group><article-title>St John&#8217;s wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole</article-title><source>Clin Pharmacol Ther</source><year>2004</year><volume>75</volume><fpage>191</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">15001970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clpt.2003.09.014</pub-id></element-citation></ref><ref id="CR496"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>LS</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>B</given-names></name><name name-style="western"><surname>Abd El-Aty</surname><given-names>AM</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>GL</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Tang</surname><given-names>ZR</given-names></name><name name-style="western"><surname>An</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>HH</given-names></name></person-group><article-title>The influence of St John&#8217;s Wort on CYP2C19 activity with respect to genotype</article-title><source>J Clin Pharmacol</source><year>2004</year><volume>44</volume><fpage>577</fpage><lpage>581</lpage><pub-id pub-id-type="pmid">15145964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0091270004265642</pub-id></element-citation></ref><ref id="CR497"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Xie</surname><given-names>W</given-names></name><name name-style="western"><surname>Wan</surname><given-names>YY</given-names></name></person-group><article-title>Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway</article-title><source>Biochem Pharmacol</source><year>2008</year><volume>75</volume><fpage>2204</fpage><lpage>2213</lpage><pub-id pub-id-type="pmid">18400206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2008.02.030</pub-id><pub-id pub-id-type="pmcid">PMC2742682</pub-id></element-citation></ref><ref id="CR498"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ong</surname><given-names>SS</given-names></name><name name-style="western"><surname>Chai</surname><given-names>SC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T</given-names></name></person-group><article-title>Role of CAR and PXR in xenobiotic sensing and metabolism</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2012</year><volume>8</volume><fpage>803</fpage><lpage>817</lpage><pub-id pub-id-type="pmid">22554043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/17425255.2012.685237</pub-id><pub-id pub-id-type="pmcid">PMC3593589</pub-id></element-citation></ref><ref id="CR499"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>S</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></name></person-group><article-title>Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy</article-title><source>Ther Clin Risk Manag</source><year>2015</year><volume>11</volume><fpage>449</fpage><lpage>467</lpage><pub-id pub-id-type="pmid">25848291</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/TCRM.S80437</pub-id><pub-id pub-id-type="pmcid">PMC4373598</pub-id></element-citation></ref><ref id="CR500"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>ZY</given-names></name><name name-style="western"><surname>Powers</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S</given-names></name><name name-style="western"><surname>Kansra</surname><given-names>V</given-names></name></person-group><article-title>Rolapitant absolute bioavailability and PET imaging studies in healthy adult volunteers</article-title><source>Clin Pharmacol Ther</source><year>2017</year><volume>102</volume><fpage>332</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">28139838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.637</pub-id></element-citation></ref><ref id="CR501"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>ZY</given-names></name><name name-style="western"><surname>Arora</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S</given-names></name><name name-style="western"><surname>Powers</surname><given-names>D</given-names></name><name name-style="western"><surname>Kansra</surname><given-names>V</given-names></name></person-group><article-title>Effects of rolapitant administered intravenously on the pharmacokinetics of a modified cooperstown cocktail (midazolam, omeprazole, warfarin, caffeine, and dextromethorphan) in healthy subjects</article-title><source>J Clin Pharmacol.</source><year>2018</year><pub-id pub-id-type="doi">10.1002/jcph.1114</pub-id><pub-id pub-id-type="pmid">29693712</pub-id></element-citation></ref><ref id="CR502"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sparidans</surname><given-names>RW</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Lebre</surname><given-names>MC</given-names></name><name name-style="western"><surname>Beijnen</surname><given-names>JH</given-names></name><name name-style="western"><surname>Schinkel</surname><given-names>AH</given-names></name></person-group><article-title>OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation</article-title><source>Br J Pharmacol</source><year>2020</year><volume>177</volume><fpage>3060</fpage><lpage>3074</lpage><pub-id pub-id-type="pmid">32087611</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bph.15034</pub-id><pub-id pub-id-type="pmcid">PMC7279963</pub-id></element-citation></ref><ref id="CR503"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watkins</surname><given-names>PB</given-names></name><name name-style="western"><surname>Murray</surname><given-names>SA</given-names></name><name name-style="western"><surname>Winkelman</surname><given-names>LG</given-names></name><name name-style="western"><surname>Heuman</surname><given-names>DM</given-names></name><name name-style="western"><surname>Wrighton</surname><given-names>SA</given-names></name><name name-style="western"><surname>Guzelian</surname><given-names>PS</given-names></name></person-group><article-title>Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients</article-title><source>J Clin Investig</source><year>1989</year><volume>83</volume><fpage>688</fpage><lpage>697</lpage><pub-id pub-id-type="pmid">2913056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI113933</pub-id><pub-id pub-id-type="pmcid">PMC303730</pub-id></element-citation></ref><ref id="CR504"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weber</surname><given-names>C</given-names></name><name name-style="western"><surname>Banken</surname><given-names>L</given-names></name><name name-style="western"><surname>Birnboeck</surname><given-names>H</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>R</given-names></name></person-group><article-title>Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin</article-title><source>J Clin Pharmacol</source><year>1999</year><volume>39</volume><fpage>847</fpage><lpage>854</lpage><pub-id pub-id-type="pmid">10434238</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/00912709922008380</pub-id></element-citation></ref><ref id="CR505"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weber</surname><given-names>C</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>R</given-names></name><name name-style="western"><surname>Birnboeck</surname><given-names>H</given-names></name><name name-style="western"><surname>Hopfgartner</surname><given-names>G</given-names></name><name name-style="western"><surname>Eggers</surname><given-names>H</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>J</given-names></name><name name-style="western"><surname>van Marle</surname><given-names>S</given-names></name><name name-style="western"><surname>Viischer</surname><given-names>HW</given-names></name><name name-style="western"><surname>Jonkman</surname><given-names>JH</given-names></name></person-group><article-title>Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers</article-title><source>J Clin Pharmacol</source><year>1999</year><volume>39</volume><fpage>703</fpage><lpage>714</lpage><pub-id pub-id-type="pmid">10392325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/00912709922008344</pub-id></element-citation></ref><ref id="CR506"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Backman</surname><given-names>JT</given-names></name></person-group><article-title>Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes</article-title><source>Eur J Clin Pharmacol</source><year>2002</year><volume>57</volume><fpage>799</fpage><lpage>804</lpage><pub-id pub-id-type="pmid">11868802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-001-0396-3</pub-id></element-citation></ref><ref id="CR507"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Werk</surname><given-names>EEJ</given-names></name><name name-style="western"><surname>Macgee</surname><given-names>J</given-names></name><name name-style="western"><surname>Sholiton</surname><given-names>LJ</given-names></name></person-group><article-title>441983; effect of diphenylhydantoin on cortisol metabolism in man</article-title><source>J Clin Investig</source><year>1964</year><volume>43</volume><fpage>1824</fpage><lpage>1835</lpage><pub-id pub-id-type="pmid">14207774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI105056</pub-id><pub-id pub-id-type="pmcid">PMC441983</pub-id></element-citation></ref><ref id="CR508"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wietholtz</surname><given-names>H</given-names></name><name name-style="western"><surname>Zysset</surname><given-names>T</given-names></name><name name-style="western"><surname>Kreiten</surname><given-names>K</given-names></name><name name-style="western"><surname>Kohl</surname><given-names>D</given-names></name><name name-style="western"><surname>Buchsel</surname><given-names>R</given-names></name><name name-style="western"><surname>Matern</surname><given-names>S</given-names></name></person-group><article-title>Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism</article-title><source>Eur J Clin Pharmacol</source><year>1989</year><volume>36</volume><fpage>401</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">2500346</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00558303</pub-id></element-citation></ref><ref id="CR509"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wietholtz</surname><given-names>H</given-names></name><name name-style="western"><surname>Zysset</surname><given-names>T</given-names></name><name name-style="western"><surname>Marschall</surname><given-names>HU</given-names></name><name name-style="western"><surname>Generet</surname><given-names>K</given-names></name><name name-style="western"><surname>Matern</surname><given-names>S</given-names></name></person-group><article-title>The influence of rifampin treatment on caffeine clearance in healthy man</article-title><source>J Hepatol</source><year>1995</year><volume>22</volume><fpage>78</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">7751591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0168-8278(95)80263-0</pub-id></element-citation></ref><ref id="CR510"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilby</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Greanya</surname><given-names>ED</given-names></name><name name-style="western"><surname>Ford</surname><given-names>JE</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>EM</given-names></name><name name-style="western"><surname>Partovi</surname><given-names>N</given-names></name></person-group><article-title>A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients</article-title><source>Ann Hepatol</source><year>2012</year><volume>11</volume><fpage>179</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">22345334</pub-id></element-citation></ref><ref id="CR511"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willey</surname><given-names>JC</given-names></name><name name-style="western"><surname>Coy</surname><given-names>EL</given-names></name><name name-style="western"><surname>Frampton</surname><given-names>MW</given-names></name><name name-style="western"><surname>Torres</surname><given-names>A</given-names></name><name name-style="western"><surname>Apostolakos</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Hoehn</surname><given-names>G</given-names></name><name name-style="western"><surname>Schuermann</surname><given-names>WH</given-names></name><name name-style="western"><surname>Thilly</surname><given-names>WG</given-names></name><name name-style="western"><surname>Olson</surname><given-names>DE</given-names></name><name name-style="western"><surname>Hammersley</surname><given-names>JR</given-names></name><name name-style="western"><surname>Crespi</surname><given-names>CL</given-names></name><name name-style="western"><surname>Utell</surname><given-names>MJ</given-names></name></person-group><article-title>Quantitative RT-PCR measurement of cytochromes p450 1A1, 1B1, and 2B7, microsomal epoxide hydrolase, and NADPH oxidoreductase expression in lung cells of smokers and nonsmokers</article-title><source>Am J Respir Cell Mol Biol</source><year>1997</year><volume>17</volume><fpage>114</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">9224217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1165/ajrcmb.17.1.2783</pub-id></element-citation></ref><ref id="CR512"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>ML</given-names></name><name name-style="western"><surname>Wainer</surname><given-names>IW</given-names></name><name name-style="western"><surname>Embree</surname><given-names>L</given-names></name><name name-style="western"><surname>Barnett</surname><given-names>M</given-names></name><name name-style="western"><surname>Granvil</surname><given-names>CL</given-names></name><name name-style="western"><surname>Ducharme</surname><given-names>MP</given-names></name></person-group><article-title>Enantioselective induction of cyclophosphamide metabolism by phenytoin</article-title><source>Chirality</source><year>1999</year><volume>11</volume><fpage>569</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">10423284</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1520-636X(1999)11:7&lt;569::AID-CHIR9&gt;3.0.CO;2-R</pub-id></element-citation></ref><ref id="CR513"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>JM</given-names></name><name name-style="western"><surname>Gandhi</surname><given-names>KK</given-names></name><name name-style="western"><surname>Benowitz</surname><given-names>NL</given-names></name></person-group><article-title>2952059; carbamazepine but not valproate induces CYP2A6 activity in smokers with mental illness</article-title><source>Cancer Epidemiol Biomark Prev</source><year>2010</year><volume>19</volume><fpage>2582</fpage><lpage>2589</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1055-9965.EPI-10-0384</pub-id><pub-id pub-id-type="pmcid">PMC2952059</pub-id><pub-id pub-id-type="pmid">20719908</pub-id></element-citation></ref><ref id="CR514"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williamson</surname><given-names>KM</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>JH</given-names></name><name name-style="western"><surname>McQueen</surname><given-names>RH</given-names></name><name name-style="western"><surname>Adams</surname><given-names>KFJ</given-names></name><name name-style="western"><surname>Pieper</surname><given-names>JA</given-names></name></person-group><article-title>Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers</article-title><source>Clin Pharmacol Ther</source><year>1998</year><volume>63</volume><fpage>316</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">9542475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0009-9236(98)90163-1</pub-id></element-citation></ref><ref id="CR515"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wind</surname><given-names>S</given-names></name><name name-style="western"><surname>Schnell</surname><given-names>D</given-names></name><name name-style="western"><surname>Ebner</surname><given-names>T</given-names></name><name name-style="western"><surname>Freiwald</surname><given-names>M</given-names></name><name name-style="western"><surname>Stopfer</surname><given-names>P</given-names></name></person-group><article-title>Clinical pharmacokinetics and pharmacodynamics of afatinib</article-title><source>Clin Pharmacokinet</source><year>2017</year><volume>56</volume><fpage>235</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">27470518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-016-0440-1</pub-id><pub-id pub-id-type="pmcid">PMC5315738</pub-id></element-citation></ref><ref id="CR516"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wongvijitsuk</surname><given-names>S</given-names></name><name name-style="western"><surname>Navasumrit</surname><given-names>P</given-names></name><name name-style="western"><surname>Vattanasit</surname><given-names>U</given-names></name><name name-style="western"><surname>Parnlob</surname><given-names>V</given-names></name><name name-style="western"><surname>Ruchirawat</surname><given-names>M</given-names></name></person-group><article-title>Low level occupational exposure to styrene: its effects on DNA damage and DNA repair</article-title><source>Int J Hyg Environ Health</source><year>2011</year><volume>214</volume><fpage>127</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">21030303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijheh.2010.09.007</pub-id></element-citation></ref><ref id="CR517"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>KC</given-names></name><name name-style="western"><surname>Cui</surname><given-names>JY</given-names></name><name name-style="western"><surname>Klaassen</surname><given-names>CD</given-names></name></person-group><article-title>Effect of graded Nrf2 activation on phase-I and -II drug metabolizing enzymes and transporters in mouse liver</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e39006</fpage><pub-id pub-id-type="pmid">22808024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0039006</pub-id><pub-id pub-id-type="pmcid">PMC3395627</pub-id></element-citation></ref><ref id="CR518"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>H</given-names></name><name name-style="western"><surname>Karnik</surname><given-names>S</given-names></name><name name-style="western"><surname>Subhadarshini</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Philips</surname><given-names>S</given-names></name><name name-style="western"><surname>Han</surname><given-names>X</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Boustani</surname><given-names>M</given-names></name><name name-style="western"><surname>Rocha</surname><given-names>LM</given-names></name><name name-style="western"><surname>Quinney</surname><given-names>SK</given-names></name><name name-style="western"><surname>Flockhart</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name></person-group><article-title>An integrated pharmacokinetics ontology and corpus for text mining</article-title><source>BMC Bioinform</source><year>2013</year><volume>14</volume><fpage>35</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2105-14-35</pub-id><pub-id pub-id-type="pmcid">PMC3571923</pub-id><pub-id pub-id-type="pmid">23374886</pub-id></element-citation></ref><ref id="CR519"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>CQ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tan</surname><given-names>ZR</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>HH</given-names></name></person-group><article-title>Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants</article-title><source>Xenobiotica</source><year>2012</year><volume>42</volume><fpage>173</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">21943317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/00498254.2011.615954</pub-id></element-citation></ref><ref id="CR520"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hashizume</surname><given-names>T</given-names></name><name name-style="western"><surname>Shuhart</surname><given-names>MC</given-names></name><name name-style="western"><surname>Davis</surname><given-names>CL</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>WL</given-names></name><name name-style="western"><surname>Sakaki</surname><given-names>T</given-names></name><name name-style="western"><surname>Kalhorn</surname><given-names>TF</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>PB</given-names></name><name name-style="western"><surname>Schuetz</surname><given-names>EG</given-names></name><name name-style="western"><surname>Thummel</surname><given-names>KE</given-names></name></person-group><article-title>Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia</article-title><source>Mol Pharmacol</source><year>2006</year><volume>69</volume><fpage>56</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">16207822</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/mol.105.017392</pub-id></element-citation></ref><ref id="CR521"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>J</given-names></name><name name-style="western"><surname>Korzekwa</surname><given-names>K</given-names></name><name name-style="western"><surname>Nagar</surname><given-names>S</given-names></name></person-group><article-title>Improved predictions of drug&#8211;drug interactions mediated by time-dependent inhibition of CYP3A</article-title><source>Mol Pharm</source><year>2018</year><volume>15</volume><fpage>1979</fpage><lpage>1995</lpage><pub-id pub-id-type="pmid">29608318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.molpharmaceut.8b00129</pub-id><pub-id pub-id-type="pmcid">PMC5938745</pub-id></element-citation></ref><ref id="CR522"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamano</surname><given-names>S</given-names></name><name name-style="western"><surname>Tatsuno</surname><given-names>J</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>FJ</given-names></name></person-group><article-title>The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes</article-title><source>Biochemistry</source><year>1990</year><volume>29</volume><fpage>1322</fpage><lpage>1329</lpage><pub-id pub-id-type="pmid">2322567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/bi00457a031</pub-id></element-citation></ref><ref id="CR523"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamazaki</surname><given-names>T</given-names></name><name name-style="western"><surname>Desai</surname><given-names>A</given-names></name><name name-style="western"><surname>Goldwater</surname><given-names>R</given-names></name><name name-style="western"><surname>Han</surname><given-names>D</given-names></name><name name-style="western"><surname>Howieson</surname><given-names>C</given-names></name><name name-style="western"><surname>Akhtar</surname><given-names>S</given-names></name><name name-style="western"><surname>Kowalski</surname><given-names>D</given-names></name><name name-style="western"><surname>Lademacher</surname><given-names>C</given-names></name><name name-style="western"><surname>Pearlman</surname><given-names>H</given-names></name><name name-style="western"><surname>Rammelsberg</surname><given-names>D</given-names></name><name name-style="western"><surname>Townsend</surname><given-names>R</given-names></name></person-group><article-title>Pharmacokinetic effects of isavuconazole coadministration with the cytochrome P450 enzyme substrates bupropion, repaglinide, caffeine, dextromethorphan, and methadone in healthy subjects</article-title><source>Clin Pharmacol Drug Dev</source><year>2017</year><volume>6</volume><fpage>54</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">27273149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpdd.281</pub-id><pub-id pub-id-type="pmcid">PMC5297975</pub-id></element-citation></ref><ref id="CR524"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yasui-Furukori</surname><given-names>N</given-names></name><name name-style="western"><surname>Takahata</surname><given-names>T</given-names></name><name name-style="western"><surname>Nakagami</surname><given-names>T</given-names></name><name name-style="western"><surname>Yoshiya</surname><given-names>G</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kaneko</surname><given-names>S</given-names></name><name name-style="western"><surname>Tateishi</surname><given-names>T</given-names></name></person-group><article-title>Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes</article-title><source>Br J Clin Pharmacol</source><year>2004</year><volume>57</volume><fpage>487</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">15025747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2004.02047.x</pub-id><pub-id pub-id-type="pmcid">PMC1884483</pub-id></element-citation></ref><ref id="CR525"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeh</surname><given-names>RF</given-names></name><name name-style="western"><surname>Gaver</surname><given-names>VE</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>KB</given-names></name><name name-style="western"><surname>Rezk</surname><given-names>NL</given-names></name><name name-style="western"><surname>Baxter-Meheux</surname><given-names>F</given-names></name><name name-style="western"><surname>Blake</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Eron</surname><given-names>JJJ</given-names></name><name name-style="western"><surname>Klein</surname><given-names>CE</given-names></name><name name-style="western"><surname>Rublein</surname><given-names>JC</given-names></name><name name-style="western"><surname>Kashuba</surname><given-names>AD</given-names></name></person-group><article-title>Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers</article-title><source>J Acquir Immune Defic Syndr</source><year>2006</year><volume>42</volume><fpage>52</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">16639344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.qai.0000219774.20174.64</pub-id></element-citation></ref><ref id="CR526"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>OQP</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>N</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W</given-names></name><name name-style="western"><surname>Leroy</surname><given-names>E</given-names></name><name name-style="western"><surname>Golor</surname><given-names>G</given-names></name><name name-style="western"><surname>Schran</surname><given-names>H</given-names></name></person-group><article-title>Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects</article-title><source>Clin Drug Investig</source><year>2011</year><volume>31</volume><fpage>169</fpage><lpage>179</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/11538700-000000000-00000</pub-id><pub-id pub-id-type="pmid">21184622</pub-id></element-citation></ref><ref id="CR527"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yokota</surname><given-names>S</given-names></name><name name-style="western"><surname>Higashi</surname><given-names>E</given-names></name><name name-style="western"><surname>Fukami</surname><given-names>T</given-names></name><name name-style="western"><surname>Yokoi</surname><given-names>T</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>M</given-names></name></person-group><article-title>Human CYP2A6 is regulated by nuclear factor-erythroid 2 related factor 2</article-title><source>Biochem Pharmacol</source><year>2011</year><volume>81</volume><fpage>289</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">20887713</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2010.09.020</pub-id></element-citation></ref><ref id="CR528"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshida</surname><given-names>N</given-names></name><name name-style="western"><surname>Oda</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nishi</surname><given-names>S</given-names></name><name name-style="western"><surname>Abe</surname><given-names>J</given-names></name><name name-style="western"><surname>Kaji</surname><given-names>A</given-names></name><name name-style="western"><surname>Asada</surname><given-names>A</given-names></name><name name-style="western"><surname>Fujimori</surname><given-names>M</given-names></name></person-group><article-title>Effect of barbiturate therapy on phenytoin pharmacokinetics</article-title><source>Crit Care Med</source><year>1993</year><volume>21</volume><fpage>1514</fpage><lpage>1522</lpage><pub-id pub-id-type="pmid">8403961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00003246-199310000-00020</pub-id></element-citation></ref><ref id="CR529"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshida</surname><given-names>K</given-names></name><name name-style="western"><surname>Maeda</surname><given-names>K</given-names></name><name name-style="western"><surname>Konagaya</surname><given-names>A</given-names></name><name name-style="western"><surname>Kusuhara</surname><given-names>H</given-names></name></person-group><article-title>Accurate estimation of in vivo inhibition constants of inhibitors and fraction metabolized of substrates with physiologically based pharmacokinetic drug&#8211;drug interaction models incorporating parent drugs and metabolites of substrates with cluster newton method</article-title><source>Drug Metab Dispos</source><year>2018</year><volume>46</volume><fpage>1805</fpage><lpage>1816</lpage><pub-id pub-id-type="pmid">30135241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.118.081828</pub-id></element-citation></ref><ref id="CR530"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>TK</given-names></name><name name-style="western"><surname>Mulgaonkar</surname><given-names>A</given-names></name><name name-style="western"><surname>Ragueneau-Majlessi</surname><given-names>I</given-names></name></person-group><article-title>Drug disposition and drug&#8211;drug interaction data in 2013 FDA new drug applications: a systematic review</article-title><source>Drug Metab Dispos</source><year>2014</year><volume>42</volume><fpage>1991</fpage><lpage>2001</lpage><pub-id pub-id-type="pmid">25271211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.114.060392</pub-id></element-citation></ref><ref id="CR531"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>A</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tu</surname><given-names>M</given-names></name><name name-style="western"><surname>Ho</surname><given-names>PY</given-names></name><name name-style="western"><surname>Jilek</surname><given-names>JL</given-names></name></person-group><article-title>MicroRNA pharmacoepigenetics: posttranscriptional regulation mechanisms behind variable drug disposition and strategy to develop more effective therapy</article-title><source>Drug Metab Dispos</source><year>2016</year><volume>44</volume><fpage>308</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">26566807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.115.067470</pub-id><pub-id pub-id-type="pmcid">PMC4767381</pub-id></element-citation></ref><ref id="CR532"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>TK</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ragueneau-Majlessi</surname><given-names>I</given-names></name></person-group><article-title>Key findings from preclinical and clinical drug interaction studies presented in new drug and biological license applications approved by the food and drug administration in 2014</article-title><source>Drug Metab Dispos</source><year>2016</year><volume>44</volume><fpage>83</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">26424199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.115.066720</pub-id></element-citation></ref><ref id="CR533"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Owens</surname><given-names>KH</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>TK</given-names></name><name name-style="western"><surname>Ragueneau-Majlessi</surname><given-names>I</given-names></name></person-group><article-title>What can be learned from recent new drug applications? A systematic review of drug interaction data for drugs approved by the US FDA in 2015</article-title><source>Drug Metab Dispos</source><year>2017</year><volume>45</volume><fpage>86</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">27821435</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.116.073411</pub-id></element-citation></ref><ref id="CR534"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Loi</surname><given-names>C</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name></person-group><article-title>Physiologically Based Pharmacokinetic Modeling Of Palbociclib</article-title><source>J Clin Pharmacol</source><year>2017</year><volume>57</volume><fpage>173</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">27402157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcph.792</pub-id></element-citation></ref><ref id="CR535"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tay-Sontheimer</surname><given-names>J</given-names></name><name name-style="western"><surname>Levy</surname><given-names>RH</given-names></name><name name-style="western"><surname>Ragueneau-Majlessi</surname><given-names>I</given-names></name></person-group><article-title>Risk of clinically relevant pharmacokinetic-based drug&#8211;drug interactions with drugs approved by the U.S. Food and Drug Administration between 2013 and 2016</article-title><source>Drug Metab Dispos</source><year>2018</year><volume>46</volume><fpage>835</fpage><lpage>845</lpage><pub-id pub-id-type="pmid">29572333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.117.078691</pub-id></element-citation></ref><ref id="CR536"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Petrie</surname><given-names>ID</given-names></name><name name-style="western"><surname>Levy</surname><given-names>RH</given-names></name><name name-style="western"><surname>Ragueneau-Majlessi</surname><given-names>I</given-names></name></person-group><article-title>Mechanisms and clinical significance of pharmacokinetic-based drug&#8211;drug interactions with drugs approved by the U.S. Food and Drug Administration in 2017</article-title><source>Drug Metab Dispos</source><year>2019</year><volume>47</volume><fpage>135</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">30442649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.118.084905</pub-id></element-citation></ref><ref id="CR537"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zaccara</surname><given-names>G</given-names></name><name name-style="western"><surname>Gangemi</surname><given-names>PF</given-names></name><name name-style="western"><surname>Bendoni</surname><given-names>L</given-names></name><name name-style="western"><surname>Menge</surname><given-names>GP</given-names></name><name name-style="western"><surname>Schwabe</surname><given-names>S</given-names></name><name name-style="western"><surname>Monza</surname><given-names>GC</given-names></name></person-group><article-title>Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine</article-title><source>Ther Drug Monit</source><year>1993</year><volume>15</volume><fpage>39</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">8451779</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007691-199302000-00007</pub-id></element-citation></ref><ref id="CR538"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zand</surname><given-names>R</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>SD</given-names></name><name name-style="western"><surname>Slattery</surname><given-names>JT</given-names></name><name name-style="western"><surname>Thummel</surname><given-names>KE</given-names></name><name name-style="western"><surname>Kalhorn</surname><given-names>TF</given-names></name><name name-style="western"><surname>Adams</surname><given-names>SP</given-names></name><name name-style="western"><surname>Wright</surname><given-names>JM</given-names></name></person-group><article-title>Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans</article-title><source>Clin Pharmacol Ther</source><year>1993</year><volume>54</volume><fpage>142</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">8354023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.1993.125</pub-id></element-citation></ref><ref id="CR539"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zang</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>F</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>A</given-names></name><name name-style="western"><surname>Xing</surname><given-names>J</given-names></name></person-group><article-title>PMC4055232; auto-induction of phase I and phase II metabolism of artemisinin in healthy Chinese subjects after oral administration of a new artemisinin&#8211;piperaquine fixed combination</article-title><source>Malar J</source><year>2014</year><volume>13</volume><fpage>214</fpage><pub-id pub-id-type="pmid">24889062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-13-214</pub-id><pub-id pub-id-type="pmcid">PMC4055232</pub-id></element-citation></ref><ref id="CR540"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zanger</surname><given-names>UM</given-names></name><name name-style="western"><surname>Schwab</surname><given-names>M</given-names></name></person-group><article-title>Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation</article-title><source>Pharmacol Ther</source><year>2013</year><volume>138</volume><fpage>103</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">23333322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2012.12.007</pub-id></element-citation></ref><ref id="CR541"><mixed-citation publication-type="other">Zhang H, Custodio JM, Wei X, Wang H, Vu A, Ling J, Martin H, Quirk E, Kearney BP (2017) Clinical pharmacology of the HIV integrase strand transfer inhibitor bictegravir. In: Conference on retroviruses and opportunistic infections: abstract 40</mixed-citation></ref><ref id="CR542"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Heinzmann</surname><given-names>D</given-names></name><name name-style="western"><surname>Grippo</surname><given-names>JF</given-names></name></person-group><article-title>Clinical pharmacokinetics of vemurafenib</article-title><source>Clin Pharmacokinet</source><year>2017</year><volume>56</volume><fpage>1033</fpage><lpage>1043</lpage><pub-id pub-id-type="pmid">28255850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-017-0523-7</pub-id></element-citation></ref><ref id="CR543"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>C</given-names></name><name name-style="western"><surname>Forbes</surname><given-names>H</given-names></name><name name-style="western"><surname>Gaafar</surname><given-names>R</given-names></name><name name-style="western"><surname>Kohail</surname><given-names>H</given-names></name><name name-style="western"><surname>Beck</surname><given-names>JT</given-names></name><name name-style="western"><surname>Plestina</surname><given-names>S</given-names></name><name name-style="western"><surname>Bertran</surname><given-names>E</given-names></name><name name-style="western"><surname>Riehl</surname><given-names>T</given-names></name></person-group><article-title>Effect of rifampicin on the pharmacokinetics of a single dose of vemurafenib in patients with BRAFV600 mutation-positive metastatic malignancy</article-title><source>Clin Pharmacol Drug Dev</source><year>2019</year><volume>8</volume><fpage>837</fpage><lpage>843</lpage><pub-id pub-id-type="pmid">30570831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpdd.643</pub-id></element-citation></ref><ref id="CR544"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y</given-names></name></person-group><article-title>Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials</article-title><source>Lung Cancer</source><year>2018</year><volume>122</volume><fpage>10</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">30032815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lungcan.2018.05.011</pub-id></element-citation></ref><ref id="CR545"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>D</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Chu</surname><given-names>M</given-names></name><name name-style="western"><surname>Long</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Pharmacokinetic-based drug&#8211;drug interactions with anaplastic lymphoma kinase inhibitors: a review</article-title><source>Drug Des Devel Ther</source><year>2020</year><volume>14</volume><fpage>1663</fpage><lpage>1681</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DDDT.S249098</pub-id><pub-id pub-id-type="pmcid">PMC7198400</pub-id><pub-id pub-id-type="pmid">32431491</pub-id></element-citation></ref><ref id="CR546"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>SF</given-names></name></person-group><article-title>Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4</article-title><source>Curr Drug Metab</source><year>2008</year><volume>9</volume><fpage>310</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">18473749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/138920008784220664</pub-id></element-citation></ref><ref id="CR547"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>HH</given-names></name><name name-style="western"><surname>Anthony</surname><given-names>LB</given-names></name><name name-style="western"><surname>Wood</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>GR</given-names></name></person-group><article-title>1368151; Induction of polymorphic 4&#8242;-hydroxylation of S-mephenytoin by rifampicin</article-title><source>Br J Clin Pharmacol</source><year>1990</year><volume>30</volume><fpage>471</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">2223426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1990.tb03799.x</pub-id><pub-id pub-id-type="pmcid">PMC1368151</pub-id></element-citation></ref><ref id="CR1004"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>SF</given-names></name><name name-style="western"><surname>Yang</surname><given-names>LP</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>ZW</given-names></name><name name-style="western"><surname>Liu</surname><given-names>YH</given-names></name><name name-style="western"><surname>Chan</surname><given-names>E</given-names></name></person-group><article-title>Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2</article-title><source>AAPS J</source><year>2009</year><volume>11</volume><issue>3</issue><fpage>481</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1208/s12248-009-9127-y</pub-id><pub-id pub-id-type="pmid">19590965</pub-id><pub-id pub-id-type="pmcid">PMC2758120</pub-id></element-citation></ref><ref id="CR548"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>CH</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Yu</surname><given-names>HB</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>XT</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>ZF</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>LT</given-names></name></person-group><article-title>Effects of Danshen capsules on the pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers</article-title><source>Food Chem Toxicol</source><year>2018</year><volume>119</volume><fpage>302</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">29496531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.fct.2018.02.051</pub-id></element-citation></ref><ref id="CR549"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zilly</surname><given-names>W</given-names></name><name name-style="western"><surname>Breimer</surname><given-names>DD</given-names></name><name name-style="western"><surname>Richter</surname><given-names>E</given-names></name></person-group><article-title>Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance</article-title><source>Eur J Clin Pharmacol</source><year>1975</year><volume>9</volume><fpage>219</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">1233266</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00614021</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>